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ABSTRACT 
In Malaysia, the prevalence of osteoporosis in women age >45 
years is approximately 1 in 4 making it a major public health 
concern. Osteoporosis is usually asymptomatic in its early 
stages. Consequently, women who may have osteoporosis 
remain unidentified. This may lead to unwanted fractures. 
Fractures are associated with a reduction in quality of life. 
There is a 3-fold increased risk of death within 5 years in 
those who fracture. It is therefore imperative to encourage 
prevention and screening programmes which aid in early 
detection of osteoporosis. Current research suggests that 
many individuals with fragility fractures do not undergo 
appropriate screening and do not engage in preventive health 
behaviours. 
 
Pharmacists can work in collaboration with doctors to screen 
for osteoporosis, to educate patients on their osteoporosis 
risk, and to empower patients to take osteoporosis preventive 
measures. It is with this belief that we conducted this study to 
determine the effectiveness of a pharmacist osteoporosis 
screening programme in postmenopausal women.  
 
This study design was developed based on the United 
Kingdom Medical Research Council’s Framework of developing 
and evaluating complex intervention. Hence, this research 
project was divided into three phases: phase one was to 
explore the perceptions of the stakeholders for conducting an 
osteoporosis screening programme, phase two was to develop 
tools for the osteoporosis screening programme whilst phase 
three was to conduct the a feasibility study on the 
osteoporosis screening programme.  
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Phase one aimed to answer three research questions. The first 
research question was to explore the barriers and facilitators 
towards conducting an osteoporosis screening programme. 
Seven main barriers to the implementation of an osteoporosis 
screening programme were identified: governmental, 
organizational and management, work environment, team, 
task, individual and patient factors. The patient factors were 
targeted for our intervention.  
 
The second research question explored the role of the 
Malaysian pharmacist in osteoporosis screening. Pharmacists 
were principally perceived by all participants to be suppliers of 
medication, although there was some recognition of roles in 
providing medication advice. Nonetheless, doctors, nurses and 
policy makers were eager for pharmacists to be more 
proactive via inter-professional collaboration in osteoporosis 
screening, prevention advice and disease management.  
 
The third research question aimed to explore the components 
for an acceptable, practical and sustainable osteoporosis 
screening programme. We systematically identified four 
intervention (environment restructuring, education, 
persuasion, enablement) components to develop an 
acceptable, practical and sustainable osteoporosis programme. 
The “interventional package” consisted of counselling sessions, 
osteoporosis risk assessment and bone mineral density. 
 
In phase two, the Satisfaction Questionnaire for Osteoporosis 
Prevention (SQOP) and Osteoporosis Prevention and 
Awareness Tool (OPAAT) were developed and validated. Both 
the OPAAT and SQOP were found to be valid and reliable to 
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assess patients’ knowledge of osteoporosis and patients’ 
satisfaction towards the pharmacist screening programme. 
Additionally, six osteoporosis risk assessment tools were also 
validated among Malaysian postmenopausal women. Our 
results identified that the Osteoporosis Screening tool for 
Asians (OSTA) was the most suitable risk assessment tool as it 
had a sensitivity of 81.3% and specificity of 41.0% at an 
empirical cut-off point of ≤0. A pharmacist-led osteoporosis 
screening intervention package which consisted of the 
‘intervention package’ and collaboration between the doctors 
and pharmacists was developed and finalized.  
 
Phase three was a feasibility study of the developed 
pharmacist-led osteoporosis screening programme. Based on 
scientific, process, resources and management assessment 
the programme was found to be feasible in the Malaysian 
primary care setting. This was a good start for the 
implementation of a population-based osteoporosis screening 
programme in Malaysia as there was currently no such 
programme available. Future research should involve a 
randomized controlled trial to assess the effectiveness of the 
programme.   
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1.0 CHAPTER 1: LITERATURE REVIEW 
1.1   Definition 
1.1.1 Osteoporosis 
Osteoporosis is defined as a skeletal disorder characterized by 
low bone mass and microarchitectural deterioration of bone 
tissue predisposing a person to an increased risk of fractures 
(National Osteoporosis Foundation, 2010, Ministry of Health 
Malaysia, 2012).   
 
1.1.2 Disease profile 
Generally, osteoporosis is asymptomatic in nature (National 
Osteoporosis Foundation, 2010). Common clinical presentation 
includes: increasing dorsal kyphosis (Dowager’s hump), loss of 
height and back pain (Ministry of Health Malaysia, 2012). 
However, its clinical significance is predisposing an individual 
(with osteoporosis) to an increased risk of fracture (National 
Osteoporosis Foundation, 2010). These “fragility” fractures 
occur when individuals with osteoporosis slip and fall from a 
standing height, which  would usually be insufficient to 
fracture normal bone (World Health Organization Geneva, 
1998).  
 
1.1.3 Basic bone biology 
Bone is either cortical or cancellous with the adult skeleton 
containing 80% cortical and 20% cancellous bone.  The outer 
shell of the skeleton is formed by dense contical bone, 
whereas porous cancellous bone forms the interior structures 
in a honeycombed fashion (Koda-Kimble et al., 2009).  
 
The bone remodelling process is a continuous process 
involving, a balance between osteoblast and osteoclast 
 2 
 
activities as osteoclasts resorbs bones, whereas osteoblasts 
help reform bony surfaces and fill bony cavity. This process 
begins with bone resorption that is initiated by osteoclasts 
excavating lacuna found on the surface of cancellous bone, or 
it occurs when cavities are formed in cortical bone. This 
process produced enzymes and proteins that help dissolve 
bone mineral and protein.  Next, bone formation occurs with 
the help of osteoblast which gradually refill spaces created 
during the resorption process. Bone collagen fills in the bone 
cavities which are then calcified (Koda-Kimble et al., 2009).   
 
Figure 1.1 shows the bone remodelling cycle at the cellular 
level. The top panels are of normal adults, the bone removed 
by the osteoclasts (left) is replaced completely by the 
osteoblasts (right).  However when there is a high-turnover 
bone loss (middle panels) such as in women after menopause, 
the osteoclasts create a deeper resorption cavity that is not 
refilled completely. In low-turnover bone loss (bottom panel) 
which occurs with aging the osteoclasts create a resorption 
cavity of normal or decreased depth but the osteblasts fail to 
refill it (Koda-Kimble et al., 2009). 
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Figure 1.1: The bone remodelling cycle t the cellular level 
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Several hormones are involved in bone remodelling such as 
the parathyroid hormone (PTH), glucocorticoid hormones, 
calcitonin, estrogen and testosterone. Calcium and vitamin D 
are important nutrients required for bone growth. PTH and 
glucocorticoid hormones are involved in bone resoprtion 
whereas calcitonin, estrogen and testosterone have been 
associated with bone formation. The skeleton system serves 
as a reservoir for calcium, the small intestine is the site for the 
absorption of dietary calcium and the kidneys reabsorb 
calcium in the tubular system.  Calcium is regulated by the 
actions of PTH, vitamin D and calcitonin. PTH is released by 
the parathyroid gland when there is low serum calcium. This 
facilitates the mobilization of calcium and phosphate from 
bone and stimulates reabsorption of calcium through the 
tubular system in the kidneys. Vitamin D aids in intestinal 
absorption of calcium as well as phosphorous and magnesium. 
Increases in vitamin D levels decreases PTH levels. Calcitonin 
is released in response to high serum calcium levels. 
Calcitonin decreases intestinal absorption of calcium and 
phosphorous, inhibits calcium excretion in the kidneys and 
prevents bone resorption (Koda-Kimble et al., 2009). 
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1.1.4 Bone Mass 
Bone mass peaks during the third decade of life. Bone begins 
to gradually decreases 0.3% to 0.5% yearly at about age 35 
for both men and women. However with menopause due to 
the decrease in 17β-estradiol concentrations bone loss is 
accelerates by 2% to 3% per year that is superimposed on 
age-related bone loss. This loss gradually decreases over the 
next 8 to 10 years (Koda-Kimble et al., 2009). 
 
1.1.5 Classification of osteoporosis 
Osteoporosis can be classified into primary and secondary 
osteoporosis(Koda-Kimble et al., 2009). 
 
1.1.5.1 Primary osteoporosis 
Primary osteoporosis can be further classified into type I or 
type II (Koda-Kimble et al., 2009).  
 
1.1.5.1.1 Type I primary osteoporosis 
Type I is known as postmenopausal osteoporosis which is an 
increase in bone loss resulting in increased bone resorption. 
This affects women in the first 3-6 years of menopause (Koda-
Kimble et al., 2009).   
 
1.1.5.1.2 Type II primary osteoporosis 
Type II is known as senile osteoporosis which occurs in both 
women and men 75 years of age or older(Koda-Kimble et al., 
2009).  
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1.1.5.2 Secondary osteoporosis 
Secondary osteoporosis results from the use of various 
medications or the presence of particular disease states. This 
type of osteoporosis can affect a person at any age and is 
equally common in men and women (Koda-Kimble et al., 
2009). About 5% of all osteoporosis cases are secondary 
osteoporosis and about 20%of all osteoporosis fractures are 
caused by secondary osteoporosis (Bartl and Frisch, 2004). 
Table 1.1presents the list of medical conditions and 
medications which may lead to secondary osteoporosis. 
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Table 1.1: Medical conditions and medications which may lead 
to secondary osteoporosis (Reid, 2011) 
Type of medications Type of diseases 
Glucocorticosteroids 
Thyroxine 
Anticonvulsants 
Depo-provera 
Heparin 
Lithium 
Cytotoxic drugs 
Gonadothrpin-releasing 
Tamoxifen 
Aluminum 
Vitamin D toxicity 
Hyperoxia 
Chronic liver diseases 
Chronic renal failure 
Hyperthyroidism 
Primary hyperparathyroidism 
Cushing’s syndrome 
Insulin dependent diabetes 
Gastrointestinal resection 
Malabsorption 
Irritable bowel disease 
Chronic obstructive pulmonary 
disease 
Acquired immune deficiency 
syndrome or human 
immunodeficiency virus  
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1.1.6 Epidemiology of osteoporosis 
1.1.6.1 Prevalence of osteoporosis worldwide 
Approximately one-tenth of women aged 60, one-fifth of 
women aged 70, two-fifths of women aged 80 and two-thirds 
of women aged 90 will be affected by osteoporosis worldwide. 
It is estimated that osteoporosis will affect 200 million women 
worldwide (Kanis, 2007). 
 
1.1.6.2 Prevalence of osteoporosis in Europe 
In Europe, due to the changes in population demography the 
number of men and women with osteoporosis in Europe will 
rise from 27.5 million in 2010 to 33.9 million in 2025, 
corresponding to an increase in 23% (Hernlund et al., 2013). 
Data from 2010 showed that the United Kingdom has 
approximately 3.21 million people aged ≥50 with osteoporosis 
(Svedbom et al., 2013). 
 
1.1.6.3 Prevalence of osteoporosis in United States 
(US) 
Based on figures in 2013, the United States (US) estimated 
that more than 54 million women and men aged 50 and older 
was affected by osteoporosis and low bone mass (Wright et 
al., 2014, National Osteoporosis Foundation, 2014). The figure 
will climb to more than 71.2 million by 2030 (National 
Osteoporosis Foundation, 2014). 
 
1.1.6.4 Prevalence of osteoporosis in Latin America 
In Brazil, 10 million people which approximates to one person 
in every 17 has osteoporosis (Siqueira et al., 2005).   
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1.1.6.5 Prevalence of osteoporosis in Middle East 
The prevalence in Egypt was also high with 53.9 of 
postmenopausal women have osteopenia while 28.4 have 
osteoporosis (Mohy Taha, 2011). 
 
1.1.6.6 Prevalence of osteoporosis in Australia 
Similarly in Australia, 2.2 million Australian are affected by 
osteoporosis (Sambrook et al., 2002).  
 
1.1.6.7 Prevalence of osteoporosis in Asia 
The elderly population is expected to increase in all regions 
and all countries (United Nations, 2011). Asia is no exception 
to this trend. It is estimated that in year 2050, Asia will be 
having 29% of its citizens to be more than 60 years of age as 
compared to 11% in year 2011 (United Nations, 2011).  The 
rapid development of an aging society produces an increase in 
diseases specific to aging particularly osteoporosis. In year 
2003-2006, China’s prevalence was found to be 15.7% for 
individuals’ age above 50; which means that about 69.4 
million people are affected with osteoporosis (International 
Osteoporosis Foundation, 2009). Data from Japan and 
Pakistan indicate that 12 million and 9.91 million people, 
respectively are affected by osteoporosis (International 
Osteoporosis Foundation, 2009). Similarly, there is a high 
prevalence of osteoporosis in Taiwan at 38.3% (Lin and Pan, 
2011). 
 
1.1.6.8 Prevalence of osteoporosis in Malaysia 
Malaysia (located at the South East region of the Asian 
continent) is projected to have three times the amount of 
individuals aged 60 years and above from 1.4 million in year 
2000 to 3.3 million in year 2020 (Mafauzy, 2000). Similarly to 
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other Asian countries, Malaysia has a high prevalence of 
osteoporosis of 24.1 %(Lim et al., 2005). The prevalence of 
osteoporosis will almost certainly increase together with Asia’s 
rapid growth in its aging population. Therefore, this study is 
focused on the Malaysian population. 
 
1.1.7 Risk factors of osteoporosis 
1.1.7.1 Non-modifiable risk factors 
1.1.7.1.1 Age 
The risk of fracture doubles approximately with each decade 
(The Royal Australian College of General Practitioners, 2010). 
Fracture risk is strongly affected by age for both genders (The 
Royal Australian College of General Practitioners, 2010). 
 
1.1.7.1.2 Ethnicity 
Black women of African ancestry typically have a higher BMD 
than do white and Hispanic women(The North American 
Menopause Society (NAMS), 2010). Asian and Caucasians tend 
to have a lower average bone mass and smaller bones (The 
Royal Australian College of General Practitioners, 2010). 
 
1.1.7.1.3 Gender  
Men have an approximately 50% lower risk of osteoporotic 
fractures than women at a comparable age and bone density 
T-score, using young reference ranged matched for gender 
(The Royal Australian College of General Practitioners, 2010).  
 
1.1.7.1.4 Early menopause 
Women with early menopause have significantly lower bone 
density which has been associated with a higher fracture risk. 
Women whom had early menopause at a particular young age 
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may not have reached the peak bone density and will 
therefore be at further risk for osteoporosis (Meeta, 2013). 
 
1.1.7.1.5 Personal history of fragility fracture as an 
adult 
There is a five-fold increase on subsequent vertebral fracture 
risk with a single vertebral fracture.  Additionally the risk of 
hip fracture also increases after one or more spinal fracture. 
Evidence show that 46% of women and 30% of men suffered 
further fractures over the following seven years (The Royal 
Australian College of General Practitioners, 2010). After an 
initial low trauma fracture from a simple fall, both older men 
and women have an increased equivalent risk of all types of 
subsequent fractures, especially in the next 5-10 years 
(Center et al., 2007). 
 
1.1.7.1.6 First degree relatives with fracture 
It has been found that women with a first-degree relative with 
osteoporosis typically have low bone mass (Kanis et al., 
2004b).  It has been suggested that approximately 75% if the 
genetic effect on a person’s chance to develop osteoporosis is 
owing to a particular gene (Morrison et al., 1994). 
 
1.1.7.2 Modifiable risk factors 
1.1.7.2.1 Calcium intake 
More than 99% of the body’s calcium is in the teeth and 
bones. At a young age, prolong low calcium intake causes a 
negative calcium balance with a compensatory increase in 
PTH-medicated bone resorption which results in attainment of 
low peak bone mass. This later increases age-related bone 
loss and in postmenopausal women contributes to 
osteoporosis (Daroszewska, 2012). Therefore, an adequate 
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amount of calcium intake is needed to help achieve and 
maintain optimal bone mass(Koda-Kimble et al., 2009).  
 
1.1.7.2.2 Vitamin D intake 
Exposure to sunlight causes the skin to synthesized vitamin D. 
However, many factors such as latitude, overcast sky, skin 
pigmentation and ageing, clothing and the use of sun blocks 
diminish this process. Vitamin D is necessary for effective 
calcium absorption from the gut. Vitamin D is important as it 
helps regulate calcium by a complex interaction that involved 
PTH, thereby having a direct effect on the bone (The North 
American Menopause Society (NAMS), 2010). Vitamin D has a 
role in strengthening the bones via calcium absorption. It is 
the cofactor that facilitates the intestinal absorption of calcium 
and facilitates reabsorption of filtered calcium from the 
glomerular tubules back into plasma within the kidney 
(Cosman et al., 2014). It also assists in increasing bone mass 
and decreases fracture rates (Koda-Kimble et al., 2009). 
Deficiencies of vitamin D in adults will manifest as 
osteoporosis.  
 
1.1.7.2.3 Other dietary considerations 
Other dietary considerations are a diet in high in caffeine, 
protein, phosphorous and sodium has been associated with an 
increased risk of fractures by adversely effecting calcium 
balance. However, patients with adequate calcium intake may 
negate the effects of these dietary risks (NIH consensus 
development panel on osteoporosis prevention, 2001). 
 
1.1.7.2.4 Small body built or low body weight 
Low bone mineral status and increased fracture risk is 
associated with low body weight and excessive dieting 
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(Nguyen et al., 1998). It is recommended to maintain a body 
mass index (BMI) of not less than 19kg/m2 for the prevention 
of osteoporosis (WHO technical report series 843, 1994). 
 
1.1.7.2.5 Exercise 
Exercise plays an important role in building bone in youth and 
helps slow down bone lost in adults. It assist in reducing the 
risk of fall as it strengthens muscles, increases flexibility and 
improves coordination and balance (International Osteoporosis 
Foundation, 2006). Prolonged bed rest and immobility 
especially in the elderly has been associated with decreased 
bone mass (Gutin and Kasper, 1992).  
 
1.1.7.2.6 Smoking 
It has been found that cigarette smokers may have impaired 
calcium absorption and lower 17β-estradiol levels but the 
mechanisms of how it affects bone mass are unknown (The 
North American Menopause Society (NAMS), 2010). 
Nonetheless, women who smoke, especially those who are 
thin, have been found to have an increased risk for fractures 
compared with non smokers (Baron et al., 2001).  
 
1.1.7.2.7 Alcohol 
Consuming excessive alcohol by both men and women may 
predispose them to low bone mineral density (BMD). However, 
it is unclear whether moderate alcohol consumption has an 
effect on bone mass. Nonetheless consuming as few as two 
alcoholic drinks daily significantly increases the fracture risks 
(Kanis et al., 2004a). This may be due to the effect of alcohol 
on osteoblasts or it may be secondary nutritional compromise 
that could results in impaired calcium and vitamin D intakes 
with subsequent decrease in bone formation (Moniz, 1994). 
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Those who are alcoholics also may be at risk for increased falls 
(Koda-Kimble et al., 2009). 
 
1.1.8 Screening strategies 
Screening can be performed by administering questionnaires 
or by using a machine. 
 
1.1.8.1 The administration of questionnaires 
There are several tools available to assess the risk of 
osteoporosis (Lim et al., 2011, Koh et al., 2001b, Weinstein 
and Ullery, 2000, Cadarette et al., 2000, Lydick et al., 1998, 
Michaëlsson et al., 1996). Further details on these 
questionnaires will be discussed in Chapter 5. However we 
would like to highlight the osteoporosis screening tool for 
Asians (OSTA). OSTA is a simple method to assess if a person 
is at risk of osteoporosis. It asks information about the age 
and how heavy the patient is. Additionally it will ask if the 
patient has any risk factors for osteoporosis. A score will then 
be calculated and the patient can be categorized to high, 
medium or low risk for osteoporosis. If the patient is 
categorized to the high or medium risk group for osteoporosis, 
a BMD scan is recommended (Koh et al., 2001b). 
 
1.1.8.2 Quantitative ultrasound scanning 
Quantitative ultrasound scanning (QUS) is also a simple and 
painless heel ultrasound. The scanners are also smaller, 
transportable and less expensive. The shape, intensity and 
speed of the propagating wave are altered by the physical and 
mechanical properties of the bone. QUS can be used as a 
screening tool to identify women who are at risk of 
osteoporosis. However, it cannot be used to confirm the 
diagnosis of osteoporosis. Eventually like all other risk 
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assessment tools, a BMD scan will still have to be performed 
for the diagnosis of osteoporosis (The Royal Australian College 
of General Practitioners, 2010, Moayyeri et al., 2012, National 
Osteoporosis Society, 2001). 
 
1.1.9 Diagnosis of osteoporosis 
1.1.9.1 Bone mineral density (BMD) 
According to the WHO, the gold standard in diagnosing 
osteoporosis is to have a BMD scan. BMD scans are conducted 
using a dual energy x-ray absorptiometry (DEXA) machines 
(Kanis, 2007, National Osteoporosis Foundation, 2010). It 
uses very small amounts of radiation to determine the BMD of 
the spine and hip which are the main areas for osteoporosis 
fractures. This is a non-invasive, painless procedure that takes 
less than 15 minutes (National Osteoporosis Foundation). The 
results of the BMD scan at the hip or spine will be compared to 
a reference range of young healthy adults with average bone 
density. The difference between this average and the patient’s 
bone density is then calculated and expressed in terms of 
standard deviation (SD) called the T-score. Based on this the 
patient can be categorised into three main categories: 
osteoporosis, osteopenia or normal (National Osteoporosis 
Foundation, 2010). Table 1.2 displays the World Health 
Organization (WHO) working group classification of 
osteoporosis for postmenopausal women. 
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Table 1.2: The World Health Organization (WHO) Working 
group classification of osteoporosis for postmenopausal 
women (National Osteoporosis Foundation, 2010) 
Classification of osteoporosis T-score 
Normal ≥-1.0 
Osteopenia -1.0> T-score >-2.5 
Osteoporosis ≤-2.5 
Severe/Established osteoporosis ≤-2.5 with presence of 1 or 
more fragility fractures 
 
  
 17 
 
As bones take a long time to change, it is recommended to 
perform another BMD testing one to two years after initiating 
medical therapy for osteoporosis and every two years 
thereafter (National Osteoporosis Foundation, 2010). 
However, more frequent BMD testing may be warranted in 
certain clinical situations or if there is a change in therapy 
(National Osteoporosis Foundation, 2010, The Royal Australian 
College of General Practitioners, 2010). Additionally, the 
interval between repeat BMD screenings may be longer for 
patients without major risk factors and who have an initial T-
score in the normal or upper lower bone mass range (National 
Osteoporosis Foundation, 2010).   
 
1.1.10 Prevention of osteoporosis 
1.1.10.1 Calcium 
1.1.10.1.1 Dietary calcium intake 
An adequate amount of calcium intake is needed to help 
achieve and maintain optimal bone mass (Koda-Kimble et al., 
2009).  Increasing age and menopause increases the daily 
requirements of calcium [Table 1.3]. Calcium can be obtained 
from diet and supplements. Examples of food rich in calcium 
are milk, cheese, tofu, sardines, mussels, nuts and yoghurt 
[Table 1.4] (National Coordinating Commitee on Food and 
Nutrition, 2005, Ministry of Health Malaysia, 2012). 
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Table 1.3: Calcium daily requirements (National Coordinating 
Commitee on Food and Nutrition, 2005) 
   Age Recommended 
Intake 
Infants 0 - 6 months 300 mg (breast-fed) 
400 mg (non-
breast-fed) 
6 - 12 months 400 mg 
Children 1 – 3 500mg 
4-6 600mg 
7-9 700mg 
Adolescents 
(boys & girls) 
10 - 18 1000mg 
Men 19 – 49 800 mg 
> 50 years 1000 mg 
Women 19 – 49 800 mg 
> 50 years 1000 mg 
Pregnant Third trimester 1000 mg 
Lactating   1000 mg 
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Table 1.4: Calcium content of some common foods (National 
Coordinating Commitee on Food and Nutrition, 2005) 
Food Calcium content (mg) 
1 glass of high calcium milk (200 ml) 500 
1 glass of skimmed milk (200 ml) 250 
1 glass of full cream milk (200 ml) 220 
1 cup of yoghurt (150 g) 200 
1 piece of tofu (150 g) 200 
1/2 cup of yellow dhal (100 g) 170 
1 cup of spinach (56 g)   160 
1 cup of ice-cream (156 g) 150 
1 cup of watercress (sai-yong choy) (50 
g) 
100 
1 piece of cheddar cheese (20 g) 100 
1 cup of mussels (160 g) 100 
1/2 cup of anchovies (dried without head 
& entrails) (20 g) 
100 
1 piece of canned sardine (40 g) 100 
1 cup of baked beans (240 g) 100 
1 cup of mustard green (sawi), cekur 
manis, kai lan or  pucuk ubi kayu (green 
vegetables) (50 - 80 g) 
100 
1 piece of tempeh (70 g) 50 
1 cup of soyabean milk (200 ml) 40 
1 cup of broccoli (95 g) 40 
10 almonds (15 g) 30 
* 1 cup = 200 ml 
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1.1.10.1.2 Calcium supplements 
The best way to meet the daily requirement of calcium is 
through the intake of high calcium foods. Dairy products are 
the best sources of calcium due to their high elemental 
calcium content, high absortive rate and relative low cost. 
However, individuals who are unable to obtain enough calcium 
from foods should take a supplement to meet these guidelines 
(Koda-Kimble et al., 2009). The absorption of calcium 
supplements can vary from 20-40% depending on formulation 
[Table 1.5] (Koda-Kimble et al., 2009). Calcium is best 
absorbed by the body when it is taken several times a day 
(Karkkainen et al., 2001).  However doses exceeding 
2500mg/day of elemental calcium can results in 
hylercalcemia, hypercalciuria and possibly urinary stones 
(Koda-Kimble et al., 2009). However, the typical American 
diet is low in calcium (Koda-Kimble et al., 2009). Similarly the 
Malaysian diet is low in calcium which is between 300-500mg 
daily (Chee et al., 1997). 
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Table 1.5: Percentage of calcium in various salts (Koda-Kimble 
et al., 2009) 
Salt % Calcium 
Calcium carbonate 40 
Tricalcium phosphate (calcium phosphate, tribasic) 39 
Calcium chloride 27 
Dibasic calcium phosphate dihydrate 23 
Calcium citrate 21 
Calcium lactate 13 
Calcium gluconate 9 
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1.1.1.10.1.3 Calcium for prevention of osteoporotic 
fractures in postmenopausal women  
Calcium have been shown to reduce BMD loss in 
postmenopausal women and reduce the risk of osteoporotic 
fractures (Cummings and Nevitt, 1997, Jackson et al., 2006, 
Robbins et al., 2014, Neelemaat et al., 2012, Shea et al., 
2004). A meta-analysis reviewed the literature from 1996-
1997 assessing the effectiveness of calcium supplementation 
and/or dietary calcium for the prevention of osteoporotic 
fractures in postmenopausal women. There were 14 studies of 
calcium supplements and 18 studies of dietary calcium. The 
analysis revealed relative risk reductions between 25% and 
70% for osteoporotic fractures. Most of these trials reported 
an approximate 30% fracture reduction with an intake of 
approximately 1000mg/day of elemental calcium (Cummings 
and Nevitt, 1997). 
 
Another meta analysis of 15 trials that randomized 
postmenopausal women to calcium supplementation or usual 
calcium intake in diet found that calcium alone caused a 
positive mean percentage on BMD change from baseline of 
2.05% for total body bone density, 1.66% at the lumbar 
spine, 1.6% at the hip and 1.9% at the distal radius (Shea et 
al., 2004). These data from these studies indicate the vital 
role for calcium related to optimal bone health.  
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1.1.10.2 Vitamin D 
1.1.10.2.1 Natural sources of Vitamin D 
Adequate vitamin D can be obtained from exposure to sunlight 
and diet. Exposure of the hands, face and arms to sunlight for 
about 15 minutes a day should be adequate. Fairer persons 
will only need 5 minutes of exposure to the sun. Darker 
persons will probably need about 30 minutes of exposure. 
However prolonged exposure to the sun should be avoided. It 
is important to note that glass prevents the transmission of 
ultraviolet B radiation which is necessary for the skin to 
produce vitamin D. Sunscreens also reduce the transmission 
of ultraviolet B and should only be applied if exposure to the 
sun will be over a longer period of time. A smaller amount of 
vitamin D is from the diet such as margarine, butter, milk, 
salmon, tuna, eggs, breakfast cereal, liver and other fatty fish  
(Koda-Kimble et al., 2009, Holick, 2004). Most adults are 
unlikely to obtain more than 10-20% of their vitamin D 
requirement from dietary sources(Daroszewska, 2012). If this 
is not possible, multivitamin and vitamin D supplements are 
available as previously mentioned. 
 
 The National Osteoporosis Foundation (NOF) recommends an 
intake of 800 to 1,000 international units (IU) of vitamin D per 
day for adults age 50 and older (National Osteoporosis 
Foundation, 2010). The Institute of Medicine Dietary 
Reference Intakes for vitamin D are 600 IU per day until age 
70 and 800 IU per day for adults age 71 years and older (Ross 
et al., 2011). It has been estimated that there is a 29% 
reduction of hip fracture in women who take calcium and 
vitamin D supplements as compared to women who have have 
vitamin D deficiencies (Jackson et al., 2006, Robbins et al., 
2014). However the use of vitamin D alone is unclear and it 
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has been found that using higher than recommended doses 
could lead to increase risk including hypercalciuria and 
hypercalcemia (The North American Menopause Society 
(NAMS), 2010).  
 
1.1.10.2.2 Vitamin D supplements 
There are 2 types of vitamin D: vitamin D2 (ergocalciferol) 
and vitamin D3 (cholecalciferol). Vitamin D3 is formed from 
the skin through the action of ultraviolet B radiation and the 
main ingredient in supplements. Vitamin D2 is produced by 
plants. Supplements  can come from either source (Sunyecz, 
2008). Some calcium supplements and most multivitamin 
tablets also contain vitamin D (Cosman et al., 2014). Various 
studies have noted improvement in muscle strength and 
balance, reduction in bone loss as well as reduce risk of falls 
with vitamin D supplementation(The North American 
Menopause Society (NAMS), 2010, Neelemaat et al., 2012). 
 
1.1.10.3 Other dietary considerations 
Although some promote the use of magnesium and 
isoflavones in osteoporosis prevention, the current data are 
insufficient to support its use for this purpose (The North 
American Menopause Society (NAMS), 2010).  
 
1.1.10.4 Exercise 
Weight bearing exercises such as walking, running and lifting 
weights helps prevent bone loss. Exercise helps maintain 
skeletal mass and may help reduce bone loss in 
postmenopausal women. This is because exercise appears to 
stimulate osteoblastic activity to help maintain bone mass 
(Gutin and Kasper, 1992). Improvements of bone density and 
a reduced hip fracture risk in older women have been 
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associated with thirty minutes of weight bearing exercise three 
times a week. This study noted a 41% lower risk of hip 
fracture compared with postmenopausal women who 
conducted weight bearing exercise for less than one hour per 
week (Feskanich et al., 2002). Additionally, studies have 
shown that weight bearing exercises are able to increase the 
BMD at the femoral neck by 0.9-1.6% (Heinonen et al., 1996, 
Nelson et al., 1994) and 1.0-1.3% in the lumbar spine (Nelson 
et al., 1994, Hinton et al., 2015). 
 
A systematic review by Howe et al (2011) that examined the 
effectivieness of exercise intervention in preventing bone loss 
and fractures in postmenopausal women found 47 RCTs. The 
results of this review suggest a relatively small, statistically 
significant but possibly important effect of exercise on bone 
density. They suggest that the most effective types of exercise 
on BMD for the neck of femur appear to be resistance strenght 
training such as leg press and shoulder press. However, for 
the BMD at the spine they recommended a combination of 
both weight bearing exercises and strength training (Howe et 
al., 2011). These exercises should be conducted regularly in 
order to maximize and maintain the bones (Koda-Kimble et 
al., 2009). 
 
1.1.10.5 Smoking cessation 
Smoking cessation should be encouraged for people with 
osteoporosis as smoking is associated with lowered BMD and 
increased fracture risk as well as other health problems (The 
North American Menopause Society (NAMS), 2010). 
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1.1.10.6 Fall prevention 
Many older people fall in the home, so it is important to try to 
reduce hazards that could cause a trip and fall. Fall prevention 
measures should be adopted in the elderly because nearly 
90% of fractures are precipitated by falling (Cummings and 
Melton, 2002). These measures include intrinsic, extrinsic and 
environment factors. Environmental factors refer to the 
removal of all loose wires, cords, loose rugs and carpets. It is 
important to ensure rugs are anchored and smooth.  Halls, 
stairways and entrances should be well lid (Koda-Kimble et al., 
2009). Bathrooms are another common area where falls 
occur. Grab bars and non skid tape in the tub and shower 
should be installed. Additionally stairs should have treads and 
rails. The elderly should take their time when using the stairs 
and hold on to the railings. Furniture should also be in its 
usual places and not moved around (Daroszewska, 2012).  
 
Extrinsic factors refer to appropriate foot wear such as sturdy, 
rubber-soled shoes. The elderly should also avoid lifting heavy 
objects. Medication can sometimes cause the elderly to be 
dizzy or drowsy leading to falls. Examples of these 
medications are antidepressants, sleeping pills, 
antihypertensives, antiepileptics, pain killers, antiparkinson 
medication, antihistamines and antidiabetics (Koda-Kimble et 
al., 2009). 
 
Intrinsic factors refer to balance, gait problems, visual or 
hearing impairment (Koda-Kimble et al., 2009). Annual 
checkups on eyesight and hearing should be conducted. Poor 
eyesight can increase the risk of falling and deafness can 
affect balance.  It is also important to identify other health 
problems such as Parkinson’s disease, arthritis or stroke are 
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common causes of fall (Ministry of Health Malaysia, 2012). 
Hence, fall risks should be evaluated at least annually (Koda-
Kimble et al., 2009). 
 
1.1.11 Treatment of osteoporosis 
1.1.11.1 Medications 
As the scope of the study is mainly on prevention, this will be 
a brief introduction to the types of osteoporosis medication. 
There are many well established medications currently 
available for the treatment of osteoporosis [Table 1.6]. These 
medications will help rebuilt the bones and prevent further 
bone loss. 
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Table 1.6: Types of osteoporosis medications (Koda-Kimble et 
al., 2009, Ministry of Health Malaysia, 2012) 
Therapeutic 
class 
Generic name 
Bisphosphonates Alendronate 
Ibandronate 
Risedronate 
Zoledronate 
HRT Oestrogen/Oestrogen + progesterone 
SERMs Raloxifene 
r-PTH Teriparatide 
New generation 
drug 
Strontium ranelate 
Calcitonin Calcitonin salmon 
Human 
monoclonal 
antibody (IgG2) 
Denosumab 
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1.1.11.1.1 Hormone replacement therapy (HRT) 
Oestrogen therapy (with or without progestin) is beneficial in 
the prevention and treatment of osteoporosis as it increases 
the BMD of the lumbar spine and femoral neck up to 7.6% and 
4.5% respectively over 3 years. A reduction in the risk of 
spine, hip and other osteoporosis fractures was by 33-40% 
(Cauley et al., 2003, The Women's Health Initiative Steering 
committee, 2004). The concern with this type of HRT is the 
increased risk of stroke, myocardial infarction and breast 
cancer (Rossouw et al., 2013, Schairer et al., 2000, 
Henderson and Lobo, 2012, Grodstein et al., 2008). Hence, 
HRT is less likely to be prescribed  for the sole purpose of 
osteoporosis prevention (Koda-Kimble et al., 2009).  
 
1.1.11.1.2 Selective Estrogen Receptor Modulators 
(SERMs) 
SERM are hormone related pharmacological agents that have 
estrogen agonist, antagonist or both activities in various 
tissues where estrogen receptors are present.  Raloxifene is 
an example of a SERM that may be an alternative therapeutic 
choice for osteoporosis prevention and treatment. Raloxifene 
has an agonistic effect on bone and serum lipid profiles and 
antagonistic effects on endometrial and breast tissues.  Its 
agonistic effect on bone tissues is believed to occur through a 
reduction of bone resorption and a decreased rate of bone 
turnover which results in an increased BMD.  In a one year 
study of osteopenic patients, raloxifene increased the lumbar 
spine and hip BMD by 2.2% and 0.8% respectively (Sambrook 
et al., 2004). The concern with SERMs is the increase in 
vasomotor symptoms (flushing and palpitations). Other 
adverse effects include an increased risk for venous 
thromboembolic disease which is greatest during the first 4 
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months of therapy. To decrease the risk of thrombosis 
associated with immobilization, raloxifene should be 
discontinued 72 hours before immobilization (surgery) (Koda-
Kimble et al., 2009).  
 
1.1.11.1.3 Biphosphonates 
Another alternative pharmacological agent for the prevention 
and treatment of osteoporosis is biphosphonates. Alendronate, 
risendronate and ibandronate have been approved for 
osteoporosis treatment and prevention in postmenopausal 
women.  Alendronate is an aminobiphosphonate that works by 
decreasing bone resorption resulting in decreased fracture 
rates in postmenopausal women who are at risk for 
osteoporosis. In an osteoporosis prevention study for 2 years 
in postmenopausal women >60 years using  a dose of 
5mg/day of alendronate, there is an increase in lumbar spine, 
hip and total BMD by 3.5%, 1.9% and 0.7% respectively 
compared to placebo. A dose of 5mg/ day had a higher BMD 
increase as compared to a dose of 2.5mg/day (Hosking et al., 
1994).  
 
As for risendronate, a study of women 40-60 years of age with 
normal BMD received a dose of 5mg/day for 2 years had a 
BMD increase of 5.7% at the lumbar spine and 5.4% in the hip 
compared to women taking placebo (Mortensen et al., 1998).  
Ibandronate versus placebo has also shown benefits in 
increasing BMD. There was significant BMD increase in lumbar 
spine (1.9%) and total hip (1.2%) in early postmenopausal 
women after 2 years (McClung et al., 2003).   
 
However, the adverse effect of biphosphonates includes 
gastrointestinal (GI) symptoms such as regurgitation, 
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oesophageal ulcer and gastritis. Hence patients need to sit 
upright for 30-60 minutes after ingestion. Another adverse 
effect is the osteonecrosis of the jaw (ONJ) or dead jaw which 
occur if blood loss in bone tissue is temporarily or permanently 
impaired resulting in the eventual collapse of the bone. 
However most ONJ cases are cancer patients receiving 
chemotherapy and concurrent intravenous (IV) biphosphonate 
therapy (Koda-Kimble et al., 2009).  
 
1.1.11.1.4 Other pharmacological agents 
Other pharmacological agents are available such as the 
recombinant human PTH 1-34(r-PTH), teriparatide is a potent 
anabolic agent and is indicated for individuals with severe 
osteoporosis (Ministry of Health Malaysia, 2012). It stimulates 
new bone formation and activates remodelling which results in 
an increased BMD and connectivity in trabecular bone more 
than cortical bone (Koda-Kimble et al., 2009).   
 
Strontium ranelate reduces bone resorption while promoting 
bone formation (Meunier et al., 2004). Calcitonin on the other 
hand acts directly on osteoclasts to inhibit bone resorption 
primarily from vertebral and femoral sites. It can be 
administered via injection and the intranasal spray for the 
postmenopausal women who have been diagnosed for at least 
5 years (Koda-Kimble et al., 2009). Denosumab is a IgG2 that 
inhibits the formation, function and survival of osteoclasts by 
preventing RANK (receptor activator of nuclear factors Kappa 
B) ligand from activating its only receptor, RANK, thus 
reducing bone resorption (Whyte, 2006).  
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1.1.11.1.5 Activated vitamin D 
Activated Vitamin D such as calcitriol and alfacalcidol has been 
shown to increase BMD in those with established osteoporosis 
and reduce vertebral fractures (Orimo et al., 1994, Richy et 
al., 2004b, Gallagher, 1990). 
 
1.1.12 Impact of osteoporosis 
1.1.12.1 Clinical considerations (Medical impact) 
The end result of osteoporosis is a fragility fracture. Fragility 
fractures can occur in various sites most notably the hips, 
vertebrae and forearm (National Osteoporosis Foundation, 
2010). The World Health Organization provides that the 
worldwide projection of hip fractures cases due to osteoporosis 
will rise from 1.7 million in 1990 to 6.3 million by 2050 with a 
steep increase to be observed in developing countries (World 
Health Organization Geneva, 1999). Correspondingly, Cooper 
et al (1992) projected that 51.1% of osteoporotic fracture will 
occur in Asia by year 2050 which is a 19.9% increase as 
compared to year 1990 (Cooper et al., 1992) The ultimate 
goal of osteoporosis management is the prevention of 
fractures. 
 
1.1.12.1.1 Hip fractures 
Hip fracture is considered the most serious osteoporosis 
fracture. It may occur following a fall from the standing 
position. A hip fracture is painful and most probably 
necessitates hospitalization (Kanis, 2007).  
 
Hip fracture is a fracture of the proximal femur, either through 
the femoral cervix or through the trochanteric region. 
Trochanteric fractures are more commonly osteoporotic 
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fractures. There is a greater increase risk for age-specific and 
sex-specific risks for hip fractures at trochanteric region than 
for cervical region. It has been found that in many countries 
these two fractures occur with equal frequency. However, the 
average age of patients with trochanteric fractures is 
approximately five years older than for cervical fractures 
(Kanis, 2007).  
 
1.1.12.1.1.1 Incidence of hip fractures globally 
In the past decades studies have shown geographic variation 
in the incidence of hip fractures across continents. Hip 
fractures incidences are highest in Sweden and North America. 
In Asia and Latin American population the hip fracture rates 
are lower. However three-quarters of the world’s population 
live in Asia and it is projected that Asian countries will 
contribute more to the pool of hip fractures in coming years 
(Dhanwal et al., 2011).  
 
1.1.12.1.1.2 Incidence of hip fractures in Europe 
The incidence rates of hip fracture vary from North to South 
Europe. Sweden and Norway had the highest rates of hip 
fracture and the lowest in France and Switzerland. In Norway, 
the reported age-standardizes annual incidence rate of hip 
fracture is 920/100 000 in women and in Switzerland is 
346/100 000 (Dhanwal et al., 2011). In central Europe, the 
United Kingdom showed an increase incidence rates by 32% in 
women up to 1991-1992 and thereafter remained stable 
(Balasegaram et al., 2001). As for the German studies, the 
age incidence of hip fracture increased by 0.5% annually from 
1995-2004 (Icks et al., 2008). 
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1.1.12.1.1.3 Incidence of hip fractures in United 
States of America 
The US population has the highest hip fracture rates in the 
world. A study reported age-standardized annual incidence of 
hip fracture of 511/100 000 for women (Melton et al., 1998). 
However a more recent study showed that hip fracture 
increased from 1986-19995 and then steadily declined from 
1995-2005 (Brauer et al., 2009). Canadian women’s overall 
fracture rate was 30% lower than in US women in 2001 (Leslie 
et al., 2010, Dhanwal et al., 2011). 
 
1.1.12.1.1.4 Incidence of hip fractures in 
Australia/New Zealand 
Initially in New Zealand, there was a disproportionate increase 
in the number of fractures in relation to the increase in 
population size from year 1950-1987 (Rockwood et al., 1990). 
However a later study from 1988-1999 showed a significant 
drop in fracture rate for females in all age bands (Fielden et 
al., 2001).As for Australia, a study in 1989-2000 showed a 
significant reduction in the overall fracture incidence rate  45 
per year in women (Chang et al., 2004). 
 
1.1.12.1.1.5 Incidence of hip fractures in Asia 
However, epidemiological information is more widely available 
for hip than for other sites, although fragility fractures in other 
sites significantly contribute to the burden of osteoporosis. For 
instance, mainland China previously had one of the lowest 
incidence of hip fracture in the world in 1988, at 10 per 10 
000. However, this has noticeably increased at about 10% per 
year from 2002-2006 (International Osteoporosis Foundation, 
2009, Xia et al., 2012). Similarly, in Hong Kong there is a 
300% increase of hip fracture incidence from the 1960s to the 
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1990. However, the rates in Thailand and Malaysia increased 
200% and 150% respectively (International Osteoporosis 
Foundation, 2009). As for Singapore, the hip fracture 
incidence was 5 times more from 1960 to 1998 (Koh et al., 
2001a).  In Japan, incidence of hip fractures increased by 1.6 
fold in men and 1.5 fold in women from 1986-1998 (Hagino et 
al., 2005). Korea also shows an increase of more than 6 fold 
in women and 2.5 fold in men (Lim et al., 2008). The 
Philippines similarly noted an increase in the number of hip 
fractures from 28 000 in 2003 and 34 000 in 2005, expecting 
the number to reach 175 000 in 2050 (International 
Osteoporosis Foundation, 2009). Additionally, conservative 
estimates shows that the number of hip fractures occurring 
annually in India exceeds 140 000 (International Osteoporosis 
Foundation, 2009).  
 
1.1.12.1.1.6 Impact of hip fractures 
The trochanteric fracture has a greater morbidity and 
mortality when compared with the cervical fractures. Studies 
have shown that up to 20%of patients die in the first year 
following a hip fracture and less than half of survivors regain 
the level of function that they had prior to the hip fracture 
(Chapuy et al., 1994, Trivedi et al., 2003). It has been found 
that the mortality, morbidity and social burden of hip fractures 
in Asian countries are similar to those in the West. A 
Singaporean study has found that after a hip fracture, 20% of 
patients will die within two years , 33% remain ambulant 
without  aids, 40% are ambulant with aids, and 10% are 
wheel chair or bed bound (Mitra et al., 1994).  
 
 
  
 36 
 
1.1.12.1.2 Vertebral fractures 
The most difficult osteoporosis-related fracture to define is 
vertebral fractures. This is because diagnosis is made on a 
change in the shape of the vertebral body. These deformities 
as a results from osteoporotic fractures are usually classified 
as a crush fracture (involving compression of the entire 
vertebral body), a wedge fracture (in which there is anterior 
height loss), and biconcavity (where there is relative 
maintenance of the anterior and posterior heights with central 
compression of the end-plate regions). However, there is a 
widely used clinical system to classify vertebral fractures. A 
20-25% height loss is classified as mild vertebral fractures, 
moderate (>25-40% height loss) or severe (>40% height 
loss)(Kanis, 2007). 
 
1.1.12.1.2.1 Incidence of vertebral fractures 
worldwide 
Vertebral fractures are rarely reported as it is difficult to 
quantify accurately. In the UK the lifetime risk of symptomatic 
vertebral fracture for a 50 year old white women was 
calculated to be 11% (Cooper, 1993). In the US, it is 
estimated that there are 550 000 to 700 000 osteoporotic 
vertebral compression fractures annually (Black et al., 1999, 
Burge et al., 2007). 
 
There is limited data on vertebral fractures in Asia. In Japan, 
the prevalence of vertebral fracture in a population-based 
sample was 5.7- 13.0% in people aged 60-69 years of age 
(Kitazawa et al., 2001). Chinese in Beijing showed a 
comparable prevalence of vertebral fractures in individuals age 
over 50 at 15% (International Osteoporosis Foundation, 
2009). Vertebral fracture incidence in women and men aged 
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over 50 years in Thailand was 32.1/1000 and 54.5/1000 
person-year respectively (Jitapunkul et al., 2008). Currently, 
there is no data on the incidence of vertebrae fracture in 
Malaysia. 
 
1.1.12.1.2.2 Impact of vertebral fractures 
It has been estimated that 28% of patients with a vertebral 
fracture will die in the first year (Johnell et al., 2004). Even if 
a fracture does not occur, spinal bones may get 
crushed/compressed resulting in back pain, height loss and 
difficulty in breathing since there is less space under the ribs 
(Kauffman et al., 2007, Cosman et al., 2014). 
 
1.1.12.2 Other types of fractures 
Colles fracture is the most common distal forearm fracture. It 
lies within 2.5cm of the wrist joint margin and is associated 
with dorsal angulation and displacement of the distal fragment 
of the radius. This fracture normally occurs from a fall on the 
outstretched hand. Wrist fractures normally cause less 
morbidity than hip fractures and are rarely fatal. However, its 
consequences are often underestimated. About 1% of patients 
with a forearm fracture become dependent as a result of 
fractures (Writing Group for the Women’s Health Initiative, 
2002). It often leads to pain, tenderness, stiffness and 
swelling of the hand and more rarely to frozen shoulder (Neer 
et al., 2001). Additionally the risk of other osteoporotic 
fracture in later life is much increased after Colles fracture 
(Bagger et al., 2004). It has been estimated that 6% of wrist 
fracture patients will die within a year (Johnell et al., 2004). 
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1.1.12.2.1 Economic impact 
Osteoporosis takes a huge economic toll. The disability due to 
osteoporosis in Europe is greater than that caused by cancers 
except for lung cancer. Osteoporosis’s disabilities is 
comparable or greater than that lost to a variety of chronic 
non-communicable diseases, such as rheumatoid arthritis, 
asthma and high blood pressure related heart disease (Johnell 
and Kanis, 2006). 
 
1.1.12.2.1.1 The economic impact of osteoporosis in 
Europe 
For example, the cost of osteoporosis, including 
pharmacological intervention in the EU in 2010 was estimated 
at €37 billion. This includes the costs of treating incident 
fractures represented 66%, pharmacological prevention 5% 
and long-term fracture care 29% (Hernlund et al., 2013).In 
year 2010, there were approximately 536,000 new fragility 
fractures each year in the United Kingdom. The economic 
burden of new and prior fractures was £ 3,496 (€ 5,408) 
million each year. It is predicted that by 2025 the burden will 
increase by 24 % to £ 5,465 (€ 6,723) million (Svedbom et 
al., 2013). 
 
1.1.12.2.1.2 The economic impact of osteoporosis in 
the United States 
In the US, there are two million fractures  annually and are 
attributed to osteoporosis, causing more than 432,000 
hospital admissions, almost 2.5 million medical office visits 
and about 180,000 nursing home admissions1. Currently, 
Medicare pays for approximately 80 percent of these fractures, 
with hip fractures accounting for 72 percent of fracture costs. 
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As the population ages, the cost of care is expected to rise to 
$25.3 billion by 2025 (NOF 2014). 
 
1.1.12.2.1.3 The economic impact of osteoporosis in 
Latin America 
The estimate direct cost in Latin Americans is  $13 billion for 
year 2050. It is estimated that there will be 655,648 hip 
fractures (Johnell, 1997).   
 
1.1.12.2.1.4 The economic impact of osteoporosis in 
Australia 
As for Australia the total costs relating to osteoporosis are 
$7.4 billion per year of which $1.9 billion are direct costs 
(Sambrook et al., 2002). 
 
1.1.12.2.1.5 The economic impact of osteoporosis in 
Asia 
Similarly, China spent $1.5 billion in year 2006 treating hip 
fracture. This expenditure is estimated that this will rise to 
$12.5 billion in 2020 and by 2050 to more than $ 264.7 billion 
(Luo and Xu, 2005). The direct hospitalisation cost for hip 
fractures in Malaysia from year 1997 was estimated at RM22 
million (~$6000 000). This is an underestimate as it does not 
include the cost incurred in rehabilitation and long term 
nursing care. Therefore, without proper intervention the cost 
will escalate as the population ages (Ministry of Health 
Malaysia, 2012). 
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1.1.13 Osteoporosis knowledge among patients and 
healthcare professionals 
Osteoporosis knowledge among patients vary from country to 
country. Previous studies have found that the knowledge of 
osteoporosis in adult women aged 21-90 years in Europe 
(Alexandraki et al., 2008, Gemalmaz and Oge, 2007, Ungan 
and Tumer, 2001), Canada (Cadarette et al., 2007), United 
States (Ailinger and Emerson, 1998, Burke-Doe et al., 2008), 
Middle East (Baheiraei et al., 2005b), and Australia 
(Winzenberg et al., 2003) was low. Conversely, women and 
men aged 16-79 years in Norway were knowledgeable about 
osteoporosis (Magnus et al., 1996). In Asia, the knowledge of 
osteoporosis  ranged from low to moderate for women aged 
19-90 in Brunei (Liza et al., 2009), Singapore (Saw et al., 
2003) and Malaysia (Abdulameer et al., 2013, Yeap et al., 
2010, Khan et al., 2014). However, another study in Malaysia 
found that the knowledge of osteoporosis was moderate in 
women aged 49-84 (Lai et al., 2008). 
 
Women in Europe had generally  moderate knowledge 
regarding osteoporosis (Alexandraki et al., 2008, Gemalmaz 
and Oge, 2007, Ungan and Tumer, 2001). However, they had 
poor knowledge in the risk factors of osteoporosis, and its 
consequences if left untreated (Alexandraki et al., 2008, 
Gemalmaz and Oge, 2007, Ungan and Tumer, 2001). 
Conversely, a Canadian study showed that elderly women 
appear to be aware of osteoporosis risk factors, but had 
knowledge deficits regarding the consequences of osteoporosis 
and the treatment available to prevent further bone loss 
(Cadarette et al., 2007). On the other hand, studies in the 
United States and Middle East showed that patients had a lack 
of knowledge in osteoporosis risk factors and preventive 
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behaviour (Ailinger and Emerson, 1998, Burke-Doe et al., 
2008, Baheiraei et al., 2005b). There was also a low level of 
osteoporosis knowledge in all areas for Australia (Winzenberg 
et al., 2003). Similarly in Asia, there were low levels of 
osteoporosis knowledge in all areas of osteoporosis such as 
the definition, risk factors, consequences of osteoporosis and 
treatment (Abdulameer et al., 2013, Yeap et al., 2010, Khan 
et al., 2014, Liza et al., 2009, Saw et al., 2003).  However 
there was one study conducted in Malaysia where osteoporotic 
women had moderate knowledge on osteoporosis. This may 
me because these women had already been counselled on how 
to take medications by pharmacists as part of standanrd 
healthcare and the questionnaire used in these study 
consisted of general questions to test whether patients knew 
how to take their medications (Lai et al., 2008). 
 
Additionally not only there is a lack of osteoporosis knowledge 
in patients but there is also a lack of osteoporosis knowledge 
in healthcare professionals (Guzman-Clark et al., 2007, 
Claesson et al., 2015, Chen et al., 2005) (Otmar et al., 2012, 
Jaglal et al., 2003, Duyvendak et al., 2011). These studies 
assessed the knowledge of primary care nurses (Guzman-
Clark et al., 2007, Claesson et al., 2015, Chen et al., 2005), 
primary care physicians (Otmar et al., 2012, Jaglal et al., 
2003, Duyvendak et al., 2011) and internal medicine specialist 
(Guzman-Clark et al., 2007),  
 
The lack of osteoporosis knowledge in healthcare professionals 
may cause some osteoporosis cases to be missed even after a 
fragility fracture (Kim et al., 2011). Additionally a lack of 
osteoporosis knowledge may lead to healthcare professionals 
prioritizing other diseases instead of osteoporosis (Otmar et 
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al., 2012, Claesson et al., 2015). Another study by Jaglal et al 
(2003) involving primary care physicians had similar issues 
(Jaglal et al., 2003). Their analysis revealed that primary care 
physicians lack a rational for BMD testing and were confused 
about the recommended management of osteoporosis (Jaglal 
et al., 2003). In another study, they have noted that the lack 
of knowledge, especially concerning the use of BMD-results 
may led to the under-treatment of the presented patients 
(Duyvendak et al., 2011). This leads us to the gap in 
osteoporosis managment which is discussed in the next 
section. 
 
1.1.14 Gaps in osteoporosis management 
Although treatment for osteoporosis are available, cost 
effective, well-tolerated and effective to reduce fracture risk, 
only approximately 20 percent of women who have an 
osteoporosis-related fracture receive either a bone mineral 
density test or a prescription for a drug to treat osteoporosis 
in the six months after the fracture (Cosman et al., 2014, 
National Committee for Quality Assurance, 2014, Hajcsar et 
al., 2000).  
 
Additionally, a systematic review by Giangregorio et al (2006) 
found that an osteoporosis diagnosis was reported in 1 to 45% 
of patients with fractures, laboratory test was ordered for 1-
49% and 1 to 32% of patients had bone density scans. As for 
calcium/vitamin D and pharmacological treatment was 
reported in 2-62% and 1 to 65% of patients, respectively. 
However fall assessments were not often reported 
(Giangregorio et al., 2006). This gap in the osteoporosis 
management is persistent as a more recent prospective 
observational study of >60 000 women aged ≥55 years 
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recruited from 723 primary care practices in ten countries, 
reported that less than 20% of women with new fractures 
received osteoporosis treatment (Greenspan et al., 2012). To 
further emphasize the gap, a province-wide study in Canada 
demonstrated that post-fracture diagnosis and treatment rate 
have not substantially changed between year 1996/1997 and 
2007/2008 (Leslie et al., 2011). 
 
A systematic review from Elliot-Gibson et al (2004) revealed 
that the reason the care gap exist and persist is multi-factorial 
in nature. They identified several issues: cost concerns 
relating to diagnosis and treatment, time required for 
diagnosis and case finding, concerns relating to polypharmacy 
and lack of clarity regarding where clinical responsibility 
resides (Elliot-Gibson et al., 2004). 
 
A systematic review by Ganda et al (2012) noted prevention 
measures and screening interventions to be cost effective and 
is able to slow down the progression of osteoporosis (Ganda et 
al., 2012). Therefore, prevention measures and screening 
which aid in early detection are the most effective and cost-
effective ways to slow down the progression of osteoporosis 
and reduce the number of hospital admittance due to 
osteoporotic fractures (Hajcsar et al., 2000, Cranney et al., 
2008, Davis et al., 2007, Richy et al., 2004a, Cooper et al., 
2011, Ganda et al., 2012). It is indeed a challenge to translate 
knowledge into practice and should be multifaceted with 
efforts directed at patient, provider and the healthcare system 
in order to achieve a variable success at the population level. 
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1.1.15 Strategies for multi-faceted approach 
towards an osteoporosis screening programme 
Early detection of osteoporosis can be conducted via screening 
of osteoporosis. Osteoporosis screening can be targeted at 
primary or secondary prevention. Primary prevention of 
osteoporosis is directed at identifying high risk non-
osteoporotic individuals without a prior fragility fracture and 
are asymptomatic. Secondary prevention of osteoporosis 
refers to the detection of the disease and prevention of 
subsequent fragility fracture. These are individuals who had 
atleast one fragility fracture  (Lundy and Janes, 2009).  
 
Additionally, osteoporosis screening can be conducted using 
BMD scans alone or identifying high risk individuals for BMD 
scans using various screening tools as highlighted in section 
1.1.8 and 1.1.9. However, screening the population using BMD 
test alone is not possible due to BMD tests being expensive 
and DEXA machines are not widely available. Due to this, 
patients are normally assessed for their osteoporosis risk 
before undergoing a BMD scan (International Osteoporosis 
Foundation, 2009).   
 
The most common risk factor used to stratify patients at high 
risk of osteoporosis is if a patient has had a history of fragility 
fracture. Therefore, most efforts in osteoporosis screening are 
targeted at secondary prevention as it has been found to be 
cost effective (Hajcsar et al., 2000, Cranney et al., 2008, 
Davis et al., 2007, Cooper et al., 2011).A systematic review 
by Little et al (2011) identified nine randomized controlled 
trials (RCTs) targeted at secondary prevention conducted by 
other healthcare professionals such as clinical researchers, 
physicians, orthopaedic surgeons and nurses to tackle 
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osteoporosis screening (Cranney et al., 2008, Majumdar et al., 
2008, Miki et al., 2008, Rozental et al., 2008, Davis et al., 
2007, Majumdar et al., 2007, Solomon et al., 2007, Feldstein 
et al., 2006, Gardner et al., 2005, Jaglal et al., 2012). These 
studies designed interventions to modify the behaviour of 
healthcare professionals or implement service delivery 
changes in osteoporosis management in the primary care 
setting. All of these interventions had similar components such 
as an education component, osteoporosis risk assessment and 
reminders (Cranney et al., 2008, Majumdar et al., 2008, Miki 
et al., 2008, Rozental et al., 2008, Davis et al., 2007, 
Majumdar et al., 2007, Solomon et al., 2007, Feldstein et al., 
2006, Gardner et al., 2005, Jaglal et al., 2012). This 
systematic review noted that although all interventions 
demonstrated a positive effect towards BMD scanning and 
osteoporosis treatment post fracture, only three were 
considered to be at low risk of bias (Little and Eccles, 2010, 
Miki et al., 2008, Cranney et al., 2008, Majumdar et al., 
2007). 
 
Further efforts have been made in year 2012 when the 
International Osteoporosis Foundation (IOF) launched a 
campaign called ‘Capture the Fracture’ (International 
Osteoporosis Foundation, 2012a, International Osteoporosis 
Foundation, 2012b). The aim of this campaign was to reduce 
the incidence of secondary fractures throughout the world by 
the establishment of a new standard of care for fragility 
fracture sufferers. Healthcare providers were urged to respond 
to the first fracture to prevent the second and subsequent 
fractures. It has been found that the most effective way to 
achieve this is through the implementation of coordinator-
based, post fracture models of care which includes 
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identification, assessment and treatment of patients at high 
risk for osteoporosis as part of the service. To date various 
model known as ‘Fracture Liaison Services’ have been 
conducted in the United Kingdom (McLellan et al., 2003, 
Wright et al., 2005, Clunie and Stephenson, 2008, Premaor et 
al., 2009, Wallace et al., 2011), Europe (Boudou et al., 2011, 
Huntjens et al., 2010) and Australia (Cooper et al., 2011, 
Inderjeeth et al., 2010, Lih et al., 2011). In Canada these 
services are called ‘Osteoporosis Coordinator Programmes’ 
(Bogoch et al., 2006)and in the US it is called the ‘Care 
Manager Programmes (Dell et al., 2008). Despite, the 
considerable progress made in terms of establishment of 
exemplar services in many countries (International 
Osteoporosis Foundation, 2012a), these services are currently 
only available in a very small proportion of facilities that 
receive fracture patient worldwide. These services are also the 
beginning of inclusion of secondary fracture prevention in 
national health policy (National Institute for Health and Clinical 
Excellence, 2012, Ström et al., 2011, Australian government, 
2006). However, many governments are yet to create the 
political framework to support funding of these new services. 
Additionally these services only target the population who 
have had a previous history of fractures.   
 
Due to this high risk patients with other risk factors or who are 
asymptomatic may be missed by efforts of secondary 
prevention. Therefore, there is a need to explore primary 
prevention using other methods such as using a risk 
assessment tools. A literature search revealed three RCTs 
targeting primary prevention conducted by pharmacists using 
a risk assessment tools to identify high risk patients to 
undergo the BMD scan. Each of these studies used a different 
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risk assessment method: the QUS and Canadian guideline risk 
factor checklist (Yuksel et al., 2010), risk assessment 
questionnaire (Crockett et al., 2008) and identifying patients 
who are using long term glucocorticoids (McDonough et al., 
2005). These studies did not analyze the cost effectiveness of 
the intervention in terms of fracture reduction but there was 
an increase in BMD scans, osteoporosis treatment or calcium 
intake (Crockett et al., 2008, Yuksel et al., 2010, McDonough 
et al., 2005). Nonetheless, evidence already exists for fracture 
reduction with many of the current osteoporosis medications 
in patient at hight risk for fractures (Koda-Kimble et al., 2009, 
Papaioannou et al., 2010). To date, there has been no 
prospective study that systematically screens all 
postmenopausal women. However, a retrospective study using 
4035 medical records of postmenopausal women ≥45 years 
suggest that primary prevention of osteoporosis using a risk 
assessment tool can be cost-effective (Richy et al., 2004a).  
 
Several guidelines have been developed based on expert 
opinion, cost effectiveness criteria, systematic reviews and/or 
predictive models. The U.S. Service Task force (U.S. 
Preventive Service Task Force, 2014), the National 
Osteoporosis Foundation (Cosman et al., 2014), the Malaysian 
Clinical Guidance and Management of Osteoporosis (Ministry 
of Health Malaysia, 2012) and the North American Menopause 
Society (The North American Menopause Society (NAMS), 
2010) suggests that all women ≥65 years should have a BMD 
scan and that women ≥50 should have a BMD scan based on 
their risk factor profile. Other guidelines such as the National 
Institute of Health (NIH) (NIH consensus development panel 
on osteoporosis prevention, 2001), The WHO task Force for 
osteoporosis (World Health Organization, 2004, Kanis, 2007), 
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the Canadian Medical Association (Papaioannou et al., 2010), 
and the National Osteoporosis Guideline Group UK(Compston 
et al., 2014) recommended selecting patients for BMD 
measurement based on particular risk factors.  
 
Additionally, the osteoporosis risk assessment tools such as 
the questionnaires and QUS does not harm the patients (Lim 
et al., 2011, Koh et al., 2001b, Weinstein and Ullery, 2000, 
Cadarette et al., 2000, Lydick et al., 1998, Michaëlsson et al., 
1996). The BMD scan is also a non invasive procedure 
(National Osteoporosis Foundation). As these test are not 
harmful, the benefits of preventing a fragility fracture 
outweighs the minimal risk pose by these test. Additionally, 
WHO has recommended that the use of clinical risk factors 
together with BMD provides a mechanism for the effective and 
efficient delivery of healthcare for individual at high risk of 
osteoporosis and the avoidance of unnecessary treatment to 
others (World Health Organization, 2004).  
 
1.1.16 Pharmacists’ role in osteoporosis 
management 
There is a growing body of literature supporting the roles of 
pharmacists in osteoporosis. Studies conducted in various 
settings around the globe have shown those pharmacists’ 
interventions improved adherence to osteoporosis medication. 
Some studies have also reported improvements in both clinical 
and economic outcome (Van Boven et al., 2014, Stuurman-
Bieze et al., 2014, George et al., 2010, Lai et al., 2013).  
 
Although, most pharmaceutical care services are mainly 
targeted at treatment of osteoporosis. A further literature 
search revealed that there are three randomized control trials 
 49 
 
(RCTs) conducted overseas by community pharmacies to 
evaluate the impact of pharmacist’s interventions on 
osteoporosis management (Yuksel et al., 2010, Crockett et al., 
2008, McDonough et al., 2005). However, two of these studies 
were considered biased (Elias et al., 2011). The study by 
Crockett et al had a high risk of both selection and information 
bias as self-reported assessment was used (Elias et al., 2011, 
Crockett et al., 2008). As for the study by McDonough et al 
the study suffered from a high risk of selection bias as the 
recruitment size and followed up differed between groups 
(Elias et al., 2011, McDonough et al., 2005). The third study 
by Yuksel et al demonstrated low bias in both aspects (Elias et 
al., 2011, Yuksel et al., 2010). Nonetheless, all three studies 
provided attestation that the intervention of pharmacists 
increased the number of patients that had their BMD tested 
and calcium intake initiated, indicating that pharmacists may 
have a role to play in reducing the gap in osteoporosis 
management (Yuksel et al., 2010, Crockett et al., 2008, 
McDonough et al., 2005). To date, there have been no studies 
on a pharmacist-led osteoporosis screening programme using 
the OSTA in Malaysia.  
 
1.1.17 The development of a pharmaceutical care 
service 
1.1.17.1 Definition of pharmaceutical care 
‘Pharmaceutical care is the responsible provision of drug 
therapy for the purpose of achieving definite outcomes that 
improve a patient’s quality’ (Hepler and Strand, 1990). The 
outcomes referred to in this definition are: cure of a disease, 
elimination or reduction of a patient’s symptoms, arresting or 
slowing a disease process; or preventing a disease or 
symptom (Hepler and Strand, 1990). On the other hand, 
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Barber (2001) argued that the outcomes measures refer to 
the patient’s clinical condition whereby the goals are stated in 
terms of disease. This led to the development of many other 
definitions (Barber, 2001). 
 
From a humanistic perspective, Cipolle, Strand and Morley 
proposed a definition of ‘Pharmaceutical care is a practice in 
which the practitioner take responsibility for a patient’s drug-
related needs and is held accountable for this commitment 
(Cipolle et al., 2004). This referred to pharmacists practicing 
in a patient-centred manner whereby pharmacists’ decision 
should be made based upon the wants and needs of the 
patients, who may have specific drug-related needs. 
Pharmaceutical care should be part of a pharmacists’ daily 
activity in addition to the traditional role of purchasing and 
dispensing medications. 
 
1.1.17.2 Practice of pharmaceutical care in Europe 
and other developed countries 
In the European setting, pharmaceutical care is seen to be the 
professional care for the individual patient in a pharmacy 
(Foppe van Mill et al., 2004). Pharmacists were to counsel 
individual patients about medication. This concept also 
includes medication surveillance, counselling and evaluation of 
all the outcomes of care.  
 
Although there are various definitions, pharmaceutical care is 
generally the philosophy behind pharmacy practice in many 
countries across the globe (Foppe van Mill, 2004). There are 
various terminologies used to describe pharmacy services that 
embrace the concept of pharmaceutical care. An example 
would be from the United States, they use a term called 
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medication therapy management (MTM) services which refers 
to a strategy to incorporate the philosophy of pharmaceutical 
care into everyday pharmacy practice for a defined patient 
population of patients with certain diagnosis (McGivney et al., 
2007, Pellegrino et al., 2009). 
 
1.1.17.3 Practice of pharmaceutical care in Malaysia 
In Malaysia pharmaceutical care services are provided but are 
referred to as Medication Therapy Adherence Clinic (MTAC) by 
the Malaysian Ministry of Health. MTACs are normally provided 
in public hospitals (Lim and Lim, 2010). Aside from MTAC, the 
concept of pharmaceutical care is also embedded in other 
clinical pharmacy services that are being provided in hospitals 
and community pharmacist in Malaysia. 
 
1.1.17.4 Pharmaceutical care research 
There is a need for an increase in pharmaceutical care 
research with its expansion to tackle a range of disease 
management. Pharmaceutical care research falls under the 
category of health services research. However, research in this 
area is context specific as it depends on the local health care 
system.  
 
Foppe van Mill et al (2004) has suggested that it is vital to 
first conduct a needs assessment study as the first phase in 
developing a pharmaceutical care service. A needs assessment 
refers to basic research which tries to identify the types of 
pharmaceutical care required in a given patient which will 
eventually lead to the development of a proposal for a 
pharmaceutical care intervention. The second phase refers to 
impact assessment which investigate whether the provision of 
pharmaceutical care improves the patients’ clinical, humanistic 
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and economic out comes. It has been found that most 
pharmaceutical care studies focus on the second phase of the 
research in determining whether the intervention has led to 
the expected outcomes. This lacks consideration or 
explanation given to the mechanisms by which those 
outcomes are mediated. An example of this  is that the there 
is an assumption that the intervention worked as planned; 
that the pharmacists were comfortable with their new roles; 
that patients welcomed the service and that the necessary 
collaboration with other health care professionals had taken 
place. However, in reality there may be many barriers that 
hinder the provision of service. Due to this there is a need to 
understand the components that are most likely to affect the 
provision of the pharmaceutical care prior to finalizing the 
design of the pharmaceutical care intervention or in evaluating 
the outcome of the service. 
 
Various factors contribute to the success of pharmaceutical 
care delivery and it is difficult to measure specific outcomes. 
This shows that pharmaceutical care is a ‘complex 
intervention’ (Tulip and Campbell, 2001, Medical Research 
Council, 2008). Some pharmaceutical care may involve the 
need to improve therapeutic outcomes while other 
components may work through psycho-social or behavioural 
modification in an individual patient through patient education 
and counselling (Wong, 2004). Further examples of this is that 
some components have an organisational nature whereby 
inter-professional communication between pharmacists, 
physicians and other health care professionals is important in 
the delivery of pharmaceutical care (Wong, 2004). This shows 
that pharmaceutical care interventions are multifaceted in 
nature. 
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1.1.18 Theoretical framework (United Kingdom 
Medical Research Council framework) 
A complex intervention as defined by the UK Medical Research 
Council (MRC) is “interventions comprising of separate 
elements which seem essential to the proper functioning of 
the intervention although the active ingredient is difficult to 
specify (Medical Research Council, 2000). Not only the number 
of elements in the intervention package are complex, there 
are other dimensions of complexity which includes the range 
of possible outcomes the behavioural differences of those 
delivering and receiving the intervention and the variability in 
the target population (Craig et al., 2008).The active 
ingredients of pharmaceutical care may consists of difference 
elements such as the pharmacist’s personality and expertise, 
skills, patient characteristics and behaviours, inter-
professional relationship and organisational culture. Therefore 
research in pharmaceutical care should consider these 
elements (Tulip and Campbell, 2001). 
 
The UK Medical Research Council‘s (MRC) Framework of 
developing and evaluating complex interventions was 
designed to improve healthcare services making it applicable 
to the field of pharmacy practice (Medical Research Council, 
2008). Therefore, the current study will adopt this conceptual 
framework. The framework provides a flexible guideline which 
assists in developing a practical complex intervention (Medical 
Research Council, 2008). Complex interventions are 
interventions that contain various interconnecting 
components. There are four key elements of the MRC 
Framework [Figure 1.2] (Medical Research Council, 2008). 
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Figure 1.2: Key elements of the development and evaluation process 
 
 
  
 
 
 
 
 
 
 
  
Development 
1. Identifying the evidence base 
2. Identifying/developing theory 
3. Modeling process and 
outcome 
Evaluation 
1. Assessing effectiveness 
2. Understanding change process 
3. Assessing cost-effectiveness 
Implementation 
1. Dissemination 
2. Surveillance and monitoring 
3. Long term follow-up 
Feasibility/piloting 
1. Testing procedures 
2. Estimating recruitment/retention 
3. Determining sample size 
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1.1.19 Developing a complex intervention 
The first step of the MRC framework is identifying the evidence 
base by carrying out a literature review or a systematic review 
(Medical Research Council, 2008). This will then allow for the 
identification or development of relevant theories resulting in 
a more effective intervention (Medical Research Council, 
2008). The next step involves modelling of the process and 
outcomes which requires an understanding of a particular 
intervention and its possible effects (Medical Research Council, 
2000).  Modelling prior to a full scale evaluation will assist in 
providing information about the intervention design such as 
identifying weaknesses that may lead to refinements of the 
design (Medical Research Council, 2008). In this study, 
qualitative methods such as in depth interviews were 
employed to explore stakeholders’ perspective in osteoporosis 
prevention as well as the feasibility to providing a pharmacist 
assisted osteoporosis screening programme. With this data, 
we developed and validated tools pertaining to patients’ 
knowledge of osteoporosis and satisfaction towards the 
pharmacist screening programme.  Additionally, we validated 
various osteoporosis risk assessment tools. These tools will be 
used in the complex intervention. 
 
1.1.20 Assessing feasibility and piloting methods 
The feasibility and piloting stage involves testing procedures 
for their acceptability, estimating likely rates of recruitment 
and retention, and the calculation of appropriate sample size 
(Medical Research Council, 2008). This may include both 
quantitative and qualitative methods (Medical Research 
Council, 2008). With regards to this study the feasibility of 
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providing a pharmacist assisted osteoporosis screening 
programme was examined.  
 
1.1.21 Evaluating a complex intervention 
All aspects of this stage should be tested in the previous 
stages and the complex intervention should have considered 
randomisation, appropriate outcomes, adequate statistical 
power, informed consent and other standard features of well-
designed trials (Medical Research Council, 2008, Medical 
Research Council, 2000). The next stage is the understanding 
processes where a process evaluation nested within the trial 
can be used to assess reason for intervention failure, fidelity 
and quality of implementation, clarify causal mechanism and 
identify contextual factors associated with variation in 
outcomes (Medical Research Council, 2008). In addition, an 
economic evaluation should be included if possible to ensure 
that the cost of the study is justified by the potential benefits 
of evidence it will generate (Medical Research Council, 2008).  
However this phase is beyond the scope of this PhD project. 
Nonetheless, it will provide data that will facilitate future work 
concentrating in the implementation of a randomized control 
trial of a pharmacist assisted osteoporosis screening 
programme. 
 
1.1.22 Implementation and beyond 
The last stage of the complex intervention is dissemination 
which is getting the evidence translated into routine practice 
or policy (Medical Research Council, 2008). Although 
surveillance, monitoring and long term outcomes of complex 
interventions are uncommon, it is necessary to determine 
whether the short term changes persist and whether the 
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benefits previously documented can be sustained (Medical 
Research Council, 2008).  
 
1.1.23 The problem statement 
The World Health Organization projects that the worldwide 
rate of hip fractures cases due to osteoporosis will rise from 
1.7 million in 1990 to 6.3 million by 2050 with a steep 
increase to be observed in developing countries(World Health 
Organization Geneva, 1999). Correspondingly, Cooper et al 
projected that 51.1% of osteoporotic fractures will occur in 
Asia by year 2050, which is a 19.9% increase as compared to 
year 1990(Cooper et al., 1992). In Malaysia, the prevalence of 
osteoporosis is 24.1% (Lim et al., 2005).  
 
Due to the asymptomatic nature of osteoporosis, women who 
have osteoporosis are often not aware that they are at an 
increased risk of sustaining a fracture(International 
Osteoporosis Foundation, 2009). Fractures are costly to treat, 
increase morbidity and mortality(International Osteoporosis 
Foundation, 2009, Ministry of Health Malaysia, 2012). In 
1997, hip fractures cost about RM 22 million (£3.35 million) to 
treat. This figure however does not include the costs incurred 
in rehabilitation and long term nursing care(Ministry of Health 
Malaysia, 2012). Hip fractures are also associated with a 
reduction in quality of life. Up to 20% will die within two years 
as compared to those who do not sustain fractures (Koh, 
2007). Therefore, prevention measures and screening which 
aid in early detection are the most cost-effective ways to 
reduce the number of hospital admittance due to osteoporotic 
fractures (Hajcsar et al., 2000, Cranney et al., 2008, Davis et 
al., 2007, Richy et al., 2004a, Cooper et al., 2011, Ganda et 
al., 2012). 
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Currently, there is no osteoporosis screening programme or 
fracture liaison services available in Malaysia. As the Malaysian 
healthcare system is not integrated between different 
hospitals and clinics, it is difficult to obtain patients’ complete 
fracture history. Therefore, this study focused on osteoporosis 
screening targeted at primary and secondary prevention using 
an osteoporosis risk assessment tool.  
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1.1.24 Rationale for study 
The lack of an osteoporosis screening needs to be addressed  
in Malaysia . Therefore, this calls for the development of a 
pharmaceutical care service intervention to tackle the lack of 
an osteoporosis screening program. It is envisaged that this 
study could contribute to the body of knowledge in relation to: 
- Policy makers, doctors, pharmacist, nurses and patients 
perception towards an osteoporosis screening 
programme 
- Development of the osteoporosis screening programme 
and various tools needed for the intervention. 
- The role of the pharmacist in the management of 
osteoporosis  
 
1.1.25 How did I become interested in the topic? 
I graduated with a Master of Pharmacy in 2008. Subsequently 
I worked as a clinical pharmacist in a tertiary hospital, the 
University Malaya Medical Centre (UMMC). There I 
coincidentally met one of my co supervisors (Dr Pauline Lai) 
while getting lost in one of the hospital’s back stairs. I 
remembered this incidence in particular as she was telling me 
about her research on osteoporosis and how exciting research 
can be. This further confirmed my interest on doing some 
research of my own. 
 
The following year I worked at a primary care clinic in a 
suburban area called Kuala Langat.  I conducted many home 
visits and noticed that there were numerous patients who 
were bed ridden due to a fracture. However, no action was 
conducted to investigate for osteoporosis. At that time, 
facilities for a bone mineral density scan (BMD) was limited in 
this area. Hence, I decided to look back at my old work place 
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UMMC where the BMD was available. Similarly to the suburban 
areas, investigations of fragility fractures were still low. 
Timely, I was awarded a scholarship after approaching 
another of my co supervisors (Associate Professor Mr Wong) 
from the University of Nottingham. Numerous discussions took 
place for tackling the gap in the current osteoporosis 
management from primary prevention, treatment to inpatient 
care. We finally decided that secondary prevention in primary 
care would be the best place to start in addressing the gap. 
Hence my journey for a PhD began.   
 
1.1.26 Organization of study 
This thesis is divided into five chapters. The current chapter 
provides a description on osteoporosis. Subsequently, it 
discusses the concept of pharmaceutical care and complex 
intervention. Then, it presents the literature review on the 
gaps in osteoporosis management, interventions by healthcare 
professionals, role of pharmacists in osteoporosis 
management. It then presents the rationale for the study and 
how I became interested in this issue.It ends with the 
presenting the aim and objectives of the study. 
  
Chapter 2 describes the methodology underpinning phase 
one.  It describes the qualitative methods that were chosen 
and how validity and reliability can be assessed. It illustrates 
the data collecting process and methods of analysis in detail. 
It then presents and discusses the findings for the three 
research questions. 
  
Chapter 3 describes the methodology and methods used in 
phase two study. It provides the explanation on what tools 
were needed for the screening programme, detailing on the 
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development and validation process of the tools. The chapter 
also explains the development of the intervention package for 
the pharmacist-led osteoporosis screening programme.  
 
Chapter 4 describes the methodology and methods used in 
phase three study. It discusses the feasibility of the 
pharmacist-led osteoporosis screening programme, 
highlighting the factors for improvement. 
 
Chapter 5 summarises the overall findings and concludes 
with the implications for practice, policy and research. 
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1.1.27 Aims and objectives 
1.1.27.1 Aims 
To develop a pharmacist-led osteoporosis screening 
programme. 
 
1.1.27.2 Objectives 
- To identify the barriers and facilitators of conducting an 
osteoporosis screening programme  
- To explore the pharmacist role in osteoporosis screening 
- To develop the intervention package for the pharmacist-
led osteoporosis screening programme 
- To develop and validate a tool to assess the satisfaction 
of patients’ towards the pharmacist-led osteoporosis  
screening programme 
- To develop and validate a tool to assess the awareness 
and knowledge of osteoporosis in Malaysian 
postmenopausal women 
- To validate and compare various osteoporosis risk 
assessment tools in a Malaysian setting 
- To assess the feasibility of the pharmacist-led 
osteoporosis screening programme 
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2     CHAPTER 2: PHASE ONE: A 
QUALITATIVE STUDY EXPLORING 
THE PERSPECTIVES OF NURSES, 
DOCTORS, PHARMACISTS, 
PATIENTS AND POLICY MAKERS 
REGARDING AN OSTEOPOROSIS 
SCREENING PROGRAMME IN 
MALAYSIA  
2.1   Introduction 
In order to understand the relevant stakeholders’ views of 
osteoporosis screening, we had three research questions:   
- What are the barriers and facilitators encountered by 
nurses, doctors, pharmacists, patients and policy makers 
regarding an osteoporosis screening programme?  
- Can Malaysian pharmacists expand their non-dispensing 
role in an osteoporosis screening? 
- What are the components for an acceptable, practical 
and sustainable osteoporosis screening programme? 
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2.2   Aim 
To identify the problems and needs of postmenopausal women 
as well as the views of policy makers, pharmacists, doctors 
and nurses in osteoporosis screening.  
 
2.3   Objectives 
The specific objectives of phase one were to: 
- Understand the barriers and facilitators encountered by 
nurses, doctors, pharmacists, patients and policy makers 
regarding an osteoporosis screening programme 
- Explore the current pharmacists’ role and the expansion 
of their non-dispensing role in osteoporosis screening 
- Identify the components for an acceptable, practical and 
sustainable osteoporosis screening programme 
 
Phase one was divided into three sections to answer the above 
objectives. 
 
  
 65 
 
2.4   What are the barriers and facilitators 
encountered by nurses, doctors, pharmacists, 
patients and policy makers regarding an 
osteoporosis screening programme? 
2.4.1 Methods 
To date, there is no existing population-based osteoporosis 
screening programme in Malaysia. A lack of reported evidence 
on stakeholder’s perception on osteoporosis screening 
programme in Malaysia noted that there was a need to 
explore these issues in Malaysia. Hence, a qualitative research 
approach using in-depth interviews was chosen for this phase.  
 
2.4.1.1 Study design 
A qualitative research design was used as there were no prior 
information about the barriers and facilitators towards an 
osteoporosis screening programme in Malaysia. Qualitative 
interviews are the most commonly employed approach in 
health and pharmacy practice research (Smith, 2002). It 
enables the researcher to discover what people think of the 
world they live in, to evaluate their experience and to uncover 
why they behave the way they do (Murphy et al., 1998). As 
stated by Murphy and colleagues “If you want to understand 
what people do, believe and think, ask them.”  
 
2.4.1.2 Setting 
The study was conducted at the primary care clinics of the 
University Malaya Medical Centre (UMMC), Kuala Lumpur, 
Malaysia.   
 
2.4.1.3 Period of study 
Data collection occurred from October to December 2012. 
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2.4.1.4 Participants 
2.4.1.4.1 Patient group 
Included were English or Malay speaking postmenopausal 
women aged ≥ 50 years old who have not been diagnosed as 
osteopenia/osteoporosis. Excluded were those not well enough 
to participate in the study. 
 
2.4.1.4.2 Healthcare professional group 
2.4.1.4.2.1 Nurses 
Included were registered nurses working at the primary care 
or osteoporosis clinic, UMMC and with more than one year of 
working experience. Excluded were nurses from other 
departments.   
 
2.4.1.4.2.2 Pharmacists 
Included were out patient pharmacists from the UMMC with 
more than one year of working experience. Excluded were 
pharmacists undergoing internship.  
 
2.4.1.4.2.3 Doctors 
Included were doctors with more than one year of working 
experience in the primary care clinics. Excluded were year one 
clinical master candidates as they were not on site. 
 
2.4.1.4.2.4 Policy makers 
Policy makers in our study were individuals who have the 
authority to influence the practice of the primary care clinic. 
We planned to recruit the head of the primary care clinic, head 
of the outpatient pharmacy, head of the store pharmacy, the 
chief pharmacist, head of in-patient pharmacy, matron, chief 
executive officer (CEO) of the hospital and deputy CEO of the 
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hospital were recruited. Excluded were policy makers from 
departments not related to activities in the primary care clinic.  
 
2.4.1.5 Sample size 
It is not required for qualitative research to have a large or 
statistically representative sample which is the norm for 
quantitative research (Bowling, 2009). Qualitative samples are 
concerned with the ‘richness’ of the data to increase our 
insight into a specific research question. Hence the samples 
recruited are generally small (Bowling, 2009). Nevertheless, it 
is important to have an effective sampling strategy in 
qualitative research. 
 
2.4.1.6 Qualitative sampling 
In relation to the selection of participants for interviews, a 
variety of sampling techniques have been described in the 
literature (Smith, 2002). These include purposive sampling, a 
technique where participants selected are believed to have 
particular characteristics relevant to the research. 
Convenience sampling involves selecting participants based on 
ease of accessibility or willingness to participate in the study. 
Snowballing involves asking participants to suggest others 
whom they know are in the target group and who could be 
invited to take part in the study (Bowling, 2009). 
 
In this study, we wanted to explore the views and experiences 
of patients, pharmacists, nurses, doctors and policymakers 
towards conducting an osteoporosis screening programme at 
the primary care clinic. Hence, purposive and snowballing 
sampling strategies were adopted. Purposive sampling was 
used to select non-osteoporotic post menopausal women ≥50 
years of age from the three main ethnics groups (the Malays, 
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Chinese, and Indians) in Malaysia. Initially, it was not intended 
to recruit patients using the snowballing method. However, 
many patients of Malay ethnicity declined participation. We 
then asked participants to recommend potential participants of 
Malay ethnicity.  Therefore, in order to gain access to the 
Malay population we employed the snowballing method.  
 
Purposive sampling was also used to recruit nurses, doctors 
and pharmacists. Nurses from the primary clinic with more 
than one year of working experience in the primary clinic were 
selected. We interviewed these nurses as they were involved 
with patient registration, screening and their medical records. 
These nurses provided information on the workflow of the 
clinic in general.  
 
Similarly, doctors with more than one year of working 
experience in the primary clinic were selected using purposive 
sampling. The doctors were interviewed as they were involved 
with examining the patients. The information they provided 
allowed us to understand how osteoporosis could be 
incorporated into the consultations.  
 
Pharmacists were also selected using purposive sampling. The 
outpatient pharmacy department was divided into four 
departments namely the main outpatient department, 
PharmCare which is the dispensary for long term medication 
patients, retail pharmacy and specialist item pharmacy. 
Pharmacist with at least one year of working experience in the 
outpatient pharmacy was selected.  Pharmacists were 
interviewed as the patients would visit the pharmacy for their 
medications after their doctor’s visit. The pharmacists were 
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able to provide information on the final stage of the patients’ 
visit to the primary care. 
 
We selected healthcare professionals with more than one year 
of working experience in the primary care clinic as they would 
have sufficient working experience and understanding of the 
primary care clinics barriers, facilitators and management 
issues.  
 
As for policy makers, it was not possible to obtain thematic 
saturation as we were only able to identify eight policy makers 
that would contribute to our data. Therefore, policy makers 
who were believed to be able to produce ‘rich’ information 
were approached and recruited for in-depth interviews. We 
included the head of the primary care clinic as this 
participants’ view would represent the views of the primary 
care doctors at a management level.  We also included the 
head of the outpatient pharmacy, head of the store pharmacy, 
the chief pharmacist, head of in-patient pharmacy as they 
were all involved in the policy in medication purchasing. 
However, the matron, the CEO of the hospital and deputy CEO 
did not response to the invitation to participate in this study. 
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2.4.1.7 Instruments used 
2.4.1.7.1 Baseline demographics 
Baseline demographic information such as patients’ medical 
history, lifestyle and medication history was collected 
(Appendix 1). Healthcare professionals’ baseline information, 
work experience and education level were also collected 
(Appendix 2). 
 
2.4.1.7.2 Topic guide 
Three topic guides were developed to assist in the interviewing 
process: for patients (Appendix 3), healthcare professionals 
(nurses, pharmacists, doctors- Appendix 4) and policy makers 
(Appendix 5). Although all three topic guides essentially follow 
the same questions, each question was phrased according to 
the perspective of the targeted group. Additional questions 
were added for policy makers with regards to budgeting. In 
addition, questions regarding the experiences towards 
osteoporosis were removed for policy makers.  
 
The topic guides were developed based on literature search as 
well as discussion with an expert panel involving a consultant 
endocrinologist and four pharmacists with many years of 
research and clinical experience. A pilot test was then 
conducted with three individuals (one for each topic guide) to 
fine tune the topic guide.  
 
Translation of the topic guide for patients (Appendix-6) and 
healthcare professionals (nurses, pharmacists, doctors- 
Appendix 7) to Malay was performed as some interviews were 
conducted in Malay. Translation from English to Malay was 
performed by a pharmacist was also a native Malay speaker. 
The Malay version was translated back to English by another 
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pharmacist who understood both English and Malay. 
Differences were discussed with the researcher until a final 
Malay version was developed.    
 
2.4.1.8 Data collection 
2.4.1.9 Interview type 
Qualitative interviews are commonly referred to as being 
structured, semi-structured or unstructured (Smith, 2002). 
Semi-structured and unstructured interviews may be referred 
to collectively as in depth interviews (Bryman, 2004). 
Structured interviews are conducted with the researcher 
having a pre-defined set of questions limiting the response of 
the participants (Bryman, 2004).  In contrast, an unstructured 
interview is conducted with the researcher using at most a 
brief set of prompts to deal with a certain range of topic and 
allowing the participant to answer freely (Bryman, 2004). 
 
The semi structured approach is one where the researcher has 
a list of questions or fairly specific topics to be covered and 
this is often referred to as an topic guide (Bryman, 2004). 
However, there is still a great deal of leeway on how 
participants can reply. It is also not necessary for the 
questions to be asked in the exact order as outlined by the 
topic guide and additional questions may be added for probing 
new emerging topics (Bryman, 2004, Bowling, 2009). This 
method allows for a fairly clear focus on the interview topic 
while allowing the participant to raise issues of personal 
relevance or concern (Bryman, 2004). The semi-structured in-
depth interview was deemed the most appropriate method for 
this study based on these reasons.  
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Interviews can be conducted individually or in a group 
(Bryman, 2004). The latter, a group discussion or ‘focus 
groups’ has the advantage of exploring the dynamics of 
communication between the research participants (Bryman, 
2004). However, individual in-depth interviews were chosen 
for this study as they enable individual respondents’ 
perspectives to be explored in more detail as compared to 
using a focus group (Smith, 2002). Therefore, the discussion 
here focuses on issues pertaining to individual interviews. 
 
2.4.1.10 Interview location  
Eight patients were interviewed in a quiet location (e.g. an 
unused doctor’s room, conference room or seminar room) that 
was suitable for an interview within the clinic setting. The 
other 12 patients were interviewed in their homes. All health 
care professionals and policymakers were interviewed in their 
respective offices or in the seminar room located at the 
primary care clinic except for one who chose to be interviewed 
in his home. 
 
2.4.1.11 Procedure 
Patients were recruited while they were waiting for their 
doctors’ appointment. To ascertain that patients were not 
diagnosed with osteoporosis/osteopenia, the patients’ medical 
notes were checked. A patient information sheet in English of 
Malay depending on preference (Appendix 8 and 9) was 
provided to selected patients. The purpose of the study and 
the process of the interview were explained to the participants 
using the research information sheet. Upon agreement to 
participate in the study, participant’s written consent 
(Appendix 10 and 11) was obtained and permission to audio-
record was sought. Demographic data were also collected 
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from each participant. They were also reminded that the 
information collected was strictly confidential and that they 
were not obliged to respond to any questions they were not 
comfortable with. They were also informed that they can 
withdraw from the study without giving a reason and that it 
would not affect their hospital care. It is hoped that this 
process would be able to provide the participants with a 
comfortable environment in order to encourage them to speak 
freely. 
 
Depending on the patients’ preference, the interview was 
conducted on the same day or at another time convenient to 
them. Patient recruitment and interview continued until new 
themes ceased to emerge. This was achieved after 
interviewing 20 patients.  
 
Similarly, the nurses, doctors, pharmacists and policy makers 
identified. An information sheet in English of Malay depending 
on preference of the nurses (Appendix 12 and 13) was 
provided to patients identified. For the other healthcare 
professionals and policy makers only the English version of the 
information sheet was available (Appendix 14, 15 and 16). 
The purpose of the study and the process of the interview 
were then explained to the participants using the research 
information sheet. Upon agreement to participate in the study, 
participant’s written consent (Appendix 17-21) was obtained 
and permission to audio-record was sought. 
 
All patient, healthcare professional and policy maker 
interviews were conducted by the researcher (TLS), except for 
one patient interview where an experienced qualitative 
researcher (SO) conducted the interview. This was performed 
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as a teaching session for the novice researcher (TLS). In 
addition, for three policy maker interviews, one of the 
researcher’s supervisors (a senior pharmacist and previously a 
policy maker himself) assisted (WKT).  Refreshments were 
provided after each interview session with the patients, 
healthcare professionals and policy makers. 
 
The researcher is bilingual and is able to speak English and 
Malay fluently. Sixteen patient interviews were conducted in 
English, two were conducted in both English and Malay, and 
two were conducted in Malay. Eight nurse interviews were 
conducted in both English and Malay, whilst two were 
conducted in English. Nine pharmacist interviews were 
conducted in English, whilst two were conducted in both Malay 
and English. Four doctor interviews were conducted in English, 
whilst six were conducted in both Malay and English. Lastly, all 
five interviews with the policy makers were conducted in a mix 
of English and Malay. 
 
2.4.1.12 Theoretical framework: Framework of factors 
influencing clinical practice 
Generally in healthcare, human error is routinely blamed for 
clinical incidents. However, these quick judgments obscure a 
more complex truth. A closer analysis usually reveals a series 
of events and departure from safe practice, each influenced by 
the working environment and the wider organizational context 
(Vincent et al., 2000).  
 
We used the protocol for the investigation and analysis of 
clinical incidents for our analysis, as it ensures a systematic, 
comprehensive, and efficient investigation of incidents, to 
generate ways of assessing risk and to focus research on the 
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causes and prevention of adverse outcomes. This protocol 
uses the framework of factors influencing clinical practice  to 
guide the analysis regarding the lack of a population based 
screening programme in a primary care clinic in Malaysia  
(Vincent et al., 2000, Vincent et al., 1999). Figure 2.1 
summarizes the adapted investigation process (Vincent et al., 
1999). 
 
  
 76 
 
Figure 2.1: The adapted investigation process based on the 
protocol for the investigation and analysis of clinical incidents 
 
 
 
 
 
 
 
 
 
  
Collate the interviews and assemble a composite analysis under each of the 
CMPs identified at the start. For each CMP identify both specific and, where 
appropriate, general contributory factors. 
 
Interview staff using the structured approach: 
- Establish the chronology of events. 
- Revisit the sequence of events and ask questions about each of the 
clinical management problems identified at the initial stage 
- Use the framework to ask supplementary questions about the reasons 
for the occurrence of each clinical management problem. Record each 
CMP and its contributory factors. 
 
Investigators will establish the circumstances as they initially appear and 
complete an initial summary. Decide which part of the process of care 
requires investigation and prepare an outline chronology of events.  Identify 
any obvious Care Management Problems (CMPs)  
 
Trigger the investigation procedure. 
 
Identify a serious clinical incident or an incident as being fruitful in terms of 
organisational learning. 
 
Implement the action arising from the report and monitor progress. 
Submit report to senior clinicians and management according to local 
arrangements. 
 
Compile the report of the events, listing the causes of the CMPs and make 
recommendations to prevent recurrence. 
. 
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Normally the protocol is used on a single clinical incident case. 
As there was no population based osteoporosis screening in 
our setting, we used the framework to investigate the lack of 
osteoporosis screening in the primary care clinic as a single 
case. The framework consists of seven main factors 
influencing clinical practice as shown in Table 2.1 (Vincent et 
al., 1999). The seven main factors are: governmental, 
organizational and management, work environment, team, 
task, individual and patient. The term “institutional context” 
was modified to “governmental context” as our setting is 
managed by the ministry of higher education. 
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Table 2.1: Framework of factors influencing clinical practices 
FACTOR TYPES  INFLUENCING 
CONTRIBUTORY FACTORS 
Governmental Factors Economic and regulatory context 
National health service executive 
Clinical negligence scheme for 
trusts 
Organisational and Management 
Factors 
Financial resources & constraints 
Organisational structure 
Policy standards and goals 
Safety culture and priorities 
Work Environment Factors Staffing levels and skills mix 
Workload and shift patterns 
Design, availability and 
maintenance of equipment 
Administrative and managerial 
support 
Team Factors Verbal communication 
Written communication 
Supervision and seeking help 
Team structure (congruence, 
consistency, leadership) 
Individual Factors Knowledge and skills 
Competence 
Physical and mental health 
Task Factors Task design and clarity of 
structure 
Availability and use of protocols 
Availability and accuracy of test 
results 
Patient Factors Condition (complexity & 
seriousness) 
Language and communication 
Personality and social factors 
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The clinical incident investigated in this study was fractures 
due to undiagnosed osteoporosis. The first step in the 
investigation using the protocol was to identify the Care 
Management Problem (CMP). CMPs were active failures, 
unsafe acts or omissions which can have a direct of indirect 
effect on the eventual adverse outcomes for the patients. We 
identified the Care Management Problem (CMP) as failure to 
screen for osteoporosis. Figure 3.2 below demonstrates the 
chronology of events for a patient who visits the primary care 
clinic for a regular follow up appointment. Based on the Figure 
2.2 we noted that several stakeholders were involved in this 
process: namely the nurses, doctors and pharmacists. We 
then conducted in-depth interviews with these stakeholders, 
as well as patients and policy makers.  
 
Various factors contributing to the incident was identified. 
However, a further distinction between specific contributory 
factors and general contributory factors was needed. Specific 
contributory factor refer to factors that are relevant on a 
particular occasion whereas a general contributory factor 
refers to a factor that is quite frequent with more general 
implications. As our study investigated the primary care 
setting as a whole all factors identified were general 
contributory factors. Additionally, if a new CMP were to 
emerge during the interview it will be noted but would not be 
explored as it is beyond the scope of this study. Our study did 
not encounter new CMPs. 
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Figure 2.2: Chronology of events for a patient who visits the 
primary care clinic for their regular follow up appointment  
 
 
  
Patient A arrives at the 
hospital and registers to 
see the doctor at the 
triage counter. Staff 
involved nurses. 
Patient A waits for his/her 
turn to see the doctor. 
Patient A sees the doctor. 
Staff involved doctors and 
nurses.  
Patient A makes an 
appointment for the next 
doctor’s visit. Staff 
involved clerks. 
Patient A collects 
medications from the 
outpatient pharmacy. 
Staff involved 
pharmacists. 
Waiting 
time 10 
minutes- 
1 hour 
Waiting 
time ~1-
3 hours 
Consultat
ion time 
~15-30 
minutes  
Waiting 
time 10-
15 
minutes 
Waiting 
time 30 
minutes- 
2 hours  
(Time) 
0700 
1000 
1100 
High risk 
patients 
not 
identified 
 
High risk 
patients 
not 
identified 
 
High risk 
patients not 
identified 
 
Failure to 
screen for 
osteoporo
-sis 
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2.4.1.13 Data management 
Interviews were audio recorded using a digital interview 
recorder. The audio files were downloaded to a personal 
computer and played using the Sony Memory stick Voice 
editor, to “slow” conversations, in order to facilitate 
transcribing. 
 
2.4.1.14 Field notes 
After each interview, the researcher jotted down field notes in 
a notebook. Feelings during the interview and main themes of 
the interviews were noted. This was referred to during data 
analysis as it assisted in highlighting immediate emerging 
themes. 
 
2.4.1.15 Transcripts 
All audio-recordings were transcribed verbatim. The first ten 
recorded interviews were transcribed by the researcher. 
Subsequent recordings were transcribed by undergraduate 
science students or pharmacists. In order to ensure that the 
data was rigorous and trustworthy, the transcripts performed 
by the researcher were checked by another pharmacist who 
was fluent in both languages. The transcripts performed by 
the undergraduate students or pharmacist were checked by 
the researcher for accuracy and completeness. All transcripts 
were offered to each interviewee to check for accuracy but 
they all declined.  
 
2.4.1.16 Translations 
Translation for this study is defined as the transfer of meaning 
from a source language (Malay) to a target language (English) 
(Esposito, 2001). It must be acknowledged that there is 
potential for intentional and unintentional modification of the 
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data through mistranslation, partial omission of 
oversimplification which is unavoidable during translation 
(Escott and Walley, 2005). However, the reliability of the 
translation to reflect the participants’ intended response will 
influence the validity of the data (Escott and Walley, 2005). 
For this study, the translations were meant to capture the 
meaning of the statements, rather than giving a literal 
translation (Esposito, 2001). For example, a Malay participant 
was asked about the reasons why people do not care about 
osteoporosis, she mentioned “Sebab tak kena kat batang 
hidung.” This can be translated to ‘Because we, ourselves did 
not suffer from osteoporosis’ and if this were to be literally 
translated from Malay it would be “Because we did not get it 
at the stick of our nose.” 
 
Based on Twinn et al recommendations all non-English 
transcripts were translated to English by one person (the 
researcher) to ensure consistency and reliability (Twinn, 
1997). Consequently, the translation took a large amount of 
time taking nearly two to three hours to translate one page 
(Squires, 2008). Nonetheless, this was necessary as one of 
my supervisors was British (CA) and does not speak or 
understand Malay. Several factors may affect the quality of 
the translation. This includes the linguistic competency of the 
translator and the translator’s knowledge of the people and 
environment under study (Wild et al., 2005). The researcher 
was a suitable choice as she was fluent in both languages and 
has previously worked in hospital understudy as a pharmacy 
intern. 
 
Some researchers may suggest back translating translated 
interviews as a way to validate the translation (Chen and 
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Boore, 2009, Wild et al., 2005). Chen & Boore subsequently 
suggests the involvement of an expert panel in reaching the 
final agreement on the translation in order to gain conceptual 
equivalence (Chen and Boore, 2009). However, it has been 
disputed that back translation does not necessarily ensure the 
trustworthiness of the results incurring additional costs and 
time to the study (Squires, 2008). A bilingual individual 
competent in the qualitative researcher’s discipline was 
considered adequate for validating the conceptual equivalence 
of the translation (Squires, 2008). Hence, back translation was 
not conducted in this study. Steps were taken to ensure 
accurate translation from Malay to English by verifying the 
translation with another Malay pharmacist who was fluent in 
both languages. The researcher revisited and retranslated 
some of the excerpts until agreement was reached between 
the researcher and the Malay pharmacist. Consensus 
validation was the finalization point. 
 
Although all transcripts were translated to English for 
verification purposes, the original language was used during 
data analysis. Misinterpretation was reduced as this facilitated 
cross checking the data with the audio recordings when there 
was a need to consider voice modulations of the participants.  
 
During data analysis, selected themes and sub-themes from 
Malay were translated to English. This repeat translation 
helped the researcher to reduce misinterpretation. The 
process allowed the researcher to check for discrepancies 
between the first version from the translated transcripts and 
the second version from translated selected themes. After 
comparing the first and second version of the translation the 
actual meaning was represented more appropriately in the 
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second version. Rendering it better to translate selected 
themes rather than translating the whole transcript. The study 
by Chen & Boore concurs that verbatim transcripts and data 
analysis can be conducted in the original language and only 
emergent concepts, themes and sub-themes needed 
translation to English (Chen and Boore, 2009). 
 
2.4.1.17 Ethical approval 
Prior to the commencement of the interviews, ethical approval 
was obtained from, the University Malaya Medical Centre 
Ethics Committee (approval  number: 914.14, Appendix 22). 
All required documents were submitted and approval was 
obtained one month after submission. In accordance with the 
ethics committee requirements, a report upon completion 
form has been submitted. Ethical issues such as anonymity, 
confidentiality and informed consent were considered in this 
study. 
 
2.4.1.17.1 Anonymity and confidentiality 
Only the researcher and the supervisors had access to the 
audiotapes. All information were coded and anonymized. At 
the end of the PhD, the audiotapes will be destroyed. The 
information collected as paper copies were stored under lock 
and key, while the electronic data can only be accessed by the 
researcher and supervisors with a secure password. The data 
collected were used only for the purpose of this research; if 
data were to be used for future studies, further Research 
Ethics Committee approval will be sought. All information 
which is collected was confidential and any form of identity will 
not be included in any publications. 
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2.4.1.17.2 Informed consent 
Prior to the start of any research activity, written informed 
consent for participating and audio recording of the interviews 
was obtained from each participant. 
 
2.4.1.18 Data analysis 
Thematic analysis informed by constant comparison was used 
to analyse the interview data (Boyatzis, 1998, Braun and 
Clarke, 2008). It involves analysing the data as a whole to 
find repeated patterns of meaning (Braun and Clarke, 2008, 
Boyatzis, 1998). The analysis of the data involved repeatedly 
reading the transcripts while listening to the audio recording, 
and emerging topics were coded and constantly compared and 
contrasted with other transcripts (Braun and Clarke, 2008).   
 
QSR International Pty Ltd. NVivo  version 10 for Windows, 
2012 was used to aid in the analysis of the data. This software 
eases the handling of large data, facilitating constant 
comparison between interpretation and illustrative statements 
from the original transcripts (Bazeley, 2007). The documents 
containing the transcripts were imported from Microsoft Word 
to NVivo (Bazeley, 2007). These documents can then be 
opened in NVivo and coded for analysis (Bazeley, 2007). 
These codes are called ‘nodes’ in NVivo (Bazeley, 2007). There 
are three types of nodes: free nodes, tree nodes and case 
nodes (Bazeley, 2007). Analysis normally begins by identifying 
free nodes which are stand-alone nodes (Bazeley, 2007). Tree 
nodes can be used to show the relation between nodes as they 
can be organized into hierarchy (Bazeley, 2007). Case nodes 
can organize coding according to cases (Bazeley, 2007). In 
this study, tree nodes and free nodes were used. 
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Analysis began during data collection. At the end of each 
interview, the researcher wrote memos of interesting topics 
that were raised in the interview. All data was collected and 
analyzed by the same researcher enabling the researcher 
familiar with the data (Braun and Clarke, 2008). However, the 
entire interview was read through prior to generating initial 
codes (Braun and Clarke, 2008). 
 
The researcher identified and labelled text that was related to 
a node. This process is called coding (Bazeley, 2007, Miles and 
Huberman, 1994). The coding of this research were ‘data 
driven’ meaning that the nodes formed depended on the data 
(Braun and Clarke, 2008). The transcripts were read line by 
line and key nodes were identified (Miles and Huberman, 
1994). In some cases, the same texts were coded with 
different nodes as they may have had more than one 
meaning. A coding framework was developed using the 
identified nodes. This framework was used for coding 
subsequent data. Newly identified codes were added to the 
coding framework. The whole process was iterative and 
involved rereading, linking and connecting text to the 
represented nodes. Subsequently, previously coded texts were 
revisited and checked whether they represented the nodes 
that they were assigned to, otherwise they were transferred to 
a more suitable codes.  
 
The next phase of analysis began by refocusing the analysis at 
a broader level of themes (Braun and Clarke, 2008). This 
involved sorting the themes into broader themes and collating 
all the relevant coded data extracts within the identified 
theme. The ‘one sheet of paper’ (OSOP) analysis as described 
by Ziebland and McPherson (2006) was used to progress the 
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analysis of the data. OSOP involved reading through each 
code and then noting on a piece of paper all issues that were 
raised and making connections between them (Ziebland and 
McPherson, 2006). This process allowed identification of 
deviant cases that did not fit into the emerging story. These 
deviant cases were than reanalysed and accounted for in the 
analysis (Bazeley, 2009). During these phase the tree nodes 
were arranged into parent nodes (themes) and child nodes 
(subthemes) (Braun and Clarke, 2008). Nvivo assisted in the 
illustration of the hierarchical organisation (Bazeley, 2007). 
This process continued until all transcripts had been analysed 
and the codes were compared until data saturation. Data 
saturation involves bringing new participants into the study 
until no new codes emerged (Bowen, 2008).  
 
In our study, the analysis of each stakeholder: patients, 
pharmacists, nurses, doctors and policy makers were 
conducted separately. However, the themes which emerged 
within each group were similar and the analyses of all the 
stakeholders were combined.  
 
The analysis was enriched by going back to the literature 
noting how other research and theories fitted and how it could 
further inform the analysis (Braun and Clarke, 2008). Themes 
and sub themes were further refined based on the literature.  
Finally the themes and sub themes were reviewed to ensure 
that they ‘accurately’ reflect the meaning evident in the data 
set as a whole. 
 
The concept of reliability and validity is explored in the next 
section. 
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2.4.1.19 Reliability and validity of data and methods 
Qualitative research is often criticized as biased, lacking 
generalisability,  small scale, anecdotal, and/or lacking rigor 
(Anderson, 2010). Nonetheless, qualitative studies can be 
unbiased, in depth, valid, reliable, credible and rigorous when 
carried out appropriately (Anderson, 2010). 
 
2.4.1.19.1 Validity 
Validity of the research findings refer to the extent at which 
the findings are accurate representation of the phenomena or 
the ‘truth’ of the data (Smith, 2010). There are a number of 
methods to substantiate validity such as respondent 
validation, triangulation use of contradictory evidence, and 
constant comparison (Anderson, 2010, Mays and Pope, 2000). 
In our study we planned to use four validation methods: 
respondent validation, triangulation, constant comparison and 
cumulative validation. However, due to the circumstances 
which are explained below we were only able to use two 
methods: constant comparison and cumulative validation. 
 
 Respondent validation allows participants to read the data 
and analyses as well as provide feedback on the researcher’s 
interpretations of their responses (Mays and Pope, 2000). This 
provides the opportunity for the researcher to re-analyze their 
data, checking for inconsistencies and challenging the 
researcher’s assumptions (Mays and Pope, 2000) . 
Unfortunately, all participants declined to participate in this 
process. This may be due to the low literacy level of the 
patients and the lack of time by both patients and healthcare 
professionals.  These findings were presented to the staff of 
the primary care department. Although not all participants 
were present, this provided an opportunity for the healthcare 
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professionals to raise issues during the question and answer 
session which guide the researcher to revisit the transcripts 
and field notes to confirm some of the issues.  
 
Triangulation is defined by using two or more methods to 
study the same even (Mays and Pope, 2000). Initially, both 
individual interviews and focus groups discussions were meant 
to be conducted for this study. Unfortunately, due to the 
hectic working hours of the healthcare providers and 
accessibility barriers of the patients only individual interviews 
was feasible. However, contradictory evidence was sought out, 
examined and accounted for during the analysis to ensure that 
the researcher’s bias has minimum interference with the data.  
 
Constant comparison played a major role in this study. This 
involved looking at all the interviews as a whole rather than 
fragmenting it (Anderson, 2010). For example, an interview is 
compared with the previous data and not considered on its 
own enabling the researcher to identify 
emerging/unanticipated themes within the research project. 
 
Another technique used in this study for the process of 
validation is cumulative validation in which the researchers 
may use literature to demonstrate whether the findings were 
consistent with existing knowledge of the subject (Smith, 
2002). This led the researcher to revisit the transcripts to 
verify some issues. 
 
In a qualitative study, validity may be compromised by the 
researcher who is responsible for data collection and analysis. 
Hence, it is vital to acknowledge the ways (i.e. interpretation 
and research experience) that the researcher may influence 
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the outcomes (Charmaz, 2006). Another way that validity can 
be compromised is whether participants felt comfortable in 
expressing their thoughts or opinions (Smith, 2002).  
 
The location of the interview also plays and important part. 
Patients had the choice of being interviewed at their own 
homes or in the hospital depending on their preference. All 
healthcare professionals were interviewed in counselling or 
seminar rooms. However, at certain times some of their 
colleagues walked in and out of these rooms whilst the 
interview was going on. This might have prevented them from 
raising or discussing certain issues. 
 
The inexperience of the researcher in interviewing may have 
compromised the validity of the study at the initial stages. A 
deeper understanding of qualitative research towards the end 
of study allowed the researcher to detect cues that were not 
grasped during the initial interviews. This could have led to 
further probing and gaining a deeper understanding about the 
phenomena.  
 
In addition, the fact that participants knew the researcher is a 
pharmacist could have affected the way they responded to the 
questions. Most of the healthcare professionals and some of 
patients were previously acquainted with the researcher. This 
may have led patients to give socially acceptable answers to 
avoid being judged negatively. As for the healthcare 
professional, they might have expected the researcher to be 
aware of certain things and could have left out some of them.  
Nonetheless, these data are not considered invalid but it’s 
potential influence of the context should be considered 
(Murphy et al., 1998). 
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2.4.1.19.2 Reliability 
Reliability refers to the reproducibility of the findings. In an 
ideal situation, to ensure consistency in analysis the coding 
procedures should be undertaken by two or more researchers 
independently (Smith, 2002). However, this was time 
consuming. Therefore, to ensure reliability of the data analysis 
of this study, sections of the coded transcripts were presented 
to two supervisors independently (PLSM and CA). One 
supervisor was familiar with the field environment (PLSM) and 
the other supervisor was based in the UK independent of the 
field, and and experienced qualitative researcher (CA). 
Sections of the coded transcripts were presented to these 
supervisors on separate occasions to establish agreements on 
the codes assigned to each section of the data.  Assessments 
were also made for the data within each code to confirm that 
the code represented the data.  
 
The end stage of the analysis involved a presentation of the 
summary of all the interviews to the researcher’s supervisors 
(CA, PLSM, WKT, SO and LBY). This allowed them to obtain a 
complete understanding of the study. The confirmation of the 
themes and matching of the transcribed quotes with the 
themes and sub-themes derived from the analysis was 
finalized using consensus validation. 
 
The results will be presented in four sections: Participants’ 
characteristics, barriers and facilitators to an osteoporosis 
screening programme, pharmacists’ role in osteoporosis and 
development of the intervention using the behavioral wheel 
change.  
  
 92 
 
2.4.2 Results 
2.4.2.1 Participants’ characteristics 
Recruitment commenced until no new themes emerged this 
was achieved with a total of 20 patients, 10 nurses, 10 
doctors, 11 pharmacists and five policy makers. It was noted 
that more information was needed to clarify some issues 
(workload of osteoporosis clinic and knowledge of 
osteoporosis) and therefore, nurses from the osteoporosis 
clinic were recruited in addition to the primary care nurses. An 
aid nurse was mistakenly interviewed instead of a staff nurse 
and was excluded in the data analysis.  The characteristics of 
the participants are shown in Table 2.2. 
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Table 2.2: Participants characteristics 
No Participants Age Gender Years of practice 
1.  PT-1 58 Female  
2.  PT-2 66 Female  
3.  PT-3 55 Female  
4.  PT-4 60 Female  
5.  PT-5 61 Female  
6.  PT-6 72 Female  
7.  PT-7 64 Female  
8.  PT-8 52 Female  
9.  PT-9 63 Female  
10. PT-10 62 Female  
11. PT-11 63 Female  
12. PT-12 59 Female  
13. PT-13 65 Female  
14. PT-14 59 Female  
15. PT-15 55 Female  
16. PT-16 70 Female  
17. PT-17 58 Female  
18. PT-18 57 Female  
19. PT-19 57 Female  
20. PT-20 62 Female  
21. NUR-1 44 Female >10 
22. NUR-2 51 Female >10 
23. NUR-3 43 Female >10 
24. NUR-5 45 Female >10 
25. NUR-6 55 Female >10 
26. NUR-7 52 Female >10 
27. NUR-8 37 Female >10 
28. NUR-9 42 Female >10 
29. NUR-10 42 Female >10 
30. NUR-11 40 Female >10 
31. PHARM-1 26 Male 1-4 
32. PHARM-2 24 Female 1-4 
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33. PHARM-3 25 Female 1-4 
34. PHARM-4 23 Male 1-4 
35. PHARM-5 29 Female 1-4 
36. PHARM-6 27 Female 1-4 
37. PHARM-7 25 Male 1-4 
38. PHARM-8 29 Female 5-10 
39. PHARM-9 27 Female 5-10 
40. PHARM-10 28 Male 1-4 
41. PHARM-11 28 Female 1-4 
42. DR-1 33 Male 5-10 
43. DR-2 30 Male 1-4 
44. DR-3 36 Female 5-10 
45. DR-4 38 Male 5-10 
46. DR-5 30 Male 5-10 
47. DR-6 48 Female >10 
48. DR-7 28 Female 5-10 
49. DR-8 29 Female 5-10 
50. DR-9 30 Female 5-10 
51. DR-10 32 Male 5-10 
52. POL-1 50 Male >10 
53. POL-2 51 Female >10 
54. POL-3 57 Male >10 
55. POL-4 45 Female >10 
56. POL-5 44 Male >10 
Abbreviations: PT=patient, NUR= nurse, PHARM=pharmacist, 
DR= doctor, POL= policy maker 
 
 
  
 95 
 
2.4.2.2 Barriers and facilitators to an osteoporosis 
screening programme 
Our study found that there is currently no population based 
osteoporosis screening programme in existence in our setting 
and in Malaysia. Based on the protocol for the investigation 
and analysis of clinical incidents, seven main factors  as 
barriers leading to the failure to screen for osteoporosis were 
identified: governmental, organizational and management, 
work environment, team, individual, task, and patient factors. 
 
On the other hand, participants focused on barriers and few 
issues regarding facilitators were raised. Therefore, these 
facilitators were discussed within the barriers. There was only 
one facilitator in each of these factors: organizational and 
management factor, patient factor, team factor and work 
environment factor.   Table 2.3 presents a brief summary of 
the results where elaborations of the results can be found in 
the next section. 
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Table 2.3: Barriers towards an osteoporosis screening 
programme 
Factors Barriers 
Governmental factors  No dedicated executive at the 
Malaysian Ministry of Health for 
osteoporosis  
Organizational and 
management factors 
 
 Financial and resources 
constraints  
 Organization and structure 
constraints   
 Lack of policy standards and 
goals 
Work environment  Administrative and managerial 
support 
 Building and design 
 Education and training 
 Environment 
 Equipment and supplies 
 Staffing 
 Time constraint 
 Workload 
Team  General communication 
Task   Availability of protocol to staff 
 Availability and accuracy of test 
results 
Individual  Knowledge and skill 
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Patient  Condition (complexity and 
seriousness) 
 Personality 
 Knowledge 
 Communication 
 Social factors 
 Difficulty to adhere to 
osteoporosis prevention 
measure 
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2.4.2.2.1 Governmental factors 
2.4.2.2.1.1 No dedicated executive at the Malaysian 
Ministry of Health for osteoporosis 
In Malaysia, there is currently no dedicated executive at the 
Malaysian Ministry of Health for osteoporosis. Hence, there is 
a lack of governmental policy for a population based screening 
for osteoporosis. Patients are currently screened for 
osteoporosis when they have experienced a low trauma 
fracture, are symptomatic, or on an ad hoc basis. The lack of 
policy for osteoporosis screening at the governmental level 
may be the reason why osteoporosis may be under diagnosed. 
In order for osteoporosis to be screened effectively a 
nationwide policy is required.  
 
“… When…the government… adopt(s) (a) certain policy… for 
example… the immunization (policy)… (the) whole population 
is… screened. …this is actually very effective because 
everyone… (has) to do it.”    (DR-2/M/30y) 
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2.4.2.2.2 Organizational and management factors 
Organizational and management factors can be further 
categorized into financial and resources constraints, 
organization and structure constraints, and lack of policy 
standards and goals. 
 
2.4.2.2.2.1 Financial and resources constraints 
According to the WHO, osteoporosis is diagnosed when the T 
score is ≤ -2.5 standard deviations. The gold standard to 
diagnose osteoporosis is via a BMD scan. In Malaysia, DEXA 
machines are primarily located in bigger urban hospitals, as 
smaller hospitals do not receive funding to purchase such 
expensive equipments. This then limits the number of patients 
that can be screened for osteoporosis. In order to perform a 
population based screening programme for osteoporosis, a 
specific budget should be allocated to ensure its success. At 
present, resources required to screen for osteoporosis is taken 
from existing financial resources (such as the medication 
budget), which is not ideal. 
 
“I don’t think there’s any specific budget for prevention 
programmes.”      (POL-4/F/45y) 
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2.4.2.2.2.2 Organizational and structure 
constraints 
2.4.2.2.2.2.1 Lack of leadership to head the 
population based osteoporosis screening 
programme, people are disorganized 
Currently, there is a lack of leadership from the healthcare 
professionals to conduct an osteoporosis screening 
programme. According to the policy makers, opportunities to 
improve health services were given but the response from the 
healthcare professionals (such as pharmacists and doctors) 
were poor. In recent years, several activities have been 
implemented in our hospital, such as the medication therapy 
adherence clinic for diabetes and warfarin. The successful 
implementation of these programmes shows that the 
hospital’s upper management is supportive towards activities 
which would improve patient well being. Hence, participants 
felt that the attitude of the hospital’s upper management was 
a facilitator, as they would not be opposed to a population 
based osteoporosis screening programme in the future.  
 
“All the bosses are ok... if you have anything (an idea), you 
just voice out, they will listen...”  (PHARM-6/F/27y) 
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2.4.2.2.2.3 Policy standards and goals 
2.4.2.2.2.3.1 There is no clinic policy to screen for 
osteoporosis 
Currently, there is no clinic policy to screen for osteoporosis. 
Hence, the doctors at the primary care clinic are screening 
patients opportunistically. The doctors then compared 
osteoporosis screening to other screening programmes such 
as breast cancer screening. They perceived that a policy to 
screen for osteoporosis screening will aid in its success; noting 
the success of a policy for breast cancer screening. The 
doctors all agreed that there should be a new programme to 
screen for osteoporosis. However, they suggested that 
screening of osteoporosis should be conducted 
opportunistically and eventually shifting to systematically 
screening everyone. This is to ensure that the new programme 
is sustainable. 
 
“... Especially  in... menopause ladies… (when) the blood 
pressure is well controlled. Then we... ask for... other thing(s) 
that (are) related to menopause. That’s how we captured 
them (osteoporosis cases).”   (DR-1/M/33y) 
 
2.4.2.2.2.3.2 Primary care practitioners are not 
allowed to prescribe osteoporosis medications 
(Prescribing restrictions) 
Medications to treat osteoporosis are expensive. In our 
setting, the Drugs and Therapeutics subcommittee has 
decreed that only endocrinologists, gynaecologists and 
orthopaedic specialists are able to prescribe medications to 
treat osteoporosis. Primary care physicians are not able to 
prescribe these medications. This was seen by the primary 
care physicians as a hindrance to diagnose and treat 
 102 
 
osteoporosis. In order for a successful osteoporosis screening 
programme to take place, doctors, nurses and pharmacists 
suggested a more flexible prescribing policy.  
 
“I think they should make it (prescribing restrictions) a bit 
more flexible so that our doctors can also write (prescribe) it 
(osteoporosis medication). I don’t know (if) it’s a bit 
expensive... I’m not sure of the price, so these... medicines, 
our RUKA (Primary Care Clinic)... doctors can’t write 
(prescribe). Somehow (the patients) have to go back to the 
osteoporosis clinic, see the.... specialist then get it 
(osteoporosis medications).     (NUR-6/F/55y) 
 
2.4.2.2.3 Work environment factors 
The participants highlighted a range of barriers faced from the 
work environment factors. The list includes administrative and 
managerial support, building and design, education and 
training, environment, equipment or supplies, staffing, time 
constraints and workload. 
 
2.4.2.2.3.1 Administrative and managerial support 
2.4.2.2.3.1.1 Long waiting time for bone mineral 
density scan appointments 
The difficulty in diagnosing osteoporosis arises from a long 
waiting time for the patient to obtain a bone mineral density 
appointment with the department of nuclear medicine (There 
was a 6-12 months waiting period). In addition, patients can 
only see their primary care doctors once they have had their 
BMD scan. Subsequently, patients who need to be treated for 
osteoporosis need to be referred to the osteoporosis clinic as 
primary care physicians are not allowed to prescribe 
osteoporosis medications. In addition, the waiting time to see 
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the specialist at the osteoporosis clinic was 6-12 months. 
Although the doctors noted a facilitator whereby the process 
ran smoothly, the long waiting time was cited by all 
participants as a barrier. 
   
“I find that (it) is... too long (a) process. Because... to get to 
your osteoporosis (bone mineral density) done... It takes 
about six months... And then... (she has) to come back again 
(for clinic appointments)… They are not doing it very fast. 
Because once you take six months, the person who (is) 
suffering with that disease either will go chronic or… (I) don’t 
know whether she’ll... still (be) alive or not. (PT-7/F/64y) 
          
2.4.2.2.3.2 Building and design 
2.4.2.2.3.2.1 Lack of space to conduct osteoporosis 
screening 
A specific room or partitioned area is required to conduct 
specialised services such as diabetic screening or counselling 
as it would provide a conducive environment. Participants’ 
cited that having a dedicated space for osteoporosis screening 
was a factor as the clinic was crowded, and all available space 
has been utilised.  
 
“… No one thought about it or there is no facility in terms of 
place.”  (POL-4/F/45y) 
 
2.4.2.2.3.3 Education and training 
2.4.2.2.3.3.1 Lack of education and training for 
healthcare professionals 
A majority of continuous medical education focuses on topics 
such as diabetes and cardiovascular diseases. There seems to 
be a paucity of training programmes targeting osteoporosis, 
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indicating a lack of emphasis to train or reinforce healthcare 
professionals’ knowledge in managing osteoporosis. 
Nonetheless, the healthcare professionals were eager to 
attend an osteoporosis workshop should there be one.  
 
“I always hear of urology for BPH, urology, diabetic 
workshop... I also go... for Alzheimer’s, hypertension. 
Osteoporosis, I have never been. Psychiatry, I have been... to 
a workshop but osteoporosis I have never been.”  
        (NUR-1/F/44y) 
 
2.4.2.2.3.4 Environment 
2.4.2.2.3.4.1 Primary care services are not elderly 
friendly 
In order for any health promotional programme to succeed, it 
must be easily accessible to patients. Osteoporosis screening 
is targeted at the elderly. There should be ample ramps for 
wheelchair access, parking support bars and adequate 
signage. Despite the availability of these elderly friendly 
facilities at the primary care clinic, patients commented that a 
more personalized service would aid the elderly in undergoing 
osteoporosis screening. Patients felt that the services provided 
by the primary care clinic were not as elderly friendly 
compared to the private sector. This was seen as a barrier 
when visiting the hospital.  
 
 “... Went to KPJ (private hospital) because it was too painful 
to come here (RUKA) ... that day when I arrived here, I 
couldn’t walk. My husband had to park (the car), I thought to 
myself ‘how am I going to get down (to the clinic by myself)?’ 
... the nurses (at the private hospital) was waiting with a 
wheelchair, I then sat on the wheelchair. I was pushed on the 
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wheel chair to the therapy room, the nurse straight away sent 
me to physio. Even if I have to see the specialist... the nurse 
will send.”   
       (PT-5/F/61y)  
 
2.4.2.2.3.5 Equipment or supplies 
2.4.2.2.3.5.1 Lack of DEXA machines 
While there are currently functional DEXA machine in this 
setting, many other smaller hospitals do not have DEXA 
machines. Despite osteoporosis being screened 
opportunistically, the waiting time is 6 months to a year. If a 
population based osteoporosis screening programme was 
started, the number of DEXA machines will not be able to cope 
with the amount of BMD scans ordered. Therefore the number 
of DEXA machines need to be increased so that it is available 
nationwide.  
           
“... (If) we screen everyone for osteoporosis... certain place(s) 
don’t have the BMD (Bone Mineral Density) measurements 
(machine)... Here got (we have)... but you know if everyone 
uses that facility then we’re kind of swamp (ed).”                               
        (DR-7/F/28y) 
 
2.4.2.2.3.5.2 Lack of osteoporosis medications 
Healthcare professionals were concerned that if osteoporosis 
population screening was provided, treatment should also be 
provided. The primary care clinic is part of a public hospital 
whereby the medication cost is heavily subsidized by the 
government. For example, government workers and 
pensioners are entitled to free medications where else private 
patients paid a nominal sum of RM20 per month. Nonetheless 
some of these patients are still unable to afford these fees. 
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However, social welfare funds are availably but only to the 
lower income population. Healthcare professionals feared that 
not only the patients cannot afford the medications but also 
the government would not be able to cope with the increase in 
demand of osteoporosis medication. 
 
“And this thing (osteoporosis medication) is quite expensive... 
Because, if we go for... screening there is a cure. But the cure 
should be available for all... There is no point... telling a 
person (to do) a BMD (Bone Mineral Density)... and telling her 
that you are osteoporotic and she is not a government 
servant. She cannot afford the cost of it.”   
      (DR-6/F/48y) 
 
2.4.2.2.3.6 Staffing 
2.4.2.2.3.6.1 Lack of workforce 
There was a lack of workforce with regards to doctors, 
pharmacists and nurses. The hospital was seen to be barely 
coping with the daily services. This would lead to difficulty in 
conducting any new services such as the osteoporosis 
screening programme. Essentially there should be enough 
staff to replace a staff who may call in sick. Unfortunately, this 
is not possible with the current amount of staff.  
 
“I supposed... the challenge; it would be the manpower... That 
would be our first... hurdle. Once we have that, the person, 
then it can... be done.”    (POL-2/F/51y) 
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2.4.2.2.3.7 Time constraints 
2.4.2.2.3.7.1 Short consultation time with all 
healthcare professionals 
Currently the consultation with the doctors only involved 
addressing the chief complaint as the waiting time is about 1-
3 hours. The screening of osteoporosis would increase the 
consultation time leading to an increased waiting time. Hence, 
patients perceived that time would be a barrier for doctors to 
routinely screen for osteoporosis. 
 
“... Because most doctors are so busy, they won’t spend (the) 
time talking about something not related to your condition.” 
       (PT-9/F/63y) 
    
2.4.2.2.3.7.2 Restrictive key performance indicator 
The healthcare professionals raise the limitations of two key 
performance indicators (KPI). The first is the 15-30 minutes 
consultation time between the doctors and patients. The 
second is the 30 minute dispensing time which includes the 
waiting time between the pharmacists and the patients. These 
two KPIs were intended to ensure that the patients did not 
have a waiting time. However, these time restrictions made 
osteoporosis screening not possible as healthcare 
professionals only had enough time to address the chief 
complaint.  
 
“But with the outpatient setting here in our hospital. I don’t 
think we can talk so much to the patients...Because we need 
to meet our quality objectives... So, there’re limitations.” 
     (PHARM-6/F/27y) 
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2.4.2.2.3.7.3 Workload 
There is a large amount of patients at UMMC. Because of this 
healthcare professionals have to multitask and may not be 
able to spend additional time with the patients to screen for 
osteoporosis.  
 
“They (healthcare professionals) are very busy… they (have) a 
lot of patient (s)… waiting.”   (PT-6/F/72y)  
       
Conversely, osteoporosis clinic nurses described the workload 
in the osteoporosis clinic to be low. These nurses suggest that 
more osteoporosis clinic referrals are needed from the primary 
care clinic.  
 
“The (osteoporosis) clinic does not have that many patients. A 
hundred is not many.”  (NUR-7/F/52y) 
 
2.4.2.2.4 Team factors 
2.4.2.2.4.1 Lack of communication in the primary 
care department 
A lack of communication between departments and healthcare 
professionals has resulted in poor teamwork among the 
healthcare teams. Examples of poor communication and 
teamwork were of patients going for their osteoporosis clinic 
appointment without their bone mineral density scan results, 
healthcare professionals conveying different information to the 
patients or the lack of trust between the healthcare 
professionals to carry out screening. Therefore, all the 
participants expressed the need for an inter-professional 
collaboration. Additionally, although communication with 
patients was considered poor by the participants, a facilitator 
was noted as a small group of patients had good 
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communication skills and was open to communicate with the 
healthcare professionals. 
 
 “… The nurse(s)… the communication, how good is the 
communication between the pharmacists and the doctors and 
the patient(s)… communication could be a barrier. Thus, if the 
pharmacists (are) thinking on a different line, the doctors 
thinking on a different level, then they would end up 
nowhere.”       (DR-6/F/48y) 
 
2.4.2.2.5 Task factors 
The task factors could be divided to two barriers: availability 
of an updated osteoporosis guideline and availability and 
accuracy of an osteoporosis risk assessment tool. 
 
2.4.2.2.5.1 Availability of an osteoporosis guideline 
Some of the healthcare professionals were not aware that an 
osteoporosis guideline was available. Others noted that the 
guidelines were not updates. The osteoporosis guideline was 
not update since 2006. This led healthcare professionals to 
look for other sources of information such as overseas 
guidelines from the United Kingdom or United States of 
America.  
 
“…I think... they do (have an osteoporosis guideline), (it) is 
mainly (on) non-pharmacological, promote weight-bearing 
exercises… But it’s an old guideline. We have never updated 
our osteoporosis guidelines, I think, our CPG (Clinical Practice 
Guideline) is (updated a) long, long (time) ago.”  
        (DR-9/F/30y)   
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2.4.2.2.5.2 Availability and accuracy of and 
osteoporosis risk assessment tool 
Despite the limited number of DEXA machines, there is 
currently no osteoporosis risk assessment tool suitable for the 
Malaysian population. The participants identified that an 
osteoporosis risk assessment tool would aid in optimizing the 
usage of current resources by screening patients at high risk 
for osteoporosis to go for a BMD scan. This tool should be able 
to accurately screen patients quickly and cheaply. Additionally 
participants mentioned that a general screening booklet 
whereby they can record screening activities would aid in the 
monitoring of whether osteoporosis screening or other 
diseases have been conducted.    
 
“...If there is a screening tool which is... available... 
affordable... feasible and reachable for everyone, it’ll be very 
helpful... we can’t expose everyone to the BMD…”  
                                                            (DR-4/M/38y) 
 
2.4.2.2.6 Individual factors 
Individual factors refer to healthcare professionals and policy 
makers. It can be divided to two types of barriers:  personality 
and knowledge.  
 
 
2.4.2.2.6.1 Personality 
2.4.2.2.6.1.1 Healthcare professionals are not 
initiative during work 
The lack of initiative from the healthcare professionals to start 
a new programme may be a barrier to start osteoporosis 
screening. This was seen as a barrier based on the failure of 
the smoking cessation and the osteoporosis medication 
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therapy adherence and compliance (MTAC) programme. 
Healthcare professionals were seen to not keep themselves up 
to date and took a nonchalant approach towards osteoporosis 
screening as it seen to be not part of their core job scope. 
Nonetheless, the healthcare professionals considered 
osteoporosis to be a rising problem and are supportive of the 
idea for an osteoporosis screening programme.  
  
“...I’ve... send people for quit something (smoking) and yet 
why can’t the pharmacist open up the quit smoking clinic 
here?... they are not able to do it... they say, they don't have 
enough energy, they don't have the passion?” 
        (POL-3/M/57y) 
 
2.4.2.2.6.2 Knowledge 
There was a lack of osteoporosis knowledge seen in the 
healthcare professionals. Policy makers, doctors, pharmacists 
and nurses had a basic knowledge on osteoporosis but this 
was not sufficient. The gap in the knowledge includes all areas 
such as: osteoporosis as a disease, risk factors, and 
consequences of untreated osteoporosis, symptoms, 
screening, prevention and treatment. Because of the lack of 
knowledge on the screening and diagnosis of osteoporosis 
inappropriate tests such as x-rays and blood calcium level 
have been used to screen for osteoporosis instead of using the 
BMD scan.  
 
Additionally, the lack of knowledge on the consequences of 
untreated osteoporosis and its symptoms, osteoporosis was 
seen to be not life threatening and is not taken seriously. The 
effect of this has led the healthcare team to focus on the 
treatment of osteoporosis when a fracture has occurred or 
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prioritizing other diseases such as diabetes. Health efforts 
have also been directed to the younger generation due to the 
perception that osteoporosis will not have an impact on the 
society as it only effects the elderly. Therefore, it is imperative 
to ensure that the healthcare professionals are equipped with 
the knowledge and are made aware that prevention is better 
than cure. Table 2.4 demonstrates the areas of osteoporosis 
which lack knowledge. 
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Table 2.4 Quotes highlighting healthcare professionals lack of 
knowledge on osteoporosis 
Areas with a lack of 
knowledge 
Quotes 
Consequences of 
untreated osteoporosis: 
Osteoporosis is not life 
threatening 
“... Osteoporosis (is) not urgent. Osteoporosis... cannot 
kill you).” 
                                                            (NUR-8/F/37y) 
Risk factors:  
Women who gave birth 
many times are at 
higher risk for 
osteoporosis 
“... Usually it will affect woman, old woman that... give 
birth more than a few times... Maybe more than four 
times... Then they are prone to get osteoporosis when 
they are getting older...”  
                                                       (PHARM-7/M/25y) 
Symptoms: 
Unaware osteoporosis 
is asymptomatic 
“... We don’t really ...  screen without any complain 
(symptoms)...” 
                                                            (POL-2/F/51y) 
Screening: 
Blood calcium levels 
can be used to screen 
for osteoporosis 
“The other one... (the doctors screened me with a) blood 
test, they (doctors) said the calcium level is good.”                
(PT-20/F/62y) 
 
Diagnosis: 
BMD scan is high in 
radiation 
“So women who is in the reproductive age, we cannot... 
(be) exposed to the... BMD (Bone Mineral Density) and 
then the X-Rays. So the screening tool will be... helpful 
for that group of people where we can avoid certain 
exposure to X-Rays.”                               (DR-2/M/30y)                              
                                                                          
 
Prevention: 
Swimming can help 
strengthen bones 
“Like... brisk walk, brisk walk, swimming... if the patient 
willing.... maybe jogging.”                     (DR-5/M/30y)                                               
 
Lack of focus on 
screening and 
prevention of 
osteoporosis 
“... Awareness and education... cause right now all we’re 
doing is treatment... waiting for the thing to happen. So 
there isn’t enough... on prevention...”  (PHARM-8/F/29y)                                      
 
Treatment: 
Lack of osteoporosis 
medication knowledge 
“Plus they (primary care doctors) may not... have the 
experience required to treat and review osteoporotic 
patients from time to time. Primary care is basically quite 
raw, it’s generalized medicine. They’re probably the 
doorkeepers.”                                (PHARM-11/F/28y) 
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2.4.2.2.7 Patient factors 
Barriers contributing to the patient factors can be broken 
down to smaller subthemes such as condition, communication, 
personality, social factors and difficulty to adhere to 
osteoporosis prevention measures. Based on our data an 
additional subtheme emerged which was a lack of osteoporosis 
knowledge. 
 
2.4.2.2.7.1 Condition 
2.4.2.2.7.1.1 Osteoporosis was perceived to be not 
serious 
The first barrier contributing to patient factor was that 
patients perceived osteoporosis to be a condition that was not 
serious mainly because it is normally asymptomatic in nature. 
This led patients to prioritize other diseases such as diabetes 
or cancer screening.  
 
“As far I know (osteoporosis) is not life threatening, so why 
bother? There are other many things to worry about.” 
      (PT-13/F/65y) 
 
2.4.2.2.7.2 Personality  
2.4.2.2.7.2.1 Nonchalant attitude towards 
osteoporosis 
As osteoporosis was perceived to be not serious, patient had a 
nonchalant personality towards osteoporosis. Furthermore, 
there were some patients who were in denial and did not want 
to find out if they had osteoporosis. Conversely, there was a 
facilitators noted as there were patients who had a pro-active 
attitude of health seeking behavior. These group of patients 
believed that prevention is better than cure and are willing to 
conduct screening as necessary. In order to conduct and 
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sustain and osteoporosis screening programme the healthcare 
professionals urged patients to take ownership of their health. 
This referred to patients being proactive about their own 
health issues.  
 
“Some are just ignorant to it... ‘I’m getting old... it’s normal to 
(get) it, so don’t bother.”      
       (PHARM-9/F/27y) 
 
2.4.2.2.7.2.2 Unwilling to listen to healthcare 
professionals’ advice 
Another personality barrier was some patients’ unwillingness 
to listen to the advice of other healthcare professionals such 
as pharmacists or nurses. They were only willing to listen to 
advice from doctors. There were also some patients who 
preferred to listen to the advice given by a specialist, over a 
primary care physician.  
 
“... We’re also having problems here... some of them... (will) 
say, “... What (kind of)... doctor are you?” “I’m a general 
doctor.” “No, no, no, I don’t want to see a general doctor, I 
want to see a specialist.”   (DR-2/F/30y) 
  
2.4.2.2.7.2.3 Negative perception towards healthcare 
professionals 
2.4.2.2.7.2.3.1 Competence 
There was a perception that patients perceived that some 
healthcare professionals were incompetent. Patients found 
that some of the healthcare professionals seemed 
inexperienced or not capable to conduct their duties. This 
perception came from experiences of friends or family whom 
previously had a bad experience in the hospital or patients 
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themselves receiving wrong information. These stories led 
patients to perceive that some healthcare professionals were 
incompetent, finding it unnecessary and risky to do non urgent 
test such as a BMD scan. This type of perception was seen 
towards doctors, nurses, radiologists and pharmacists.  
 
“I backed out. I am very scared. Because you hear a lot of 
people said this (and)… that happens... our lab technician(s), 
are they capable of handling (all these tests)?”  
        (PT-18/F/57y) 
2.4.2.2.7.2.3.2 Healthcare professionals do not 
conduct themselves professionally 
In UMMC, teaching sessions are conducted with doctors as 
part of part of continuing education. This sometimes caused 
the doctors to be late for their clinic sessions. Therefore, 
stakeholders noted that patients perceived that the healthcare 
professionals did not conduct themselves professionally. This 
is because patients are unaware that doctors are required to 
attend teaching sessions, and believe that doctors are 
intentionally late. Some of the patients also commented that 
the doctors, nurses or pharmacists did not answer their 
questions satisfactorily or answered them in an unprofessional 
manner. 
 
“... It (is) about one hour late (for the clinic session)… because 
they (doctors) say, they have to be in the ward. So (I) don’t 
know (if it is) true or not.” 
      (PT-13/F/65y) 
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2.4.2.2.7.3 Knowledge 
The stakeholders unanimously agreed that another barrier was 
a lack of osteoporosis knowledge among patients. Patients had 
a basic knowledge to what was osteoporosis. However, 
knowledge beyond that was limited especially in the areas of 
the consequences of untreated osteoporosis. Other topics 
which patients had poor knowledge includes: osteoporosis in 
general, screening for osteoporosis, prevention of osteoporosis 
and treatment of osteoporosis. It was also mentioned that 
rural patients had less osteoporosis knowledge as compared to 
city patients. Various methods and strategies have been 
suggested by the stakeholders interviewed for the 
dissemination of osteoporosis information: group counselling, 
individual counselling, campaigns, pamphlets and media 
advertisement. Table 2.5 demonstrates the areas lacking in 
knowledge. 
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Table 2.5: Quotes highlighting patients lack of osteoporosis 
knowledge 
Areas with a lack of 
knowledge 
Quotes 
Osteoporosis as a 
disease: 
Osteoporosis was 
perceived to be part of 
aging and confused 
with osteoarthritis  
“They thinks it’s part of aging.... like.. (it’s) normal.”   
                                                               (DR-7/F/28y) 
 
“… It’s because they have… knee pain, they thought (this) 
is osteoporosis”                                         (DR-3/F/36y)        (DR-39/F/36y) 
 
Cause  of osteoporosis: 
Patients did not know 
the cause of 
osteoporosis 
“Maybe it’s got to do with... blood circulation slowing 
down.”  
                                                                (PT-11/F/63y) 
 
Consequences of 
untreated osteoporosis: 
Osteoporosis is not life 
threatening 
“As far I know is not life threatening, so why bother? There 
are other many things to worry about.”       (PT-13/F/65y) 
 
“...People just do not know... the severity of having 
osteoporosis.” (PHARM-4/M/23y)                                                           
Risk factors:  
Women who gave birth 
many times and being 
overweight were 
thought to be at higher 
risk for osteoporosis 
“Don’t be overweight... don’t ah burden... your bones.”   
                                                                 (PT-1/F/58y) 
 
“During childbearing where...  some say the calcium... 
taken up by the baby.”                              (PT-12/F/59y)                                                
 
Symptoms: 
Unaware osteoporosis 
is asymptomatic 
“When your teeth start... decaying a little... you start 
losing teeth... that’s another indicator.”        (PT-11/F/63y)                           
 
“Osteoporosis affects the joint.”                   (PT-20/F/62y) 
 
“I got a friend they don’t know (that they have 
osteoporosis) until they do a BMD. (Then they realized) “Ey 
I got osteoporosis but they... look healthy.” (NUR-3/F/43y)                                         
 
 
Diagnosis: 
BMD scan is high in 
radiation 
“Radiation, isn’t it dangerous?”                  (PT-18/F/57y) 
 
“I don’t know what (are the available) type of bone 
screening facility. If you just putting the foot there... I 
don’t think that’s accurate.”  
                                                             (PT-20/F/62y) 
Prevention: 
Unaware of all areas of 
calcium supplements, 
exercise and other 
preventive methods 
“Cause you will get stones in your kidney.” (PT-14/F/59y) 
 
“Maybe I take the wrong dose... I don’t know.”   
                                                               (PT-18/F/57y) 
 
“I don’t think my exercises... I mean (it) cannot prevent 
osteoporosis.”                                            (PT-17/F/58y) 
 
“...When is the (best time for the absorption of) vitamin D 
at what time? I don't think they know.”  (POL-3/M/57yr)  )                                      
  
Treatment: 
Lack of osteoporosis 
medication knowledge 
“Here pain (points at shoulder) then the doctor (gave an) 
injection. Then 9 months, 1 year... injection again.” 
                                                                 (PT-6/F/72y)                  
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2.4.2.2.7.4 Communication 
2.4.2.2.7.4.1 Language barrier 
Communication gap between healthcare professionals and 
patients was seen as barriers by the stakeholders. Reasons for 
the communication gap may be due to language barrier. 
Malaysia is a multiracial country. Although Malay is the 
national language and English is widely spoken, not all elderly 
are able to communicate in these languages. Some elderly 
patients may only speak in Mandarin or Tamil making 
communication difficult for staff who do not know these 
languages.  
 
“... Sometimes (there is a) language problem with the 
patients... patients doesn’t understand what... we’re trying 
to tell them (or) what we’re going to do them (screening)...”   
(NUR-6/F/55Y) 
 
2.4.2.2.7.5 Social factors 
2.4.2.2.7.5.1 Financial constraints 
Financial constraints contribute to the patient factor. In 
Malaysia, government workers or government pensioners are 
entitled to free healthcare. However, the rest of the population 
would need to pay a minimum fee. Despite the government 
subsidy, the cost of medication, supplements and services 
were still seen to be unaffordable for some of the patients.  
 
 
“They (patients) are all... financially constrain(ed). So when 
you tell them... Fosamax is  RM70. It’s not cheap.”   
       (NUR-2/F/51y) 
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2.4.2.2.7.6 Time constraints 
Time constraint was another barrier, due to the lack of the 
DEXA machines and manpower waiting time for clinics and 
medications can be long. The whole process from the clinic 
appointment to the collection of medications will take at least 
half a day.  This has led to patients choosing not to go for 
their clinic appointment prioritizing jobs or chores until their 
condition becomes unbearable. Screening for osteoporosis was 
perceived to add on to their waiting time and further deter 
patients from coming to the primary care clinic. A facilitators 
to this, is that although some patients consider the clinic 
appointment to be time consuming, there were some patients 
who considered a clinic appointment to be a social outing 
where they could make new friends. Nonetheless, a short 
clinic waiting time would assist the successful clinic attendance 
of the patients. 
 
“Yes I can go (for jogging or screening) but there are plenty of 
chores. Previously I wasn’t looking after my grandchildren. 
How can I leave them at home?”     
       (PT-17/F/58y) 
 
2.4.2.2.7.6.1 Short consultation time 
Patients mentioned that there was not enough consultation 
time to address other issues such as prevention or screening 
aside from the chief complaint. The consultations seemed 
rushed and felt that they would be bothersome to their 
doctors if they asked additional questions.   
 
“Doctors, they are so busy... if you are not sick... (and you) 
go and ask them... they won’t spend much time with (you)... 
maybe 5 minutes... finish.”    (PT-1/F/58y) 
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2.4.2.2.7.7 Family circumstances 
Most of the elderly in Malaysia depend on their children to 
bring them to the hospital making multiple clinic appointments 
difficult to adhere to.  
 
“… They (elderly) depend a lot on their children, even to come 
to (the) hospital… Their children have to take leave... if you 
want… them to do… screening… they will feel that it is very 
troublesome because... they don’t want to come a few times... 
just for the test.”     (DR-3/F/36y) 
 
2.4.2.2.7.8 Difficulty to adhere to osteoporosis 
prevention measures 
Osteoporosis prevention measures and screening were seen to 
be a difficult task to some patients. For example, some 
patients feel too unfit to exercise or fear of safety when 
exercising. Others have difficulty in swallowing the calcium 
tablets and difficulty in drinking milk. These topics are not well 
discussed; difficulties and confusions are not addressed 
leading to patients giving up on their prevention efforts. 
 
“When I feel “cloudy”, then I just… (take) a short nap. Then 
after that I won’t do that (brisk walking/treadmill) everyday. 
Just... on(c)e (a) week… I do.” 
                                                        (PT-14/F/59y) 
 
2.4.3 Discussion 
This study highlights the range of barriers in conducting an 
osteoporosis screening programme as perceived by 
policymakers, doctors, pharmacists, nurses and patients in a 
primary care clinic. There were seven main factors that 
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contributed to the barriers of running an osteoporosis 
screening programme: governmental, organizational and 
management, work environment, team, task, individual and 
patient factors.   
 
These barriers encountered in a multicultural, Asian country 
were similar to barriers reported in overseas studies (Guzman-
Clark et al., 2007, Jaglal et al., 2003, Beaton et al., 2012, 
Duyvendak et al., 2011, Kim et al., 2011, Simonelli et al., 
2002, Feldstein et al., 2008, Papa and Weber, 1997, Otmar et 
al., 2012, Taylor et al., 2001, Claesson et al., 2015). Thematic 
consistency is apparent between all these studies and our 
study, suggesting that these barriers are widely held ideas 
that the results of this study are generalisable. 
 
However, barriers from the governmental and, organisational 
as well as management factors are specific to our study. A 
lack of an osteoporosis screening policy at the national level in 
Malaysia influenced the lack of policy to screen for 
osteoporosis at the clinic level.  This led to organizational and 
management barriers where a lack of funding and leadership 
occurred. Therefore, it is crucial to ensure that policy makers 
are equipped with knowledge on the importance of 
osteoporosis screening. This is essential in order to gain their 
support as it will assist in securing resources  to begin the 
osteoporosis screening programmes and to ensure their 
sustainability (Straus et al., 2011). The lack of literature in 
this area may be due to the lack of studies on the barriers for 
screening of osteoporosis at the policy maker level. Studies 
were mainly conducted on patients or healthcare professionals 
perspectives (Guzman-Clark et al., 2007, Jaglal et al., 2003, 
Beaton et al., 2012, Duyvendak et al., 2011, Kim et al., 2011, 
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Simonelli et al., 2002, Feldstein et al., 2008, Papa and Weber, 
1997, Otmar et al., 2012, Taylor et al., 2001). 
 
Another policy barrier under the organizational and 
management factor identified is that primary care practitioners 
were not allowed to prescribe osteoporosis medications 
(prescribing restrictions). This has become an obstacle to 
screening and treating osteoporosis cases. The pharmacists, 
doctors and nurses unanimously suggested for a more flexible 
‘prescribing restriction’ policy. This was a similar situation in a 
Canadian study which eventually allowed primary care 
practitioners to prescribe osteoporosis medication, suggesting 
that this is the way forward in order to successfully conduct a 
population based osteoporosis screening programme 
(Guzman-Clark et al., 2007).  
 
The lack of leadership and funds at the governmental, 
organizational and management levels, resulted in several 
work environment factors. The work environment factors in 
our study concurs to previous studies, such as the lack of: 
DEXA machines (Milsom et al., 2013) leading to a long waiting 
time, education and training in osteoporosis (Taylor et al., 
2001, Feldstein et al., 2008), osteoporosis medications 
(Simonelli et al., 2002). Another barrier cited from the work 
environment factor was a lack of space to conduct 
osteoporosis screening. This may be because there was 
currently no osteoporosis screening programme. Hence, a 
location was not allocated. Lack of manpower leading to a high 
workload and short consultations time was a particular barrier 
highlighted in our study.  
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Further analysis of the data identified an issues which were 
only identified from our setting was a restrictive key 
performance indicator (KPI) whereby a doctors consultation 
time should not exceed 30 minutes and a pharmacists’ 
dispensing duration should not exceed 30 minutes These KPIs 
were designed to ensure that patients did not have too long a 
waiting time at the clinic, and at the pharmacy. However, the 
downside of having this KPI is that doctors will only focus on 
the patient’s chief medical complaint, and pharmacy staff will 
dispense medications as quickly as possible, so that the crowd 
can be cleared. Despite these KPIs, the waiting time for a 
patient to see a doctor can range from 1-3 hours, whilst the 
waiting time for their prescription to be filled can range from 
30 minutes to 2 hours. This suggests that screening can be 
conducted during this waiting time period, so that the patient’s 
time maybe used effectively. 
 
Another barrier identified specifically for our setting was the 
lack of elderly friendly services at the primary care centre. 
Despite the availability of some elderly friendly facilities, 
hospital staff were not at hand to assist the elderly (such as 
pushing them in a wheel chair from the point where they are 
dropped off to the doctor’s clinic) to assist the elderly.  This in 
turn affected the patients’ accessibility to the hospital.  
 
As for the team factor, communication gaps between the 
healthcare professionals, departments and patients resulted in 
poor teamwork. One of the ways suggested to address this 
barrier was to conduct an inter-professional osteoporosis 
screening programme. Previous studies have shown that inter-
professional collaboration improves communication and clinical 
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outcomes  (Hjalmarson et al., 2013, Dolovich et al., 2008, 
Majumdar et al., 2008).  
 
The barriers from the task factors were a lack of awareness 
towards the availability of an osteoporosis guideline. This was 
not a new barrier as previous studies have found that only 
42% of general practitioners declared any awareness of an 
osteoporosis guideline (Taylor et al., 2001). Participants also 
cited that the guideline was not updated. However, the 
Malaysian osteoporosis guideline from year 2006 has now 
been updated in year 2012 (Ministry of Health Malaysia, 
2012). Nonetheless this updates guideline does not mandate 
osteoporosis screening where as in Canada, guidelines have 
been  released to ensure that all women >65 with a fracture 
should be screened for osteoporosis (Papaioannou et al., 
2010).  
 
Another barrier from the task factor cited specifically for our 
setting was a lack of an osteoporosis risk assessment tool, as 
it was difficult to access the DEXA machines. Several risk 
assessment tools have been developed (Koh et al., 2001b, Lim 
et al., 2011, Ministry of Health Malaysia, 2012). And previous 
studies have shown that the use of a risk assessment tools 
increased the number of BMD scans ordered and the number 
of osteoporosis cases detected (Yuksel et al., 2010, Crockett 
et al., 2008). In the Malaysian osteoporosis guidelines (2012), 
it was recommended that OSTA should be used as a screening 
tool. However, the OSTA has not been validated, whilst the 
MOST has been validated.  Hence phase two of this study 
involved conducting a study to validate the OSTA in the 
Malaysian population and compared it to the MOST.  
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Individual factors noted a new theme called personality arose 
which was not part of the framework. This referred to 
perceptions of the personality of the healthcare professionals 
who did not show much initiative at work. Additionally, in the 
patient factor, patients’ had a negative perception of the 
healthcareprofessional perceiving that they do not act 
professionally. Studies have shown that a high workload may 
lead to such behaviour of lack of initiative and lack of 
professionalism (Reader and Gillespie, 2013). Nonetheless, 
the healthcare professionals were supportive towards the idea 
of a screening programme. These healthcare professionals 
unanimously agreed that there is a growing demand for 
osteoporosis awareness. This indicates that the healthcare 
professionals are willing to take on the new osteoporosis 
screening programme which is essential for its success.  
 
The most common barrier seen from the individual factors is 
the lack of osteoporosis knowledge of healthcare professionals 
(Guzman-Clark et al., 2007, Beaton et al., 2012, Kim et al., 
2011, Claesson et al., 2015) (Sale et al., 2014).  Similar 
results were found where some osteoporosis cases are missed 
even after a fragility fracture (Kim et al., 2011) or other 
diseases were prioritized due to the lack of osteoporosis 
knowledge (Otmar et al., 2012, Claesson et al., 2015). In our 
setting, healthcare professionals prioritized other diseases or 
treatment of osteoporosis when a fracture has occurred 
instead of screening osteoporosis which is more cost effective. 
Additionally, if patients find that their healthcare providers did 
not see osteoporosis as important, they were less likely to be 
tested for their BMD (Beaton et al., 2012). Another study by 
Jaglal et al (2003) involving healthcare providers had similar 
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issues raised by the participants in our study (Jaglal et al., 
2003). Their analysis consist of focus group discussions with 
Ontario family physicians, revealing that family physicians lack 
a rational for testing and were confused about the 
recommended management of osteoporosis (Jaglal et al., 
2003). Some of the principle barriers to osteoporosis care 
raised by the physicians were also described by the patients in 
their focus group: patient having too many co-morbidities, 
lack of knowledge regarding appropriate follow up. These 
concerns might all results at least in part from the limited time 
(Jaglal et al., 2003). Thus although patients are reliant on 
their doctors for directing their osteoporosis care, many 
physicians experience much the same uncertainty about the 
management of osteoporosis as patients. In another study, 
they have noted that the lack of knowledge, especially 
concerning the use of BMD-results may led to the under-
treatment of the presented patients (Duyvendak et al., 2011). 
This was not an issued raise by our participants. Our PCPs 
seem to be confident to interpret the BMD results.   
 
As for the patient factors, various studies were similar where 
they have noted that patients had poor knowledge on 
osteoporosis. They perceived it as a non serious disease as 
they could not link osteoporosis and fragility fractures (Beaton 
et al., 2012, Feldstein et al., 2008, Ha et al., 2014). Based on 
literature, the linking of osteoporosis and fractures is a difficult 
task as not only do non osteoporotic women have difficulty 
linking osteoporosis and fractures but women who are already 
diagnosed with osteoporosis are also unable to see the link 
(Besser et al., 2012). Beaton et al conducted a study involving 
focus group discussions with patients (men and women) who 
had fragility fractures echoed many of the issues raised by the 
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focus group participants in our study (Beaton et al., 2012). 
Similarly to the study by Beaton et al, our study shows that 
patients had a misconception that the BMD scan was an 
invasive procedure (Beaton et al., 2012). They feared that it 
was high in radiation.  
 
Although this seems to be a common problem in osteoporosis, 
the patients’ lack of osteoporosis knowledge is a new theme 
identified that was not part of the framework. However, for 
the effective prevention of osteoporosis and its fractures, 
patients should be equipped with the knowledge of the various 
prevention measures available. Hence, it was included as a 
theme in the patient factors. The lack of osteoporosis 
knowledge is perhaps the most modifiable barrier seen from 
the patient factors. Patients found themselves exposed to 
conflicting results and had difficulty accessing osteoporosis 
information.  The study identified many specific 
misunderstanding that could be addressed by patient 
education. However, patients differed in their requirement of 
osteoporosis knowledge levels. This suggests the need for 
individualized patient-centred information that addresses their 
particular needs and enables them to develop a coherent 
mental representation of their illness and its 
management(Lorish et al., 1985).  
 
The lack of osteoporosis knowledge and a perception that it is 
not serious led our patients to have a nonchalant attitude 
towards osteoporosis prioritizing other diseases. Similar 
findings were found by Beaton et al where other health 
conditions were noted as barriers to starting osteoporosis 
treatment (Beaton et al., 2012). Patients also were perceived 
to have difficulty in adhering to treatment and preventive 
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lifestyle measures. It was suggested that patient education 
can assist to manage this problem (Sedlak et al., 2000, Burke-
Doe et al., 2008). However whether these interventions affect 
patient outcomes and future fracture incidence has not been 
well studied. In addition, even if osteoporosis educational 
materials are provided to the patients at risk for osteoporosis, 
this is often not enough to change knowledge, attitude and 
behaviours regarding prevention of osteoporosis (Etemadifar, 
2013, Kasper et al., 1994). Nonetheless, knowledge of 
osteoporosis plays an important role in developing attitudes 
towards the disease which in turn impacts health care 
behaviours (Andersen, 1995).  
 
Other findings, which have implications for future 
interventions in osteoporosis screening includes 
communication and the doctor-patient relationships. Previous 
studies have shown that the doctor-patient relationship were 
important to ensure that patients follow treatment advice 
(Haskard Zolnierek and DiMatteo, 2009, Lau et al., 2008). 
Patients from these studies commented that when they had a 
good relationship with their doctors, they wanted to follow 
their instructions which could possibly include advice on 
preventive measures. Improved doctors-patient 
communication can be incorporated into future interventions, 
including education for healthcare professionals. Relationships 
should also be supportive and address the fears and concerns 
that patients have about osteoporosis, but may have difficulty 
expressing. Feedback from BMD scans was crucial motivations 
of adherence for this group. Scans provide concrete 
information about disease progression which is fundamentally 
important in a condition which is asymptomatic and often 
invisible to patients (Besser et al., 2012).    
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Additionally, patient factor noted barriers such as the 
healthcare professionals were perceived to be incompetent. 
This may be because UMMC is a teaching hospital and some of 
the healthcare professionals are currently undergoing a family 
medicine training programme, and may not be as experienced 
as their senior colleagues. Another explanation to this would 
be the effect of a high workload may increase the probability 
of the healthcare professionals making errors leading to the 
perception of incompetency (Tully and Buchan, 2009).  
 
Other patient factors include language barriers. Patients with 
limited language proficiency have problems with healthcare 
access, comprehension, adherence and receive lower quality 
of care overall. As prevention activities are not easily 
monitored an understanding of its importance is crucial to 
ensure it is practiced as necessary. Strategies to overcome 
language barriers in practice include employing diverse 
healthcare workforce and using translation services when 
necessary. Preparing healthcare professionals to serve in 
diverse communities can be done by offering medical language 
courses in medical schools to help familiarize students with 
medical terminologies they will encounter in different 
communities.  
 
The cost of medications and BMD scans influenced the 
likelihood of patients going for osteoporosis screening(Ha et 
al., 2014). Conversely, a study in US found that the cost of 
medication and screening was not seen as a major problem for 
the patients (Feldstein et al., 2008). Nonetheless, in our study 
participants perceive that the cost of medications and 
screening procedures are expensive. However, UMMC is a 
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government clinic which means that the prices that patients 
are experiencing is a very minimal fee. 
 
Another common issue noted by patient’s in our and in other 
studies were time constraints whereby there was a lack of 
time for consultations between the patients and healthcare 
professionals (Beaton et al., 2012). It was mentioned that 
there was not enough time to address other issues such as 
prevention or screening aside from the chief complaint. 
Meadows and colleagues reported failure to communicate was 
a persistent barrier to osteoporosis treatment, as described in 
interviews conducted with women aged 45-65 years following 
a fragility fracture in an urban Canadian centre (Meadows et 
al., 2007). Other patients prioritize looking after grandchildren 
and their jobs instead of their doctors visit due to long waiting 
hours. This was similar in the study by Backett-Milburn where 
patients prioritize jobs as they needed to ‘keep going’ where 
dwelling on future health risk or illnesses were seen to be a 
diversion from getting on with the present (Backett-Milburn et 
al., 2000). 
  
In addition, access to the clinic was a particular barrier in our 
study unlike the west where access was not seen as a major 
barrier (Feldstein et al., 2008). Most Malaysian elderly are 
dependent on their children for transport to their clinic 
appointments. This may be because of the Malaysian culture 
where children are expected to take care of their elderly. 
Additionally, public transport to the clinic is not elderly 
friendly. Nonetheless, this was seen as barrier for our setting 
as a survey conducted on primary care practitioners noted 
that they were more likely to treat independently living adults 
(Simonelli et al., 2002). 
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2.4.4 Strength of the study 
The strength of our study was that we interviewed all relevant 
stakeholders for their views and opinions regarding an 
osteoporosis screening programme. Hence, we were able to 
gain an in depth understanding of the barriers towards this 
programme.  
 
2.4.5 Limitations of the study 
Only five policy makers were recruited out of a possible seven. 
However, the themes raised by the policy makers were similar 
to that raised of other healthcare professionals such as 
doctors, pharmacists and nurses suggesting that data 
saturation have occurred. We also did not include men in our 
study. It is possible that different factors will affect men in 
osteoporosis screening, which need to be explored by further 
research. An expansion to this study would be to include the 
perceptions of endocrinologist or orthopaedic surgeons.  
 
2.4.6 Conclusion 
Our study identified the various barriers and facilitators 
encountered by nurses, doctors, pharmacists, patients and 
policy makers regarding an osteoporosis screening 
programme. Barriers and facilitators occurred at seven 
different levels of the healthcare system: governmental, 
organizational and management, work environment, 
individual, team, task and patients. Tackling the issue of 
osteoporosis screening should not happen only at the work 
force level. A more comprehensive osteoporosis screening 
programme should be designed and developed involving upper 
management.  
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2.5   Research question 2: Can Malaysian 
pharmacists expand their non dispensing role 
in an osteoporosis screening? 
2.5.1 Introduction 
In order to answer this research question we began by 
exploring the relevant stakeholders’ perception on the: current 
role of pharmacists, future pharmacists’ role and the relevance 
of inter-professional collaboration. To the best of our 
knowledge, there is no study specifically exploring the role of 
the Malaysian pharmacist in osteoporosis. A lack of reported 
evidence on stakeholder’s perception on the pharmacists’ role 
noted that there was a need to explore these issues in 
Malaysia. Therefore, a qualitative research approach using in-
depth interviews was chosen for this phase.  
 
2.5.2 Method 
The second research questions were explored concurrently 
with the first research question. The research methods, data 
management and analysis were conducted exactly the same 
way as described previously (section 3.4.1). However a 
different theoretical framework was used during the analysis 
of the relevance of was different. Hence, only the theoretical 
framework will be discussed for this section.  
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2.5.2.1 Theoretical framework: D’Amour Model 
We used the D’Amour model as it was developed based on a 
model of collaboration, which applies to inter-professional and 
inter-organizational collaboration in healthcare organizations. 
It can be used to analyze the increasingly complex and 
heterogeneous multi level systems of personels collaborating 
such as in the primary care clinic. D’Amour et al developed 
this model following a study of inter-professional collaboration 
in a primary-healthcare setting and tested it in healthcare 
networks. This model allows us to determine the level of inter-
professional collaboration and areas of improvement (D'Amour 
et al., 2008).  
 
The D’Amour model suggest that collective action can be 
analyzed in terms of four dimensions operationalized by ten 
indicators. Figure 2.3 shows that the four dimensions are 
interrelated and influence each other. Two of the dimensions 
involve relationships between individuals: shared goals and 
visions and internalization. The other two dimensions 
(governance and formalization) involve organizational setting 
which influences collective action. Table 2.6 presents 
description of each dimension. These four dimensions and 
their interaction capture the processes inherent in 
collaboration. Nonetheless, they are subjected to influences 
such as resources, financial constraints and policies and 
should be taken into account as determinants of collaborative 
processes (D'Amour et al., 2008).  
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Figure 2.3: The D’Amour model of collaboration (D'Amour et al., 2008) 
 
                             
Governance 
- Centrality 
- Leadership 
- Support for innovation 
- Connectivity 
Shared goals and vision 
- Goals 
- Client-centred orientation vs other 
allegiances 
Internalization 
-Mutual acquaintanceship 
-Trust 
Formalization  
- Formalization of tools 
-Information exchange 
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Table 2.6: Description of each dimension (D'Amour et al., 
2008) 
Dimension Description 
Shared goals 
and vision 
The existence of common goal and appropriation by 
the team, the recognition of divergent motives and 
multiple allegiances and the diversity of definitions 
and expectations regarding collaboration 
Internalization Awareness by professionals of their 
interdependencies and of the importance of 
managing them. This translates into a sense of 
belonging, knowledge of each other’s values and 
discipline and mutual trust 
Governance Leadership function that support collaboration by 
giving direction to and supports professionals as 
they implement innovations related to inter-
professional and inter-organizational collaborative 
practices.   
Formalization Structuring clinical care by documented procedures 
that communicate desired outputs and behaviours 
exist are being used. It clarifies expectations and 
responsibilities 
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The 10 indicators can then be categorized to three levels 
representing the level of achievement of an indicator. Level 
three is called active collaboration which is the maximum level 
of achievement. It refers to a setting that has successfully 
established stable collaboration and is sustainable despite 
uncertainties in the health care system. Level two is called 
developing collaboration, it is collaboration that is not stable 
and may still be subjected to re-evaluation as a consensus has 
not been reached. Although progress on collaboration is being 
made, it would require more time to achieve an active 
collaboration. The minimum level of achievement is level one 
known as potential/latent collaboration. This level refers to 
collaboration that does not yet exist or has been blocked by 
conflicts that are so serious that the system cannot move 
forward. The level 1-3 for each indicator are explained in Table 
2.7. Based on these levels, a visual representation of 
collaborations is possible (D'Amour et al., 2008).  
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Table 2.7: Indicators of collaboration according to levels (D'Amour et al., 2008) 
Indicators Active Collaboration LEVEL 3 Developing Collaboration 
LEVEL 2 
Potential or Latent Collaboration 
LEVEL 1 
Goals Consensual, comprehensive 
goals 
Some shared ad hoc goals Conflicting goals or absence of 
shared goals 
Client-centred 
orientation vs. 
other allegiances 
Client-centred orientation Professional or organizational 
interests drive orientations  
Tendency to let private interests 
drive orientations  
Mutual 
acquaintanceship 
Frequent opportunities to 
meet, 
regular joint activities 
 
Few opportunities to meet, 
few 
joint activities 
No opportunities to meet, no 
joint 
activities  
Trust Grounded trust Trust is conditional, is taking 
shape. 
Lack of trust 
Centrality Strong and active central 
body that 
fosters consensus 
Central body with an ill-
defined role, ambiguous 
political and strategic role. 
Absence of a central body, quasi 
absence of a political role. 
Leadership Shared, consensual 
leadership 
Unfocused, fragmented 
leadership 
that has little impact 
Non-consensual, monopolistic 
leadership 
Support for 
innovation 
Expertise that fosters 
introduction 
of collaboration and 
innovation 
Sporadic, fragmented 
expertise 
Little or no expertise available to 
support collaboration and 
innovation 
Connectivity Many venues for discussion 
and 
participation 
Ad hoc discussion venues 
related 
to specific issues 
Quasi-absence of discussion 
venues 
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Formalization 
tools 
Consensual agreements, 
jointly 
defined rules 
Non-consensual agreements, 
do 
not reflect practices or are in 
the process of being 
negotiated or 
constructed 
No agreement or agreement not 
respected, a source of conflict 
Information 
exchange 
Common infrastructure for 
collecting and exchanging 
information 
Incomplete information-
exchange 
infrastructure, does not meet 
needs or is used 
inappropriately 
Relative absence of any common 
infrastructure or mechanism for 
collecting or exchanging 
information 
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2.5.3 Results 
Results were divided to three sections the current role of the 
pharmacists, the expansion of the pharmacists’ role and the 
need for inter-professional collaboration. 
 
2.5.3.1 Participants’ characteristics 
Please refer to section 3.4.2.1 and Table 3.2 for the 
participants’ characteristics. 
 
2.5.3.2 The current role of the pharmacists as 
perceived by the patients, nurses, doctors, 
pharmacists and policy makers 
Pharmacists were principally perceived by participants to be 
suppliers of medication, although there was some recognition 
of roles in providing medication safety, medication costing and 
medication advice [Table 2.8].  
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Table 2.8: Current perceived pharmacists’ role by patients, 
nurses, doctors, pharmacists and policy makers 
Current perceived pharmacists 
role 
Sub themes 
Suppliers of medication Dispensing of medications 
Approval of medication supply 
Medication safety Ensure patients receives the 
appropriate medications 
Medication advice Medication advice to patients 
Medication advice to other 
healthcare professionals 
Medication costing Budgeting of  medication fund 
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2.5.3.2.1 Suppliers of medication 
2.5.3.2.1.1 Dispensing medications 
The supplying of medications by dispensing was seen to be the 
core duty of the pharmacists. Dispensing was perceived to be 
an activity where the pharmacists receives a prescription from 
the patients at the counter and supplies the appropriate 
medication. If it is a repeated prescription, the pharmacists 
would set another appointment date for the patients to collect 
the medication. 
 
“So I take the (medication from the pharmacist for the) first 
time... (then) they give me another date to, replenish... (my 
medication in about) six months or one year... appointment. 
That’s all...”     (PT-16/F/70y) 
 
2.5.3.2.2 Approval of medication supply 
Additionally, the supplying of medications also refers to the 
pharmacists’ role in the UMMC Drugs and Therapeutics sub-
committee whereby policies about medication usage are 
determined. Various policies are approved to only allow certain 
group of specialist to prescribe certain medications. For 
example, osteoporosis medications can only be dispensed if a 
BMD scan indicates osteoporosis and if it is prescribed by an 
endocrinologists, orthopaedics and gynaecologists. Therefore, 
the pharmacists would need to ensure the appropriate forms 
and procedures are conducted before the medication can be 
dispensed to the patients.  
 
“So the pharmacists will assess if the patients can get the 
medication for free, whether the doctor can prescribe the 
medication or not. Because previously, Fosamax we had to 
attach the BMD report.”    (NUR-9/F/42y) 
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2.5.3.2.3 Medication safety 
2.5.3.2.3.1 Ensure patients receives the 
appropriate medication 
The pharmacists were seen to be the final safety net before 
the patients take home their medications. As the primary care 
clinic has a lot of trainee doctors, the pharmacists’ role to 
ensure that the patients receive the appropriate medication is 
crucial. To elaborate on this, the pharmacists play an 
important role to check the appropriateness of the medication 
in terms of: indication, dose and interaction. 
 
“... At the moment the role... (is) making sure that... the 
med(ication), the patient is receiving is safe... The main focus 
is safety... whatever prescription that come in... (we ensure 
the) dose, the combination of products... is safe for the 
patient(s)...”      (PHARM-8/F/29) 
 
2.5.3.2.4 Medication advice 
2.5.3.2.4.1 Medication advice to patients  
The pharmacists were also recognised for their role in giving 
medication advice. The pharmacists would dispense the 
medications and provide information to the patients regarding 
the medications. The information provided includes the 
indication, mode of action, side effects and method of taking 
the medications. The monitoring of the patients adherence 
and compliance is also part of this process. There were some 
patients who recognized the pharmacists’ role in advice for 
minor ailments and supplements.  
 
“Pharmacist, I think it’s very important... the role would be to 
explain to the patients regarding the indication of the 
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medication, the mode of action and the proper way of taking 
the medications.”   (DR-3/F/36y) 
 
2.5.3.2.4.2 Medication advice to other healthcare 
professionals 
Apart from that, pharmacists were seen by the other 
healthcare professionals such as doctors and nurses to be 
medication experts. They would seek advice from the 
pharmacists regarding: side effects, interactions, dosage, 
approval to prescribe and availability. However this is not a 
common occurrence.  
 
“But for me... the pharmacist relationship is... just to ask 
about the drugs side effects, the drugs whether (it) can be 
prescribe, about the dosage, everything...” (DR-8/F/29y) 
 
2.5.3.2.5 Medication costing 
2.5.3.2.5.1 Budgeting of medication fund 
Pharmacists were seen to be involved in medication costing 
via the UMMC Drugs and Therapeutics sub-committee. The 
policy to only allow certain groups of specialist to prescribe 
certain medications is part of fund management. Due to the 
shortage of funds there was a shortage of medications. Hence, 
pharmacists at the upper management level would need to 
develop policies to ensure sufficient medication is available 
where as pharmacists at the frontline would need to ensure 
these policies are adhered too.  
 
 “(This policy is to) save cost because we have to ensure that 
the usage of the medication is not too high. Hence, we limited 
it to a certain amount of patients (whom are under the 
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specialists’ care). Therefore, we are forced to do screening of 
prescribed medication this way.”    (POL-5/M/44y) 
 
2.5.3.3 The expansion of the pharmacists’ non-
dispensing role to osteoporosis screening as 
perceived by patients, nurses, doctors, 
pharmacists and policy makers 
Nonetheless, doctors, nurses, patients, policy makers and 
pharmacists themselves were eager for pharmacists to expand 
their role beyond medication: supply, advice, costing and 
safety. The stakeholders perceived that the pharmacists 
should expand their role in terms of counselling, creating 
awareness and screening of osteoporosis.  
 
“But I think we are actually well position to actually do... this 
screening and in fact to do the counsel(ing) (and) educating 
the public.”      (POL-2/F/51y) 
 
2.5.3.3.1 Counselling 
Counselling was seen to be conducting activities such as the 
current medication therapy adherence and compliance (MTAC) 
clinic conducted for diabetic patients. This was an 
individualized service provided by the pharmacists. 
Pharmacists assist the patients in adjusting their insulin dose 
and give lifestyle advice. Recommendations to doctor 
regarding therapy were also given if necessary. However, this 
service is only conducted for diabetics and patients on 
warfarin. Therefore, stakeholders noted the possibility of this 
kind of services to be extended to osteoporosis and other 
diseases. Additionally, group counselling by the pharmacists 
was also suggested.  
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“I want the MTAC osteoporosis to be implemented again in our 
hospital after proper planning... because...  from here we 
can... reach out to the public because... my daily job. I think 
(it) is very... difficult for me to actually talk to them 
(patients).”      (PHARM-10/F/28y) 
 
2.5.3.3.2 Creating awareness of osteoporosis 
The second area suggested was creating awareness on 
osteoporosis and public health in general. Stakeholders 
suggest various ways such as creating posters, campaigns or 
giving health talks during clinic session. However, this could 
also be done opportunistically. For example, pharmacists could 
casually mention to a postmenopausal women if she has 
undergone a BMD scan. Pharmacists were seen to be most 
accessible to patients at the community level. Therefore, 
pharmacists are in an ideal position to create awareness on 
osteoporosis and various diseases.  
 
“I think they (primary care pharmacists) have (a) big role 
because... they are more... involved with community... they 
have a major role in screening, not only osteoporosis, other 
diseases as well. And then to educate patients also, they 
have... a big role.”     (DR-5/M/30y) 
 
2.5.3.3.3 Screening of osteoporosis  
Lastly, the pharmacists were seen to be in an ideal position to 
screen for osteoporosis. This is because pharmacists were 
seen to be more accessible. Patients would visit the 
pharmacists several times before their next doctor’s 
appointment for their repeat prescriptions. This gives the 
pharmacists the opportunity to tap into screening and 
prevention of osteoporosis. Patients also perceived 
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pharmacists to be knowledgeable and trust pharmacist for 
advice. 
 
“Pharmacist can explain to us... rheumatism (referring to 
osteoporosis)...  what you (kind of supplements to) take... 
we.... trust the pharmacist.”    (PT-6/F/72y) 
 
Currently, both the doctors and nurses are unable to screen 
for osteoporosis systematically due to the time constraint. If 
pharmacists were involved in osteoporosis screening it was 
seen as an improvement to the healthcare system. This 
facilitates the healthcare professionals to understand each 
others’ scope of practice better leading to a more effective 
healthcare system. Additionally, the involvement of 
pharmacists in osteoporosis screening would lighten the 
workload of doctors and nurses. This in turn saves both the 
patients and healthcare professionals’ time. The pharmacist 
would screen for osteoporosis and the doctors would focus on 
diagnosis and treatment.  Hence, the pharmacists could play a 
part in osteoporosis screening alerting the doctors when a 
BMD scan may be needed. This will assists in detecting 
untreated osteoporosis. 
 
“...Pharmacist can help to save (the) doctor’s time... because 
some patient(s) (do not) need to (be) referred (to the) doctor. 
Waste both... (the) doctors’ and patients’ time... So if (the) 
pharmacists can do that (osteoporosis screening), it’s good.” 
      (PHARM-2/F/24y)  
  
 Interviewed pharmacists referred to their current role as 
‘robotic dispensers’ and unanimously agreed for an expansion 
of the pharmacist role in osteoporosis screening. They felt that 
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they weren’t contributing enough to the society and were not 
satisfied with their current job scope. Therefore, there is a 
need to expand the pharmacist non-dispensing role in 
osteoporosis screening. 
 
“(We) dispense like (a) robot...  you just push, push, push the 
thing (medication) out.”   (PHARM-6/F/27y) 
 
Lastly, all the participants concurred that the expansion of the 
non-dispensing role of the pharmacists to osteoporosis 
screening was seen as progression for the profession. The 
pharmacists’ skills were considered underutilized and shifting 
from a more medication-centred approach to a more patient-
orientated approach. This emphasizes the need to expand the 
pharmacists’ role to osteoporosis screening. Additionally, 
pharmacists were well equipped with the knowledge on the 
disease, treatment and prevention.  Stakeholders noted the 
success of pharmacists’ independent prescribing role overseas. 
They unanimously agreed that the pharmacists’ role should be 
expanded to osteoporosis management. 
 
“(The pharmacists’) job scope is expanding all this time… I 
wouldn’t be surprised if pharmacist (start) screening (for 
osteoporosis) since (there are) all ready… pharmacist 
prescribers (overseas)...”   (PHARM-11/F/28y)  
 
2.5.3.4 Need for inter-professional collaboration in 
osteoporosis screening 
However, barriers to the expansions of the pharmacists’ role 
to osteoporosis screening were noted. These barriers include 
patients perceiving pharmacists to be profit driven, inadequate 
staffing and infrastructure. Moreover, the Malaysian 
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pharmacists do not have access to patients’ case notes and do 
not have the sole right to dispense medications with doctors 
currently dispensing is another challenge to overcome. These 
were some of the barriers but the main barrier noted by all 
stakeholders was the lack of an inter-professional 
collaboration in osteoporosis screening, prevention advice and 
disease management.  
 
“Because... we don’t understand our role and responsibility. I 
mean among the healthcare providers... We should actually 
clear... the doubts of the healthcare professionals... so that... 
everyone of us will be working quite closely together without 
much prejudice.”      (PHARM-10/M/28y) 
 
These findings were further examined using the D’Amour’s 
structural model of collaboration which encompasses four 
main themes: shared goals and visions, internalisation, 
formalisation and governance. This model supports our data 
which highlights a lack of governance and formalisation, that 
fosters consensus, leadership, protocol and information 
exchange. Based on the D’Amour’s model, this primary care 
clinic is described as developing towards an inter-professional 
collaboration in managing osteoporosis but is still in its early 
stages. The Kiviat graph [Figure 2.4] provides a schematic 
view of collaboration in our setting.  
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Figure 2.4: Kiviat graph lays out the schematic view of 
collaboration in the primary care setting. 
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2.5.3.5 Share goals and vision 
With respect to the shared goal and vision dimension, there 
were two indicators goals and client-centred orientation versus 
other allegiances. The analysis of the data showed that the 
healthcare professional team (nurses, pharmacists, doctors, 
policy makers) and patients had a common set of goals 
namely: to increase osteoporosis awareness and to increase 
osteoporosis screening.  
 
Stakeholders were eager to increase the public’s awareness of 
osteoporosis. They wanted to increase the public’s awareness 
not only of osteoporosis but of other diseases such as 
hepatitis. The stakeholders were supportive in working more 
closely with the pharmacists, suggesting that the pharmacists 
conduct counselling, give lifestyle and preventive advice. On 
top of that, they suggested that osteoporosis awareness can 
also be improved via the pharmacists giving daily health talks 
at the clinics. 
 
“If the pharmacist wants to do some counselling ….  want(s) 
to give a talk… want(s) to do a video… to create awareness 
among the public, among the patients who are here in the 
clinic. … most welcome to….”  (DR-9/F/30y)  
 
The second goal was to increase osteoporosis screening. To 
attain this goal stakeholder noted that the solution could be a 
pharmacist-led osteoporosis screening programme in 
collaboration with the doctors. This point is clearly expressed 
by the one of participants: 
 
“I think probably the pharmacist can... detect the problem 
(osteoporosis)... then  they can suggest to the physician 
 152 
 
that... the patient will benefit from the BMD (scan). But... I 
don’t think it should be... the pharmacist... ordering (the BMD 
scan) because... we (doctors)... suppose to co-relate with the 
clinical... condition and we’re suppose to... advice (on the) 
appropriate treatment.”    (DR-4/M/38y) 
 
The results for the shared goals and vision showed that the 
stakeholders had common goals centred on client needs. They 
wanted to improve the healthcare system and the progression 
of the pharmacy profession to give better quality services to 
the patients. Therefore, these two indicators are achieved at 
level 3. 
 
2.5.3.6 Internalization 
Regarding the internalization dimension, there were two 
indicators namely mutual acquaintanceship and trust. The 
doctors, pharmacists, nurses, policy makers were not mutually 
acquainted with the pharmacists’ role. Additionally, policy 
makers questioned if the pharmacists themselves understood 
their own role. Hence, the policy makers, doctors, nurses and 
pharmacists did not understand each others’ scope of practice.  
 
“I really (have) no idea what… (the pharmacist does)… 
(Laughs).”      (DR-8/F/29y) 
 
Although the mutual acquaintanceship was low at level 1, the 
indicator trust achieved a moderate level 2. Despite not fully 
understanding the role of the pharmacists, stakeholders 
believed that the pharmacist had the knowledge and 
capabilities to conduct osteoporosis screening. However, other 
doctors’ impression was that pharmacists were unable to 
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contribute in any manner except in medication supply and its 
cost. 
“..certain doctors feel superior to (the) pharmacist... They 
(doctors) think all... (pharmacists)… know is just (the) names 
of the drugs and what is available here and how much it 
costs.”     (PHARM-5/F/29y) 
 
2.5.3.7 Governance 
In relation to governance, the data showed weak centrality 
(level 1). There is a lack of directive from the upper 
management. According to the stakeholders interviewed upper 
management must become more involved to direct the 
implementation of a collective approach for an osteoporosis 
screening programme. 
 
“It boils down to policy makers, what do they want us to do. 
Then we will do it.”    (PHARM-11/F/28y) 
 
There was no data to support innovation (level 1). Nor has it 
create the impression that there is expertise or funding to 
promote innovation in a collaborative process and thus 
provided the support needed to develop collaboration. 
Leadership exist but is unfocused and has little impact (level 
2). The upper management gives the opportunity to the junior 
pharmacists to be innovative. However, the junior pharmacists 
are not ready to take up the opportunity.  
 
“Our meeting ... (we) talked about (the) pharmacists’ role and 
responsibilities and issues related to it… we want to see the 
young ones (pharmacists)… coming up.. we have to nurture 
them (young pharmacists)... But if they are not ready then it’s 
going to be very difficult.”    (POL-3/M/57y) 
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Connectivity is, as it were poor (level 1). Essentially there was 
a lack of communication between both the doctors and nurses 
with the pharmacists. Some of the interviewed participants 
mentioned that they have never spoken to a pharmacist and 
that the interviewer (TLS) was their first pharmacist 
encounter. Reasons identified were that pharmacists work 
mostly within the pharmacy area. They also were not 
integrated to participate in other hospital activities such as 
health awareness campaigns.  
 
“... Our pharmacists (are) ‘lock(ed) up’ (at the pharmacy).”      
(NUR-3/F/43y) 
 
A similar situation was noted by the patients, there was 
minimum communication with the pharmacists. 
Communication was limited to the dispensing of medications. 
Some patients perceived the pharmacists to unapproachable 
as they were too busy.  
 
“The pharmacist... I don’t communicate with them, just by the 
numbers only, whatever... but the dispensing... is ok.”  
       (PT-18/F/57) 
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2.5.3.8 Formalization 
Analysis of the formalization dimension shows that there was 
no clear guideline pertaining to osteoporosis screening or 
protocol on the division of responsibilities between the 
healthcare professionals (level 1). Stakeholders mentioned 
that the guidelines were outdated. Protocols and directives on 
who should conduct screening were unavailable making 
healthcare professionals confused on what can be done.  
 
“... Screening... I don’t know... what... legislation... says 
about pharmacists... to educate people.”    
       (DR-4/M/38y) 
 
The channels for exchanging information were level 1 as there 
were separate divisional meetings. The meetings were held 
together with junior and senior staff. However, meeting were 
either held with pharmacists or nurses or doctors only. There 
was no inter-professional meeting. Therefore, this only 
resolves issues within the pharmacy and not aid in inter-
professional collaboration. 
 
“Our meeting is professional... irrespective of grade 
(junior/senior)... (we) talk about pharmacy role and 
responsibilities and issues related to it.”(POL-3/M/57y) 
 
To sum up this primary care clinic is in its early stages of 
inter-professional collaboration in osteoporosis management. 
It achieved level 2 in the sense that it is evolving but remains 
incomplete.  
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2.5.4 Discussion 
Pharmacists were principally perceived by all participants to be 
suppliers of medication, although there was some recognition 
of roles in providing medication advice. Nonetheless, all the 
stakeholders were eager for pharmacists to be more proactive 
via inter-professional collaboration in counselling, creating 
awareness and screening of osteoporosis. Based on the 
D’Amour’s model, this primary care clinic is described as 
developing towards an inter-professional collaboration in 
managing osteoporosis but is still in its early stages. 
 
To our knowledge, there are no studies reporting on the 
perception of patients, nurses, pharmacists, doctors and 
policymakers with regard to the pharmacist’s role in 
osteoporosis screening at the primary care setting. However 
there are numerous studies on community pharmacist 
perceptions on their role in osteoporosis screening which 
found similar results to our study. A study published in 1996 
from Canada using a mailed survey found that only a few 
pharmacists reported routinely conducting prevention 
activities. However, over 90% believed it is important to 
integrate prevention into practice (O' Loughlin et al., 1999).  
Similarly another Canadian web based survey reported that 
pharmacists spend most of their time on dispensing duties but 
over 60% believed that the time had come to expand their 
role in areas such as disease prevention and health promotion 
(Jorgenson et al., 2011). This shows that the progression of 
the Malaysian pharmacists is similar to that of its overseas 
counterpart. 
 
Various studies also concur that pharmacists are considered 
credibly for counselling as they are more easily accessible 
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(Chandra et al., 2003). They also have various knowledge and 
skill regarding various public health issues (Chandra et al., 
2003, Anderson et al., 2009, MacLaughlin et al., 2005).  
 
Additionally, a systematic review conducted on the beliefs and 
attitudes of pharmacist in relation to pharmaceutical public 
health showed that although most view public health services 
as important and part of their role, various organizational 
barriers (lack of time, integration, staff and trust) limit their 
involvement (Eades et al., 2011, George et al., 2010). 
Therefore, these results confirm that the profession largely 
accepts changing the role of pharmacists from traditional 
dispensing duties to include greater involvement in health 
promotion and prevention. Another interesting point is that 
perceptions of pharmacists have not changed much in more 
than 10 years. Although pharmacists largely believe that they 
should be doing more minimal changes to the profession has 
occurred over the past 10 years (Eades et al., 2011).  
 
Conversely another survey where pharmacists were similarly 
questioned about public health issues, the majority of the 
respondents considered they should be involved in 
hypertension (82%), diabetes (76%) and smoking cessation 
(84%), only 44% and 34 % thought the same for osteoporosis 
and risk of fall respectively. These finding suggest that 
pharmacists may not regard osteoporosis and fall risk as being 
the highest importance (Laliberté et al., 2012). Indeed, the 
stakeholders in the present study admitted osteoporosis is not 
a priority. Given the demonstrated benefits of greater 
involvement in the management of osteoporosis, better ways 
must be found to translate this evidence based knowledge into 
the primary health care system (Laliberté et al., 2011). 
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Several studies have evaluated the effectiveness of primary 
care intervention to improve the management of osteoporosis. 
A recent meta analysis showed that these intervention 
(targeting at-risk patients, primary care physician and 
community pharmacists) may improve the management of 
osteoporosis but improvements are often modest (Laliberté et 
al., 2011). A Canadian study using self-administered 
questionnaires to community pharmacists and public health 
officers noted that although a majority of the pharmacists 
believed that they should be involved in osteoporosis 
screening (46.6%) and fall prevention (50.3%); however only 
17.4% of the pharmacies reported being involved in this 
activity. The barriers noted in this study were similar to our 
study such as the lack of time (78.8%) and lack of 
coordination with other healthcare professionals (54.5%) 
(Laliberté et al., 2013). This suggests that the development of 
these intervention where health care professionals work as 
individual groups does not appear to be an efficient option to 
optimize health care .Therefore, the results of the present 
study provide important information on the development of 
osteoporosis care using inter-professional collaboration. 
 
Although, research has shown that pharmacists can indeed 
improve the quality of health care delivery in areas such as 
improving prescribing, reduce healthcare utilization and 
medication cost and contributes to clinical improvements in 
many chronic medication conditions such as cardiovascular 
and diabetes (Dolovich et al., 2008, Machado et al., 2007a, 
Machado et al., 2007b, Nkansah et al., 2010). Even in the 
management of osteoporosis, integrating community 
pharmacists into osteoporosis management has results in an 
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increase in bone mineral density scan and calcium intake 
(Yuksel et al., 2010, McDonough et al., 2005, Crockett et al., 
2008, Liu et al., 2007, Barris Blundell et al., 2006, Law and 
Shapiro, 2004, Goode et al., 2004). However, the pharmacists 
are not well integrated into primary care. 
 
The areas for improvement based on the D’Amour model 
should be noted in order for an efficient osteoporosis 
screening programme to be established. At this point, we 
suggest that internalization (mutual acquaintanceship and 
trust), governance (connectivity) and formalization 
(information exchange) may be addressed by conducting a 
pharmacists-led osteoporosis screening programme.  A study 
conducted by Dolovich et al (2008) integrated the pharmacists 
into the primary care practice to prevent drug-related issues. 
Feedbacks from the physicians were that they were able to 
recognize the benefits of working with pharmacists directly 
integrated into their practice. Physicians showed an increase 
perception and understanding towards the pharmacists’ role. 
Pharmacists on the other hand recognized the need to 
improve their skills, be more proactive and improve 
communication with their fellow healthcare team members 
(Dolovich et al., 2008). An osteoporosis screening programme 
will foster opportunities to address these issues. 
 
Other areas for improvement include governance (centrality 
and support for innovation) and formalization (no clear 
guidelines). We hope that with the success of the programme 
it will render more centrality, support for innovation and a 
clear guideline on osteoporosis screening. This is known as the 
bottom-up approach which has been shown to be effective in a 
study where leaders and professionals developed 
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interdependency, measured collective performances and 
communicated feedback. Such approach makes managers 
aware of the need for inter-professional collaboration. It helps 
facilitate leadership, increased transparency and collective 
control with benefits for both patients and providers 
(Hjalmarson et al., 2013).  Given the increasing stress on the 
healthcare system due to an aging population and the 
consequent rise in the prevalence of osteoporosis, a more 
marked shift toward a wider public health role for pharmacists 
is indeed possible by incorporating inter-professional 
collaboration. 
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2.5.5 Conclusion 
Although pharmacists were primarily seen as medication 
experts, the stakeholders unanimously agree that the 
pharmacy profession should shift towards being more patient-
orientated approach. Inter-professional collaboration is needed 
to facilitate the expansion of the non-dispensing role in 
osteoporosis screening. Based on the D’Amour model our 
setting achieved level 2 which is developing towards inter-
professional collaboration in managing osteoporosis but it is 
still in its early stages. There is room for improvement in the 
areas of internalization, governance and formalization. The 
pharmacy profession in Malaysia is gradually moving in the 
direction of its overseas counterparts where inter-professional 
collaboration in osteoporosis management is currently being 
practised. Efforts extending to awareness and acceptance 
towards the pharmacists role will be crucial for a successful 
change. Important changes cannot be envisioned without a 
real integration of community pharmacists into the public 
health primary care system. 
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2.6   Research question 3: Can a practical and 
sustainable osteoporosis screening 
programme be developed? 
2.6.1 Introduction 
We wanted to develop an acceptable, practical and sustainable 
osteoporosis screening programme. In order to answer this 
research question we used the theory of behaviour change 
wheel to design the intervention.  
 
2.6.2 Methods 
The third research question was explored concurrently with 
the first and second research question, as described 
previously. Although the research methods, data management 
and analysis were conducted exactly the same way, a different 
theoretical framework was used during the analysis. Hence, 
only the theoretical framework will be discussed for this 
section.  
 
2.6.2.1 Theoretical framework: Behaviour change 
wheel (BCW) 
The behaviour change wheel (BCW) theory was utilized as we 
wanted to develop an intervention to improve implementation 
of evidence-based health care. The changing of behaviour of 
the healthcare professionals, policy makers and others 
working within and with the healthcare system can improve 
the implementation of a complex intervention such as the 
osteoporosis screening programme.  The BCW is a framework 
for analyzing target behaviours in the context of the setting 
and considering the full range of intervention functions and 
policy categories that may be relevant to the intervention 
problems [Figure 2.5] (Michie et al., 2011).  
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Figure 2.5: The behaviour change wheel (Michie et al., 2011) 
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A systematic review of 19 published frameworks was used to 
derive the framework, none of the published frameworks were 
found to contain all the intervention functions known to be 
relevant to designing a behaviour change intervention. 
Therefore, the BCW was developed to provide a basis for 
identifying what it would take to achieve the desired behaviour 
change in terms of changes to capability, opportunity and 
motivation. This was called the COM-B system [Figure 2.6].  
 
The definition of capabilities is an individual’s psychological 
and physical capacity to engage in the activity concerned. It 
includes having the necessary knowledge and skills. For 
example, the capacity to engage in the necessary thought 
process such as comprehension and reasoning is a form of 
capability. As for opportunity it is defines as all factors that lie 
outside the individual that make the behaviour possible or 
prompt it. There were two types, physical opportunity and 
social opportunity. An example of this is cultural milieu that 
dictates the way the people think about things such as words 
and concepts that make up our language. With regard to 
motivation, it is defined as all those brain processes, 
emotional responses as well as analytical decision-making. 
Motivation is further distinguished from the  reflective 
processes (involving evaluations and plans) and automatic 
processes (involving emotions and impulses that arise from 
associative learning and/or innate disposition). In Figure 2.6 
the double arrows represents potential influence between the 
components of the system. To elaborate on this opportunity 
can influence motivation as can capability; enacting behaviour 
can alter capability, motivation, and opportunity (Michie et al., 
2011). 
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Figure 2.6: The COM-B system- a framework for 
understanding behaviour (Michie et al., 2011) 
 
 
 
 
 
 
 
It then links this to nine intervention functions (education, 
persuasion, incentivisation, coercion, training, restriction, 
environmental restructuring, modelling and enablement) and 
seven types of policy that could be used to implement these 
intervention functions (mass-media/marketing legislation, 
fiscal policy, service provision, guideline development, 
regulation and environmental/social planning). It forms the 
basis of a systematic analysis of how to make the selection of 
intervention and policies. Therefore, this assists in selecting 
the intervention function or functions most likely to be 
effective in changing the target behaviour. Table 2.9 presents 
the definition of the interventions and policies (Michie et al., 
2011).   
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Table 2.9: Definitions of interventions and policies (Michie et 
al., 2011) 
Intervention Definition 
Education Increasing knowledge or understanding 
Persuasion Using communication to induce positive 
or negative feelings or stimulate action 
Incentivisation Creating expectation of reward 
Coercion Creating expectation of punishment or 
cost 
Training Imparting skills 
Restriction Using rules to reduce the opportunity to 
engage in the target behaviour (or to 
increase the target behaviour by 
reducing the opportunity to engage in 
competing behaviours) 
Environmental 
restructuring 
Changing the physical or social context 
Modelling Providing an example for people to 
aspire to or imitate 
Enablement Increasing means/reducing barriers to 
increase capability or 
opportunity1 
Policies Definition 
Communication/marketing 
 
Using print, electronic, telephonic or 
broadcast media 
Guidelines Creating documents that recommend or 
mandate practice. This includes all 
changes to service provision 
Fiscal Using the tax system to reduce or 
increase the financial cost 
Regulation Establishing rules or principles of 
behaviour or practice 
Legislation Making or changing laws 
Environmental/social 
planning 
Designing and/or controlling the 
physical or social environment 
Service provision Delivering a service 
1 Capability beyond education and training; opportunity beyond 
environmental restructuring. 
 
The intervention strategy can then be provisionally established 
and specific types of behaviour change technique can be 
selected, guided by evidence, theory and practicalities to 
deliver the intervention [Table 2.10] (Michie et al., 2013).  
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Table 2.10: Taxonomy of 93 behaviour change techniques 
based on 16 clusters (Michie et al., 2013) 
Cluster Behaviour change technique (BCT) 
Scheduled 
consequences 
Punishment 
 Response cost 
 Chaining 
 Extinction 
 Discrimination training 
 Shaping 
 Negative reinforcement  
 Counter-conditioning 
 Thinning 
 Differential reinforcement 
Reward and threat Social reward 
 Material reward 
 Self-reward 
 Non-specific reward 
 Threat 
 Anticipation of future rewards or removal of 
punishment 
 Incentive 
Repetition and 
substitution 
Behaviour substitution 
 Habit reversal 
 Habit formation 
 Graded task 
 Overcorrection 
 Behavioural rehearsal/practice 
 Generalization of a target behaviour 
Antecedents Restructuring the physical environment 
 Restructuring the social environment 
 Avoidance/changing exposure to cues for the 
behaviour 
 Distraction 
Associations Discriminative (learned) cue 
 Time out 
 Escape learning 
 Satiation 
 Exposure 
 Classical conditioning 
 Fading 
 Prompts/cues 
Covert learning Vicarious reinforcement 
 Covert sensitisation 
 Covert conditioning 
Natural 
consequences 
Health consequences 
 Social and environmental consequences 
 Salience of consequences 
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 Emotional consequences 
 Self-assessment of affective consequences 
 Anticipated regret 
Feedback and 
monitoring 
Feedback and behaviour 
 Biofeedback 
 Other (s) monitoring and awareness 
 Self-monitoring of outcome of behaviour 
 Self-monitoring of behaviour 
Goals and planning Action planning (including implementation 
intentions) 
 Problem solving/ coping planning 
 Commitment 
 Goal setting (outcome) 
 Behavioural contract 
 Discrepancy between current behaviour and 
goal standard 
 Goal setting (behaviour) 
 Review behaviour goal(s) 
 Review outcome goal(s) 
Social support Social support (practical) 
 Social support (general) 
 Social support (emotional) 
Comparison of 
behaviour 
Modelling of the behaviour 
 Information about others’ approval 
 Social comparison 
Self-belief Mental rehearsal of successful performance 
 Self-talk 
 Focus on past success 
 Verbal persuasion to boost self-efficacy 
Comparison of 
outcomes 
Persuasive arguments 
 Pros and cons 
 Comparative imagining of future outcomes 
Identity Identification of self as role model 
 Self-affirmation 
 Identity associated with changed behaviour 
 Reframing 
 Cognitive dissonance 
Shaping knowledge  Reattribution 
 Antecedents 
 Behavioural experiments 
 Instructions on how to perform a behaviour 
Regulations Regulate negative emotion 
 Conserving mental resources 
 Pharmacological support 
 Paradoxical instruction 
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The authors recommend to start by understanding the 
problem, identifying key specific behaviours (often several) by 
asking questions of who needs to do what differently, when, 
where and how. Behavioural change can occur at different 
levels in healthcare such as with patients, with healthcare 
professional and at an organisational level. Next they 
recommended understanding the behaviours in the context 
whereby the COM-B model can be used to answer questions 
such as why the behaviours are as they are and what needs to 
change for the desired behaviour to occur (Michie et al., 
2011).  
 
Subsequently the developers need to consider the full range of 
possible intervention using the behaviour change wheel to 
select broad categories of intervention type. Then identify 
specific behaviour change techniques that can be selected to 
achieve the behaviour change (Michie et al., 2011).  
 
The developers then need to decide on the mode of delivery 
which could be face-to-face (individually/group) or distance 
(population level using media or individually tailored such as 
phone calls). Additionally, when selecting an intervention, 
mode of delivery and policy categories, issues such as 
evidence of effectiveness, local relevance, practicability, 
affordability and acceptability (public, professional and 
political) should be considered. Figure 2.7 summarizes this 
process. This model is well tested and has been shown to be 
useful in evaluating the 2010 English government tobacco 
control strategy and the National Institute for Health and Care 
Excellence (NICE) obesity guideline. Therefore, we have 
decided that this is the most suitable theory to develop the 
 170 
 
pharmacists-led osteoporosis screening programme (Michie et 
al., 2011).   
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Figure 2.7: Summary of approach to developing behaviour change intervention 
 
 
 
  
Target behaviour Deliver intervention Design intervention 
Select target 
behaviour 
Specify 
(Who, what, 
where, how) 
Understand 
(Why) 
Behaviour 
change 
techniques 
Intervention 
functions 
Mode of 
delivery 
Policy 
categories 
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2.6.3 Results  
2.6.3.1 Participants’ characteristic 
Please refer to section 3.4.2.1and Table 3.2 for the 
participants’ characteristics. 
 
2.6.3.2 The development of a pharmacist-led 
osteoporosis screening programme 
For our study, the intervention efforts are targeted at the 
barriers of patient factors. Based on the framework of factors 
influencing clinical practice, patient factors most directly 
influence the practice and outcome and the probability of an 
incident (Vincent et al., 1999). Additionally targeting other 
levels of the healthcare system would be beyond the scope of 
this PhD.  Table 2.11 displays the barriers from the patient 
factors, the target behaviours derived from the barriers 
followed by identification of the cause using the COM-B model. 
The BCW was then used to pick the intervention functions, 
specific behaviour change techniques and policy category. 
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Table 2.11: Intervention functions, behaviour change techniques and policy categories used to address the patient 
factors 
Patient factors Target behaviour Understanding of the 
behaviours based on the 
COM-B model 
Intervention function Behaviour change 
technique 
Policies category 
Condition (complexity and seriousness) Environmental/ social 
planning 
 Developing a 
practical and 
sustainable 
osteoporosis 
screening 
programme 
 
 Osteoporosis is 
perceived to be 
not serious 
 
 Patients to 
understand 
that 
untreated 
osteoporosis 
can be life 
threatening 
 Psychological 
capability 
 Reflective 
motivation 
 
 Education 
 Environmental 
restructuring 
 
Shaping knowledge 
 Provide 
information on 
consequences of 
untreated 
osteoporosis 
Antecedents 
 Restructuring 
the physical and 
social 
environment by 
implementing an 
osteoporosis 
screening 
Personality 
 Nonchalant 
attitude 
towards 
osteoporosis 
 
 
 
 Patients 
willing to 
conduct 
osteoporosis 
screening and 
prevention 
measures 
 
 Psychological 
capability 
 Automatic 
motivation 
 
 
 Education 
 Persuasion 
 Environmental 
restructuring 
 
Shaping knowledge 
 Provide 
information 
about 
osteoporosis 
Comparison of outcomes 
 Persuasive 
arguments on 
benefits of 
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screening and 
prevention 
Antecedents 
 Restructuring 
the physical and 
social 
environment by 
implementing an 
osteoporosis 
screening 
 
 Unwilling to 
listen to the 
healthcare 
professionals 
advice 
 Patients to 
trust 
healthcare 
professionals 
 Social 
opportunity 
 
 
 
 Environmental 
restructuring 
 
 
Antecedents 
 Restructuring 
the physical and 
social 
environment by 
implementing an 
osteoporosis 
screening 
programme 
Knowledge 
 Lack of 
knowledge 
 
 Improve all 
aspects 
patients 
knowledge 
towards 
osteoporosis  
 Psychological 
capability 
 Education 
 Environmental 
restructuring 
 
Shaping knowledge 
 Provide 
information 
about 
osteoporosis 
Antecedents 
 Restructuring 
the physical and 
social 
environment by 
implementing an 
osteoporosis 
screening 
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Communication 
 Language 
barrier 
 Create 
opportunities 
to 
communicate 
information 
regarding 
osteoporosis 
 Social 
opportunity 
 Physical 
opportunity 
 Environmental 
restructuring 
 
Antecedents 
 Restructuring 
the physical and 
social 
environment by 
implementing an 
osteoporosis 
screening 
Social factors 
 Financial 
constraints 
 
 Affordable 
osteoporosis 
screening and 
medications 
 Reflective 
motivation 
 Physical 
opportunity 
 Environmental 
restructuring 
 Enablement  
Antecedents 
 Restructuring 
the physical and 
social 
environment by 
implementing an 
osteoporosis 
screening 
Social support 
 Social support 
(financial) 
 
 Time 
constraints 
 
 Ensure the 
osteoporosis 
screening 
programme is 
conducted at 
a time 
convenient 
for the 
patients  
 
 Reflective 
motivation 
 Physical 
opportunity 
 Environmental 
restructuring 
 Enablement 
Social support 
 The osteoporosis 
screening 
programme to 
be conducted at 
a practical time 
for the patients 
Antecedents 
 Restructuring 
the physical and 
social 
environment by 
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implementing an 
osteoporosis 
screening 
 Short 
consultation 
time 
 
 Ensure 
sufficient 
time for 
consultation 
regarding 
osteoporosis 
 
 Social 
opportunity 
 Physical 
opportunity 
 Environmental 
restructuring 
 Enablement 
Social support 
 Sufficient 
consultation 
time 
Antecedents 
 Restructuring 
the physical and 
social 
environment by 
implementing an 
osteoporosis 
screening 
 Family 
circumstances 
Ensure that 
the 
osteoporosis 
screening 
programme is 
accessible to 
the patients 
 Physical 
opportunity 
 Environmental 
restructuring 
 Enablement 
Social support 
 The osteoporosis 
screening 
programme to 
be conducted at 
a practical time 
for the patients 
Antecedents 
 Restructuring 
the physical and 
social 
environment by 
implementing an 
osteoporosis 
screening 
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Difficulty to adhere to osteoporosis prevention measure 
Difficulty to adhere to 
osteoporosis 
prevention measure 
 Ensure 
patients 
difficulty to 
adhere to 
osteoporosis 
prevention 
measure is 
addressed 
 Physical 
capability 
 Reflective 
motivation 
 Automatic 
motivation 
 Education 
 Enablement 
 Environmental 
restructuring 
 
Shaping knowledge 
 Provide 
instruction on 
how to perform 
preventive 
measures 
Goals and planning 
 Prompt barrier 
identification 
Antecedents 
 Restructuring 
the physical and 
social 
environment by 
implementing an 
osteoporosis 
screening 
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2.6.3.3 Intervention function 
2.6.3.3.1 Environment restructuring 
We addressed all the patient factors using the intervention 
function environmental restructuring via the BCT antecedents. 
Antecedents involved restructuring the physical and social 
environment of the primary care clinic by implementing a 
pharmacists-led osteoporosis screening programme. 
Restructuring of the physical environment of the primary care 
clinic refers to incorporating the programme as one of the clinic 
services. This restructures the social environment by allowing 
both patient and healthcare professionals to communicate 
regarding osteoporosis screening. The osteoporosis screening 
programme was tailored to execute various BCT directed at the 
patients’ factors which will be elaborated in sections below. 
 
Additionally, the BCT antecedent allows the healthcare 
professionals to address the issue of language barriers which are 
caused by the lack of physical and social opportunity (COM-B 
model). Physical opportunity refers to the lack of a physical 
opportunity for the patients to undergo osteoporosis screening. 
Social opportunity refers to the lack of opportunity for the 
patients to communicate with the healthcare professionals.  By 
conducting an osteoporosis screening programme, the health 
care professionals will be able to prepare the osteoporosis 
information in various languages and communicate with a larger 
population. The patients will have an opportunity to conduct 
osteoporosis screening. 
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“... So (we) have to address (this)... larger ethnic groups, that 
are maybe Mandarin, or... English, then BM (Malay), Tamil 
(speaking)... So that... they can read and maybe they would 
understand, after that they can do something about it.”  
(DR-2/M/30y) 
 
Another barrier which was addressed by this BCT was the 
patients’ unwillingness to listen to the healthcare professionals’ 
advice. By conducting the osteoporosis screening programme, 
the healthcare professionals will be able to communicate with the 
patients more addressing the lack of social opportunity. 
Therefore, they can gain the patients’ trust by proving their 
capabilities and creating rapport with the patients, increasing 
their willingness to listen to advice. 
 
“... A bonding... So they will tell us all these things. So they will 
come.”        (DR-6/F/48y) 
 
2.6.3.3.2 Education 
We found that other aspects of the patient factors: condition, 
knowledge, personality and difficulty to adhere to osteoporosis 
preventive measure can be addressed in more detail using an 
educational intervention via the BCT of shaping knowledge. 
Based on the COM-B model we evaluated that the patients’ lack 
of osteoporosis knowledge factor was affected by the lack in 
psychological capability. A lack of psychological capability in this 
case refers to the lack of osteoporosis knowledge. We aimed to 
improve all aspects of the patients’ osteoporosis knowledge.  
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As for the patient factor condition, patients perceived 
osteoporosis as not to be serious condition. We evaluated it to be 
caused by the patients’ lack of psychological capability and 
reflective motivation from the COMB-B model. Due to the lack of 
knowledge on the consequences of untreated osteoporosis, 
patients evaluated osteoporosis to be a not serious condition.  
This in turn affected the patients’ personality whereby they took 
a nonchalant attitude towards osteoporosis. We evaluated this 
issue to be due to the lack of psychological capability and 
automatic motivation from the COM-B model. As a lack of 
osteoporosis knowledge led to patients acting nonchalantly due 
to an innate dispositions such as perceiving osteoporosis to be 
not life threatening.  
 
Correspondingly, patients’ difficulties in adhering to osteoporosis 
preventive measures may be caused by a lack of psychological 
capability, physical capability, reflective motivation and 
automatic motivation. To elaborate on this, patients may have 
had difficulty to conduct weight-bearing exercises. Hence, it 
became an unpleasant activity as patients may feel pain leading 
to a reduction in motivation. Patients will then evaluate the 
preventive measures to be too difficult to adhere too. Educating 
patients will equip them with the knowledge on osteoporosis 
preventive measures suitable for their physical condition 
overcoming its difficulties. 
 
Therefore, based on stakeholders’ suggestions we developed a 
counselling session that was delivered by the pharmacist. 
Patients would receive 30 minutes of verbal counselling. Topics 
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covered during the counselling session were the definition of 
osteoporosis, consequences of untreated osteoporosis, risk 
factors for osteoporosis, the role of the BMD scan (its function, 
what the results mean, accessibility and the frequency a patient 
has to go for a BMD scan), other tests used in osteoporosis 
screening [quantitative ultrasound scanning, x-ray, blood test 
and the Osteoporosis Screening Tool for Asians (OSTA)], lifestyle 
changes (calcium intake, vitamin D intake, weight bearing 
exercise and fall prevention), and treatment of osteoporosis. 
Additionally particular emphasis was given to the consequences 
of untreated osteoporosis and how to conduct osteoporosis 
preventive measures.  
 
“I think you should counsel, counsel people because sometimes 
people are not aware of the importance of osteoporosis.”  
(PT-10/F/62y) 
 
Strategies to conduct the counselling session include using lay 
terms, pictorial descriptions and providing the patients with an 
osteoporosis booklet. Therefore during the counselling session an 
osteoporosis booklet was provided to the patients. This 
information booklet also allowed the pharmacists to engage the 
patients and assist the patients to visualize the information. 
Additionally, the patients were able to take the leaflet home with 
them and reread the information.  Please refer to Appendix 24 
for the osteoporosis booklet.  
 
“(I need osteoporosis information) pamphlets, simple thing that 
we can understand. Not too scientific.” (PT-15/F/55y) 
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2.6.3.3.3 Persuasion 
We used the intervention function persuasion to address the 
additional aspect of the patients’ nonchalant attitude caused by 
the automatic motivation.  This was achieved using the BCT 
whereby we compared the outcomes and use persuasive 
arguments on the benefits of osteoporosis screening and 
prevention specific to a patient. Stakeholders believed that an 
individualize counselling session would increase the effectiveness 
of the counselling session as it is easier for the patients to 
communicate as compared to a group counselling session. By 
individualizing the counselling sessions we can tailor the session 
based on the patients’ education background and address 
personal issues regarding osteoporosis screening and prevention.   
 
“If one to one session, I think they will... want to do it 
(osteoporosis preventive measure)... (it is) different... when we 
(compare with) dispens(ing) at the counter and (when) we talk 
to them personally. They will easily open up. They will tell us the 
problem.”       (PHARM-3/F/25y) 
 
2.6.3.3.4 Goals and planning: Prompt barrier 
identification 
Additionally, in order to address the aspect of reflective and 
automatic motivation from the factor ‘difficulty to adhere to 
preventive measures’. We used another intervention function 
called enablement where we used the BCT ‘prompt barrier 
identification when conducting an osteoporosis preventive 
measure.’ The pharmacist would discuss potential barriers (pain 
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while exercising, funding, lactose intolerant etc) of conducting 
the osteoporosis preventive measure with the patients. This 
enables the pharmacists to tailor an osteoporosis preventive 
regimen suitable to the patient.  
 
“When patients... asks ‘Should I take calcium?’ ‘Should I take 
vitamin D?’… If you are wealthy enough, you want to take 
tablets, go ahead... If you are not so wealthy, you have... ten 
tablets to take… I would say enough. But if you can actually cope 
with your amount of medication... why not?” (PHARM-9/F/27y) 
 
2.6.3.3.5 Social support 
2.6.3.3.5.1 Social support: Osteoporosis risk 
assessment tools 
We evaluated the financial constraints that were influenced by 
physical opportunity and reflective motivation. We addressed the 
lack of physical opportunity by using the intervention function 
enablement. The issue with the financial constraints is the cost of 
the BMD scan and medication. Therefore we provided an 
osteoporosis risk assessment tool which screens for patients who 
are at high risk for osteoporosis. The risk assessment tool is a 
simple and quick calculation using the patients’ weight and age. 
This allows the hospitals resources such as the BMD scan and 
funding for the scans and medications to be used more 
effectively leading to more accessible osteoporosis screening for 
these patients. By giving the patients the opportunity to go for a 
free screening they will then evaluate that their finances can 
afford an osteoporosis scan thereby addressing the aspect of 
reflective motivation.  
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“If it’s free... if you give me (a chance to go for osteoporosis 
screening). I don’t mind going.”   (PT-20/F/62y) 
 
2.6.3.3.5.2 Social support: The osteoporosis screening 
programme to be conducted at a practical time for 
the patients 
Similarly, the barrier of patients’ time constraints and family 
circumstances to attend the screening programme was affected 
by physical opportunity and reflective motivation. We addressed 
the lack of physical opportunity by using the intervention 
function enablement. Therefore, we decided to conduct the 
osteoporosis screening programme during the waiting time for 
the doctor’s appointment. The waiting can be one to three hours. 
By using this time frame we did not extend the patients’ time at 
the hospital nor did we need the patient to come to the hospital 
multiple times. This will hopefully lead to the patients positively 
evaluating the feasibility of going for the osteoporosis screening 
addressing the aspect of reflective motivation.  
 
“There should be (information and osteoporosis screening), 
maybe at the clinic while we (are) wait for the doctor (‘s) 
(appointment).” (PT-15/F/55y) 
 
2.6.3.3.5.3 Social support: Sufficient consultation 
time 
One of the patient factors was the lack of consultation time. We 
evaluated this to be caused by the lack of social opportunity and 
physical opportunity. Therefore by conducting a pharmacist-led 
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osteoporosis screening programme during the waiting time for 
the doctor’s appointment we would have created an opportunity 
for the patients to discuss issue pertaining to osteoporosis. The 
pharmacists will be able to spend the time to communicate and 
address any issues that the patients may have. We allocated 
about 15-30 minutes per patients.  
 
“... The patient comes in, first (they) see the pharmacist, catch 
them, do the risk assessment... Just write in there (case notes) 
high risk, so the doctor is aware. Because we usually as doctors 
we don’t so much... time with the patient, with the work load 
especially. So it will be a good thing.” (DR-6/F/48y) 
 
2.6.3.4 Policy category 
2.6.3.4.1 Environmental/social planning: Developing a 
practical and sustainable osteoporosis screening 
programme 
For our study the type of policies that can be used to implement 
the pharmacist osteoporosis screening programme is the policy 
category environmental/social planning. This involves designing 
and/or controlling the physical and social environment. 
Stakeholders emphasized that the planning of the programme 
was crucial. We needed to develop a practical, acceptable and 
sustainable osteoporosis programme. They suggested that in 
order for the programme to be a success upper management 
approval and support was essential.  
 
“That’s why must speak to the specialist, we must, make an 
appointment to go and see this osteoporosis specialist, talk to 
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them, encourage them to have this type of campaign... Only 
these people who can start these campaigns.” (NUR-6/F/55y) 
 
2.6.4 Discussion 
Using the behavioural change wheel to address barriers from the 
patients’ factors we identified four key intervention components: 
environment restructuring, education, persuasion and 
enablement. This referred to the restructuring of the 
environment that was the need to develop and implement an 
osteoporosis screening programme by empowering the patient 
with osteoporosis knowledge. The programme should also be 
conducted one-on-one with the patient to incorporate the 
persuasion aspect of the intervention and conducted a time 
convenient to patients without burdening the patients financially. 
All these key intervention components were used to develop an 
acceptable, practical and sustainable osteoporosis screening 
programme in a primary care clinic. 
 
We compared the BCW to other approaches such as the Theory 
of Planned Behaviour and Health Belief Model (Ajzen, 1991, 
Rosenstoack et al., 1988). We agreed with the BCW authors that 
both these theories do not address the important role of 
impulsivity, habit, self-control, associative learning and emotional 
processing. The BCW model includes automatic processing which 
broadens the understanding of behaviour beyond the reflective, 
systematic cognitive process that is normally focused of most 
behavioural research in implementation science and health 
psychology (Michie et al., 2011). These aspects have been 
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considered in the BCW making it a comprehensive theory used 
for intervention design.    
 
Additionally, the behavioural change wheel may be incorporated 
into the context very naturally. By context we mean the 
‘opportunity’ component of the model. This means that the 
behavioural can only be understood in relation to context making 
it a good starting point (Michie et al., 2011).  
 
The BCW was then compared to other frameworks such as 
MINDSPACE. MINDSPACE is a checklist for policymakers of the 
most important influences on behaviour from the UK’s Institute 
of Government (Institute for Governement, 2010). However this 
framework recognises two systems by which human behaviour 
can be influenced, the reflective and automatic. But it focused on 
the automatic part of the human behaviour and does not attempt 
to link influences on behaviour with these two systems making it 
incoherent. The BCW manages to link these two systems using 
the COM-B model (Michie et al., 2011).   
 
As for intervention mapping, a key difference between this and 
the BCW approach is that the intervention mapping aims to map 
behaviour on to its ‘theoretical determinants’ in order to identify 
potential levers for change (Bartholomew et al., 2011). However 
the BCW approach recognises that the target behaviour system 
can in principle arise from combinations of any of the 
components of the behaviour system (Michie et al., 2011).  
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A search of published literature found several randomized 
controlled trials (RCTs) for osteoporosis screening services. 
These RCTs were conducted by various healthcare professionals 
such as primary care physicians,(Gardner et al., 2005, Rozental 
et al., 2008) orthopaedic surgeons, (Rozental et al., 2008, Miki et 
al., 2008) pharmacists (Yuksel et al., 2010, Crockett et al., 2008, 
McDonough et al., 2005) and nurses.(Majumdar et al., 2007). All 
of these interventions had similar components to our 
interventions in the sense that they all had an education 
component, osteoporosis risk assessment; the services were 
provided for free at a time convenient to the patients. However, 
the rationale for the intervention used was often unclear. Only 
four studies reported that the intervention was tailored to 
identified barriers (Gardner et al., 2005, Majumdar et al., 2007, 
Majumdar et al., 2008, Cranney et al., 2008).  Nonetheless, all 
interventions demonstrated a positive effect towards bone 
mineral density (BMD) scanning and osteoporosis treatment post 
fracture. (Majumdar et al., 2007, Miki et al., 2008, Rozental et 
al., 2008, Gardner et al., 2005, Yuksel et al., 2010, Crockett et 
al., 2008, McDonough et al., 2005).  
 
Strengths of this study were that our intervention was informed 
by a theory. It has been hypothesised that interventions 
informed by psychological theory show greater efficacy than non-
theory based studies. This is because theory driven interventions 
are more likely to target theoretically consistent or empirically 
supported mechanisms of behaviour change (Craig et al., 2008). 
However, interventions described as theory-based often have an 
unclear foundation (Michie et al., 2009). Although guidelines 
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from the UK MRC framework for complex intervention advocates 
drawing on theory in intervention design, it does not specify how 
to select and apply theory(Craig et al., 2008). There is often no 
analysis undertaken to guide the choice of theories. Therefore, 
we found the BCW to be a systematic and comprehensive theory 
enabling us to clearly outline which intervention affects a specific 
behaviour. 
 
Limitations of this study include that we have tailored it 
specifically to the local setting and it may not be generalizable to 
other setting. Another criticism is that the area of intervention is 
too complex and the constructs may still be too ill-defined to be 
able to establish useful, scientifically based evidence. The 
authors of the BCW also note that no framework can address the 
level of detail required to determine what will or will not be an 
effective intervention.  However, they suggest that these are 
empirical questions and there is already evidence that character 
intervention by BCT can aid in the understanding and identifying 
which intervention are more or less effective (Michie et al., 2009, 
Michie et al., 2011, West et al., 2010).  
 
2.6.5 Conclusion 
In conclusion, based on the BCW we have systematically 
identified four intervention (environment restructuring, 
education, persuasion, enablement) components to develop an 
acceptable, practical and sustainable osteoporosis programme. 
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3     CHAPTER 3: PHASE TWO 
DEVELOPMENT AND VALIDATION OF 
TOOLS AND INTERVENTION 
PACKAGES USED FOR THE 
PHARMACIST-LED OSTEOPOROSIS 
SCREENING PROGRAMME 
3.1   Introduction 
This chapter is divided into four sections. It describes the 
development and validation of the Satisfaction Questionnaire for 
Osteoporosis (SQOP) and the Osteoporosis Prevention and 
Awareness Tools (OPAAT) which were used to evaluate the 
pharmacist-led osteoporosis screening programme. Additionally, 
this chapter presents the validation and comparison of six 
osteoporosis risk assessment tools for the Malaysian 
postmenopausal women. Then, it explains the development of a 
pharmacist-led osteoporosis screening.  
 
3.2   Satisfaction Questionnaire for Osteoporosis 
Prevention (SQOP) 
3.2.1 Introduction 
3.2.1.1 Importance of measuring satisfaction 
Patient satisfaction may potentially be used to evaluate current 
preventive efforts and to predict patients’ adherence to 
preventive advice (Pascoe, 1983). The shift from healthcare 
provider centred care to more patient centred care emphasizes 
the need to evaluate humanistic outcomes such as patient 
satisfaction.(Gourley and Duncan, 1998). The rating of 
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satisfaction by patients is a personal evaluation of healthcare 
services and providers (Hardy et al., 1996, Ware et al., 1983). 
Patient satisfaction serves as an important determinant of the 
viability and sustainability of health care services (Johnson et al., 
1997).  
 
Due to the asymptomatic nature of osteoporosis, women who 
have osteoporosis are often not aware that they are at an 
increased risk of sustaining a fracture (International Osteoporosis 
Foundation, 2009). Prevention measures and screening which aid 
in early detection are the most cost-effective ways to reduce the 
number of hospital admittance due to osteoporotic fractures. 
Evidence shows that satisfied patients are more likely to continue 
using healthcare services, value and maintain relationships with 
health care providers, follow the advice of the healthcare 
professionals, adhere to treatment and have better health 
outcomes which in this case is a reduction in fracture rates 
(Locker and Dunt, 1978, Pascoe, 1983).   
 
Evaluating satisfaction can also assist healthcare professionals to 
provide healthcare services more effectively. Patient evaluations 
will help identify patients’ needs, perceptions, concerns and 
areas of service failure. This in turn may encourage health care 
providers to be accountable for the quality of service delivered 
which ensures continuous monitoring and improvement in health 
care delivery (Ford et al., 1997). 
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3.2.1.2 Randomized controlled trials performed on 
osteoporosis screening services 
A search of published literature found several randomized 
controlled trials (RCTs) for osteoporosis screening services. 
These RCTs were conducted by various healthcare professionals 
such as  primary care physicians,(Gardner et al., 2005, Rozental 
et al., 2008, Majumdar et al., 2008, Feldstein et al., 2006, 
Mudano et al., 2013) orthopaedic surgeons, (Rozental et al., 
2008, Miki et al., 2008) pharmacists (Yuksel et al., 2010, 
Crockett et al., 2008, McDonough et al., 2005) and 
nurses.(Majumdar et al., 2007). All interventions demonstrated a 
positive effect towards bone mineral density (BMD) scanning and 
osteoporosis treatment post fracture (Majumdar et al., 2007, 
Miki et al., 2008, Rozental et al., 2008, Gardner et al., 2005, 
Yuksel et al., 2010, Crockett et al., 2008, McDonough et al., 
2005).  
 
However, only four studies assessed patient satisfaction. Of 
these studies, only two studies used a validated tool. One of the 
tools used was the Patient Satisfaction Questionnaire (PSQ-18) 
(Majumdar et al., 2008) it was a generic satisfaction 
questionnaire. The second tool used was the Osteoporosis Patient 
Satisfaction Questionnaire (OPSQ)(Lai et al., 2010), whilst the 
other studies did not provide information on how they measured 
patient satisfaction(Feldstein et al., 2006, Mudano et al., 2013). 
This highlights two facts, many studies did not assess patients’ 
satisfaction using a validated tool and many studies did not 
assess patient satisfaction as an outcome (Lai et al., 2013, 
Majumdar et al., 2008).  
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3.2.1.3 Tools to assess satisfaction in osteoporosis 
Three tools have been developed globally to assess satisfaction 
pertaining to osteoporosis and its treatment (Gold et al., 2011, 
Flood et al., 2006, Lai et al., 2010). Of which, two were 
developed and validated in the United States (Flood et al., 2006, 
Gold et al., 2011), whilst one was developed in Malaysia (Lai et 
al., 2010). The Osteoporosis Patient Treatment Satisfaction 
Questionnaire (OPSAT-Q) contains 16-items with four domains: 
convenience, confidence with daily activities, side effects and 
overall satisfaction. OPSAT-Q was used to evaluate patients’ 
satisfaction towards biphosphonates treatment for osteoporosis 
and osteopenia. Convenience, confidence with daily functioning 
and overall satisfaction are rated on a 7-point Likert-like scale 
where as side effect was rate on a 5-point bother scale.  
 
The second tool was called the Preference and Satisfaction 
Questionnaire (PSQ) to evaluate the preference, satisfaction and 
bother with a weekly oral tablets versus a once every 6 months 
subcutaneous injection for treatment of postmenopausal bone 
loss. The PSQ was a 20-item questionnaire with five domains: pill 
satisfaction, injection satisfaction, pill bother, injection bother 
and preference for pill or the injection.  
 
The Osteoporosis Patient Satisfaction Questionnaire (OPSQ) was 
a 16-items questionnaire developed to assess the opinion of 
postmenopausal osteoporosis women towards pharmaceutical 
care. It has two domains (satisfaction on delivery of 
pharmaceutical care and usefulness of the counselling session) 
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and used a five-point Likert-like scale. However, all these 
satisfaction tools were not suitable to assess the satisfaction of 
patients of an osteoporosis screening and prevention 
programme, as their focus was on osteoporosis and its 
treatment.(Lai et al., 2010, Gold et al., 2011, Flood et al., 2006) 
To date, no instrument has been developed and validated 
specifically to assess patients’ satisfaction towards an 
osteoporosis screening and prevention programme in Malaysia.  
 
3.2.2 Objectives  
To develop and validate the English version of the SQOP to 
evaluate patients’ satisfaction towards an osteoporosis screening 
and prevention programme in Malaysia. 
 
3.2.3 Methods 
Based on the UK MRC framework, it is imperative to assess the 
effectiveness of an intervention conducted. Therefore, this 
section presents the development and validation of a satisfaction 
questionnaire called the SQOP will be used as one of the methods 
to evaluate the osteoporosis screening and prevention 
programme.   
 
3.2.3.1 Quantitative methods 
Quantitative methods are employed to investigate frequencies of 
events involving calculation of summary statistics, to establish 
the proportion of a population who hold certain views or have 
had particular experiences or to compare differences in outcomes 
between groups (Smith, 2010).  
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In our study we needed an instrument to measure the 
satisfaction level of patients’ towards an osteoporosis screening 
and prevention programme. Such a tool is currently unavailable.  
In the following section, I shall discuss the quantitative research 
method that was adopted to develop and validate the 
questionnaire. 
 
3.2.3.2 Questionnaires 
Survey research using questionnaires provides a quantitative or 
numeric description of trends, attitudes, or opinions of a 
population by studying a sample of that population (Creswell, 
2009). The strength of survey research using questionnaires are 
useful for collecting factual information from large samples 
relatively cheaply in a reasonably short time, well structured 
questionnaires can collect the relevant information in a 
systematic way(Smith, 2010). Structured questionnaires involve 
questioning respondents in a highly standardized manner using a 
precise sequence and wording of questions. The methods of 
recording answers are specified in advance on the questionnaire 
(Campbell et al., 1999). Survey questionnaires should be 
acceptable and attractive to potential respondents by being 
reasonable in length and well-presented (Smith, 2002).  
 
Surveys can be designed to measure events, behaviour and 
attitudes of the population of interest. These types of surveys are 
called descriptive surveys, as the information is collected from 
the population and descriptive measures are calculated. Data 
collected from the population at one point in time are called cross 
sectional surveys. Most cross sectional studies collect data by 
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recalling the past and are known as retrospective surveys. 
However, retrospective studies are frequently criticised for 
potential recall bias where respondents may be selective in 
recalling the past. Nonetheless, descriptive surveys are a 
relatively cheap data collection method in terms of time and 
resources, as large numbers of people can be surveyed relatively 
quickly, compared to longitudinal studies in which a sample is 
followed up over a period of time (Bowling, 2009). 
 
Another type of survey aims to investigate casual associations 
between variables and is carried out at more than one point in 
time. These types of analytical surveys are called longitudinal 
surveys. Most longitudinal surveys collect data prospectively over 
a specified period of time. Prospective, longitudinal surveys 
require careful definitions of the study group, variables for 
measurement, data collection frequency of time intervals and 
response rates need to be high. This method is of value for 
studying the effects of new interventions (Bowling, 2009). 
 
Surveys can be conducted via self-administration, personal 
interview, telephone, postal or internet (Smith, 2010, Bowling, 
2009). Self-administering questionnaires often use closed ended 
questions and if well constructed they are easier and quicker for 
respondents to answer and are also easier for the researcher to 
code and incorporate into quantitative analysis (Smith, 2010). 
Personal interviews are normally used for less structured 
instruments which often comprises of open ended questions 
allowing for more complex questions, flexibility and clarifications 
of misunderstanding (Smith, 2010, Vaus, 2002). However, 
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interviews are more laborious.  In addition, there are several 
limitations that needs to be considered including the cost, issue 
of anonymity, unwillingness of respondents to reply honestly to 
certain questions and an inability to control behaviour which 
interviewers may introduce reporting bias (Vaus, 2002, Campbell 
et al., 1999, De Leeuw, 2005). Many questionnaires that are 
designed for self-completion can also be used in interviews to 
optimize respond rates (Smith, 2010, De Leeuw, 2005).  
 
Questionnaires can also be administered via the telephone or 
mail. In general, these types of methods are more suited for a 
structured questionnaire. Administration over the telephone has 
an advantage over postal administration as they data can be 
collected quicker, than waiting for the questionnaires to arrive by 
post. Telephone interviews are best arranged in advance at a 
time convenient for the interviewee. Email and internet are 
options that have become increasingly used as a data collection 
method (Smith, 2010).  
 
For this phase of the study, we needed a questionnaire to 
measure the satisfaction level of the patients towards an 
osteoporosis screening and prevention programme. Therefore, 
we developed and validated a structured longitudinal 
questionnaire for self-administration. Self-administration was 
chosen to ensure that it is practical to be used in future daily 
practice. The researcher assisted participants who encountered 
difficulty in reading the questionnaire themselves. At retest, the 
questionnaire was administered over the telephone, so that 
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participants need not make a second trip to the hospital just to 
answer the questionnaire  (De Leeuw, 2005).   
 
3.2.3.3 Development of the Satisfaction Questionnaire 
for Osteoporosis Prevention (SQOP) 
The SQOP was developed based on modifications from the 
Osteoporosis Patient Satisfaction Questionnaire (OPSQ) and 
findings from Phase one qualitative study which examined the 
barriers and needs towards an osteoporosis screening and 
prevention service in Malaysia.  
 
3.2.3.3.1 Language 
The SQOP was developed in English. Despite Malay being the 
national language of Malaysia, postmenopausal women aged 50 
years residing in Malaysia are more fluent in English as schooling 
was only conducted in the English language then. 
 
3.2.3.3.2 Modification from the Osteoporosis Patient 
Satisfaction Questionnaire (OPSQ) 
Of the 16 items in the OPSQ, 9 items were removed. Eight of 
these items were on satisfaction related to osteoporosis 
medication, whilst one item was on a follow up visit. Four items 
from the OPSQ were rephrased. In item 2, the word ‘session’ was 
used instead of ‘appointment’ as we did not set appointments 
with the participants. For item 7 ‘How useful was the service 
provided by the pharmacist in this study?’ was considered 
leading and was rephrased to ‘How would you rate the advice 
given by the pharmacist?’ The word overall was added to item 9: 
‘How would you rate the ‘overall’ quality of service that was 
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given by the pharmacist to you?’ to make the question more 
specific. The original question for item 18 was ‘How would you 
rate your understanding of osteoporosis since you participated in 
the study?’ was modified to ‘How would you rate your 
understanding of osteoporosis now?’ as we wanted the 
questionnaire to be used in clinical practice after the completion 
of our study. Three items were retained from the OPSQ without 
any modifications.  
 
3.2.3.3.3 Development of the Satisfaction 
Questionnaire for Osteoporosis Prevention 
(SQOP) based on the qualitative data in 
Phase one 
Based on the results from our qualitative findings (Phase one: 
Barriers to an osteoporosis screening programme) we 
categorized the factors to the following domains which may 
influence patients’ satisfaction when utilizing an osteoporosis 
screening and prevention service: outcomes/efficacy, 
accessibility/convenience, technical quality, interpersonal 
relationship, finance and continuity.  
 
A literature search noted that these domains were similar to 
those recommended by Ware et al. (1983) they developed a 55 
item Patient Satisfaction Questionnaire (PSQ) to measure patient 
satisfaction in general with specific feature of care. The PSQ 
represents the content of characteristics of providers and 
services described most often in the literature and in response to 
open ended-questions. However, the model developed by Ware 
et al. (1983) had an additional domain (physical condition and 
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availability). Hence, the domain of physical condition was also 
included in the SQOP. However, the domain availability was not 
included as the service was not yet available at the current 
setting and will not be relevant to our participants. Table 3.1 
displays the definition of each domain. 
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Table 3.1: The definition of the domains of the Satisfaction 
Questionnaire for Osteoporosis Prevention (SQOP) and the 
factors addressed based on Phase one results 
Domain Definition Factors addressed 
Outcomes/ 
efficacy 
The results of medical care 
encounters (e.g., 
helpfulness of medical care 
providers in improving or 
maintaining health). 
 
Patient factor: 
Osteoporosis is perceived to be 
not serious 
Osteoporosis is perceived to be 
not serious 
Knowledge 
Difficulty to adhere to osteoporosis 
prevention measure 
 
Accessibility/con
venience  
Factors involved in 
arranging to receive 
medical care (e.g., time 
and effort 
required to get an 
appointment, waiting time 
at office, ease of reaching 
care location) 
Patient factor: 
Time constraints 
Short consultation time 
Family circumstances 
Technical quality Competence of providers 
and adherence to high 
standards of diagnosis and 
treatment (e.g., 
thoroughness, accuracy, 
unnecessary risks, making 
mistakes). 
 
Individual factor: 
 Knowledge  
Competence 
 
Patient factor: 
Unwilling to listen to healthcare 
professionals advice 
 
Interpersonal 
relationship 
Features of the way in 
which providers interact 
personally with patients 
(e.g., 
Concern, friendliness, 
courtesy, disrespect, 
rudeness). 
Patient factor: 
Language barrier 
 
Individual barrier: 
 Healthcare professional do not 
conduct themselves professionally 
Finance  Factors involved in paying 
for medical services (e.g., 
Patient factor: 
Financial constraint 
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reasonable costs, 
alternative payment 
arrangements, 
comprehensiveness of 
insurance coverage). 
Continuity Sameness of provider 
and/or location of care 
(e.g., see same physician). 
Patient factor: 
Nonchalant attitude towards 
osteoporosis 
Physical 
condition 
Features of setting in 
which care is delivered 
(e.g., orderly facilities and 
equipment, pleasantness 
of atmosphere, clarity of 
signs and directions). 
Work environment factor: 
Primary care services are not 
elderly friendly 
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Therefore 16 new items were added. The final SQOP consists of 
23 items, and was divided into 7 domains. Each item had a five-
point Likert-like response.  Please refer to Appendix 23 for the 
finalized version of the SQOP.  
 
3.2.3.4 Validation of the Satisfaction Questionnaire for 
Osteoporosis Prevention (SQOP) 
Before a research instrument such as a questionnaire can be 
used to measure what it intends to measure, it needs to be 
validated. A questionnaire is valid only after successfully 
undergoing a validation process which gauges the validity 
measure of a concept (Smith, 2002, Bryman, 2004). The 
validation process involves testing the instrument, in its entirety 
or by selecting individual questions for which it is to be used to 
ensure that the responses are a true reflection of the variables or 
attributes of interest. A validated tool is necessary as it ensure 
the validity and the reliability of the results. 
 
The process of validation also ensures that the cultural 
differences and language used are suitable for its local 
population. This ensures that the questionnaire can effectively 
collect the data required, eases data processing, data analysis 
and the scientific robustness such as the validity and the 
reliability of the instrument used (Smith, 2010, Smith, 2002, Lai, 
2013).  Figure 3.1 displays the summary of the validation 
process. 
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Figure 3.1 Summary of validation process 
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3.2.3.4.1 Validity 
Validity refers to the questionnaire measuring the object of 
desire. For the development and validation of the SQOP, this 
phase is concerned with the measurement validity (face, content 
and construct validity) and discriminative validity. The 
measurement validity of a questionnaire refers to the extent to 
which the questions collect accurate data relevant to the study 
objectives (Smith, 2002, Bryman, 2004). 
 
3.2.3.4.1.1 Face validity 
This is generally the first test of validity (Smith, 2002). Face 
validity indicates whether, on the face of it, the instrument 
appears to be assessing the desired qualities.  It represents a 
subjective judgement based on a review of the measure itself by 
one or more experts and rarely uses any empirical approaches. 
Participants from the target population such as patients can also 
be used to critically review the content of the scale. Alternatively, 
a more formal approach such as focus groups and in-depth 
interviews may be conducted to explore whether the 
questionnaire is covering all aspects of the topic relevant to 
patients. Occasionally, cognitive interviews can be used where 
respondents verbalize their reaction to each question as they 
answer them to indicate the questionnaire perceived by the 
respondents. Linguistics can also be tested to indicate whether 
the phrasing of the questions were clear (McDowell, 2006). Face 
validity aims to uncover problems such as identification of 
questions which respondents may be unable or reluctant to 
answer, questions that might be ambiguous or misinterpreted or 
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questions that might not be an accurate reflection of the variable 
of interest (Smith, 2002).  
 
3.2.3.4.1.2 Content validity 
Content validity is concerned with the comprehensiveness or 
whether the questions selected are representative of all relevant 
issues that were specified in the conceptual definition of its scope 
(McDowell, 2006). This is generally obtained from preliminary 
fieldwork such as qualitative interviews which aims to uncover 
the perspective of the population of interest leading to the 
development of the instrument (Smith, 2002).  
 
3.2.3.4.1.3 Construct validity 
For assessing variables such as pain, happiness and satisfaction, 
gold standards do not exist and thus validity testing becomes 
more challenging. Therefore, for such abstract constructs, 
“construct validation” can be used (McDowell, 2006). This begins 
with a conceptual definition of the topic (or construct) to be 
measured. This will give an indication of the internal structure of 
its components and the way it relates to other constructs. 
Construct validity  involves testing a scale not against a single 
criterion but in terms of theoretically derived hypotheses 
concerning the nature of the underlying variable or construct 
(Pallant, 2011). The main types of methods to determine 
construct validity include correlational evidence such as factor 
analysis and evidence for the ability of measure to discriminate 
among different groups (McDowell, 2006).  
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3.2.3.4.2 Factor analysis 
Factor analysis is an analytical tool in describing the 
correspondence of alternative indicators to the underlying 
concepts that they may record. It uses the pattern of inter-
correlations among replies to questions. Factor analysis then 
analyses and forms the questions into groups or factors that 
appear to measure common themes, each factor being distinct 
from the others. Factor analysis can also be used to describe the 
underlying conceptual structure of an instrument. It can show 
how far the items accord in measuring one or more common 
themes guiding the selection of items on the basis of their 
association with the trait of interest. It can also indicate the 
association among subscales component of measurement or 
even complete measures. A scale measuring the same topic 
would be expected to be grouped by the analysis onto the same 
factor (McDowell, 2006). 
 
Factors analysis can be divided into two parts: a structural model 
and measurement model. The structural model posits underlying 
constructs to be measured. The measurement model presents 
the relationship between variables recorded (answers to 
questions) and the underlying concepts. It can be further divided 
to confirmatory factor analysis and exploratory factor analysis. 
Confirmatory factor analysis begins with the structural model and 
is used to test how far the empirical data support the proposed 
conceptual structure. On the other hand, exploratory factors 
analysis begins with the measured variables and shows how they 
cluster together to represent underlying constructs even where 
these have not been formally defined (McDowell, 2006). 
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3.2.3.4.3 Discriminative validity 
For the purpose of this study, discriminative validity was referred 
to as the extent to which the classification system (in our case 
the SQOP) was able to differentiate between participants with 
and without the ‘intervention package’ (Streiner and Norman, 
2008).  
 
3.2.3.4.4 Reliability 
Reliability of a survey instrument refers to the extent to which 
the findings are reproducible (Smith, 2002). Two frequently used 
indicator for reliability is internal reliability and test-retest 
(Pallant, 2011, Smith, 2002). We conducted the Cronbach’s α 
and test-retest to assess the internal consistency and stable 
reliability of the questionnaire, respectively. 
 
3.2.3.4.4.1 Internal reliability 
Internal reliability is the degree to which the items that make up 
the scare are all measuring the same underlying attribute 
(Pallant, 2011). Cronbach’s α is the most common statistics used 
to measure internal consistency which provides an indication of 
the average correlation among all the items that make up the 
scale. A value of zero indicates no correlation among the items, 
whereas a value of one would indicate perfect correlation among 
the items (McDowell, 2006).  
 
3.2.3.4.4.2 Test-retest 
Test-retest is assessed by administering the questionnaire to the 
same people on two different occasions and calculating the 
correlation between the two scores obtain. The questionnaire is 
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considered reliable if the correlations between results are high 
(Pallant, 2011). The researcher needs to consider how long to 
wait before administering the retest. On average, a maximum of 
two to four weeks is a reasonable period of time between the 
initial and follow-up administration of the questionnaire to 
minimize the possibility of real or random change occurring 
(Aday and Cornelius, 2006).  
 
3.2.3.5 Study design 
The validation process was a randomized controlled trial. 
 
3.2.3.6 Setting  
The study was conducted at the primary care clinics of the 
University Malaya Medical Centre (UMMC), Kuala Lumpur, 
Malaysia. 
 
3.2.3.7 Period of study 
The data collection began in September 2013 and went on until 
Dec 2013. 
 
3.2.3.8 Participants 
3.2.3.8.1 Inclusion/exclusion criteria 
English or Malay speaking postmenopausal women aged ≥ 50 
years old who had not previously been diagnosed with 
osteopenia/osteoporosis were included. Eligible participants who 
were feeling too unwell to participate in the study were excluded.  
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3.2.3.9 Sampling procedure 
The first consideration of any researcher is the identification of, 
and access to the population of interest. There are a variety of 
sampling methods such as random sampling. Random sampling 
is defined as a method in which every member of the population 
has an equal chance of being selected. This normally involves a 
sampling frame which consists of a list of all members of the 
population. Based on this list, a random sample can be selected 
using random numbers or a systematic procedure such as the 
selection of every tenth person on the list can be employed if 
there is no order to the entries On the other hand, convenience 
sampling selects the most readily accessible participants. These 
are cheap and quick ways to obtain the data but jeopardizes 
representativeness of the findings (Smith, 2002). 
 
In this study, random sampling was used as it allows for 
generalisation to the population from which the sample is drawn. 
Additionally, the random sampling procedure was used as there 
was only one researcher making it not possible to recruit all 
patients or conduct convenience sampling. The researcher 
screened for potential participants by using a 1:2 systematic 
random sampling procedure. Participants were recruited at the 
clinic’s waiting area while they were waiting to see their doctor. 
Randomization of participants to either the control or 
intervention group was performed by drawing pieces of paper 
stating control or intervention from a bag, while participants 
were filling up the demographic form. 
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3.2.3.10 Sample size 
In quantitative studies a statistically representative sample is 
required. The sample size required for survey research is 
determined by the degree of accuracy desired when the estimate 
base on the sample is applied to the wider population (Smith, 
2010). For validation studies, the sample size can be calculated 
based on a 5:1 subject to item ratio for factor analysis (Gorsuch, 
1983). Additionally, the anticipated response rate must be 
considered. In general, a larger sample size leads to a more 
accurate estimate and the narrower the confidence intervals 
(Smith, 2010). Hence, the sample size should be calculated at 
the design stage of the study to ensure it is statistical power (a 
measure of how likely the study is to produce a statistically 
significant result) (Bowling, 2009). Our sample size was 
calculated based on a 5:1 subject to item ratio for factor analysis 
(Gorsuch, 1983). Allowing for a 20% loss to follow up, the total 
number of participants required was 70 in each arm.  
 
3.2.3.11 Instruments used 
3.2.3.11.1 Baseline demographics 
Baseline demographic information such as participants’ medical 
history, lifestyle and medication history was collected. Healthcare 
professionals’ baseline information, work experience and 
education level were also collected (Appendix 1). 
 
3.2.3.11.2 Satisfaction Questionnaire for Osteoporosis 
Prevention (SQOP) 
The final SQOP consists of 23 items, and was divided into 7 
domains (outcomes/efficacy, accessibility/convenience, technical 
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quality, interpersonal relationship, physical condition, finance and 
continuity). Each item had a five-point Likert-like response. One 
indicates the lowest satisfaction for that item and five indicates 
the highest satisfaction. Scores ranged from 30 to 150, and was 
converted to percentage, ranging from 0-100%. Zero indicates 
the lowest level of satisfaction, whilst 100 indicates the highest. 
 
3.2.3.12 Intervention package provided 
Intervention participants received 30 minutes of verbal 
counselling and an osteoporosis booklet (Appendix 24). Topics 
covered during the counselling session were the definition of 
osteoporosis, consequences of untreated osteoporosis, risk 
factors for osteoporosis, the role of the BMD scan (its function, 
what the results mean, accessibility and the frequency a patient 
has to go for a BMD scan), other tests used in osteoporosis 
screening [quantitative ultrasound scanning, x-ray, blood test 
and the Osteoporosis Screening Tool for Asians (OSTA)], lifestyle 
changes (calcium intake, vitamin D intake, weight bearing 
exercise and fall prevention), and treatment of osteoporosis.  
 
Control participants received standard care. Standard care 
involved a regular visit to the doctor. Any counselling on 
osteoporosis by the doctor was opportunistic and at the doctors’ 
discretion. 
 
3.2.3.13 Procedure 
Eligible participants were first screened and then randomly 
recruited by the pharmacist at the waiting area. The study was 
explained to participants using the patient information sheet 
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(Appendix 25). Informed consent and the participants’ baseline 
demographic data were obtained (Appendix 26). Subsequently, 
the participants were randomly allocated to the control or 
intervention group. The intervention group received the 
‘intervention package’ and the control group received the 
standard care. The SQOP was then administered to both groups. 
Participants answered the questionnaire themselves. However, 
for those who experienced some difficulty in reading the 
questions themselves, the researcher read the questions out for 
them and assisted them in filling the questionnaire. The 
researcher ensured that all questions have been answered. All 
questionnaires and intervention were administered by the 
researcher. The researcher was trained by one of the supervisor 
who was well versed in osteoporosis to deliver the counselling. 
 
Two weeks after baseline, a telephone follow up was conducted 
to administer the SQOP to both groups. The control group was 
provided the intervention package over the phone and were 
mailed the osteoporosis booklet at the end of the study. Figure 
3.2 presents the validation process. 
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 Figure 3.2 Validation process 
  
Informed consent and baseline information obtained. 
 
Randomly allocated 
Intervention group 
N=70 
Control group 
N=70 
Counselling session + 
osteoporosis booklet 
provided 
1st Follow up 
(Two weeks 
later) 
Baseline 
 
Counselling session provided 
over phone + osteoporosis 
booklet was provided via mail. 
SQOP was administered over 
the phone 
SQOP was administered over 
the phone 
SQOP was administered 
 
SQOP was administered 
No. of participants recruited (n=140) 
Abbreviations: 
PIS=Patient information sheet 
SQOP= Satisfaction questionnaire for 
osteoporosis prevention 
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3.2.3.14 Source of data 
The source of data varied from medical registers, medical 
records, observations to observe if patients were too unwell to 
participate in the study, interviews, questionnaire and informal 
discussions to find out informally if patients have osteoporosis 
during recruitment. Some of the data such as participants’ 
clinical information were obtained from medical records prior to 
the provision of service, whilst other data were obtained during 
the counselling session with the pharmacist. 
 
3.2.3.15 Ethics approval 
Ethical approval from the University Malaya Medical Centre Ethics 
Committee was obtained prior to the study (ref no. 920.27) 
(Appendix 27). All required documents were submitted and 
approval was obtained one month after submission. In 
accordance with the ethics committee requirements, a report 
upon completion form has been submitted. Ethical issues such as 
anonymity, confidentiality and informed consent were considered 
in this study. 
 
3.2.3.15.1 Anonymity and confidentiality 
Only the researcher and the supervisors had access to the 
questionnaire. All information were coded and anonymized. The 
information collected as paper copies were stored under lock and 
key, while the electronic data can only be accessed with a secure 
password. The data collected were used only for the purpose of 
this research; if data were to be used for future studies, further 
Research Ethics Committee approval will be sought. All 
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information which is collected was confidential and any form of 
identity will not be included in any publications. 
 
3.2.3.15.2 Informed consent 
Prior to the start of any research activity, written informed 
consent for participating was obtained from each participant. 
 
3.2.3.16 Data analysis 
All data was entered into the IBM® SPSS® version 20 (IBM 
Corporation, Armonk, NY, US).  Baseline demographic data of the 
control and intervention group was compared using chi square 
test for categorical variables or the independent t-test for 
continuous variables. Non-parametric test were used since the 
data obtained was not of normal distribution. A p-value < 0.05 
was considered as statistically significant. 
 
3.2.3.17 Face and content validity 
The face and content validity of the SQOP was established via 
consultation with an expert panel (a consultant endocrinologist 
and four pharmacists with many years of research and clinical 
experience). Comprehension of the questionnaire was tested on 
10 postmenopausal women who understood English. This 
involved asking the participants for their opinions about the 
phrasing, format and content of the instrument. This resulted in 
a change of item 8 from ‘Has the advice given by the pharmacist 
affected your life in general?’ to ‘How would you rate the advice 
given by the pharmacist?’ as participants commented that it was 
difficult to gauge the effect of newly given advice. 
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3.2.3.18 Exploratory factor analysis (EFA) 
EFA was performed to provide information about the validity of 
the items within each domain and to explore the appropriateness 
of the factor structure of the current questionnaire.  It is 
important to note that the control group were not required to 
answer items 19-23 as these items were specifically assessing 
the satisfaction of the intervention conducted. However, all items 
(i.e. items 1-23) in the EFA were included for 2 reasons. Firstly, 
although the control group did not answer items 19-23, it still is 
represented as one of the seven domains. Secondly if control 
participants were excluded from the EFA, then we would not 
have satisfied the minimum number of participants require (i.e. 
100 participants) where there are more than six factors present 
(Mundform et al., 2005). The extraction method used was 
maximum likelihood and the rotation method was promax. To 
determine how many factors were retained a criterion of 
eigenvalue greater than 1.0 was considered.  Corrected item-
total correlations were used to identify items which did not 
measure the same main component as the other items. A value 
of less than 0.3 indicates that the item is measuring a different 
component from the scale as a whole. 
 
3.2.3.19 Cronbach’s α 
The mean score ± S.D. was calculated for each item.. The results 
for intervention and control were combined to test for internal 
reliability (Cronbach’s α). Cronbach’s α greater than or equal to 
0.70 indicates good internal reliability(Cronbach, 1951). 
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3.2.3.20 Test retest 
To assess test-retest reliability, the Wilcoxon-signed rank test 
and the Spearman’s correlation was used. The higher the 
correlation indicates a higher reliability (Pallant, 2011).  
 
3.2.3.21 Discriminative validity 
Discriminative validity was performed on the control and 
intervention group to assess if the SQOP was able to differentiate 
between the satisfaction levels of the two groups. Since, the 
control group was not required to answer items 19-23, the total 
score of both control and intervention group were converted into 
percentages. The Mann Whitney U test was then used to analyse 
if the SQOP was able to discriminate between the control and 
intervention group using their percentages. 
 
3.2.3.22 Flesch reading ease 
Microsoft Office Word 2007 was used to calculate the Flesch 
reading ease. Flesch reading ease was performed to assess the 
reading comprehension level necessary to understand the written 
document. An average document should have a score of 60-70 
(Flesch, 1948).  
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3.2.4 Results (Phase two- Satisfaction Questionnaire for 
Osteoporosis Prevention (SQOP)) 
3.2.4.1 Participants 
A total of 173 participants were approached: 33 declined and 140 
participants (80.9%) were recruited (control= 70 and 
intervention=70). No significant differences were found between 
the control and intervention group in all demographic aspects 
[Table 3.2]. 
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Table 3.2: Baseline demographic characteristics of participants 
Characteristics Control (n=70) Intervention 
(n=70) 
t-value/ 
chi2a,c 
p-value 
Mean age ± S.D (years) [range], Median 58.51±7.06 
[50-77], 56.00 
60.57±7.26 
[50-77], 
60.00 
-1.700 0.091 
Age range (years) [n (%)] 
<65 
≥ 65 
 
56 (80.0) 
14 (20.0) 
 
50 (71.4) 
20 (28.6) 
 
1.398 
 
0.237 
Ethnicity [n (%)] 
    Malay 
    Chinese 
    Indian 
    Others  
 
 
13 (18.6) 
31 (44.3) 
24 (34.3) 
2 (2.9) 
 
17 (24.3) 
29 (41.4) 
19 (27.1) 
5 (7.1) 
 
 
2.467 
 
 
0.495 
Mean BMI ± S.D., Median 25.33±6.50, 
23.52 
25.32±5.75, 
23.63 
0.003 0.997 
BMI [n (%)] 
<18.5 (underweight) 
18.5-24.9  (normal) 
25.0-29.9 (overweight) 
≥30.0 (obese) 
 
5 (7.1) 
37 (52.9) 
17 (24.3) 
11 (15.7) 
 
5 (7.1) 
32 (45.7) 
19 (27.1) 
14 (20.0) 
 
0.833 
 
0.841 
Level of education [n (%)]     
Primary(6 years of education) 4 (5.7) 3 (4.3)  
 
1.727 
 
 
0.631 
Secondary (11-13 years of education) 33 (47.1) 28 (40.0) 
Diploma/Technical (12-14 years of education) 15 (21.4) 14 (20.0) 
Tertiary/Postgraduate (15-21 years of 
education) 
18 (25.7) 25 (35.7) 
Abbreviations:S.D. = standard deviation; BMI=body mass index 
a Chi square test was used for all categorical variables whilst the independent t-test was used for all continuous variables. 
b Others include four Eurasian, one Portuguese and one Thai. 
c Fisher’s exact test was used as the number of cells with expected count less that 5 is more than 20% of the total number of cells  
 221 
 
3.2.4.2 Factor analysis and psychometric properties of 
the Satisfaction Questionnaire for Osteoporosis 
Prevention (SQOP) 
EFA extracted seven domains with a criterion of eigenvalue 
greater than 1.0. This explains the 79.1% of the cumulative 
variances. The eigenvalue and the proportion of variance explain 
are shown in Table 3.3.  The factor loading of the items to each 
factor are shown in table 3.4 (0.118-0.977). All items had a 
factor loading of more than 0.3 except item 17 which had a 
factor loading of 0.118. However this item was maintained due to 
its importance based on findings from the qualitative study. 
Correlations between the factors resulting from the rotation were 
similar and the residuals ranged from -0.184-0.167are shown in 
Table 3.5.  
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Table 3.3: Eigenvalue of the Satisfaction Questionnaire for Osteoporosis Prevention (SQOP) and the 
proportion of variance explained using promax and maximum likelihood 
 Before rotation After rotation  
Factor Eigenvalue 
Percentage 
of variances 
Cumulative 
percentage 
of variances 
Eigenvalue 
Percentage of 
variances 
Cumulative 
percentage of 
variances 
Factor 1 3.520 15.30 15.30 7.548 32.82 32.82 
Factor 2 2.981 12.96 28.27 2.908 12.64 45.46 
Factor 3 2.364 10.28 38.54 1.977 8.56 54.05 
Factor 4 2.363 10.27 48.81 1.768 7.69 61.74 
Factor 5 2.287 9.94 58.76 1.523 6.62 68.36 
Factor 6 1.631 1.09 65.85 1.354 5.89 74.25 
Factor 7 1.122 4.88 70.73 1.112 4.84 79.09 
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Table 3.4: Factor loading of items in the Satisfaction Questionnaire for Osteoporosis Prevention (SQOP) 
Items Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6  Factor 7 
Q1 .037 .339 .283 .034 .373 .417 .423 
Q2 .428 .304 .340 .108 .040 .914 .163 
Q3 .078 .392 .141 .063 .977 .078 .004 
Q4 .109 .462 .277 .173 .379 .166 -.120 
Q5 .122 .046 -.004 .188 -.058 .082 .451 
Q6 -.169 .125 .052 -.035 .826 -.130 -.001 
Q7 .502 .427 .298 .387 -.079 .545 .170 
Q8 .451 .199 .593 .462 .041 .555 .222 
Q9 .590 .703 .472 .114 .430 .153 -.035 
Q10 .761 .232 .403 .049 .066 .258 .008 
Q11 .788 .225 .603 .433 .036 .472 .384 
Q12 .519 .250 .383 .367 -.063 .378 .110 
Q13 .530 .622 .669 .434 .080 .565 .430 
Q14 .714 .318 -.035 .338 -.053 .562 .240 
Q15 .841 .400 .350 .520 -.019 .365 .210 
Q16 .432 .315 .563 .910 .164 .094 .010 
Q17 -.311 .037 -.633 -.239 .118 -.112 .106 
Q18 .363 .675 .338 .164 .227 .404 .243 
Q19 .331 .701 .159 .178 .257 -.017 -.286 
Q20 -.014 .762 .027 .135 .125 .265 .355 
Q21 .384 .669 .771 .467 .287 .358 .175 
Q22 .191 .288 .351 .924 .084 .368 .536 
Q23 .308 .660 .818 .406 .401 .475 .452 
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Table 3.5 Correlations between the factors resulting from the rotation using promax and maximum 
likelihood 
Correlation  Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 Q19 Q20 Q21 Q22 Q23 
Q1 1.000 .320 .351 .336 -.095 .196 .167 .221 .242 .142 .221 .221 .238 .150 .019 .000 .000 .360 .074 .216 .353 .188 .381 
Q2 .320 1.000 .104 .231 -.116 -.131 .526 .539 .240 .367 .411 .382 .470 .515 .317 .021 -.207 .368 .084 .109 .334 .078 .367 
Q3 .351 .104 1.000 .390 -.055 .808 -.016 .038 .435 .082 .038 -.035 .064 .087 .051 .174 .190 .247 .306 .152 .242 .109 .331 
Q4 .336 .231 .390 1.000 -.110 .170 .193 .154 .448 -.082 .000 .139 .127 .044 .202 .248 -.195 .131 .515 .140 .451 .109 .378 
Q5 -.095 -.116 -.055 -.110 1.000 -.136 .198 .137 .021 -.004 .239 .013 .228 .211 .226 .082 .150 .081 -.115 .051 -.027 .317 .125 
Q6 .196 -.131 .808 .170 -.136 1.000 -.155 -.101 .147 -.090 -.101 -.122 -.167 -.161 -.132 .076 .298 -.143 .084 .031 .155 .047 .192 
Q7 .167 .526 -.016 .193 .198 -.155 1.000 .471 .353 .198 .471 .462 .486 .436 .542 .317 -.113 .316 .352 .237 .348 .324 .366 
Q8 .221 .539 .038 .154 .137 -.101 .471 1.000 .243 .438 .576 .440 .427 .283 .386 .481 -.449 .337 .051 -.046 .420 .429 .522 
Q9 .242 .240 .435 .448 .021 .147 .353 .243 1.000 .521 .398 .341 .532 .288 .524 .301 -.218 .435 .574 .351 .557 .031 .508 
Q10 .142 .367 .082 -.082 -.004 -.090 .198 .438 .521 1.000 .666 .531 .350 .511 .478 .184 -.240 .431 .204 -.064 .375 -.046 .280 
Q11 .221 .411 .038 .000 .239 -.101 .471 .576 .398 .666 1.000 .440 .603 .524 .759 .481 -.449 .337 .051 -.046 .420 .429 .522 
Q12 .221 .382 -.035 .139 .013 -.122 .462 .440 .341 .531 .440 1.000 .411 .452 .411 .374 -.272 .189 .115 -.017 .509 .292 .316 
Q13 .238 .470 .064 .127 .228 -.167 .486 .427 .532 .350 .603 .411 1.000 .370 .640 .455 -.347 .559 .232 .352 .697 .462 .722 
Q14 .150 .515 .087 .044 .211 -.161 .436 .283 .288 .511 .524 .452 .370 1.000 .690 .175 .144 .301 .165 .207 .170 .291 .148 
Q15 .019 .317 .051 .202 .226 -.132 .542 .386 .524 .478 .759 .411 .640 .690 1.000 .513 -.250 .285 .301 .110 .397 .433 .382 
Q16 .000 .021 .174 .248 .082 .076 .317 .481 .301 .184 .481 .374 .455 .175 .513 1.000 -.416 .176 .288 .021 .606 .777 .507 
Q17 .000 -.207 .190 -.195 .150 .298 -.113 -.449 -.218 -.240 -.449 -.272 -.347 .144 -.250 -.416 1.000 -.026 -.025 .301 -.289 -.127 -.319 
Q18 .360 .368 .247 .131 .081 -.143 .316 .337 .435 .431 .337 .189 .559 .301 .285 .176 -.026 1.000 .478 .562 .447 .183 .447 
Q19 .074 .084 .306 .515 -.115 .084 .352 .051 .574 .204 .051 .115 .232 .165 .301 .288 -.025 .478 1.000 .472 .395 .018 .292 
Q20 .216 .109 .152 .140 .051 .031 .237 -.046 .351 -.064 -.046 -.017 .352 .207 .110 .021 .301 .562 .472 1.000 .307 .235 .372 
Q21 .353 .334 .242 .451 -.027 .155 .348 .420 .557 .375 .420 .509 .697 .170 .397 .606 -.289 .447 .395 .307 1.000 .432 .804 
Q22 .188 .078 .109 .109 .317 .047 .324 .429 .031 -.046 .429 .292 .462 .291 .433 .777 -.127 .183 .018 .235 .432 1.000 .492 
Q23 .381 .367 .331 .378 .125 .192 .366 .522 .508 .280 .522 .316 .722 .148 .382 .507 -.319 .447 .292 .372 .804 .492 
1.000 
 
 
Reproduced 
correlation 
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 Q19 Q20 Q21 Q22 Q23 
Q1 .382
a
 .320 .351 .169 .089 .242 .152 .198 .213 .086 .195 .086 .310 .135 .089 .008 .037 .289 .039 .263 .271 .187 .422 
Q2 .320 .999
a
 .104 .232 -.115 -.131 .526 .539 .240 .367 .411 .382 .469 .515 .317 .021 -.207 .368 .084 .109 .334 .078 .367 
Q3 .351 .104 .999
a
 .389 -.055 .808 -.016 .039 .435 .083 .038 -.035 .064 .087 .051 .174 .190 .246 .306 .153 .243 .109 .331 
Q4 .169 .232 .389 .368
a
 -.150 .238 .179 .159 .365 .072 .027 .111 .238 .040 .091 .258 -.071 .286 .397 .249 .395 .108 .351 
Q5 .089 -.115 -.055 -.150 .319
a
 -.046 .061 .036 -.012 .057 .250 .064 .158 .213 .237 .086 .099 .065 -.123 .130 -.002 .317 .101 
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Q6 .242 -.131 .808 .238 -.046 .746
a
 -.209 -.087 .186 -.095 -.116 -.170 -.124 -.157 -.160 .076 .186 .034 .094 .004 .069 .047 .170 
Q7 .152 .526 -.016 .179 .061 -.209 .489
a
 .408 .318 .328 .438 .383 .505 .497 .493 .318 -.173 .371 .258 .255 .398 .324 .365 
Q8 .198 .539 .039 .159 .036 -.087 .408 .594
a
 .228 .347 .579 .415 .522 .307 .431 .480 -.434 .235 .025 -.047 .481 .429 .501 
Q9 .213 .240 .435 .365 -.012 .186 .318 .228 .778
a
 .517 .414 .288 .504 .308 .489 .302 -.159 .518 .597 .332 .565 .031 .528 
Q10 .086 .367 .083 .072 .057 -.095 .328 .347 .517 .679
a
 .641 .377 .422 .455 .584 .182 -.310 .292 .203 -.076 .309 -.046 .292 
Q11 .195 .411 .038 .027 .250 -.116 .438 .579 .414 .641 .884
a
 .501 .627 .542 .738 .480 -.413 .306 .031 -.060 .455 .429 .516 
Q12 .086 .382 -.035 .111 .064 -.170 .383 .415 .288 .377 .501 .370
a
 .442 .379 .480 .377 -.296 .250 .154 .043 .369 .292 .338 
Q13 .310 .469 .064 .238 .158 -.124 .505 .522 .504 .422 .627 .442 .753
a
 .391 .570 .455 -.321 .515 .291 .368 .672 .462 .716 
Q14 .135 .515 .087 .040 .213 -.157 .497 .307 .308 .455 .542 .379 .391 .836
a
 .673 .174 .076 .344 .188 .205 .131 .291 .134 
Q15 .089 .317 .051 .091 .237 -.160 .493 .431 .489 .584 .738 .480 .570 .673 .806
a
 .515 -.224 .374 .286 .142 .412 .433 .381 
Q16 .008 .021 .174 .258 .086 .076 .318 .480 .302 .182 .480 .377 .455 .174 .515 .990
a
 -.418 .174 .288 .020 .603 .777 .507 
Q17 .037 -.207 .190 -.071 .099 .186 -.173 -.434 -.159 -.310 -.413 -.296 -.321 .076 -.224 -.418 .612
a
 -.024 .010 .290 -.397 -.127 -.335 
Q18 .289 .368 .246 .286 .065 .034 .371 .235 .518 .292 .306 .250 .515 .344 .374 .174 -.024 .508
a
 .422 .485 .475 .184 .500 
Q19 .039 .084 .306 .397 -.123 .094 .258 .025 .597 .203 .031 .154 .291 .188 .286 .288 .010 .422 .715
a
 .453 .433 .018 .288 
Q20 .263 .109 .153 .249 .130 .004 .255 -.047 .332 -.076 -.060 .043 .368 .205 .142 .020 .290 .485 .453 .791
a
 .329 .235 .365 
Q21 .271 .334 .243 .395 -.002 .069 .398 .481 .565 .309 .455 .369 .672 .131 .412 .603 -.397 .475 .433 .329 .784
a
 .432 .770 
Q22 .187 .078 .109 .108 .317 .047 .324 .429 .031 -.046 .429 .292 .462 .291 .433 .777 -.127 .184 .018 .235 .432 1.000
a
 .492 
Q23 .422 .367 .331 .351 .101 .170 .365 .501 .528 .292 .516 .338 .716 .134 .381 .507 -.335 .500 .288 .365 .770 .492 .865
a
 
Residual Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 Q19 Q20 Q21 Q22 Q23 
Q1  .000 .000 .167 -.184 -.047 .015 .023 .029 .056 .026 .135 -.072 .016 -.069 -.008 -.037 .071 .035 -.047 .082 .000 -.041 
Q2 .000  .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 
Q3 .000 .000  .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .001 .000 .000 .000 .000 .000 
Q4 .167 .000 .000  .040 -.068 .014 -.005 .083 -.154 -.027 .029 -.111 .003 .112 -.009 -.124 -.155 .117 -.109 .056 .000 .027 
Q5 -.184 .000 .000 .040  -.090 .137 .101 .033 -.061 -.011 -.051 .070 -.002 -.011 -.004 .051 .015 .008 -.079 -.025 .000 .024 
Q6 -.047 .000 .000 -.068 -.090  .054 -.013 -.039 .005 .016 .049 -.042 -.005 .028 .000 .112 -.178 -.010 .026 .086 .000 .023 
Q7 .015 .000 .000 .014 .137 .054  .063 .035 -.130 .033 .079 -.019 -.060 .049 -.001 .060 -.055 .094 -.018 -.050 .000 .000 
Q8 .023 .000 .000 -.005 .101 -.013 .063  .016 .091 -.003 .025 -.095 -.023 -.045 .001 -.014 .103 .025 .001 -.061 .000 .021 
Q9 .029 .000 .000 .083 .033 -.039 .035 .016  .004 -.016 .054 .028 -.020 .036 -.002 -.060 -.082 -.023 .019 -.008 .000 -.020 
Q10 .056 .000 .000 -.154 -.061 .005 -.130 .091 .004  .024 .153 -.072 .056 -.106 .002 .069 .139 .001 .012 .066 .000 -.013 
Q11 .026 .000 .000 -.027 -.011 .016 .033 -.003 -.016 .024  -.061 -.024 -.018 .021 .000 -.036 .031 .020 .014 -.035 .000 .006 
Q12 .135 .000 .000 .029 -.051 .049 .079 .025 .054 .153 -.061  -.031 .074 -.069 -.003 .024 -.061 -.038 -.060 .140 .000 -.022 
Q13 -.072 .000 .000 -.111 .070 -.042 -.019 -.095 .028 -.072 -.024 -.031  -.021 .070 .001 -.026 .045 -.059 -.015 .025 .000 .005 
Q14 .016 .000 .000 .003 -.002 -.005 -.060 -.023 -.020 .056 -.018 .074 -.021  .018 .001 .068 -.042 -.022 .002 .039 .000 .014 
Q15 -.069 .000 .000 .112 -.011 .028 .049 -.045 .036 -.106 .021 -.069 .070 .018  -.002 -.026 -.089 .015 -.032 -.015 .000 .001 
Q16 -.008 .000 .000 -.009 -.004 .000 -.001 .001 -.002 .002 .000 -.003 .001 .001 -.002  .001 .003 .000 .001 .003 .000 .000 
Q17 -.037 .000 .000 -.124 .051 .112 .060 -.014 -.060 .069 -.036 .024 -.026 .068 -.026 .001  -.001 -.035 .011 .108 .000 .016 
Q18 .071 .000 .001 -.155 .015 -.178 -.055 .103 -.082 .139 .031 -.061 .045 -.042 -.089 .003 -.001  .056 .076 -.028 .000 -.052 
Q19 .035 .000 .000 .117 .008 -.010 .094 .025 -.023 .001 .020 -.038 -.059 -.022 .015 .000 -.035 .056  .020 -.038 .000 .004 
Q20 -.047 .000 .000 -.109 -.079 .026 -.018 .001 .019 .012 .014 -.060 -.015 .002 -.032 .001 .011 .076 .020  -.023 .000 .007 
Q21 .082 .000 .000 .056 -.025 .086 -.050 -.061 -.008 .066 -.035 .140 .025 .039 -.015 .003 .108 -.028 -.038 -.023  .000 .035 
Q22 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000  .000 
Q23 -.041 .000 .000 .027 .024 .023 .000 .021 -.020 -.013 .006 -.022 .005 .014 .001 .000 .016 -.052 .004 .007 .035 .000  
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3.2.4.3 Cronbach’s α 
The items representing each domain are shown in Table 3.6. The 
Cronbach’s α of each domain are shown in Table 4.6 ranging 
from 0.531-0. 812. All items had a corrected item-total 
correlation of more than 0.3.  
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Table 3.6: Psychometric properties of the Satisfaction Questionnaire for Osteoporosis Prevention (SQOP) 
Items Questions Corrected 
item-total 
correlation 
Cronbach’s α if 
item deleted 
Cronbach’s 
α 
 
Domains 
1 The service was conducted at 
 a time that   _______ (fill in the blank) 
for you.  
0.508 0.527 0.661 Accessibility/ 
convenience 
2 During the session, what did you think 
about the time given to discuss your 
problems with the pharmacist? 
0.486 0.549  
3 How would you rate the location of this 
service? 
0.432 0.618  
4 How would you rate the comfort of the 
location? 
0.363 - 0.531 Physical 
12 If you have questions about osteoporosis, 
would you ask the pharmacist?   
0.363 -  
5 Was the pharmacist easy to talk to? 0.378 - 0.535 Technical quality 
9 How would you rate the service provided 
by the pharmacist? 
0.378 -  
*6 How would you rate the advice given by 
the pharmacist? 
   Interpersonal 
relationship 
7 How would you rate the overall quality of 
service that was given by the pharmacist 
0.439 0.801 0.812 Outcomes/ 
Efficacy 
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to you? 
8 This pharmacist service should _______ 
(fill in the blank) 
0.426 0.803  
10 What do you think about having the same 
pharmacist to see you for subsequent 
osteoporosis care? 
0.263 0.813  
13 Pharmacist in other hospitals  
should ______ (fill in the blank) this 
service 
0.574 0.788  
14 How would you rate the amount of 
information provided to prevent falls? 
0.500 0.797  
15 How would you rate the amount of 
information provided to change your diet 
to prevent bone loss? 
0.480 0.799  
18 How would you rate the amount of 
information provided on the exercises to 
help strengthen bones? 
0.551 0.791  
19 Would you pay for a pharmacist 
counselling service? 
0.421 0.802  
20 If yes, how much are you willing to pay 
for each visit to the pharmacist?  
If you are not willing to pay anything for 
the service, please proceed to question 
18.** 
0.509 0.794  
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21 How would you rate your understanding of 
osteoporosis now? 
0.440 0.801  
22 Explanation of osteoporosis 0.446 0.800  
23 Explanation of consequences of untreated 
osteoporosis 
0.543 0.793  
*11 Explanation on how osteoporosis  can be 
prevented via lifestyle change(s) 
   Continuity 
*16 Explanation on the available methods to 
screen for osteoporosis 
   Finance 
#17 Osteoporosis booklet provided     
Notes: 
*There was only one item in these domains. Hence Cronbach’s α could not be conducted. 
# This was an optional questions. Hence it was excluded from calculating the Cronbach’s α 
** Please refer to Appendix one for the full questionnaire 
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3.2.4.4 Test retest 
At retest, eight participants (5.7%) dropped out from the study: 
three (2.1%) were overseas and five (3.6%) could not be 
contacted, leaving 132 (94.3%) at retest. Results from the 
control and intervention group were analyzed separately. All test-
retest scores were significantly correlated for both the control 
(p<0.05) and intervention (p<0.05) group. No significant 
difference was found for all items in the control group except for 
items five and six [Table 3.7]. For the intervention group, no 
significant difference was found for all items except for items 
four, five, 13, 20, 21 and 23 [Table 3.7].  
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Table 3.7: Test and retest reliability of the Satisfaction Questionnaire for Osteoporosis Prevention (SQOP) 
Group Control 
 Test (n=70) Retest (n=70) Wilcoxon-signed rank test Spearman’s 
correlation test*  Mean±SD Median Mean±SD Median Mean/rank z-value p-value 
Items         
1 3.17±0.72 3.00 3.13±0.78 3.00 4.00/4.00 -1.134 0.257 0.938 
2 2.90±0.98 3.00 2.91±1.03 3.00 1.00/2.00 -0.447 0.655 0.978 
3 3.73±1.23 4.00 3.74±1.21 5.00 4.00/4.00 -0.378 0.705 0.949 
4 3.59±1.17 4.00 3.63±1.17 5.00 9.33/8.00 -0.688 0.491 0.877 
5 3.26±1.37 3.00 3.31±1.37 4.25 0.00/2.50 -2.000 0.046* 0.983 
6 3.49±1.13 4.00 3.23±1.22 4.00 8.32/4.50 -2.508 0.012* 0.745 
7 3.59±0.81 4.00 3.63±0.85 4.00 3.00/3.00 -1.342 0.180 0.958 
8 3.29±0.95 3.00 3.13±1.06 4.00 8.61/5.50 -1.639 0.101 0.726 
9 3.14±0.97 3.00 3.11±0.93 4.00 3.50/3.50 -0.816 0.414 0.955 
10 3.36±0.84 3.00 3.41±0.83 4.00 3.50/5.10 -1.100 0.271 0.908 
11 3.91±1.03 4.00 3.86±0.92 5.00 5.25/4.50 +1.155 0.248 0.925 
12 3.33±0.78 3.00 3.33±0.78 3.25 1.50/1.50 0.000 1.000 0.996 
13 2.41±1.10 3.00 2.31±0.96 3.00 11.09/8.50 -1.170 0.242 0.802 
14 2.20±0.97 2.00 2.19±1.01 3.00 9.00/8.00 -0.229 0.819 0.862 
15 2.20±0.97 2.50 2.13±0.95 3.00 11.82/12.28 -0.923 0.356 0.796 
16 2.01±1.35 1.00 1.99±1.29 3.00 3.33/2.50 -0.707 0.480 0.947 
17 3.25±1.71 4.00 3.73±1.61 5.00 0.00/1.00 -1.000 0.317 0.726 
18 3.01±0.12 3.00 3.00±0.00 3.00 1.00/0.00 -1.000 0.317 0.981 
#19         
#20         
#21         
#22         
#23         
Total 61.87±8.76 61.18 61.23±8.96 61.77 29.79/24.41  -1.580 0.114 
 
 
0.941 
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Notes:  
*Statistically significant at p<0.05  
**Item 17 was excluded from the total score calculation as it was an optional question. 
# The control group were not required to answer items 19-23 as these items were specifically assessing the satisfaction of the 
intervention conducte
Group Intervention 
 Test (n=70)  
Retest 
(n=62 
 Wilcoxon-signed rank test 
Spearman’s 
correlation test  Mean±SD Median Mean±SD Median Mean/rank t-value p-value 
Items        
1 4.49±0.79 5.00 4.55±0.92 5.00 7.50/5.00 -1.387 0.166 0.818 
2 4.47±0.85 5.00 4.50±0.99 5.00 4.50/4.50 -1.414 0.157 0.849 
3 4.67±0.76 5.00 4.69±0.78 5.00 3.50/3.50 -0.816 0.414 0.868 
4 4.49±0.68 5.00 4.63±0.73 5.00 5.50/5.50 -2.530 0.011* 0.794 
5 4.27±1.01 5.00 4.35±0.98 5.00 0.00/3.50 -2.333 0.020* 0.900 
6 4.97±0.17 5.00 4.97±0.18 5.00 1.50/1.50 0.000 1.000 0.483 
7 4.60±0.49 5.00 4.68±0.47 5.00 4.00/4.00 -1.890 0.059 0.769 
8 4.83±0.38 5.00 4.84±0.37 5.00 2.50/2.50 0.000 1.000 0.762 
9 4.31±0.60 4.00 4.39±0.58 4.00 3.00/3.60 -1.667 0.096 0.815 
10 4.81±0.46 5.00 4.79±0.48 5.00 2.50/2.50 0.000 1.000 0.794 
11 4.51±0.78 5.00 4.42±0.90 5.00 2.50/1.00 -1.069 0.285 0.910 
12 4.66±0.66 5.00 4.69±0.64 5.00 3.00/3.00 -1.342 0.180 0.822 
13 4.43±0.75 5.00 4.50±0.74 5.00 0.00/3.50 -2.449 0.014* 0.869 
14 4.40±0.75 5.00 4.45±0.74 5.00 5.50/5.50 -1.265 0.206 0.751 
15 4.46±0.76 5.00 4.47±0.76 5.00 2.50/2.50 -1.000 0.317 0.915 
16 2.76±1.47 3.00 2.28±1.48 3.00 0.00/1.00 -1.000 0.317 0.967 
17 3.25±1.48 4.00 3.23±1.42 3.50 1.00/0.00 -1.000 0.317 0.987 
18 4.64±0.54 5.00 4.69±0.50 5.00 0.00/2.00 -1.732 0.083 0.929 
19 4.20±4.67 4.00 4.29±0.49 4.00 3.50/3.50 -1.633 0.102 0.785 
20 4.06±0.59 4.00 4.19±0.62 4.00 6.00/6.00 -2.111 0.035* 0.798 
21 4.26±0.50 4.00 4.37±0.52 4.00 4.50/5.06 -2.309 0.021* 0.699 
22 4.19±0.55 4.00 4.23±0.64 4.00 3.50/3.50 -1.633 0.102 0.849 
23 4.44±0.50 4.00 4.77±0.42 5.00 0.00/11.50 -4.690 0.000* 0.459 
Total 88.10±5.87 88.18 89.36±5.98 89.09 13.79/25.79 -4.995 0.000* 0.948 
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3.2.4.5 Discriminative validity 
The instrument in this study showed that the intervention group 
had a significantly higher participant satisfaction compared to the 
control group (88.10±5.87 versus 61.87±8.76, p<0.05). Thus 
the SQOP was able to discriminant between a group with higher 
satisfaction and lower satisfaction. This also demonstrated that 
our intervention had an effect on participants’ satisfaction level 
[Table 3.7]. 
 
3.2.4.6 Flesch reading ease 
Flesch reading ease was 62.9. 
 
3.2.4.7 Comparison of the Satisfaction Questionnaire 
for Osteoporosis Prevention (SQOP) with other 
validated instruments 
The psychometric properties of the SQOP were similar to that of 
other validated instruments for measuring participant satisfaction 
[Table 3.8]. 
  
 234 
 
Table 3.8: Comparison of psychometric properties of the Satisfaction Questionnaire for Osteoporosis 
Prevention (SQOP) to other validated patient satisfaction instruments 
 SQOP OPSQ OPSAT-Q PSQ PSQ-An DMET DDSM-Q PEQD 
No. of subjects 
 
140 180 104 1583 312 202 114 1472 
Mean age ± S.D. 
(years) 
 
59.5±7.2 65.6±9.3 65.1 ±10.3 65.4 60.2±11.8 55.7 61.9±9.4 51.0±16.
0 
Type of study RCT RCT Observational RCT Observational Observational Observational RCT 
No. of items 
 
23 16 16 20 11 73 31 12 
No. of domains 
 
7 2 4 6 2 2 3 4 
Cronbach’s α 0.81 0.86 0.72-0.89 0.61-0.93 0.83 0.79-0.95 - 0.73-
0.84 
Factor analysis: no. 
of components 
 
7 1 - 5 - 13 3 - 
No. of times 
administered 
 
Twice Once Twice Once Twice Once Once Twice 
(n=202) 
Interval between 
administration 
 
2 weeks NA 2 weeks NA 4 weeks N A NA Mean= 
66 ± 14 
days 
Test-retest 
reliability (intraclass 
correlations) 
0.46-0.98 NA 0.62-0.81 NA 0.45-0.67 NA NA 0.66-
0.83 
Abbreviations: 
DDSM-Q= Diabetes Disease State Management Questionnaire;(Krass et al., 2009) DMET= Diabetes Management Evaluation 
tool;(Paddock et al., 2000) NA= Not applicable; OPSAT-Q= Osteoporosis Patient Treatment Satisfaction Questionnaire;(Flood et al., 
2006) OPSQ= Osteoporosis Patient Satisfaction Questionnaire;(Lai et al., 2010) PEQD= Patients’ Evaluation of the Quality of Diabetes 
Care;(Pouwer and Snoek, 2002) PSQ= Preference and Satisfaction Questionnaire;(Gold et al., 2011) PSQ-An= Patient Satisfaction 
Questionnaire for Anaemia Treatment;(Nordyke et al., 2006) RCT= Randomized Controlled Trial; SQOP= Satisfaction Questionnaire for 
Osteoporosis Prevention  
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3.2.5 Discussion 
The SQOP performed satisfactorily in both the EFA and 
psychometric properties. This indicates that the SQOP is suitable 
to assess patient satisfaction towards an osteoporosis screening 
and prevention service in Malaysia. 
 
EFA showed that there were seven domains of satisfaction being 
measured within the main component to assess patients’ 
satisfaction towards an osteoporosis screening and prevention 
programme in Malaysia. This was as expected, as the 
researchers initially designed this tool to assess seven domains, 
namely: outcomes/efficacy, accessibility/convenience, technical 
quality, interpersonal relationship, finance, physical condition and 
continuity.  The seven domains were deemed to be significant to 
assess patients’ satisfaction as it concurred with the themes from 
a previous qualitative study (Ware et al., 1983).  
 
The domains measured by SQOP were then compared to that of 
other satisfaction tools related to osteoporosis. For example, the 
OPSQ measured convenience, time, trusts and usefulness of the 
counselling session.(Lai et al., 2010) The OPSAT-Q measured 
convenience, confidence with daily activities, side effects and 
overall satisfaction (Flood et al., 2006). PSQ on the other hand 
measured preference, bother or satisfaction (Gold et al., 2011). 
It was difficult to compare the domains of the OPSAT-Q, PSQ and 
OPSQ as these tools were targeted at osteoporosis treatment 
instead of prevention. However, there were similarities in terms 
of some of the domains measured such as convenience and 
usefulness.  
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Corrected item-total correlations showed that all items measured 
the same main component which is satisfaction. SQOP was 
designed as a multi-dimensional tool rendering an overall 
Cronbach’s α unsuitable. Hence the Cronbach’s α was conducted 
for each domain. The physical and technical quality domains had 
a low Cronbach’s α of 0.531 and 0.535 respectively due to the 
small number of items in each domain (George and Mallery, 
2003). Nonetheless, the other two domains had an acceptable 
and good Cronbach’s α of 0.661 (accessibility/convenience) and 
0.812 (outcomes/efficacy) (George and Mallery, 2003). However, 
Cronbach’s α was not computed for the domains: interpersonal 
relationship, continuity and finance as these domains only had 
one item. These domains comprise a total of 4 items out of the 
23 items. Flesch reading ease was satisfactory at 62.9 as this 
represents the standard level reading of documents for adults. 
 
The SQOP performed satisfactorily at test-retest indicating that 
the SQOP achieved stable reliability. Only items five and item six 
‘was significantly different at test-retest for control participants. 
This may be because participants may have been more “satisfied 
with the service” provided by the pharmacist.  
 
As for the intervention group, there was no significant difference 
in item scores between test and retest except items four, five, 
13, 20, 21 and 23. Item four was regarding ‘How would you rate 
the comfort of the location?’ This difference may be due to 
participants having more time to reflect on the programme and 
realizing that they were “more satisfied” leading to viewing the 
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overall comfort more positively.  Item five was regarding ‘If you 
have questions about osteoporosis, would you ask the 
pharmacist?’ Several of the participants changed to a more 
positive answer during the retest and this may be because of 
their intervention experience with the researcher who is a 
pharmacist. Items 13, 20, 21 and 23 were regarding ‘How would 
you rate the amount of information provided?’ ‘Explanation of 
consequences of untreated osteoporosis,’ ‘Explanation on how 
osteoporosis can be prevented via lifestyle changes ’and 
‘Osteoporosis booklet provided’, respectively. A possible 
explanation for this positive change could be because participants 
may have had more time to consider the information provided, 
found it useful, and hence were more satisfied. This in turn 
improved the overall score of intervention participants 
significantly.  
 
The SQOP was able to differentiate between participants who 
were expected to be more satisfied as they received an additional 
service ‘the intervention’ as compared to those who did not 
receive the intervention, indicating that the items in SQOP were 
specific in addressing the different attributes of participant 
satisfaction towards an osteoporosis screening and prevention 
service in Malaysia. 
 
Currently, there are only a limited number of studies that have 
validated instrument to measure patient satisfaction. (Gold et al., 
2011, Lai et al., 2010, Krass et al., 2009, Flood et al., 2006, 
Nordyke et al., 2006, Pouwer and Snoek, 2002, Paddock et al., 
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2000) The psychometric properties of the SQOP were similar to 
previous satisfaction tools. 
 
3.2.6 Strengths 
Surveys research using questionnaires are useful for collecting 
large samples relatively cheaply and in a reasonably short time. 
Most participants required about 10-15 minutes to complete the 
questionnaire. This method is suitable for collecting factual 
information which requires short answer and closed questions. 
Additionally, structured questionnaires can collect the relevant 
information in a systematic way(Smith, 2010). 
 
3.2.7 Limitations 
Our research used a mixed mode survey administration, where 
we used self-administration of the survey and interviewed 
participants who had difficulty in answering the questions at 
baseline. Subsequently, the follow up survey was administered 
using telephones interviews. We used the mix mode to optimize 
response rate and cost. However, mixing the survey 
administration mode increases the probability that the 
participants will give different answers due to the difference in 
administrations mode rather than in opinion (Check and Schutt, 
2012). Nonetheless, we have carefully designed the survey to 
ensure that the survey was equivalent across modes (De Leeuw, 
2005). Additionally, the researcher was also trained to reduce 
interviewer bias (Check and Schutt, 2012).  
 
A limitation of this study was that SPSS Analysis of Moment 
Structure (AMOS) was not used to conduct confirmatory factor 
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analysis as five of the seven domains were developed with two 
items or less (Finance, physical condition, interpersonal 
relationship, continuity and technical quality). This was because 
the questionnaire was designed so that participants would only 
take approximately 5 minutes to complete, to ensure the 
practicality of its usage in daily practice. The numbers of items 
per domain was determined based on the patients’ emphasis 
towards the domain during the IDIs. Nonetheless, EFA showed 
that there were seven components measuring patients’ 
satisfaction. 
 
Another limitation of this study was that SQOP was designed to 
measure the satisfaction of patients towards a pharmacist 
conducted osteoporosis screening and prevention service. Hence, 
wordings such as ‘Was the pharmacist easy to talk to?’ was used. 
The implementation of this questionnaire is limited to services 
provided by a pharmacist. Minor modifications of the SQOP will 
be required if used to assess satisfaction provided by other 
healthcare professionals. 
 
Participants in our study were mainly Chinese (42.9%) and 
Indians (30.7%). This does not represent the ethnic distribution 
of Malaysia. It only represents the ethnicity of patients who 
sought treatment in our study site, meaning that our results 
cannot be considered population-based. Future validation studies 
of our tool to Malay and Mandarin, and enrolment of participants 
from multi-sites would be more representative of the Malaysian 
population. 
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3.2.8 Conclusion 
The English version of the SQOP was found to be a reliable and 
valid instrument for assessing patient satisfaction towards an 
osteoporosis screening and prevention programme in Malaysia. 
Future studies should include the translation of the SQOP into 
Malay and Mandarin to assess patient satisfaction for Malaysians 
that are not fluent in English. 
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3.3   Osteoporosis Prevention and Awareness Tool 
(OPAAT) 
3.3.1  Introduction 
3.3.1.1 Importance of knowledge 
Knowledge of osteoporosis plays an important role in developing 
attitudes towards the disease which in turn impacts upon health 
care behaviors (Andersen, 1995). Patients’ health beliefs are 
defined by attitudes, values and knowledge about health and 
health services. Although knowledge is not the only component 
attributed to behavioural changes in patients, it is one of the 
essential components. Therefore patients should be equipped 
with the knowledge of the various prevention measures available 
to increase the likelihood of osteoporosis prevention and its 
fractures. This includes knowledge on physical activity, adequate 
calcium intake, adequate vitamin D intake, fall prevention and 
screening of osteoporosis (Ministry of Health Malaysia, 2012).  
 
Primary prevention of osteoporosis is directed at identifying high 
risk non-osteoporotic individuals, while secondary prevention of 
osteoporosis refers to the early detection of the disease and 
prevention of subsequent fragility fracture. Both primary and 
secondary prevention involve osteoporosis preventing behaviours  
(Lundy and Janes, 2009). Therefore, it is important to educate 
patients on the importance of screening and prevention, as 
studies have found that early detection of osteoporosis  is the 
most cost-effective ways to reduce the number of hospital 
admittance due to osteoporotic fractures (Hajcsar et al., 2000, 
Cranney et al., 2008, Davis et al., 2007, Richy et al., 2004a).  
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Although there are many methods to increase osteoporosis 
preventive behaviour such as patient reminder(Heyworth et al., 
2014), physician reminders (Cranney et al., 2008) and screening 
programmes (Yuksel et al., 2010), patient education has been 
found to be an effective component in increasing knowledge and 
frequency of osteoporosis preventive behavior (Nielsen et al., 
2008, Gaines and Marx, 2011, Jensen et al., 2013, Burke-Doe et 
al., 2008, Werner, 2005, Yu and Huang, 2003, Baheiraei et al., 
2005a). A study by Burke-Doe noted that an increase in 
osteoporosis knowledge was associated with an increased 
confidence to perform preventive measures (Burke-Doe et al., 
2008). Similarly, studies in Iran, Norway and Singapore have 
shown a significant relationship with knowledge scores and 
preventive practice (Saw et al., 2003, Magnus et al., 1996, Jalili 
et al., 2007). Women in Iran have noted that women who have 
insufficient knowledge on osteoporosis, have a negative attitude 
to the preventive actions (Jalili et al., 2007).  
 
 However, some studies suggest otherwise (Etemadifar, 2013, 
Kasper et al., 1994).  The differences in these studies’ 
methodologies make it difficult to generalize results,  as some 
studies used qualitative methods (Terrio and Auld, 2002) whilst 
others used quantitative methods (Etemadifar, 2013, Burke-Doe 
et al., 2008, Kasper et al., 1994). The variations in the results 
also suggest that knowledge is not the only component that 
affects behavioural change. Beliefs, attitudes and values may 
also be a barrier to implementing osteoporosis preventive efforts 
(Andersen, 1995). Nonetheless, knowledge plays an important 
component towards osteoporosis prevention and screening. 
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Hence a reliable and validated tool to assess osteoporosis 
prevention and screening knowledge in postmenopausal women 
at risk for osteoporosis is necessary.  
 
3.3.1.2 Tools to assess osteoporosis knowledge 
Seven knowledge tools for osteoporosis have been developed 
and validated: the Facts on Osteoporosis (FOOQ) (Ailinger et al., 
2003, Ailinger et al., 1998, Ailinger and Emerson, 1998), the 
Osteoporosis Knowledge Assessment Tool (OKAT) (Winzenberg et 
al., 2003), the Osteoporosis Questionnaire (OPQ) (Pande et al., 
2000), the Osteoporosis Knowledge Test (OKT) (Kim et al., 
1991), the Osteoporosis and You (Cadarette et al., 2007), the 
Osteoporosis Knowledge Questionnaire (OKQ) (Curry and 
Hogstel, 2001), and the Malaysian Osteoporosis Knowledge Tool 
(MOKT) (Lai et al., 2008). Table 3.9 summarizes the 
characteristics of the seven tools. Although these tools have been 
validated they were focused mainly on assessing knowledge of 
osteoporosis and its treatment (Lai et al., 2008, Kim et al., 1991, 
Ailinger et al., 2003, Ailinger et al., 1998, Ailinger and Emerson, 
1998, Winzenberg et al., 2003, Pande et al., 2000, Cadarette et 
al., 2007, Curry and Hogstel, 2001).
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Table 3.9: Summary of validated tools to measure osteoporosis knowledge. 
Abbreviations: FOOQ- Facts on osteoporosis; OKAT- Osteoporosis knowledge assessment tool; OPQ- Osteoporosis 
questionnaire; OKT- Osteoporosis Knowledge test; OKQ- Osteoporosis knowledge questionnaire and MOKT- Malaysian 
osteoporosis knowledge too
Instruments Scale type No. of items Domains assessed Validated in 
which country 
Validated in what 
language? 
FOOQ (Ailinger et al., 
1998) (Ailinger and 
Emerson, 1998, Ailinger 
et al., 2003) 
True or false 25 items  Risk factors and preventive behaviours 
associated with osteoporosis 
US English 
OKAT (Winzenberg et al., 
2003) 
True, false and 
do not know 
20-items  Osteoporosis in general. This includes the 
cause of osteoporosis, risk factors and 
some questions on prevention and 
treatment 
Australia English 
OPQ(Pande et al., 2000) Multiple-choice  20-items  General information of osteoporosis, risk 
factors and consequences of untreated 
osteoporosis 
United Kingdom English 
OKT (Kim et al., 1991) Multiple-choice  24-items  Calcium and exercise US English 
Osteoporosis and You 
(Cadarette et al., 2007) 
5-point Likert 
scale 
10-items  Osteoporosis risk factors, consequences of 
untreated osteoporosis, prevention and 
treatment 
Canada English 
OKQ (Curry and Hogstel, 
2001) 
Multiple-choice  12- items  Osteoporosis risk factors US English 
MOKT (Lai et al., 2008) 5-point Likert 
scale 
40-items  General information about osteoporosis, 
consequences of untreated osteoporosis, 
risk factors of osteoporosis and its 
treatment 
Malaysia English 
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In Malaysia, the MOKT (Lai et al., 2008) and the Malay version of 
the OKT (Abdulameer et al., 2013, Kim et al., 1991) have been 
validated. However, we wanted to assess the knowledge of 
osteoporosis and its prevention. Hence, these tools were 
unsuitable for use in our study as the MOKT assessed knowledge 
on osteoporosis and its treatment, while the OKT assessed 
osteoporosis knowledge by asking participants to rate the 
likelihood of getting osteoporosis based on the type of preventive 
measure taken (Kim et al., 1991, Lai et al., 2008).  Hence, the 
aim of our study was to develop and validate the English version 
of the Osteoporosis Prevention and Awareness Tool (OPAAT) in 
Malaysia. 
 
3.3.2 Objectives  
To develop and validate Osteoporosis Prevention and Awareness 
Tool (OPAAT) in Malaysia. 
 
3.3.3 Methods 
This section presents the development and validation of a 
satisfaction questionnaire called the OPAAT which will be used as 
one of the methods to evaluate the osteoporosis screening and 
prevention programme. Issues relating to quantitative methods 
and questionnaires have been previously discussed in section 
3.1.3.1 and 3.1.3.2.  
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3.3.3.1 Development of the Osteoporosis Prevention 
and Awareness Tool (OPAAT) 
The OPAAT was developed based on modifications from the 
Malaysian Osteoporosis Knowledge Tool (MOKT) and findings 
from Phase one qualitative study which examined the barriers 
and needs towards an osteoporosis screening and prevention 
service in Malaysia. 
 
3.3.3.1.1 Language 
Despite Malay being the national language of Malaysia, 
postmenopausal women aged 50 years and above are more 
fluent in English as schooling was only conducted in the English 
language then. Hence, the OPAAT was developed in English. 
 
3.3.3.1.2 Modification from the Malaysian Osteoporosis 
Knowledge Tool (MOKT) 
We took 10 out of the 50 items from the MOKT, as the other 
items were related to assessing knowledge on risk factors of 
osteoporosis, osteoporosis medication or misconceptions about 
osteoporosis. Items about risk factors and misconceptions were 
removed as our qualitative results highlighted risk factors and 
other misconceptions which were more relevant to our 
population. Items on osteoporosis medications were removed as 
this questionnaire aimed to assess osteoporosis screening and 
prevention. Six items were rephrased. For item 1, we added the 
word “fracture” in parenthesis to emphasize that the word 
“broken bones” means fracture. For item 5, “early on” was 
removed as patients were unaware that osteoporosis was 
asymptomatic and the phrase “early on” may confuse them (Toh 
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et al., 2012). As for item 13 and 16, we combined the original 
four questions to develop two questions; as “a loss of height” 
and “hunchback” were essentially assessing the same thing, and 
“joint pain” and “swelling of the fingers” were both referring to 
symptoms of osteoarthritis. Four items from the MOKT were used 
in its original format. 
 
3.3.3.1.3 Development of the Osteoporosis Prevention and 
Awareness Tool (OPAAT) based on the qualitative 
data in Phase one 
Results from the qualitative study found that patients, nurses, 
general practitioners, pharmacists and policy makers lacked 
knowledge in the following areas: osteoporosis in general, 
consequences of untreated osteoporosis and osteoporosis 
prevention (Toh et al., 2012). Further details can be found in 
chapter 3, section 3.4.2.2.7.3. Therefore 22 new items were 
added. The final OPAAT consists of 30 items, and was divided 
into three domains: osteoporosis in general (domain A), 
consequences of untreated osteoporosis (domain B) and 
osteoporosis prevention (domain C).  
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3.3.3.2 Validation of the Osteoporosis Prevention and 
Awareness Tool (OPAAT)) 
 
3.3.3.3 Study design 
The validation process was a cross sectional study.  
 
3.3.3.4 Setting  
The study was conducted at the primary care clinics of the 
University Malaya Medical Centre (UMMC), Kuala Lumpur, 
Malaysia. 
 
3.3.3.5 Period of study 
The data collection began in October 2013 to January 2014. 
 
3.3.3.6 Participants 
3.3.3.6.1 Patient  
English speaking postmenopausal women aged 50 years and 
above, who had not been diagnosed with 
osteoporosis/osteopenia were included (This information was 
obtained from the patient’s medical records). Participants who 
were feeling too unwell to participate in the study were excluded. 
The OPAAT was administered to the patient group at baseline 
and 2 weeks later to assess for reliability. 
 
3.3.3.6.2 Professional group 
To assess discriminative validity, pharmacists were recruited 
from the same tertiary hospital. Pharmacists were expected to 
have a higher knowledge of osteoporosis than patients. The 
OPAAT was administered to the pharmacists only once, as we 
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wanted to assess the instrument’s ability to discriminate between 
the knowledge scores of patients and healthcare professionals at 
baseline.  
 
3.3.3.7 Sampling procedure 
A 1:2 systematic random sampling method was used to recruit 
participants, as it was not possible for one researcher to recruit 
all the eligible participants at the clinic. The medical folders of 
eligible participants were labelled from 1-40, and a number was 
randomly drawn from a bag to determine the starting number at 
the start of each day. This was performed to ensure that 
sampling was random. Subsequently every 2nd medical folder 
was selected for recruitment.   
 
Additionally, 11 participants were also recruited using the 
“snowballing” method. As the project went on, participants began 
to refer their friends and family. Although this was a non-
randomized method of recruiting patients, only 11 (7.3%) 
participants were recruited in this manner. 
 
3.3.3.8 Sample size 
3.3.3.8.1 Patient group 
Sample size was calculated based on a 5:1 participant ratio for 
factor analysis (Gorsuch, 1983). Since the OPAAT had 30 items, 
the total number of participants needed was 150. Allowing for a 
20% loss to follow up, the final number of participants required 
was 180. 
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3.3.3.8.2 Professional group 
The total number of pharmacists recruited was based on the 
number of pharmacists working in the hospital understudy. This 
group of participants was excluded from factor analysis. 
 
3.3.3.9 Instruments used 
3.3.3.9.1 Baseline demographics 
Baseline demographic information such as patients’ medical 
history, lifestyle and medication history was collected (Appendix 
1). Healthcare professionals’ baseline information, work 
experience and education level were also collected (Appendix 2). 
 
3.3.3.9.2 Osteoporosis Prevention and Awareness 
Tool (OPAAT) 
The OPAAT consist of 30 items with three domains: osteoporosis 
in general, consequence of untreated osteoporosis and 
osteoporosis preventive measure (Appendix 28). A score of one 
was given for a correct response and zero for an incorrect or do 
not know response. The total score was converted into 
percentage ranging from 0-100. Each domain score was also 
analyzed. 
 
3.3.3.10 Procedure 
Patients were recruited at the waiting area outside the general 
practitioner’s consultation room as the waiting time to see the 
general practitioner’s appointment ranges from one to two hours. 
Utilising this period of waiting allowed the research team to 
collect data without extending the duration of the patient’s visit 
to the hospital. 
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The study was explained to the participants using an information 
sheet. Patient’s written consent was obtained (Appendix 29 and 
30). Baseline demographic information such as patients’ medical 
history, lifestyle and medication history was collected. Patients 
answered the questionnaire themselves. For those who 
experienced some difficulty in reading the questions, the 
researcher assisted them. The researcher then checked the 
questionnaire to ensure that all questions were answered. This 
took approximately 10 minutes. The OPAAT was administered 
again to the same group of patients after two weeks to assess for 
reliability. A duration of two weeks was selected for retest, as 
this time interval is generally accepted to be long enough for 
participants not to have remembered their original responses, 
and not long enough for their knowledge of the subject to have 
changed (DeVon et al., 2007). Patients were questioned if any 
significant changes or events occurred within the past two 
weeks, and all changes were documented.   
 
Pharmacists’ baseline information, work experience and 
education level were also collected using a baseline information 
form specific for pharmacist. The OPAAT was administered to the 
pharmacists only once at baseline (Appendix 31 and 32).  
 
3.3.3.11 Source of data 
The source of data varied from medical registers, medical 
records, observations to observe if patients were too unwell to 
participate in the study, interviews, questionnaire and informal 
discussions to find out informally if patients have osteoporosis 
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during recruitment. Some of the data such as patients’ clinical 
information were obtained from medical records prior to the 
provision of service, whilst other data were obtained during the 
counselling session with the pharmacist. 
 
3.3.3.12 Ethics approval 
The University Malaya Medical Centre Ethics Committee was 
obtained prior to the study (ref no. 920.27, Appendix 27). All 
required documents were submitted and approval was obtained 
one month after submission. In accordance with the ethics 
committee requirements, a report upon completion form has 
been submitted. Ethical issues such as anonymity, confidentiality 
and informed consent were considered in this study. 
 
3.3.3.12.1 Anonymity and confidentiality 
Only the researcher and the supervisors had access to the 
questionnaire. All information were coded and anonymized. The 
information collected as paper copies were stored under lock and 
key, while the electronic data can only be accessed with a secure 
password only accessible by the researcher and supervisors. The 
data collected were used only for the purpose of this research; if 
data were to be used for future studies, further Research Ethics 
Committee approval will be sought. All information which is 
collected was confidential and any form of identity will not be 
included in any publications. 
 
3.3.3.12.2 Informed consent 
Prior to the start of any research activity, written informed 
consent for participating was obtained from each participant. 
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3.3.3.13 Data analysis 
All data was entered into the IBM® SPSS® version 20 (IBM 
Corporation, Armonk, NY, US).  Flesch reading ease was 
calculated using Microsoft Office® Word® 2007 (Microsoft 
Corporation, Redmond, WA, US). Non-parametric tests were 
used since data obtained were not normally distributed.  A p-
value <0.05 was considered as statistically significant. 
 
3.3.3.14 Face and content validity 
Face and content validity of the OPAAT was established via 
consultation with an expert panel consisting of four pharmacists 
with many years of research and clinical experience. 
Comprehension of the questionnaire was tested on 10 
postmenopausal women who understood English. This involved 
asking the patients for their opinions about the phrasing, format 
and content of the tool. The patients encountered no difficulty in 
answering the questionnaire. Hence, no further changes were 
made.  
 
3.3.3.15 Factor analysis  
The construct validity of OPAAT was examined using exploratory 
factor analysis (EFA). Traditionally, factor analysis such as EFA 
and confirmatory factor analysis (CFA) can only be performed 
when data are of a continuous scale (Harrington, 2009, Kim and 
Mueller, 1978). However, Bruin (2006) developed a new 
algorithm of EFA to account for categorical data. In this study, 
EFA was performed on three separate domains to explore the 
appropriateness of factor structure (Bruin, 2006). Factors with 
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eigenvalues greater than one were considered as having 
significant contribution in explaining the overall model variation 
and were retained (Kaiser, 1960, Harman, 1976).  
 
3.3.3.16 Cronbach’s α 
Cronbach’s α coefficient is a tool used to assess internal 
consistency. Cronbach’s α value: >0.9- Excellent, >0.8- Good, 
>0.70- Acceptable, >0.6- Questionable, >0.5 – Poor and <0.5- 
Unacceptable (George and Mallery, 2003). If omitting an item 
increases Cronbach’s α significantly, then excluding the item will 
increase the homogeneity of the scale (Cronbach, 1951). 
 
3.3.3.17 Test retest 
For test- retest, categorical data were analysed using the kappa 
measure of agreement and the Mc Nemar’s test. In order to 
define inter-rater reliability, a kappa measure of agreement was 
calculated for each item. A kappa value of 0.5 represents 
moderate agreement, above 0.7 represents good agreement and 
above 0.8 represents very good agreement (Peat, 2001). Mc 
Nemar’s test was used to examine the test-retest reliability on 
the individual items. Continuous data of the individual items and 
total domain scores were analyzed using the Wilcoxon signed-
rank test and Spearman’s rho correlation coefficient. According to 
Cohen 1988, a value of 0.10-0.29 showed a low correlation, 
0.30-0.49 moderate correlation and 0.50-1.00 high correlation 
(Cohen, 1988).  
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3.3.3.18 Discriminative validity 
To assess discriminative validity, the chi square test was used on 
categorical data of the individual items to detect the difference 
between the patient group and professional group. The Mann-
Whitney U test was used for continuous data of the individual 
items and total domains score to compare if there was any 
significant difference between the patient and professional group. 
 
3.3.3.19 Flesch reading ease 
Flesch reading index is a tool used for estimating the reading 
comprehension level necessary to understand a written 
document based on the average number of syllables per word 
and the average number of words per sentence. The Flesch 
reading ease was calculated using the formula below: Flesch 
reading ease= 206.835- (1.015x average sentence length) - 
(84.6 x average number of syllables per word). 
 
The Flesch reading score (which range from 0 to 100) indicates 
the level of difficulty in understanding the document. The lower 
the score, the greater the difficulty. An average document should 
have a score of 60-70 (Flesch, 1948). 
 
3.3.3.20 Factors associated with knowledge 
Linear multiple regression was used to identify factors associated 
with knowledge. It used to estimate the linear relationship 
between a dependent variable (knowledge score) and one or 
more independent variables (demographic variables).   
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3.3.4 Results (Phase two- Osteoporosis Prevention and 
Awareness Tool (OPAAT)) 
3.3.4.1 Participants 
A total of 253 patients were approached, 19 declined. 234 
participants were recruited (patients=203, hospital 
pharmacists=31), [patient response rate=91.4%, pharmacists 
response rate= 100.0%]. Patients’ demographic data are shown 
in Table 3.10. Pharmacists recruited worked in different areas of 
the pharmacy, with working experience ranging from 1-10 years.  
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Table 3.10: Baseline demographic characteristics of patients 
Characteristics Patients (n=203) 
Mean age ± S. D. (years) [range] (Median) 62.1±7.2 [50-79] 
(61.0) 
Age range (years) [n (%)] 
<65 
≥ 65 
 
120 (59.1) 
83 (40.9) 
Ethnicity [n (%)] 
Malay  
Chinese 
Indian 
Eurasian 
 
30 (14.8) 
126 (62.1) 
44 (21.7) 
3 (1.5) 
Mean BMI (kg/m2) ± S.D. (Median) 24.2±4.6 (23.3) 
BM I (kg/m2) [n (%)] 
<18.5 (underweight) 
18.5-24.9 (normal) 
25.0-29.9 (overweight) 
≥30.0 (obese) 
 
10 (4.9) 
118 (58.1) 
55 (27.1) 
20 (9.9) 
Level of education [n (%)] 
                      Primary (6 years of education) 
Secondary (11-13 years of education) 
Diploma/Technical school training (12-14 years of 
education) 
Tertiary/Postgraduate (15-21 years of education) 
 
10 (4.9) 
78 (38.4) 
39 (19.2) 
 
76 (37.4) 
Income per month [n (%)] 
<RM1000 (<$ 310.7) 
RM1000-1999 ($ 310.7-621.0) 
RM2000-2999 ($ 621.3- 931.7) 
RM3000-3999 ($ 932.0- 1242.3) 
RM4000-4999 ($ 1242.6-1553) 
>RM5000 (>$1553.3) 
 
36 (17.7) 
25 (12.3) 
23 (11.3) 
21 (10.3) 
17 (8.4) 
81 (39.9) 
 S.D. = standard deviation; BMI=body mass index; $= US dollar 
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3.3.4.2 Factor analysis and psychometric properties of 
the Osteoporosis Prevention and Awareness Tool 
(OPAAT) 
As shown in Table 3.11 (a), for domain A, EFA yielded one factor 
with an eigenvalue of 4.04 which contributed to 81.0% of total 
variation. Ten items within this domain have factor loadings 
greater than 0.3 in Table 3.12 (a), suggesting substantial 
contribution in explaining the overall variation. In Table 3.11 
(b),for domain B, EFA also produced only one factor with an 
eigenvalue greater of 1.9, which explained 87.3% of the total 
variation. All five questions within this domain had factor 
loadings greater than 0.3 as shown in Table 3.12(b). In Table 
3.11(c), for domain C, EFA generated only one factor with an 
eigenvalue greater than one (4.4). This factor contributed to 
69.4% of total variation. Table 3.12 (c) showed that the factor 
loadings of all 12 items within this domain were above 0.3. 
Overall, the data from the three EFAs suggested the adequacy of 
one factor for each domain [Table 3.11 and 3.12]. 
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Table 3.11: Eigenvalues of the domains in the Osteoporosis 
Prevention and Awareness Tool (OPAAT) using exploratory factor 
analysis (EFA) 
(a) Eigenvalues of domain A 
 
Domain A Eigenvalue 
Factor1 4.04065 
Factor2 0.80586 
Factor3 0.50583 
Factor4 0.22203 
Factor5 0.11458 
Factor6 0.01873 
Factor7 -0.02871 
Factor8 -0.10657 
Factor9 -0.16125 
Factor10 -0.19727 
Factor11 -0.22522 
 
(b) Eigenvalues of domain B 
Domain B Eigenvalue 
Factor1 1.8924 
Factor2 0.74467 
Factor3 -0.04495 
Factor4 -0.19105 
Factor5 -0.23417 
 
(c) Eigenvalues of domain C 
Domain C Eigenvalue 
Factor1 4.36008 
Factor2 0.84406 
Factor3 0.56791 
Factor4 0.44087 
Factor5 0.31589 
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Factor6 0.26055 
Factor7 0.17115 
Factor8 0.01055 
Factor9 -0.04459 
Factor10 -0.15964 
Factor11 -0.21151 
Factor12 -0.27104 
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Table 3.12: Factor loadings of the Osteoporosis Prevention and Awareness Tool (OPAAT) using exploratory 
factor analysis (EFA) 
(a) Factor loadings of domain A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Only the factor loadings (represented as eigenvalue) greater than 1 were selected (Harman, 1976) 
 
 
 
 
 
Variable Factor1 Factor2 Factor3 Factor4 Factor5 Factor6 Factor7 Factor8 
ITEM1 0.3207 0.2394 -0.1778 0.1858 0.2448 0.2203 -0.0682 0.0334 
ITEM2 0.3641 -0.2981 0.389 0.1759 0.1214 -0.05 -0.177 -0.0281 
ITEM3 0.6867 0.4137 -0.0234 -0.2121 -0.1167 0.0259 -0.1924 0.0187 
ITEM4 0.5165 -0.277 0.1993 0.0702 -0.2318 0.104 -0.0083 0.0588 
ITEM5 0.7448 0.2325 0.057 0.3106 -0.1576 -0.1444 -0.0722 -0.0153 
ITEM6 0.4156 0.4079 0.0697 0.27 0.0308 -0.0044 0.2128 -0.012 
ITEM7 0.6944 -0.1801 0.1375 -0.04 0.1071 0.2178 0.0844 -0.0266 
ITEM8 0.3345 0.1019 0.359 -0.1986 0.0684 0.0893 0.1261 0.019 
ITEM9 0.6472 0.0113 -0.1588 -0.1892 -0.1781 0.172 -0.0105 -0.0556 
ITEM10 0.6949 -0.3275 -0.3495 0.0851 0.1654 0.0115 -0.04 0.0059 
ITEM11 0.7208 0.0986 0.0598 -0.2682 0.2446 -0.256 0.0009 0.0059 
ITEM12 0.8021 -0.264 -0.1945 -0.0087 -0.1141 -0.1628 0.1512 0.0155 
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(b) Factor loadings of domain B 
 
 
 
 
 
 
 
 
Only the factor loadings (represented as eigenvalue) greater than 1 were selected (Harman, 1976) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Factor1 Factor2 Factor3 Factor4 Factor5 Factor6 Factor7 Factor8 
ITEM12 0.3207 0.2394 -0.1778 0.1858 0.2448 0.2203 -0.0682 0.0334 
ITEM13 0.3641 -0.2981 0.389 0.1759 0.1214 -0.05 -0.177 -0.0281 
ITEM14 0.6867 0.4137 -0.0234 -0.2121 -0.1167 0.0259 -0.1924 0.0187 
ITEM15 0.5165 -0.277 0.1993 0.0702 -0.2318 0.104 -0.0083 0.0588 
ITEM16 0.7448 0.2325 0.057 0.3106 -0.1576 -0.1444 -0.0722 -0.0153 
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(c) Factor loadings of domain C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Only the factor loadings (represented as eigenvalue) greater than 1 were selected (Harman, 1976) 
 
 
 
 
Variable Factor1 Factor2 Factor3 Factor4 Factor5 Factor6 Factor7 Factor8 
ITEM17 0.3207 0.2394 -0.1778 0.1858 0.2448 0.2203 -0.0682 0.0334 
ITEM19 0.3641 -0.2981 0.389 0.1759 0.1214 -0.05 -0.177 -0.0281 
ITEM20 0.6867 0.4137 -0.0234 -0.2121 -0.1167 0.0259 -0.1924 0.0187 
ITEM21 0.5165 -0.277 0.1993 0.0702 -0.2318 0.104 -0.0083 0.0588 
ITEM22 0.7448 0.2325 0.057 0.3106 -0.1576 -0.1444 -0.0722 -0.0153 
ITEM23 0.4156 0.4079 0.0697 0.27 0.0308 -0.0044 0.2128 -0.012 
ITEM24 0.6944 -0.1801 0.1375 -0.04 0.1071 0.2178 0.0844 -0.0266 
ITEM25 0.3345 0.1019 0.359 -0.1986 0.0684 0.0893 0.1261 0.019 
ITEM26 0.6472 0.0113 -0.1588 -0.1892 -0.1781 0.172 -0.0105 -0.0556 
ITEM27 0.6949 -0.3275 -0.3495 0.0851 0.1654 0.0115 -0.04 0.0059 
ITEM29 0.7208 0.0986 0.0598 -0.2682 0.2446 -0.256 0.0009 0.0059 
ITEM30 0.8021 -0.264 -0.1945 -0.0087 -0.1141 -0.1628 0.1512 0.0155 
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3.3.4.3 Difficulty factors 
The mean ± SD accuracy rate was 0.60±0.22 (range: 0.26-
0.94). Four out of 30(13.3%) items had values <0.3 and 
11/30(36.7%) items had values of >0.75. The remaining 
15/30(50.0%) items had values between 0.3-0.75 [Table 3.13]. 
 
3.3.4.4 Cronbach’s α 
Cronbach’s α was analyzed for the three domains. All domains 
had a Cronbach’s α of ≥0.6 except for domain B (0.286). 
Thirteen out of 30 items had corrected item –total correlations 
<0.3 [Table 3.13].  
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Table 3.13: Psychometric properties of the Osteoporosis Prevention And Awareness Tool (OPAAT) 
Domains Item 
Number 
 Difficulty 
factor 
Cronbach’s α Corrected 
Item 
correlation 
Cronbach’s α if 
item deleted 
 
 
 
Osteoporosis 
in general (A) 
1 Makes bones weaker, more brittle and more likely 
to break (fracture)  
0.91  
 
 
 
0.668 
0.421 0.639 
2 Everybody will get osteoporosis as it is part of aging  0.32 0.173 0.672 
3 Osteoporosis occurs because bone is removed 
faster than it is formed 
0.52 0.176 0.673 
4 Osteoporosis and osteoarthritis are different names 
we can use to describe the same disease  
0.58 0.455 0.619 
5 Osteoporosis usually has no symptoms  0.48 0.065 0.693 
6 Postmenopausal women are not at risk for 
osteoporosis  
0.72 0.416 0.629 
7 Osteoporosis is an untreatable disease. 0.56 0.232 0.663 
8 A bone mineral density test is used to diagnose 
osteoporosis  
0.76 0.428 0.628 
9 I do not need a bone mineral density test unless I 
fracture my bones.  
0.79 0.555 0.608 
10 A bone mineral density test is high in radiation  0.45 0.321 0.646 
11 A bone mineral density test should be performed 
monthly to monitor bone loss  
0.60 0.407 0.629 
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Consequences 
of untreated 
osteoporosis 
(B) 
12 Results in back pain  0.72  
 
0.286 
0.272 0.095 
13 Loss of height or hunchback  0.88 0.235 0.173 
14 Loss of mobility (unable to move around myself) 0.78 0.164 0.215 
15 Results in tooth loss  0.26 0.006 0.373 
16 Results in joint pain or swelling of fingers 0.27 0.056 0.319 
 
 
 
 
 
 
Osteoporosis 
prevention 
(C) 
17 The recommended daily intake for calcium in 
women above 50 years of age is 1000mg  
0.61  
 
 
 
 
 
 
0.748 
0.274 0.744 
18 It is too late to increase calcium intake after the 
age 50 
0.55 0.417 0.727 
19 Glucosamine can help prevent osteoporosis 0.29 0.181 0.753 
20 Calcium supplements can help prevent osteoporosis  0.85 0.397 0.731 
21 The regular dose of calcium supplements can cause 
kidney stones. 
0.26 0.264 0.744 
22 Foods such as milk, tofu, anchovies (ikan bilis), 
yellow dhal and spinach are rich in calcium  
0.90 0.398 0.73 
23 You can obtain your recommended daily intake of 
vitamin D via exposing your skin to sunlight for 
about 15 minutes a day 
0.87 0.300 0.739 
24 Increasing coffee and tea intake can help in 
osteoporosis prevention 
0.67 0.479 0.719 
25 Weight bearing exercise (such as brisk walking and 
line dancing) can decrease bone loss. 
0.68 0.248 0.747 
26 Exercise will wear out bones  0.78 0.459 0.723 
27 Certain medications (such as sleeping tablets or 0.57 0.421 0.726 
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high blood pressure medications) may reduce the 
risk of falling  
28 To prevent falls, comfortable shoes with a good grip 
should be used.  
0.94 0.524 0.728 
29 Poor vision may lead to falls 0.92 0.380 0.734 
30 Being under weight helps prevent osteoporosis  0.60 0.490 0.718 
Total  Cronbach’s α   0.820   
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3.3.4.5 Test retest 
At retest, 9 (4.4%) patients could not be contacted. Hence, only 
194 participants were included at retest (response rate = 95.6%) 
[See table 3.14]. The Kappa measurement of agreement for 
29/30 items (96.7%) were ≥0.8, and 1/30 items (3.3%) was 
≥0.7. The McNemar’s test showed no significant differences for 
all 30 items at test retest. The Wilcoxon signed-rank test showed 
no significant difference for all domain scores except for the 
domain on the ‘consequences of untreated osteoporosis.’ 
However, the total score showed no significant difference. All 
domains and items were significantly correlated using the 
Spearman’s rho correlation coefficient (0.760-0.990, p<0.05) 
[Table 3.14].  
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Table 3.14: Test and retest reliability of the individual items for the Osteoporosis Prevention And 
Awareness Tool (OPAAT) 
Domain Item 
number 
Test (n=203)  Retest (n=194) McNemar
’s test p-
value  
 
Kappa 
measurem
ent of 
agreement
* 
P-value 
Spearman’s 
rho 
correlation 
coefficient* 
Wilcoxon signed-rank test 
Mean±SD 
 
Median No. of 
correct 
responses 
[n (%)] 
Mean±SD 
 
Median No. of correct 
responses 
[n (%)] 
Mean/rank z-value P-value 
Osteoporosis 
in general 
(A) 
1 0.91±0.28 1.00 185 (91.1) 0.89±0.32 1.00 172 (88.7) 0.219 0.833 0.838    
2 0.32±0.47 0.00 64 (31.5) 0.30±0.46 0.00 58 (29.9) 0.250 0.964 0.964    
3 0.52±0.50 1.00 105(51.7) 0.52±0.50 1.00 101 (52.1) 1.000 0.979 0.979    
4 0.58±0.50 1.00 117 (57.6) 0.57±0.50 1.00 110 (56.7) 1.000 0.958 0.958    
5 0.48±0.50 0.00 97 (47.8) 0.48±0.50 0.00 94 (48.5) 1.000 0.990 0.990    
6 0.72±0.45 1.00 147 (72.4) 0.71±0.46 1.00 137 70.6) 0.508 0.886 0.887    
7 0.56±0.50 1.00 113 (55.7) 0.54±0.50 1.00 105 (54.1) 0.453 0.927 0.928    
8 0.76±0.43 1.00 155 (76.4) 0.74±0.44 1.00 144 (74.2) 0.219 0.917 0.918    
9 0.79±0.41 1.00 160 (78.8) 0.78±0.42 1.00 152 (78.4) 1.000 0.970 0.970    
10 0.45±0.50 0.00 92 (45.3) 0.46±0.50 0.00 90 (46.4) 0.219 0.938 0.938    
11 0.60±0.49 1.00 121 (59.6) 0.60±0.49 1.00 118 (60.8) 0.754 0.892 0.893    
Domain 
score (%) 
60.7±22.2 63.64  60.0±23.8 63.63    0.953 14.54/11.33 -0.724 0.469 
Consequenc
es of 
untreated 
12 0.72±0.45 1.00 147 (72.4) 0.72±0.45 1.00 140 (72.2) 1.000 0.923 0.923    
13 0.88±0.33 1.00 178 (87.7) 0.89±0.31 1.00 173 (89.2) 0.250 0.925 0.927    
14 0.78±0.42 1.00 158 (77.8) 0.78±0.41 1.00 152 (78.4) 0.500 0.970 0.971    
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*Statistically significant at p<0.05.  Wilcoxon signed-rank test and Spearman’s rho correlation coefficient was used for continuous variables. 
McNemar’s test and Kappa measurement of agreement was conducted for categorical variables 
osteoporosis 
(B) 
15 0.26±0.44 0.00 52 (25.6) 0.27±0.45 0.00 53 (27.3) 0.453 0.908 0.908    
16 0.27±0.44 0.00 54 (26.6) 0.29±0.45 0.00 56 (28.9) 0.219 0.923 0.924    
Domain 
score (%) 
58.0±21.3 60.00  59.2±21.7 60.00    0.909 7.50/10.27 -2.216 0.027* 
Prevention 
of 
osteoporosis 
(C) 
17 0.61±0.49 1.00 123 (60.6) 0.60±0.49 1.00 116 (59.8) 0.687 0.935 0.936    
18 0.55±0.50 1.00 112 (55.2) 0.55±0.50 1.00 106 (54.6) 1.000 0.948 0.948    
19 0.29±0.46 0.00 59 (29.1) 0.28±0.45 0.00 55 (28.4) 1.000 0.962 0.962    
20 0.85±0.36 1.00 173 (85.2) 0.83±0.38 1.00 161 (83.0) 0.250 0.943 0.945    
21 0.26±0.44 0.00 52 (25.6) 0.26±0.44 0.00 51 (26.3) 0.375 0.932 0.933    
22 0.90±0.30 1.00 183 (90.1) 0.88±0.32 1.00 171 (88.1) 0.375 0.869 0.872    
23 0.87±0.34 1.00 176 (86.7) 0.85±0.36 1.00 165 (85.1) 0.453 0.852 0.854    
24 0.67±0.47 1.00 137 (67.5) 0.68±0.47 1.00 131 (67.5) 0.727 0.905 0.905    
25 0.68±0.47 1.00 138 (68.0) 0.65±0.48 1.00 126 (64.9) 0.070 0.908 0.910    
26 0.78±0.41 1.00 159 (78.3) 0.76±0.43 1.00 148 (76.3) 0.289 0.882 0.884    
27 0.57±0.50 1.00 116 (57.1) 0.55±0.50 1.00 106 (54.6) 0.405 0.760 0.761    
28 0.94±0.24 1.00 191 (94.1) 0.92±0.28 1.00 178 (91.8) 0.125 0.846 0.856    
29 0.92±0.28 1.00 186 (91.6) 0.90±0.30 1.00 174 (89.7) 0.250 0.910 0.914    
30 0.60±0.49 1.00 122 (60.1) 0.59±0.49 1.00 115 (59.3) 1.000 0.947 0.947    
Domain 
score (%) 
67.8±20.2 71.42  66.4±22.6 71.43    0.937 21.17/19.50 -1.339 0.171 
Total OPAAT score (%) 63.6±17.4 66.67  62.9±19.1 66.67    0.950 28.98/27.05 -0.107 0.914 
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3.3.4.6 Discriminative validity 
The overall total knowledge score for the pharmacist group 
was significantly higher than the patient group (80.9±8.7 vs 
63.6±17.4, p<0.001) [Table 3.15]. No significant difference 
was seen for 16/30(53.3%) items. 
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Table 3.15: Knowledge scores of the patient and pharmacist group at test and retest 
Domains Item 
Number 
Patients(n=203) Pharmacist(n=31) Mann-Whitney U-test p-value 
a 
 Mean±SD Median Participants 
that 
answered 
correctly 
[n (%)] 
Mean±SD Media
n 
Participant
s that 
answered 
correctly 
[n (%)] 
Mean/rank Z-
value 
p-value 
Osteoporosis 
in general 
(A) 
1 0.91±0.28 1.00 185 (91.1) 0.97±1.80 1.00 30 (96.8)    0.482 b 
2 0.32±0.47 0.00 64 (31.5) 0.58±0.50 1.00 18 (58.1)    0.007* 
3 0.52±0.50 1.00 105(51.7) 0.90±0.30 1.00 28 (90.3)    0.000* 
4 0.58±0.50 1.00 117 (57.6) 0.94±0.25 1.00 29 (93.5)    0.000* 
5 0.48±0.50 0.00 97 (47.8) 0.55±0.51 1.00 17 (54.8)    0.590 
6 0.72±0.45 1.00 147 (72.4) 1.00±0.00 1.00 31 
(100.0) 
   0.002* 
7 0.56±0.50 1.00 113 (55.7) 0.68±0.48 1.00 21 (67.7)    0.284 
8 0.76±0.43 1.00 155 (76.4) 0.94±0.25 1.00 29 (93.5)    0.052 
9 0.79±0.41 1.00 160 (78.8) 0.97±0.18 1.00 30 (96.8)    0.033* 
10 0.45±0.50 0.00 92 (45.3) 0.48±0.51 0.00 15 (48.4)    0.900 
11 0.60±0.49 1.00 121 (59.6) 0.77±0.43 1.00 24 (77.4)    0.088 
Domain 
score (%) 
60.7±22.2 63.64  79.8±12.6 81.82  109.23/171.68 -4.834 0.000*  
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Consequenc
es of 
untreated 
osteoporosis 
(B) 
12 0.72±0.45 1.00 147 (72.4) 0.77±0.43 1.00 24 (77.4)    0.713 
13 0.88±0.33 1.00 178 (87.7) 0.84±0.37 1.00 26 (83.9)    0.565 b 
14 0.78±0.42 1.00 158 (77.8) 0.81±0.40 1.00 25 (80.6)    0.905 
15 0.26±0.44 0.00 52 (25.6) 0.51±0.51 1.00 16 (51.6)    0.006* 
16 0.27±0.44 0.00 54 (26.6) 0.74±0.44 1.00 23 (74.2)    0.000* 
Domain 
score (%) 
58.0±21.3 60.00  73.6±17.4 80.00  110.98/160.21 -4.086 0.000*  
Prevention 
of 
osteoporosis 
(C) 
17 0.61±0.49 1.00 123 (60.6) 0.58±0.50 1.00 18 (58.1)    0.944 
18 0.55±0.50 1.00 112 (55.2) 0.84±0.37 1.00 26 (83.9)    0.005* 
19 0.29±0.46 0.00 59 (29.1) 0.78±0.43 1.00 24 (77.4)    0.000* 
20 0.85±0.36 1.00 173 (85.2) 0.94±0.25 1.00 29 (93.5)    0.271 b 
21 0.26±0.44 0.00 52 (25.6) 0.61±0.50 1.00 19 (61.3)    0.000* 
22 0.90±0.30 1.00 183 (90.1) 1.00±0.00 1.00 31 
(100.0) 
   0.084 b  
23 0.87±0.34 1.00 176 (86.7) 0.81±0.40 1.00 25 (80.6)    0.405 b 
24 0.67±0.47 1.00 137 (67.5) 0.94±0.25 1.00 29 (93.5)    0.006* 
25 0.68±0.47 1.00 138 (68.0) 0.71±0.46 1.00 22 (71.0)    0.900 
26 0.78±0.41 1.00 159 (78.3) 0.84±0.37 1.00 26 (83.9)    0.638 
27 0.57±0.50 1.00 116 (57.1) 0.94±0.25 1.00 29 (93.5)    0.000* 
28 0.94±0.24 1.00 191 (94.1) 0.97±0.18 1.00 30 (96.8)    1.000 b 
29 0.92±0.28 1.00 186 (91.6) 1.00±0.00 1.00 31 
(100.0) 
   0.138 b 
30 0.60±0.49 1.00 122 (60.1) 0.87±0.34 1.00 27 (87.1)    0.007* 
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* Statistically significant at p<0.05, The Mann-Whitney U-test was conducted for continuous variables and the chi square was conducted for categorical 
variables.  
a Chi-square test  b Fisher’s exact test was used as the number of cells with expected count less that 5 is more than 20% of the total number of cells 
 
  
Domain 
score (%) 
67.8±20.2 71.42  84.3±10.5 85.71  109.14/172.26 -4.876 0.000*  
 Total (%) 63.6±17.4 66.67  80.9±8.7 83.33  107.67/181.84 -5.694 0.000*  
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3.3.4.7 Flesch reading ease 
Flesh reading ease was 59.2. 
 
3.3.4.8 Factors associated with knowledge 
Knowledge was higher in patients who completed their high 
school education, and patients who conducted fall prevention 
activities (R2=0.208, F=3.949, df=18, p<0.001).  These two 
factors explained 27.9% of the variances. 
 
3.3.4.9 Comparison of the Osteoporosis Prevention 
and Awareness Tool (OPAAT) with other 
validated instruments 
The OPAAT had a similar Flesch reading ease as the MOKT. 
The Cronbach’s α of the OPAATs domain was 0.29, 0.67 and 
0.75. Two of OPAAT’s domains had similar Cronbach’s α to the 
MOKT, Osteoporosis and you, OKAT and FOOQ which ranged 
from 0.60-0.82. This shows that the psychometric properties 
of the OPAAT were similar to that of other validated 
instruments for measuring patients’ knowledge [Table 3.16]. 
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Table 3.16: Comparison of psychometric properties of the Osteoporosis Prevention And Awareness Tool (OPAAT) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OPAAT: Osteoporosis Prevention And Awareness Tool;  MOKT: Malaysian Osteoporosis Knowledge Test (Lai et al., 2008), Osteoporosis and You 
(Cadarette et al., 2007); OKAT: Osteoporosis Knowledge Assessment Tool (Winzenberg et al., 2003); FOOQ: facts on Osteoporosis Quiz (Ailinger et al., 
1998, Ailinger et al., 2003); OKQ: Osteoporosis Knowledge Questionnaire (Curry and Hogstel, 2001); OPQ: Osteoporosis Questionnaire (Pande et al., 
2000) 
 
 
 OPAAT MOKT Osteoporosis 
and You 
OKAT FOOQ OKQ OPQ 
Age (years) 
 
50-79 49-84 65-90 25-44 - ≥ 60 ≥ 50 
Number of 
subjects 
 
203 88 871 467 256 188 50 
Number of 
items with low 
difficulty level 
(%) 
 
4(13.3) 19 
(47.5) 
6 (60) 3(15) - - (44) 
Flesch reading 
ease 
59.2 57 - 45 81-90 - 74.3 
Cronbach’s α or 
Kuder 
Richardson 
(KR) 
 
0.27-
0.75 
0.82 0.60 0.70 0.76 0.80 
(KR) 
0.84 
(KR) 
Mean score (%) 63.6 69.0 37.7 44.0 - 57.4 - 
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3.3.5 Discussion 
The OPAAT performed satisfactorily in its psychometric 
properties and was able to discriminate between knowledge 
level of patients and pharmacists. This indicates that the 
English version of OPAAT is suitable to assess knowledge of 
postmenopausal women about osteoporosis prevention in 
Malaysia. 
 
EFA confirmed that there were three domains (osteoporosis in 
general, consequences of untreated osteoporosis and 
osteoporosis prevention) in the OPAAT to assess patient’s 
knowledge on osteoporosis and its prevention. This provides 
support for the construct validity of our tool. To the best of 
our knowledge no other osteoporosis knowledge assessment 
tool has validated the construct of their tool via this method.  
 
Flesch reading ease was at 59.2. This indicates the OPAAT can 
be understood by patients who have completed primary 
education. Since all of our participants have completed 
primary education, they were able to complete the OPAAT 
without any problems.  The mean ± SD accuracy rate was 
0.60±0.22 (range:0.26-0.94). Out of the 30 items, four items 
were considered difficult (accuracy rates <0.3) and five 
considered easy (accuracy rates >0.7). The optimum difficulty 
level would be 0.5. This indicates that the OPAAT was 
moderately easy for the participants to answer.  
 
The construct of the tool was considered to be multi-
dimensional and an overall Cronbach’s α was unsuitable. We 
then analyzed the Cronbach’s α by domain. All domains 
demonstrated good and acceptable internal reliability except 
the domain on the ‘consequences of untreated osteoporosis’ 
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with a Cronbach α value of 0.286.  This could be because 
there were only 5 items in this domain, and knowing the 
correct answer for one item may not necessarily mean that 
they knew the correct answer for the next item. However, 
increasing the number of items within the domain would have 
made the questionnaire too lengthy reducing the likelihood of 
completion. Corrected item-total correlations showed that all 
items measured the same main component which was 
satisfactory except items 13/30(43.3%). However all items 
were retained as removing any of the items did not improve 
the overall Cronbach’s α significantly.  
 
All 30 items performed satisfactorily at test-retest. Kappa 
measurement of agreement showed that 29/30 items (96.7%) 
were in very good agreement, and 1/30 items (3.3%) was in 
good agreement. As for the domains all domains performed 
satisfactorily except for the domain on “consequences of 
untreated osteoporosis.”  Patients may have forgotten the 
answer they selected at test (as they might have been 
guessing) as opposed to knowing the right answer. This led to 
a significant difference in this domain score as it had a small 
number of items. Although this limits how well this domain 
can measure the knowledge on the consequences of untreated 
osteoporosis, the guessing of answer reflects actual practice.  
Nonetheless, there was no significant difference in the overall 
scores. This indicates the OPAAT has achieved stable 
reliability. The domains and items had a high Spearman’s rho 
correlation coefficient ranging from 0.760-0.990. They were all 
significantly correlated at p<0.05. Therefore, all items were 
retained. 
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Although pharmacists were expected to have a higher score 
than patients for all items, there were three items (items no. 
13, 17 and 23) where no significant difference was found.  
This may be because more than 80.0% of both patients and 
pharmacists correctly answered items no. 13 and 23, 
indicating that their knowledge level for these items were 
high. As for item no. 17 which was pertaining to calcium 
intake, less than 60.6% of patients and pharmacists answered 
this item correctly. This concurs with our previous qualitative 
findings that found that both patients and pharmacists lacked 
knowledge in this area. (Toh et al., 2012). Nonetheless, the 
overall score and all domain scores of the OPAAT showed a 
significant difference between the patient and pharmacist 
group. This indicates that the OPAAT has achieved 
discriminative validity. 
 
Previous studies have found that the knowledge of 
osteoporosis in adult women aged 21-90 years in Europe 
(Alexandraki et al., 2008, Gemalmaz and Oge, 2007, Ungan 
and Tumer, 2001), Canada (Cadarette et al., 2007), United 
States (Ailinger and Emerson, 1998, Burke-Doe et al., 2008), 
Middle East (Baheiraei et al., 2005b), and Australia 
(Winzenberg et al., 2003) was low. Conversely, women and 
men aged 16-79 years in Norway were knowledgeable about 
osteoporosis (Magnus et al., 1996). In Asia, the knowledge of 
osteoporosis  ranged from low to moderate for women aged 
19-90 in Brunei (Liza et al., 2009), Singapore (Saw et al., 
2003) and Malaysia (Abdulameer et al., 2013, Yeap et al., 
2010, Khan et al., 2014). However, another study in Malaysia 
found that the knowledge of osteoporosis was moderate in 
women aged 49-84 (Lai et al., 2008). In our study, patients’ 
overall knowledge score was 63.6±17.4, which indicate that 
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their knowledge level was moderate. Our results were similar 
to a previous study conducted in Malaysia which assessed 
knowledge on osteoporosis and its prevention (Lai et al., 
2008). This may be because both studies were conducted in 
the same setting. In addition, participants in both studies were 
mainly health seeking urban patients.  
 
However, we would like to highlight that the cohort of patients 
used in the Lai et al (2008) study were patients who had 
osteoporosis, whilst our cohort were patients who did not have 
osteoporosis (Lai et al., 2008). This shows that there was no 
difference in knowledge in patients with or without 
osteoporosis.  Another tool, the Osteoporosis Knowledge 
Questionnaire (OKQ) assessed knowledge on osteoporosis risk 
factors, diagnosis, prevention and treatment in female 
population aged 60 and above scored 57.4% (Curry and 
Hogstel, 2001). The OKQ score was similar to the OPAAT as 
they assessed non-osteoporotic postmenopausal population of 
a similar age group. Additionally, we would like to highlight 
the lack of knowledge on osteoporosis occurs in women who 
have not experienced a fracture, as well as those who had a 
previous fracture (Beaton et al., 2012). The different tools 
used to assess knowledge and the different cohorts in which 
the tool was administered to (Lai et al., 2008, Abdulameer et 
al., 2013, Khan et al., 2014, Yeap et al., 2010) made 
comparison between studies difficult. In addition, most studies 
did not report the use of validated tools to assess knowledge 
levels (Alexandraki et al., 2008, Gemalmaz and Oge, 2007, 
Ungan and Tumer, 2001, Burke-Doe et al., 2008, Liza et al., 
2009, Yeap et al., 2010, Khan et al., 2014, Kasper et al., 
1994, Etemadifar, 2013, Magnus et al., 1996). 
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Patients’ knowledge was lowest on the domain on the 
‘consequences of untreated osteoporosis.’ This concurs with 
findings from our qualitative research which indicates that 
there is a need to educate patients in this area (Toh et al., 
2012). Correspondingly, Osteoporosis and You noted a deficit 
in knowledge in the area of consequences of untreated 
osteoporosis (Cadarette et al., 2007). These tools were 
developed mainly to assess the knowledge of domains of 
osteoporosis in general and treatment, the OPAAT was 
developed specifically to evaluate osteoporosis prevention.  
 
In our study, factors with a positive correlation to the 
knowledge score includes patients with a secondary or higher 
education level, and patients who conducted fall prevention 
activities. Similarly, a Greek and Turkish study noted an 
association with knowledge and level of education 
(Alexandraki et al., 2008, Gemalmaz and Oge, 2007, Khan et 
al., 2014). Additionally, Khan et al’s (2014) findings concurred 
with our study as they noted a significant association between 
knowledge and ethnicity (Khan et al., 2014). Conversely, 
Ailinger et al stated neither education level, age nor the 
menopause status increase osteoporosis knowledge (Ailinger 
and Emerson, 1998). Patients who conduct fall preventive 
measure had more knowledge of osteoporosis. This further 
justifies the importance of a higher knowledge level about 
osteoporosis prevention to ensure its implementation.  
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3.3.6 Strengths 
The strength of our study was that we developed the OPAAT 
based on literature review as well as findings from a previous 
qualitative study. By utilising findings from our qualitative 
data, we were able to identify the areas in which knowledge of 
osteoporosis was low in our population.  
 
3.3.7 Limitations 
One of the limitations of our study was that convergent 
validity could not be performed. This was because during the 
period of our study, no such tool exists.  The participants that 
we recruited also did not represent the ethnic distribution of 
Malaysia, but it represented the patients who sought 
treatment in our study site. Nonetheless, a large proportion of 
our patients had a monthly household income above $1553 
(39.9%) which was representative of the married Malaysian 
household population income (Department of statistics 
Malaysia, 2013). Seventy six percent of our participants were 
married. (Department of statistics Malaysia, 2013). This shows 
that our participants income were representative of the 
Malaysian population.  
 
Another limitation of our study was that we used mixed 
methods of administration. At baseline, majority of 
participants answered the OPPAT themselves, whilst a 
minority (2.5%) required assistance. At retest, the OPAAT was 
administered over the telephone as we wanted to optimize 
response rates. There is a possibility that participants may 
answer the items differently due to the mixed modes of 
administration (Check and Schutt, 2012). However, this effect 
would be applicable to all participants, hence its effects on the 
calidation process would be negated. 
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Additionally, our study used a mixed method of recruitment. 
Eleven (7.3%) of the participants was recruited using the 
snowballing method instead of random sampling. This was an 
error by the researcher. Although this was a non-randomized 
method of recruiting the patients, it only comprised of 7.3% of 
the participants in our study and should not affect the 
outcomes as 15% of the sample size was allocated for drop 
out. 
 
3.3.8 Conclusion 
The English version of the OPAAT was found to be a reliable 
and valid instrument for assessing patient knowledge on 
osteoporosis and its prevention in Malaysia. OPAAT can 
subsequently be used to evaluate the effectiveness of the 
education efforts provided. Future studies, using Bahasa 
Malaysia and Mandarin versions of the questionnaire are 
required to assess patient knowledge for Malaysians that are 
not fluent in English. 
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3.4   Validation of osteoporosis risk assessment 
tools 
3.4.1 Introduction 
3.4.1.1 Importance of screening for osteoporosis 
Despite its medical and economic impact only 17-20% of 
women with a fragility fractures were screened for 
osteoporosis (Hajcsar et al., 2000, Greenspan et al., 2012). It 
is therefore important to identify postmenopausal women who 
are at risk for developing osteoporosis to prevent unwanted 
fractures. The end result of osteoporosis is a fragility fracture. 
Fragility fractures can occur in various sites most notably the 
hips, vertebrae and forearm (National Osteoporosis 
Foundation, 2010). The World Health Organization provides 
that the worldwide projection of hip fractures cases due to 
osteoporosis will rise from 1.7 million in 1990 to 6.3 million by 
2050 with a steep increase to be observed in developing 
countries (World Health Organization Geneva, 1999).  
 
According to the World Health Organization (WHO), 
osteoporosis is diagnosed when the T-score at the hip or spine 
is ≤ -2.5 (National Osteoporosis Foundation, 2010). This 
becomes a problem for a newly industrialized country like 
Malaysia as the dual-energy x-ray absorptiometry (DEXA) 
machine is costly and not widely available (Ministry of Health 
Malaysia, 2012, International Osteoporosis Foundation, 2009). 
Therefore, screening which aid in early detection are the most 
effective and cost-effective ways to slow down the progression 
of osteoporosis. 
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3.4.1.2 Screening strategies 
We have previously discussed the available screening 
strategies such as the BMD, QUS and questionnaires in section 
1.7.3 and 1.7.4. In this chapter we would like to focus on the 
screening strategies using questionnaires. There are currently 
six validated risk assessment tools. The Simple Calculated 
Osteoporosis Risk Estimation (SCORE) (Lydick et al., 1998), 
the Osteoporosis Risk Assessment Index (ORAI) (Cadarette et 
al., 2000), the Age Bulk One or Never Estrogen (ABONE) 
(Weinstein and Ullery, 2000) , the Body Weight (WEIGHT) 
(Michaëlsson et al., 1996), the Malaysian Osteoporosis 
Screening Tool (MOST) (Lim et al., 2011) and the 
Osteoporosis Screening Tools for Asians (OSTA) (Koh et al., 
2001b) have been developed to perform an “initial screen” to 
determine if the patient requires a bone mineral density 
(BMD) scan [Table 3.17]. They do not replace the need for a 
BMD scan, but rather, these tools can be used to screen a 
larger number of women who potentially may require a BMD 
scan.  
 
 
 286 
 
 
Table 3.17: Summary on the types of screening strategies using questionnaires 
Name of 
questionnaire 
Country developed  Development cohort Specificity  Sensitivity Primary outcome 
measured 
Country validated 
SCORE (Lydick 
et al., 1998) 
US(Lydick et al., 
1998) 
1424 community-
dwelling 
postmenopausal 
women aged ≥45 
years (white, black, 
Hispanic) (Lydick et 
al., 1998) from 106 
centres 
 
50.0% (Lydick et 
al., 1998) 
89.0% (Lydick et 
al., 1998) 
Femoral neck T-
score ≤-2 (Lydick 
et al., 1998) 
United States of 
America (Lydick et al., 
1998, Geusens et al., 
2002), 
Netherlands(Geusens et 
al., 2002), Belgium 
(Sedrine et al., 2001, 
Richy et al., 2003, 
Gourlay et al., 2005) 
and Singapore (Chan et 
al., 2006) 
ORAI 
(Cadarette et 
al., 2000) 
Canada(Cadarette 
et al., 2000) 
The database of the 
Canadian Multicentre 
Osteoporosis Study 
comprising of 926 
non-institutionalized 
female subjects aged 
45.1%(Cadarette et 
al., 2000) 
90.0% (Cadarette 
et al., 2000) 
Either femoral 
neck of lumbar 
spine T-score ≤-
2(Cadarette et 
al., 2000) 
Canada (Cadarette et 
al., 2000), Singapore 
(Chan et al., 2006), 
Belgium (Gourlay et al., 
2005, Richy et al., 
2003), United States of 
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≥45 years from 
three 
centres(Cadarette et 
al., 2000) 
America(Geusens et al., 
2002) and the 
Netherlands (Geusens 
et al., 2002) 
ABONE 
(Weinstein and 
Ullery, 2000) 
US (Weinstein and 
Ullery, 2000) 
1610 
postmenopausal 
white women using a 
questionnaire using 
logistic regression 
(Weinstein and 
Ullery, 2000) 
The sensitivity and the specificity of this 
tool was not published (Weinstein and 
Ullery, 2000) 
T-score ≤-2.5 of 
either the total 
hip, femoral neck 
or spine 
(Weinstein and 
Ullery, 2000) 
Singapore (Chan et al., 
2006). 
 
WEIGHT 
(Michaëlsson 
et al., 1996) 
Sweden 
(Michaëlsson et al., 
1996) 
175 randomly-
selected women 
aged 28-74 years in 
Sweden(Michaëlsson 
et al., 1996) 
36.0%(Michaëlsson 
et al., 1996) 
94.0%(Michaëlsson 
et al., 1996) 
Femoral neck T-
score <-2.5. 
(Michaëlsson et 
al., 1996) 
Singapore (Chan et al., 
2006) 
38.0%(Michaëlsson 
et al., 1996) 
89.0%(Michaëlsson 
et al., 1996) 
T-score <-2.5 of 
the lumbar 
spine(Michaëlsson 
et al., 1996) 
MOST(Lim et 
al., 2011) 
Malaysia(Lim et al., 
2011) 
Secondary analysis 
from a large scale 
study involving a 
lifestyle intervention 
61.6%(Lim et al., 
2011) 
73.2% (Lim et al., 
2011) 
T-score ≤-2 of 
the either the 
femoral neck of 
the lumbar spine 
Malaysia (Lim et al., 
2011) 
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programme. A total 
of 514 healthy 
Malaysian women 
aged ≥45 were 
recruited. (Lim et al., 
2011) 
(Lim et al., 2011) 
OSTA (Koh et 
al., 2001b) 
China, Taiwan, 
Hong Kong, Korea, 
Malaysia, 
Singapore, Thailand 
and Philippines (Koh 
et al., 2001b) 
860 postmenopausal 
Asian women from 
21 clinics in eight 
countries (Koh et al., 
2001b) 
45.0%(Koh et al., 
2001b) 
91.0%(Koh et al., 
2001b) 
Femoral neck T-
scores ≤-2.5(Koh 
et al., 2001b) 
Japan (Saetung et al., 
2008) 
Belgium (Gourlay et al., 
2005, Richy et al., 
2003), United States of 
America (Geusens et 
al., 2002), Netherlands 
(Geusens et al., 2002), 
Taiwan (Li, 2008), 
Thailand (Geater et al., 
2004), Philippines (Li-
Yu et al., 2005), Hong 
Kong (Kung et al., 
2003) and Singapore 
(Chan et al., 2006) 
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3.4.1.3 The availability of osteoporosis risk 
assessment tool in Malaysia 
A literature search noted that these tools have been validated 
in the United States of America (Lydick et al., 1998, Geusens 
et al., 2002), Canada (Cadarette et al., 2004), Belgium (Richy 
et al., 2003, Gourlay et al., 2005), Netherlands (Geusens et 
al., 2002), Philippines (Li-Yu et al., 2005), Japan (Fujiwara et 
al., 2001), Korea (Park et al., 2003), Thailand (Saetung et al., 
2008, Geater et al., 2004), Taiwan (Li, 2008), Hong Kong 
(Kung et al., 2003) and Singapore (Chan et al., 2006). The 
validation of an instrument is crucial to ensure that the 
difference in the population are accounted for and the 
instrument measure what is was designed to measure (Smith, 
2002, Lai, 2013).  Despite being widely applied in the 
Caucasian and Asian population, these tools were not 
validated in the Malaysia except the MOST. However, the 
validation of the MOST was conducted with a small sample 
size of 72 participants. The OSTA was recommended by the 
Malaysian clinical practice guideline for osteoporosis as the 
OSTA’s development involved the Malaysian population (Koh 
et al., 2001b). However, it has only been validated in the 
Malay population where else, the Malaysian population 
comprises of Malays, Chinese and Indians (Muslim et al., 
2012).  
 
 
  
 290 
 
3.4.2 Objectives  
Therefore, this study aimed to determine the validity and 
reliability of six risk assessment tools in Malaysia. 
 
3.4.3 Methods 
3.4.3.1 Study design 
This was a cross sectional study. 
 
3.4.3.2 Setting  
The study was conducted at the primary care clinics of the 
University Malaya Medical Centre (UMMC), Kuala Lumpur, 
Malaysia. 
 
3.4.3.3 Period of study 
Data was collected from October 2013 until January 2014. 
 
3.4.3.4 Participants 
3.4.3.5 Patient identification and recruitment 
English speaking postmenopausal women aged 50 years and 
above, who have not been diagnosed with 
osteoporosis/osteopenia were included.  Participants who were 
feeling too unwell to participate in the study were excluded. 
 
3.4.3.6 Sampling procedure 
This study was conducted concurrently with the validation of 
the  Osteoporosis Prevention and Awareness Tool (OPAAT) the 
sampling procedure as explained in section 4.2.3.8.1.  
 
 
3.4.3.7 Sample size 
As the validation of the osteoporosis risk assessment tools was 
part of the validation of the Osteoporosis Prevention and 
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Awareness Tool (OPAAT),the sample size was calculated based 
on a 5:1 participant to item ratio required for factor analysis 
to be performed for the OPAAT (Gorsuch, 1983). Since the 
OPAAT had 30 items, the total number of participants needed 
was 150. 
 
3.4.3.8 Primary outcome 
To assess the validity and reliability of six osteoporosis risk 
assessment tools in the Malaysian population. 
 
3.4.3.9 Secondary outcomes 
3.4.3.9.1 Sensitivity and specificity 
Sensitivity was defined as the proportion of women with 
osteoporosis that tested positive using the risk assessment 
tools. Specificity was defined as the proportion of women 
without osteoporosis who tested normal using the risk 
assessment tools.  
 
3.4.3.9.2 Optimal cut-off point 
The ability of the risk assessment tool to discriminate low BMD 
as defined by T-score ≤ -2.5 was evaluated using the 
receiving operating characteristic (ROC) curve. 
 
3.4.3.10 Instruments used 
3.4.3.10.1 Baseline demographics 
This instrument was used to collect baseline demographic 
information such as patients’ medical history, lifestyle and 
medication history (Appendix 1).  
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3.4.3.10.2 Osteoporosis risk assessment tools 
Six risk assessments tools were used in this study. Table 3.18 
is a summary of the published cut-off points and the scoring 
system of the risk assessment tools: 
 
3.4.3.10.2.1 The Simple Calculated Osteoporosis 
Risk Estimation (SCORE) 
The final model of SCORE is a simple additive scoring system 
using six questions: age, weight, race, fracture history, 
rheumatoid arthritis history and estrogen use. A score of ≥6 
classified participants as having an increased risk for 
osteoporosis (Lydick et al., 1998). 
 
3.4.3.10.2.2 Osteoporosis Risk Assessment Index 
(ORAI) 
The three item additive scoring system of ORAI includes: age, 
weight and current estrogen use (yes or no) were the three 
items used. A score of ≥9 classified participants as having an 
increased risk for osteoporosis (Cadarette et al., 2000). 
 
3.4.3.10.2.3 Age Bulk One of Never Estrogen 
(ABONE) 
Any women with ≥2 score was recommended for a BMD scan 
based on the ABONE. One point was given for each of these 
categories: ≥ 65 years old, <63.5kg or have not used 
estrogen for > 6 months. (Weinstein and Ullery, 2000). 
 
3.4.3.10.2.4 Body Weight (WEIGHT) 
The tool specifies that a weight under or 70kg shows a risk for 
osteoporosis  (Michaëlsson et al., 1996).  
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3.4.3.10.2.5 Malaysian Osteoporosis Screening Tool 
(MOST) 
The MOST was an additive scoring system based on age, years 
of menopause, body mass index (BMI) and hip circumference. 
A score of ≥4 classified participants as having an increased 
risk for osteoporosis. (Lim et al., 2011).  
 
3.4.3.10.2.6 Osteoporosis Screening Tools for Asians 
(OSTA)  
The final model had 11 items but eventually all except age and 
weight were dropped. OSTA involves a calculation as follows: 
weight in kilograms were deducted with age in years and 
multiplied by -0.2. Participants with a score of ≤-1 were 
classified as having an increased risk for osteoporosis. The 
OSTA further classified the osteoporosis risk to low, moderate 
and high. An index of >-1 indicated a very low risk for 
osteoporosis where as a score of -1 to -4 indicated moderate 
risk and a score of <-4 was classified as high risk. (Koh et al., 
2001b).  
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Table 3.18: Published cut-off points and scoring system of the 
six risk assessment tools 
 
 
  
Tool Published 
cut-off point 
Scoring system 
SCORE Score ≥ 6 Race: 5 if not black 
 Rheumatoid arthritis: 4 if applicable 
 History of minimal trauma fracture after age 45 years: 4 
for each fracture of the wrist, hip, or ribs (12 point 
maximum) 
 Age: 3 times of the first digit of age in years 
 Estrogen therapy: 1 if never used 
 Weight:-1 times the weight in pounds 2.2 x kg (lb) 
divided by 10 and truncated to an integer 
ORAI Score ≥ 9 Age: 15 ≥ 75 years 
         9 if 65-74 years 
         5 if 55-64 years 
 Weight: 9 if < 60 kg 
              3 if < 60.0- 69.9kg 
 Estrogen use: 2 if not currently taking estrogen 
ABONE Score ≥ 2 Age: 1 if >65 years 
 Weight: 1 if <63.5kg 
 Estrogen use: 1 if never used oral contraceptive or 
estrogen therapy for at least 6 months 
WEIGHT ≤70kg Weight ≤70kg 
MOST Score  4 Age: 20if >61 years 
         6 if 56-60 years 
         2 if 51-55 years 
         0 if <50 years  
Years post menopause 
         22 if >10years 
         6 if 6-10 years 
         4 if 1-5 years 
         0 if 0 years   
BMI : 4 if <19  kg/m2 
           2 if 19-24  kg/m2 
           0 if > 24 kg/m2 
Hip circumference  
       2 if <90cm 
       0 if >90  cm 
OSTA Score ≤ -1 0.2 x (body weight (kg) – age (years)) 
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3.4.3.10.2.7 Dual energy X-ray absorptiometry 
(DEXA) machine 
DEXA was used to measure the left femoral neck and lumbar 
spine (L1-L4) BMD. The brand of manufacturer was IDXA 
model by GE Lunar (Milwaukee, US). The T-scores were 
calculated using the peak reference ranges for young healthy 
Asian women. The mean and precision error for femoral neck 
and lumbar spine (L1-L4) was 0.936 (1.4%CV) and 1.184 
(1.1%CV) respectively. All BMD measurements were 
conducted by two qualified radiologist. 
 
 
3.4.3.11 Procedure 
Participants were recruited while they were waiting for their 
doctor’s appointment using a 1:2 systematic random sampling 
procedure or the snowballing method. One out of every two 
postmenopausal women was asked if they were willing to 
participate in the study (Appendix 29 and 30, patient 
information sheet and consent form). Random sampling was 
used to give an equal chance to all eligible participants to be 
selected for inclusion in our sample [Figure 3.3].  
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Figure 3.3:  The validation process  of the various osteoporosis risk 
assessment tool 
 
  
Informed written consent and baseline information was 
obtained from all participants. (N=164) 
 
Participants went for their BMD scan (N=150) 
Follow up via 
phone 
(Two weeks) 
Participants were interviewed for risk factors using OSTA, SCORE, 
ORAI, WEIGHT, MOST and ABONE.  Participants’ weight, height and 
hip circumference were measured using a digital weighing machine, a 
mechanical height scale and measuring tape. 
 
Researcher arranged the BMD scan appointment for 
participants   
 
1st visit-  
(Baseline) 
The researcher screened for potential participants (N=224) 
Researcher informed the participants of their BMD results via 
telephone. Questions regarding the BMD results and 
osteoporosis prevention were answered. 
 
Participants with a T-score ≤-2.5 were advised to visit their 
doctor 
Abbreviations: 
OSTA- Osteoporosis Screening Tool for Asians 
SCORE- Simple Calculated Osteoporosis Risk Estimation  
ORAI- Osteoporosis Risk Assessment Index 
WEIGHT- Body Weight 
ABONE- Age Bulk One of Never Estrogen 
BMD- Bone Mineral Density 
MOST- Malaysian Osteoporosis Screening Tool 
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3.4.3.12 Source of data 
The source of data varied from medical registers, medical 
records, observations to observe if patients were too unwell to 
participate in the study, interviews, questionnaire and informal 
discussions to find out informally if patients have osteoporosis 
during recruitment. Some of the data such as patients’ clinical 
information were obtained from medical records prior to the 
provision of service, whilst other data were obtained during 
the counselling session with the pharmacist. 
 
3.4.3.13 Ethics approval 
This study was approved by the Medical Ethics Committee of 
the University Malaya Medical Centre (approval no: 920.27, 
Appendix 27). All required documents were submitted and 
approval was obtained one month after submission. In 
accordance with the ethics committee requirements, a report 
upon completion form has been submitted. Ethical issues such 
as anonymity, confidentiality and informed consent were 
considered in this study. 
 
3.4.3.13.1 Anonymity and confidentiality 
Only the researcher and the supervisors had access to the 
questionnaire. All information were coded and anonymized. 
The information collected as paper copies were stored under 
lock and key, while the electronic data can only be accessed 
with a secure password. The data collected were used only for 
the purpose of this research; if data were to be used for future 
studies, further Research Ethics Committee approval will be 
sought. All information which is collected was confidential and 
any form of identity will not be included in any publications. 
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3.4.3.13.2 Informed consent 
Prior to the start of any research activity, written informed 
consent for participating was obtained from each participant. 
 
3.4.3.14 Data analysis 
All data was entered into the IBM® SPSS® version 20 (IBM 
Corporation, Armonk, NY, US). The primary outcome measure 
considered in this study was femoral neck T-score. Although 
no single level of BMD should be used as the sole basis for 
treatment, the femoral neck T-score is the most reliable 
measure for predicting hip fracture risk (Johnell et al., 2005, 
Marshall et al., 1997). However, the combination of femoral 
neck and lumbar spine (L1-L4) BMD was also presented as 
participants were diagnosed as having osteoporosis if the T-
score at any given site was ≤-2.5.  
 
In our study we calculated the true positives, false negatives, 
true negative and false positives. A true positive is if the 
participant was osteoporotic and was classified as at risk for 
osteoporosis. If the participant was osteoporotic but was 
classified as not at risk for osteoporosis it is considered as a 
false negative. A true negative was a non osteoporotic 
participant classified as not at risk for osteoporosis. If a non 
osteoporosis participant was classified as at risk for 
osteoporosis, it is a false positive.  
 
Sensitivity and specificity were calculated based on the 
original published cut-off points [Table 4.18].  Sensitivity was 
analyzed as the proportion of women with osteoporosis (T-
score ≤-2.5 at the femoral neck) who tested positive on the 
risk assessment (i.e., having a value in the range determined 
by the tool as an increased risk for osteoporosis). Specificity 
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was analyzed based on the proportion of women without 
osteoporosis (T-score ≤-2.5 at the femoral neck) who tested 
normal on the risk index assessment (i.e., having a value in 
the range determined by the tool as low risk for osteoporosis). 
The sensitivity and specificity of the tools were also analyzed 
using the combination of either a T-score ≤-2.5 at the femoral 
neck or lumbar spine.  The formulas used to calculate the 
sensitivity and specificity are as below:  
 
Sensitivity (%) = [True positives/ (False negatives+ true 
positives)] x 100 
Specificity (%) = [True negatives/ (False positives+ true 
negatives)] x 100 
 
The ROC curves which plot sensitivity against (1-specificity) 
were generated to empirically determine the tools’ optimal 
cut-off points, sensitivity and specificity in the same study 
sample. It is not necessary that a risk assessment tool have 
both high sensitivity and specificity when the tool is free and 
causes no harm. Therefore the primary purpose of the tools is 
to identify most patients at risk among women whom BMD can 
then be used to obtain a definite diagnosis. We identified the 
tool with the best balance between a high sensitivity and a 
moderate specificity. The top left-hand corner of the ROC 
curve was identified as the empirical optimal cut-off point for 
the tools. The area under the curve (AUC) was calculated 
using logistic regression, was used to compare the diagnostic 
performance of the two tests. In general a realistic classifier 
should not have an AUC <0.500 (Fawcett, 2006).  
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3.4.4 Results (Phase two- Validation of osteoporosis risk 
assessment tools) 
3.4.4.1 Participants 
Figure 4.4 demonstrated the recruitment process, a total of 
224 participants were approached: 60 declined and 164 
participants were recruited (73.2%). However, 14 out of the 
164 did not perform the BMD [Figure 3.4].  Table 3.19 
summarises participants’ demographic characteristics A total 
of 16/150 (7.1%) was found to be osteoporotic based on 
either a T-score ≤-2.5 of the total femoral or the spine. 
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Figure 3.4: Recruitment process 
 
 
  
Participants approached (n=224) 
Participants recruited (n=164) 
Participants 
declined (n=60) 
Participants performed the BMD 
scan (n=150) 
Drop out due to: 
- Unwell (n=10) 
- Busy (n=4) 
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Table 3.19: Demographics characteristics of participants 
Characteristics  Patients (n=150) 
Mean Age ± S.D. (years) [range] (Median) 62.0±7.0 [50.0-82.0] 
(62.0) 
Ethnicity [n (%)] 
Malay  
Chinese 
Indian 
Eurasian 
 
12 (8.0) 
108 (72.0) 
28 (18.7) 
2 (1.3) 
Mean weight ± S.D. (kg) [range] (Median) 57.9±10.0 [40.0-91.0] 
(55.8) 
Mean hip circumference (cm) [range] (Median) 93.4 ± 6.8 [78.7-121.9] 
(94.0) 
Mean BMI ± S.D. (kg/m2) [range] (Median) 23.8±3.8 [15.6-35.4] 
(23.0) 
BM I (kg/m2) [n (%)] 
<18.5 (underweight) 
18.5-24.9 (normal) 
25.0-29.9 (overweight) 
≥30.0 (obese) 
 
5 (3.3) 
97 (64.7) 
37 (24.7) 
11 (7.3) 
Household income per month [n (%)] 
<RM1000 (<$ 310.7) 
RM1000-1999 ($ 310.7-621.0) 
RM2000-2999 ($ 621.3- 931.7) 
RM3000-3999 ($ 932.0- 1242.3) 
RM4000-4999 ($ 1242.6-1553) 
>RM5000 (>$1553.3) 
 
29 (19.3) 
12 (8.0) 
15 (10.0) 
17 (11.3) 
12 (8.0) 
65 (43.3) 
Level of education [n (%)] 
Never been to school 
Primary (6 years of education) 
Secondary (11-13 years of education) 
Diploma/Technical school training (12-14 years of 
education) 
Tertiary/Postgraduate (15-21 years of education) 
 
1 (0.7) 
12 (8.0) 
47 (31.3) 
31 (20.7) 
59 (39.3) 
Mean bone mineral density ± S.D.  (g/cm2) 
[range] (Median) 
Femoral neck 
Lumbar spine L1-L4 
 
0.78 ±  1.78 [-0.89-
1.16] (0.80) 
1.05 ±  0.15 [0.64-1.46] 
(1.05) 
Mean T-score ± S.D. [range] (Median) 
Femoral neck 
 
-0.87 ± 0.93 [-2.80-
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Lumbar spine L1-L4 2.00] (-0.95) 
-0.53 ± 1.28 [-3.90-
2.90] (-0.50) 
Status of bones femoral neck BMD [n (%)] 
Normal 
Osteopenia 
Osteoporosis 
 
 
78 (34.8) 
66 (29.5) 
6 (2.7) 
Status of bones based on either femoral neck or 
lumbar spine (L1-L4) BMD [n (%)]  
Normal 
Osteopenia 
Osteoporosis 
 
 
69 (30.8) 
65 (29.0) 
16 (7.1) 
S.D. = standard deviation; BMI=body mass index; $= US dollar; BMD= bone 
mineral density 
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3.4.4.2 Sensitivity, specificity and published cut-off 
points 
The sensitivity and specificity was calculated based on the 
published cut-off points of the indices [Table 3.20]. Based on 
the femoral neck T-score, the SCORE, the ORAI, the WEIGHT 
and the MOST achieved a sensitivity of 100%, but had low 
specificity (2.1%-19.4%). The ABONE also had high sensitivity 
(83.3%), but low specificity (27.1%). The OSTA had the 
lowest sensitivity (50.0%) in comparison with the other 
instruments, but had the highest specificity (49.3%). 
 
We then calculated the sensitivity and specificity of the indices 
using the published cut-off points [Table 3.20]. Based on 
either the femoral neck or lumbar spine (L1-L4) T-score, the 
SCORE, the WEIGHT and the MOST achieved a sensitivity of 
100%, but had low specificity (2.2%-12.7%). ABONE and 
ORAI also had a high sensitivity (ABONE=87.5%, 
ORAI=93.8%) and a low specificity (ABONE=28.4%, 
ORAI=20.2). OSTA on the other hand had the lowest 
sensitivity of 68.8% in comparison with the other instruments, 
but had the highest specificity of 51.5%.  
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Table 3.20: Results of the six risk assessment tools using published cut-off points when compared with femoral 
neck bone mineral density T-score ≤-2.5 and either femoral neck or lumbar spine T-score ≤-2.5 
 Femoral neck Femoral neck or lumbar spine (L1-L4) 
 T-score 
Sensitivity 
(%) 
Specificity 
(%) 
Total 
T-score    
≤-2.5 >-2.5 ≤-2.5 >-2.5 Sensitivity 
(%) 
Specificity 
(%) 
Total 
SCORE 
High risk  ≥ 6 
Low risk <6 
 
6 (TP) 
0(FN) 
 
133 (FP) 
11 (TN) 
100.0 7.6 
 
139 
11 
 
16 (TP) 
0(FN) 
 
123 (FP) 
11 (TN) 
100.0 8.2 
 
139 
11 
ORAI 
High risk ≥ 9 
Low risk <9 
 
6(TP) 
0(FN) 
 
116(FP) 
28(TN) 
100.0 19.4 
 
122 
28 
 
15(TP) 
1(FN) 
 
107(FP) 
27(TN) 
93.8 20.2 
 
122 
28 
ABONE 
High risk ≥ 2 
Low risk <2 
 
5(TP) 
1(FN) 
 
105(FP) 
39(TN) 
83.3 27.1 
 
110 
40 
 
14(TP) 
2(FN) 
 
96(FP) 
38(TN) 
87.5 28.4 
 
110 
40 
WEIGHT 
High risk ≤70kg 
Low risk <70kg 
 
6(TP) 
0(FN) 
 
127(FP) 
17(TN) 
100.0 11.8 
 
133 
17 
 
16(TP) 
0(FN) 
 
117(FP) 
17(TN) 
100.0 12.7 
 
133 
17 
MOST 
High risk ≥  4 
Low risk < 4 
 
6(TP) 
0(FN) 
 
141(FP) 
3(TN) 
100.0 
2.1 
 
 
147 
3 
 
16(TP) 
0(FN) 
 
131(FP) 
3(TN) 
100.0 
2.2 
 
 
147 
3 
OSTA 
High risk ≤ -1 
Low risk <-1 
 
 
3(TP) 
3(FN) 
 
73(FP) 
71(TN) 
50.0 49.3 
 
76 
74 
 
11(TP) 
5(FN) 
 
65(FP) 
69(TN) 
68.8 51.5 
 
76 
74 
TP= true positive; FN=false negative; FP= false positive; TN= true negative; SCORE=Simple Calculated Osteoporosis Risk Estimation; ORAI= 
Osteoporosis Risk Assessment Index; ABONE= Age Bulk One of Never Estrogen; WEIGHT= Body Weight; MOST= Malaysian Osteoporosis Screening 
Tool; OSTA= Osteoporosis Screening Tool for Asians; BMD= Bone Mineral Density 
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ROC curves were generated based on the femoral neck T-
score are presented in Table 3.21 and Figure 3.5. Based on 
the femoral neck T-score, AUC values ranged from 0.519-
0.661, with the WEIGHT, the ORAI and the OSTA having the 
highest AUC values. Using different cut-off points the tools 
were able to achieve a sensitivity of 66.7%-100.0% and 
specificity of 27.1%-50.7%. There were three tools with a 
high sensitivity and moderate specificity: the ORAI, WEIGHT 
and OSTA. 
 
Based on either the femoral neck or lumbar spine (L1-L4) T-
score, AUC values ranged from 0.569-0.663, with the 
WEIGHT, the ORAI, the SCORE and the OSTA having the 
highest AUC values [Table 3.21 and Figure 3.6]. Using 
different cut-off points the tools were able to achieve a 
sensitivity of 75.0%-93.6% and specificity of 28.4%-53.0%. 
Similarly to the results based on femoral neck T-score, there 
were three tools with a high sensitivity and moderate 
specificity: the SCORE, ORAI, ABONE and OSTA. A lower cut-
off value for OSTA and WEIGHT represents higher risk for 
osteoporosis (low BMD). As for the other indices: SCORE, 
ORAI. ABONE and MOST, higher values indicate higher risk for 
developing osteoporosis.  
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Table 3.21: Empirically-determined cut-off points, sensitivity and specificity based on receiver operating 
characteristics (ROC) curves for identifying osteoporosis subjects using only femoral T-score ≤ -2.5 and either 
femoral neck or lumbar spine T-score ≤ -2.5 
*Statistically significant a p <0.05 
 Femoral neck T-score ≤ -2.5 Femoral neck or lumbar spine T-score ≤ -2.5 
Tool Empirical 
cut-off 
points 
Sensitivity Specificity Area under 
curve (95% 
CI) 
p-value Empirical 
cut-off 
points 
Sensitivity Specificity Area under 
curve (95% 
CI) 
p-value 
SCORE Score ≥ 9 66.7 34.0 0.558 
(0.312-
0.805) 
0.628 Score ≥ 9 81.3 35.8 0.627 
(0.482-
0.772) 
0.097 
ORAI Score ≥ 12 100.0 41.0 0.644 
(0.496-
0.792) 
0.232 Score ≥ 12 93.6 43.3 0.663 
(0.545-
0.782) 
0.033* 
ABONE Score ≥ 2 83.3 27.1 0.586 
(0.357-
0.815) 
0.475 Score ≥ 2 87.5 28.4 0.653 
(0.511-
0.795) 
0.046 
WEIGHT ≤57kg 83.3 45.1 0.661 
(0.449-
0.874) 
0.181 ≤58kg 81.3 41.0 0.592 
(0.465-
0.719) 
0.232 
MOST Score ≥ 31 66.7 50.7 0.519 
(0.284-
0.753) 
0.878 Score ≥ 31 75.0 53.0 0.569 
(0.434-
0.704) 
0.368 
OSTA Score ≤ 0 83.3 36.8 0.603 
(0.387-
0.819) 
0.393 Score ≤ 0 81.3 41.0 0.627 
(0.505-
0.748) 
0.098 
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Figure 3.5: Receiver operating characteristic curve based on femoral neck bone mineral density T-score ≤ -2.5 
(n=150). a Simple Calculated Osteoporosis Risk Estimation (SCORE). b Osteoporosis Risk Assessment Instrument 
(ORAI). c Age, Bulk, One or Never Estrogen (ABONE). d Body Weight criterion (WEIGHT). e Malaysian 
Osteoporosis Screening Tool (MOST). f Osteoporosis Screening Tool for Asians (OSTA)  
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Figure 3.6: Receiver operating characteristic curve based on either femoral neck or lumbar spine (L1-L4) bone 
mineral density T-score ≤ -2.5 (n=150). a Simple Calculated Osteoporosis Risk Estimation (SCORE). b 
Osteoporosis Risk Assessment Instrument (ORAI). c Age, Bulk, One or Never Estrogen (ABONE). d Body Weight 
criterion (WEIGHT). e Malaysian Osteoporosis Screening Tool (MOST). f Osteoporosis Screening Tool for Asians 
(OSTA)  
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3.4.5 Discussion 
This study showed that the various osteoporosis risk 
assessment tools namely: SCORE, ORAI, ABONE, WEIGHT, 
MOST and OSTA were valid, reliable and useful in identifying 
Malaysian postmenopausal women with osteoporosis. Based 
on the published cut-off points and T-score ≤-2.5, the 
sensitivity was high for all of the indices which was above 
83.3% with the exception of OSTA which had the lowest 
sensitivity of 50.0% (T-score femoral neck) and 68.8% (T-
score femoral neck and lumbar spine (L1-L4)). However, the 
specificity was low for most of the tools ranging from 2.1% to 
51.5%.  In order to optimize the tools, the empirical optimum 
cut-off points were identified by generating ROC curves. The 
sensitivity of the tools improved ranging from 66.7%- 
100.0%. Specificity on the other hand ranged from 27.1%-
53.0%. Our study found the OSTA to have the best balance 
between the sensitivity, specificity and practical usability. 
 
Our study compared the sensitivity and specificity of the six 
tools with the T-score of femoral neck alone and either 
femoral neck or lumbar spine (L1-L4) using the published cut-
off points. Based on our results the sensitivity and specificity 
of all six tools were similar for all six tools using both 
outcomes. This suggests that these risk assessment tools can 
be used to screen for osteoporosis using femoral neck T-score 
only when using the published cut-off points. 
 
We then identified the optimal cut-off points for all six tools 
using the ROC curve. A high sensitivity is crucial as it provides 
reliable evidence for physicians to start early treatment for 
patients at risk of osteoporosis. Numerically, OSTA yielded an 
AUC of 0.603, with sensitivity and specificity of 83.3% and 
 313 
 
36.8% at the empirically identified optimal cut-off point of ≤0 
using the T-score of the femoral neck. This AUC generated 
was lower as compared to the ORAI (AUC=0.644) and 
WEIGHT (AUC=0.661). However, the OSTA was considered to 
be more suitable for daily clinical use as it is a simple tool. The 
OSTA requires only the age and body weight to screen for the 
risk of osteoporosis. This is an important feature because 
other tools such as the ORAI require more detailed information 
such as oestrogen use which are more time consuming to 
obtain. A comparable tool to OSTA’s simplicity was the 
WEIGHT which yielded a higher AUC of 0.661 (sensitivity= 
83.3%, specificity=45.1%). Therefore the WEIGHT would be 
the suitable tool to assess osteoporosis risk based on T-score 
of the femoral neck.  
 
Based on either the femoral neck or lumbar spine (L1-L4) T-
score, the ORAI, ABONE, SCORE and OSTA had the highest 
AUC of 0.663, 0.653, 0.627 and 0.627 respectively. Similarly, 
we found the OSTA to be most suitable tool to use during daily 
clinic practice as the SCORE requires more details to assess 
the risk such as estrogen use, history of fractures and 
rheumatoid arthritis. On the other hand the ORAI and ABONE 
require the history of estrogen use which may difficult to 
obtain as the Malaysian healthcare system is not integrated 
between hospitals and clinics. Therefore, the OSTA would be 
the most suitable to assess osteoporosis risk based on the T-
score of either femoral neck or lumbar spine.  
 
Overall, based on both the T-score of femoral neck alone or 
either femoral neck or lumbar spine, we found the OSTA with 
a cut-off ≤-0 to be the most suitable tool to assess 
osteoporosis risk in the Malaysian population. This is because 
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although the WEIGHT was easier to use than the OSTA, it did 
not perform as well as the OSTA when assessing the overall 
osteoporosis risk when compared to T-score of either the 
femoral neck or lumbar spine. However the OSTA had a high 
AUC when assessing the osteoporosis risk based on both the 
T-score of femoral neck alone and either the T-score of 
femoral neck or lumbar spine. Additionally, although OSTA 
was more complicated than WEIGHT, studies in Singapore and 
Hong Kong which validated various risk assessment tools 
including OSTA (Chan et al., 2006, Kung et al., 2003) and 
WEIGHT (Chan et al., 2006) suggest that the OSTA would be 
the most practical and accurate tool for daily use when 
assessing osteoporosis risk based on femoral neck T-score. 
 
We would like to highlight that the empirically identified 
optimum cut-off points by generating the ROC curves were 
higher than the published results for SCORE, ORAI, OSTA and 
MOST whether comparing with only the femoral neck T-score 
or with either the femoral neck or lumbar spine (L1-L4) T-
score. Conversely, a lower empirically identified optimum cut-
off points were noted for WEIGHT. As for ABONE the optimum 
cut-off point identified was similar to the published cut-off of 
≥2. The difference of cut off points for SCORE and ORAI may 
be because the cohort in our study was of mixed ethnicity of 
Malay (8.0%), Chinese (72.0%), Indian (18.7%) and Eurasian 
(1.3%) whereas SCORE and ORAI were mainly developed for 
the Caucasian population (Lydick et al., 1998, Cadarette et al., 
2000).  A study of 135 Chinese postmenopausal women 
similarly noted higher cut-off points for the SCORE (≥8) and 
ORAI (≥20). (Chan et al., 2006).  The difference in cut-off 
points for OSTA and MOST may also be explained by 
demographic differences in the samples. The cohort in our 
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study was of women ≥50 years of age where else the original 
OSTA and MOST study included younger women ranging from 
≥45 years. As for the WEIGHT cut off point was lower 
compared to the recommended 70kg this could be because 
Malaysian women has a lower mean body weight of 58.44kg. 
Therefore, the empirical cut-off point was 57-58kg (Azmi et 
al., 2009). This demonstrates that the tools’ optimal cut-off 
points may vary with different age and ethnic groups.  
 
Different risk assessment tools were developed and validated 
using different T-score at different sites (Cadarette et al., 
2004, Lydick et al., 1998, Koh et al., 2001b, Lim et al., 2011, 
Weinstein and Ullery, 2000, Michaëlsson et al., 1996). 
Agreement on a single risk assessment tool and a single type 
or types of T-score for comparison should be identified to ease 
clinician’s decision to which is the most suitable tool. This will 
help fulfil the objective of identifying women at risk for 
osteoporosis.  
 
The prevalence of osteoporosis in our study was low (7.1%) 
as compared to another study conducted in Malaysia which 
noted a prevalence of 24.1% (Lim et al., 2005). This may be 
because the participants recruited in this study were health 
seeking individuals as they were recruited from the primary 
care clinic and may have taken preventive measures against 
osteoporosis, the women conducted in the other study were 
community dwelling women recruited via flyers (Lim et al., 
2005). 
 
3.4.6 Strengths 
Our study fills the gap of the lack of a validated osteoporosis 
risk assessment tool by validating sic type of tools. The 
 316 
 
strength of our studies was that we compared all six tools to 
identify the best tool for our population. We also identified the 
optimal cut-off point for our population. 
 
3.4.7 Limitations 
The limitation of our study was the small sample size. This 
may be the reason for the low AUC results for all the tools. 
Nonetheless, based on the estimated sample size for multi-
observer ROC studies by Obuschowski (2008), a sample size 
of 288 is required in order to achieve 80% of statistical power. 
 
Additionally, some participants (11 participants) were also 
recruited using the “snowballing” method as the validation of 
the osteoporosis risk assessment tools was conducted 
concurrently with the validation of an osteoporosis knowledge 
questionnaire called Osteoporosis Prevention and Awareness 
Tool (OPAAT). As the awareness of the project spread the 
participants began to refer their friends and family. Although 
this is a non-randomized method or recruiting the patients, it 
only comprise of 7.3% of the participants in our study and 
should not affect the outcome as 15% of the sample size was 
allocate for drop-outs. 
 
Inaccuracies of in self-reported data may have reduced the 
ability of these risk assessment tools to predict the 
osteoporosis risk. However, if this is the case, our results may 
underestimate the potential value of these tools for identifying 
women with low BMD, but are probably representative of the 
results that would be seen in clinical practices. Aside from that 
out study cohort was mainly 72.0% Chinese, this does not 
reflect the Malaysian population which consist of Malays as a 
majority. Nonetheless, these findings are useful as the 
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prevalence of osteoporosis is higher in the Chinese population 
(Koh et al., 2001b). Our results were also based on the 
Malaysian population and would not be generalized to women 
in other countries. Further studies should be carried out in 
larger samples, different ethnicity and of different age groups. 
This will assist in a more conclusive answer to the tools’ 
generalisability and applicability may be derived.  
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3.4.8 Conclusion 
This study showed that the various osteoporosis risk 
assessment tools namely: SCORE, ORAI, ABONE, WEIGHT, 
MOST and OSTA were valid, reliable and useful in identifying 
Malaysian postmenopausal women with osteoporosis. The 
OSTA was the simplest and most well balance tool for daily 
clinical use. However, further studies should be conducted in a 
larger sample with different age range and ethnicity to ensure 
it applicability. 
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3.5   The development of a pharmacist-led 
osteoporosis screening and prevention 
programme 
3.5.1 Introduction 
This section summarizes the development of a pharmacist-led 
osteoporosis screening and prevention programme. This 
intervention was developed based on the principals of the UK 
MRC framework for complex interventions. 
 
3.5.2 Objective 
To develop a pharmacist-led osteoporosis screening and 
prevention programme for use among postmenopausal women 
in Malaysia.  
 
3.5.3 Methods 
3.5.3.1 Development of a complex intervention 
The development of the intervention can be divided into three 
sections: identifying the evidence, identifying or developing 
the theory, and modelling the process and outcomes. 
 
3.5.3.2 Identifying the evidence 
An intervention must be developed to the point where it can 
reasonably be expected to have a worthwhile effect before a 
substantial evaluation is undertaken. The UKMRC framework 
recommends identifying what is already known about similar 
interventions and the methods that have been used to 
evaluate them. A high quality systematic review of relevant 
evidence should be conducted if there has been no recent 
evaluation (Craig et al., 2008). We conducted a literature 
review using Pubmed, Scopus and the Cochrane library using 
the search terms: systematic review, osteoporosis, 
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fragility/minimal/low trauma fracture, intervention, fracture 
liaison services, prevention and screening. 
 
3.5.3.3 Identifying or developing theories 
A number of psychological factors are involved in learning new 
behaviours and changing existing behaviours (Hardeman et 
al., 2005). Theories provide overarching frameworks that 
could assist in explaining behaviours. Subsequently, these 
behaviours can be targeted by an intervention (Hardeman et 
al., 2005, Craig et al., 2008). Our task was to develop a 
theoretical understanding of the best way to change 
behaviour. We achieved this by drawing on existing evidence 
and theory, supplemented with new primary research (Craig 
et al., 2008). As there was no behavioural intervention theory 
specifically targeting osteoporosis screening we conducted 
qualitative interviews with patients, nurses, pharmacists, 
doctors and policy makers as described in Chapter 3. We then 
reviewed a number of theory and behaviour change 
techniques that had shown some success in changing 
behaviour (Medical Research Council, 2008). We then used 
both methods to inform the development of our intervention. 
In Phase one, we have conducted qualitative studies using the 
theory of behavioural change wheel and behavioural change 
techniques. Using this theory we have identified the key 
components for the intervention (Michie et al., 2011). Further 
details on the methods and analysis of these three sections 
can be found in section 3.6. 
 
3.5.3.4 Modelling process and outcomes 
Modelling a complex intervention before a full scale evaluation 
can provide important information about the design of the 
intervention. The modelling process also allows for the 
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evaluation and identification of weaknesses leading to 
refinement. We used a causal modelling approach presented 
by Hardeman et al (2005). It is a modelling approach that 
focuses on the first two phases of the UKMRC framework 
which has been presented in section 1.7.12. The term causal 
modelling refers to the development of a specific causal model 
to guide the design of a programme to support behaviour 
change for RCT evaluation. Hardeman et al (2005) provided a 
generic model which contains four levels. Their causal model 
links behavioural determinant, casually through behaviour, to 
physiological and biochemical variables and health outcomes 
(Hardeman et al., 2005). This means that by targeting the 
intervention to the behavioural determinant, behaviour change 
can occur and in turn affect the physiological and biochemical 
variables which are used to measure the health outcomes. 
 
We then applied this generic model to our study [Figure 3.7]. 
This allows for graphical representation on appropriate 
intervention and measurement points and behaviour changes 
techniques. We tailored the model to the characteristics of our 
target population (postmenopausal women), social context, 
target behaviour and health outcomes. In our study, 
behavioural determinant was referred to as the psychological 
factors involved in learning new behaviours and changing 
existing behaviours. Behaviour refers to the target behaviour 
needed to make the change. Physiological/biochemical refers 
to the measure used to determine the health outcome. As for 
health outcome, it refers to predictors used to determine the 
incidence of the disease. The generic process and outcomes 
measured were mapped onto the causal pathway [Figure 3.7].  
For our study, both literature review and theories were used 
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to inform the causal model from behaviour determinants to 
health outcomes. 
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Figure 3.7: Causal modelling for the pharmacist-led 
osteoporosis screening programme 
 
 
 
 
 
 
 
 
 
 
 
  
Behavioural determinants 
Behaviour 
Physiological and biochemical variables 
Health outcomes 
Level 
1 
2 
3 
4 
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3.5.4 Results 
3.5.4.1 Identifying the evidence 
3.5.4.2 Systematic reviews of the effectiveness of 
intervention to improve osteoporosis screening 
and prevention 
We found four systematic reviews relevant to osteoporosis 
screening and prevention. A systematic review in 2012 was 
conducted to evaluate the effectiveness of published models of 
care for the secondary prevention of osteoporotic fracture 
called the fracture liaison service. They identified 42 studies 
and categorized the types of intervention into four types. Type 
A involved identification, assessment and treatment of 
patients as part of the services. Figure 3.8 represents an 
overview of a type A model of care. Type B is similar to A, 
without treatment initiation; type C involved alerting patients 
plus primary care physicians; and type D involved patient 
education only. They concluded that Type A and B services 
were cost-effective, although definition of cost-effectiveness 
varied between studies. They suggested that a fully 
coordinated, intensive model of care for secondary fracture 
prevention was more effective in improving patient outcomes 
than approaches that involved alerts and/or education only 
(Ganda et al., 2012).  
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Figure 3.8: Structure of Type A osteoporosis screening programme (Ganda et al., 2012) 
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In patients Discharged from the Emergency 
Department 
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Local Medical 
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Sale et al (2011) systematically reviewed 57 studies that 
determined the effectiveness of osteoporosis investigation and 
treatment within post-fracture initiatives, in fracture clinics 
and other orthopaedic environment. Their findings were 
similar. They noted that the most effective intervention was 
when they had dedicated personnel to implement an 
intervention which included BMDs and/or treatment. (Sale et 
al., 2011, Ganda et al., 2012).  
 
Little et al (2011) systematically assessed 9 studies to 
determine the effectiveness of an intervention to improve the 
investigation (BMD scan) and management of osteoporosis in 
patients following a fragility fracture. They found that all 
interventions reported a positive effect and measured 
outcomes of BMD scanning and osteoporosis treatment. 
However, there was only one study that showed statistical 
significance between intervention and control group. Other 
outcomes were measured such as osteoporosis diagnosis and 
percentage of patient undergoing BMD (Little and Eccles, 
2010).  
 
Elias et al (2010) examined the impact of pharmacist 
interventions in improving osteoporosis management. They 
included three randomized controlled trials. Although they 
noted that two of the studies were at high risk of bias, the 
results from the RCTs suggest that pharmacist interventions 
may improve bone mineral density testing and calcium intake 
among patients (Elias et al., 2011).  
 
Our intervention was based on the type A model of care, 
whereby we provided osteoporosis risk assessment, 
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individualized counselling (based on the patient’s needs), 
recommendations to doctors, BMD scan and treatment if 
required (Ganda et al., 2012). All these activities were 
coordinated by a dedicated personnel (a pharmacist) (Ganda 
et al., 2012). We used these systematic reviews to determine 
our primary and secondary outcomes. The primary outcome 
for our intervention is the proportion of patients undergoing a 
BMD scan. Secondary outcomes include the proportion of 
patients diagnosed with osteoporosis, the proportion of 
patients started on osteoporosis medication, as well as the 
proportion of patients that conducted osteoporosis preventive 
measures. We also measured patients’ osteoporosis 
knowledge and satisfaction towards the osteoporosis screening 
programme as or secondary outcomes.  
 
3.5.4.3 Identifying theories 
Results from the qualitative studies (Phase one) noted seven 
main barriers to conducting an osteoporosis screening 
programme: governmental, organizational and management, 
work environment, team, task, individual and patient factors. 
However, our intervention will be focusing at the patient factor 
as it most directly influences the practice, outcome and the 
probability of incident (Vincent et al., 1999).  Interventions 
were targeted at these barriers using the theory of BCW. The 
BCW highlighted four key intervention functions: 
environmental restructuring, education, persuasion and 
enablement. In this phase we found the pharmacist to be the 
most suitable healthcare professional to lead the screening 
programme. Therefore, the qualitative data was used for the 
development of the pharmacist- led osteoporosis screening 
guided by the theory of behavioural change wheel as 
described in section 3.6. 
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3.5.4.4 Modelling process and outcomes 
In our study, we targeted postmenopausal women above the 
age of 50 years who have not been diagnosed with 
osteoporosis as they were considered to be biggest cohort that 
are at high risk of having osteoporosis (Ministry of Health 
Malaysia, 2012). 
 
3.5.4.5 Behavioural determinants 
The behavioural determinants were identified as capability, 
opportunity and motivation using the BCW which were 
previously discussed in phase one, section 3.6. 
 
3.5.4.6 Behaviour 
Behaviour refers to patients undergoing a BMD scan and/or 
conducting osteoporosis prevention methods.  
 
3.5.4.7 Physiological/biochemical variable 
The physiological/biochemical variable in our study was the 
BMD results as it the gold standard to diagnose osteoporosis.  
 
3.5.4.8 Health outcomes 
As for health outcome, we measured various process measure 
such as proportion of patients going for BMD scan, proportion 
of patients started on osteoporosis medication, proportions of 
patients conducting osteoporosis preventive measures, 
number of patients diagnosed with osteoporosis, knowledge of 
osteoporosis and satisfaction towards the programme. We 
have mapped the process and outcomes of the intervention in 
Figure 3.9.
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Figure 3.9: Pharmacist-led osteoporosis screening programme causal model  
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In our intervention, we evaluated patients’ knowledge and 
satisfaction. Validated measures exist to measure knowledge 
and satisfaction pertaining to osteoporosis. However, they 
focused on treatment of osteoporosis. This led us to develop 
and validate two tools the OPAAT and SQOP (section  
4.1 and 4.2). Additionally, there was no osteoporosis risk 
assessment tool validated in our population. Therefore we 
evaluated and compared six different types of osteoporosis 
risk assessment tools. Based on our study, we used the OSTA 
as the screening tool because the OSTA was the simplest and 
most well balance tool for daily clinical use (section 4.3).   
 
3.5.5 Discussion 
A pharmacist-led osteoporosis screening and prevention 
programme was developed specifically for postmenopausal 
women aged 50 and above, at a primary care clinic in 
Malaysia. Using the first phase of the UK MRC framework we 
were able to develop an evidence and theory-based 
intervention, based on literature review, qualitative findings 
and theories. Our intervention component involved 
environment restructuring, education, persuasion and 
enablement. The causal model was established to finalize the 
intervention. Careful attention to the design of the programme 
means that we have developed an osteoporosis screening 
programme that would generate evidence on the effectiveness 
of a replicable intervention.  
 
We compared the UK MRC framework to other approaches 
such as the RE-AIM evaluation model. The RE-AIM evaluation 
model was mainly for public health impact interventions. This 
includes aspects such as reach, efficacy, adoption, 
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implementation and maintenance (Glasgow et al., 1999). 
Although this might seems to be a better fit for our 
intervention, the aspects included in the RE-Aim model has 
been incorporated into the MRC UK phases. Another approach 
was the Precede-Procede which involves needs assessment; 
this was also considered in the MRC UK framework in the 
development phase (Green and Kreuter, 1999). Intervention 
mapping was another method that could be considered. It 
describes five phases of programme development from 
definition of programme objectives to process and effect 
evaluation (Bartholomew et al., 2001). Similarly the Logic 
model links inputs and activities to programme (Conrad et al., 
1999). However, these aspects were also considered by the 
MRC UK framework. Therefore, we found the UK MRC 
framework to be a comprehensive and systematic method to 
develop our intervention.  
 
We used the causal modelling approach. The strength of the 
causal model is that it specifies steps involved in developing 
causal models and specifying measures along the causal 
pathway. Additionally it provides for a concise, one-page 
representation of theory and evidence based causal pathway 
linking the intervention components and measures. The causal 
model guides the choice of intervention point and measures 
when it hypothesizes the causal pathways. This aids in 
preventing measuring variables that do not affect the 
intervention. It also assists in the choice of BCT, making it 
possible to examine why interventions are effective or not. It 
also allows the assessment of the extent intervention targeted 
the behavioural determinants and applies specific technique.  
Lastly it enables statistical modelling of relationship between 
the measured behaviours and distant health outcomes. 
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However for our study the short follow up does now allow for 
the assessment of the relationship between undergoing a BMD 
scan and fracture (Hardeman et al., 2005). However, 
literature has shown that using similar measure can help 
reduce fracture (McLellan et al., 2011, Lih et al., 2011).  
 
Although the UK MRC framework enabled us to use a rigorous 
method to develop our intervention that is likely to be 
accepted in the setting in which it is to be delivered and 
tested, the process has some disadvantages. The UK MRC 
framework posed a number of challenges such as time and 
resources needed. This challenges were similar to other two 
other studies which used the UK MRC framework to develop 
an intervention on prevention of childhood obesity (Lakshman 
et al., 2014) and secondary prevention of coronary heart 
disease in primary care (Byre et al., 2006). Significant amount 
of resources are normally allocated for the development of 
pharmacological and other biochemical intervention but the 
development of public health intervention which do not involve 
the generation of intellectual property does not receive as 
much funding. Funding bodies need to consider if public health 
interventions are to follow a rigorous development and 
evaluation process (Lakshman et al., 2014).  
 
A limitation of our study is that the intervention was refined 
and tailored to the local setting making the generalizability to 
other settings difficult. However, by linking the intervention 
components to a theoretical framework it may provide an 
effective way to allow our finding to be generalizable. This 
may also avoid duplicating efforts for subsequent research. 
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3.5.6 Conclusion 
We developed an evidence and theory-based pharmacist-led 
osteoporosis screening programme using the MRC UK 
framework.  This innovative approach has made the 
intervention more likely to be acceptable and deepens the 
understanding of how such a complex intervention performs in 
primary care.  
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4     CHAPTER 4: PHASE THREE-
FEASIBILITY STUDY OF A 
PHARMACIST-LED OSTEOPOROSIS 
SCREENING PROGRAMME 
4.1   Introduction 
4.1.1 Feasibility and pilot study 
Various factors affect the internal, external, construct, and 
statistical validity of the design, implementation and results of 
a randomized controlled trial (RCT) intervention. Feasibility 
and pilot studies are designed to build the foundation of the 
planned intervention, to ensure that the implementation of the 
intervention is practical, to assess the potential for a 
successful implementation of the intervention studies and to 
reduce threats to the validity of the study (Tickle-Degnen, 
2013).  
 
 “Feasibility studies are pieces of research done before a main 
study (i.e randomized controlled trial) in order to answer the 
question ‘Can this study be done?’... It is used to estimate 
important parameters that are needed to design the main 
study.” Feasibility studies are different from pilot studies. A 
pilot study is “ A version of the main study that is run in 
miniature to test whether the components of the main study 
can all work together ... (and resembles) the main study in 
many respects, includes an assessment of the primary 
outcome (National Institute for Health Research, 2012).” 
Hence, a feasibility study tries out parts of the intervention, 
whereas a pilot study tries out the operation of all parts of the 
planned intervention. The outcomes of most feasibility and 
pilot studies should be measured using descriptive statistics, 
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qualitative analysis and compilation of basic data related to 
administrative and physical structure (Tickle-Degnen, 2013) 
(Lancaster et al., 2004, Grimes and Schulz, 2002).  
 
However, our feasibility study is different to published 
feasibility studies of drug trials where a single “active” 
ingredient is being tested, which is the causal effect of the 
intervention outcome. Our intervention is based on qualitative 
findings and behavioural change techniques (such as the 
behavioural change wheel) which involves “blended” active 
ingredients; a theoretical perspective that reflects an 
understanding of performance and outcomes as being at the 
intersection of person, environment and a measurement 
paradigm based on constructs and continua; and client-
centres, individualized intervention. Therefore, we used a 
typology developed by Tickle-Dengen which has been used in 
occupational therapy, and are typically derived from “blended” 
active ingredients, like our study (Tickle-Degnen, 2013).  
 
Tickle-Dengen (2013) modified a typology by Thabane et al. 
(2010) developing a systematic and comprehensive typology 
to outline four primary purposes for both pilot and feasibility 
studies: to test the (1) process, (2) resources, (3) 
management, and (4) scientific basis of planned intervention  
Process assessment refers to the expected response rates, 
follow-up rates, adherence to study intervention and 
attendance. It also assesses the suitability of the eligibility 
criteria, data collection methods including amount of data 
collected, time and capacity to collect the data. Examples of 
resources assessments refer to whether the researchers have 
the capacity to communicate and coordinate patients; whether 
there is adequate time to conduct each step at each stage, 
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and whether there is sufficient equipment. As for management 
assessments, it refers to finding out the challenges and 
strengths faced by the investigator to conduct the planned 
activities such as to accurately enter the data on to the 
computer and the management of the ethics of the research. 
Scientific assessment on the other hand refers to the safety of 
the intervention, estimates the intervention effect and the 
reliability, validity of the assessment used for the target 
population (Tickle-Degnen, 2013, Thabane et al., 2010). 
 
4.1.1.1 Importance of feasibility studies in 
osteoporosis 
Feasibility studies can be used to build the foundation for a 
planned intervention study (Tickle-Degnen, 2013). They can 
assist in identifying potential bias or problems that may occur 
in various aspects of the study such as the processes, 
resources, management and scientific aspects (Tickle-Degnen, 
2013).  
 
Three randomized control trials (RCTs) have been conducted 
internationally by community pharmacists to evaluate the 
impact of pharmacist’s interventions on osteoporosis 
management (Yuksel et al., 2010, Crockett et al., 2008, 
McDonough et al., 2005). All three studies showed that 
pharmacist intervention increased the number of patients that 
had their BMD tested and calcium intake initiated, indicating 
that pharmacists have a role to play in reducing the gap in 
osteoporosis management (Yuksel et al., 2010, Crockett et al., 
2008, McDonough et al., 2005). However, two of these studies 
were considered biased (Elias et al., 2011). The study by 
Crockett et al had a high risk of both selection and information 
bias, as self-reported assessment was used (Elias et al., 2011, 
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Crockett et al., 2008). As for the study by McDonough et al. 
the study has a high risk of selection bias as the recruitment 
size and follow up differed between the control and 
intervention groups (Elias et al., 2011, McDonough et al., 
2005). The third study by Yuksel et al demonstrated low bias 
in both aspects (Elias et al., 2011, Yuksel et al., 2010). These 
biases could have been minimised by conducting feasibility 
studies.  
 
A search of published literature found five feasibility/pilot 
studies pertaining to osteoporosis screening: one in hospital 
(Ryder et al., 2007), two in community pharmacies (Cerulli 
and Zeolla, 2004, Elliot et al., 2002) and two in a primary care 
setting (Mudano et al., 2013, Pencille et al., 2009). These 
studies used feasibility studies to preliminary assess the 
effectiveness of their interventions (Pencille et al., 2009, 
Cerulli and Zeolla, 2004, Ryder et al., 2007) recruitment 
method (Pencille et al., 2009, Mudano et al., 2013), processes 
(time spent with patients, communication, acceptance of 
physicians) (Cerulli and Zeolla, 2004, Elliot et al., 2002) and 
project cost (Cerulli and Zeolla, 2004).  
 
All four studies concluded that a feasibility study was 
informative in making decisions towards a successful 
implementation of the interventions (Cerulli and Zeolla, 2004, 
Elliot et al., 2002, Pencille et al., 2009, Mudano et al., 2013). 
For example, the studies performed in community pharmacies 
found that the planned process were suitable, and that these 
processes were positively accepted by the healthcare 
professionals involved (Cerulli and Zeolla, 2004, Elliot et al., 
2002).The other two primary care studies were able to identify 
the most suitable recruitment method for their study, thus 
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reducing bias in their study methodology (Mudano et al., 
2013, Pencille et al., 2009). Therefore, feasibility studies are 
critical to the successful implementation of RCTs and 
interventions. To date, there is a paucity of data of studies 
using the OSTA in an osteoporosis screening programme in 
the Malaysian primary care setting.   
 
4.1.2 Objectives  
To determine the feasibility of a pharmacist-led osteoporosis 
screening programme at a Malaysian primary care clinic. 
 
4.1.3 Methods 
4.1.3.1 Study design 
This is a prospective, pre and post intervention study of a 
pharmacist-led osteoporosis screening programme. 
 
4.1.3.2 Setting  
The study was conducted at the primary care clinics of the 
University Malaya Medical Centre (UMMC), Kuala Lumpur, 
Malaysia. 
 
4.1.3.3 Period of study 
Data were collected from June to August 2014. 
 
4.1.3.4 Participants 
English or Malay speaking postmenopausal women aged ≥ 50 
years old who had not been diagnosed with 
osteopenia/osteoporosis were included. Those not well enough 
to participate in the study were excluded.  
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4.1.3.5 Sampling procedure 
Randomization was not conducted as we wanted to assess if 
the components of the intervention could function well 
together in a practice setting. Therefore, convenience 
sampling was used to reflect daily clinic practice.   
 
4.1.3.6 Sample size 
A large sample size is not required for a feasibility study as 
adequate power statistics for null hypothesis testing is not 
required (Tickle-Degnen, 2013). We recruited a convenience 
sample of 50 patients.  
 
4.1.3.7 Primary and secondary outcomes 
We used the Tickle-Dengen modified typology by Thabane et 
al to categorize our primary and secondary outcomes which 
were: to test the (1) process, (2) resources, (3) management, 
and (4) scientific (Tickle-Degnen, 2013) (Thabane et al., 
2010). 
 
4.1.3.8 Primary outcome 
4.1.3.8.1 Scientific assessment 
Our primary outcome was to measure the proportion of 
patients who went for the BMD scan. We assessed this 
outcome by patient self-report and confirmed by obtaining the 
patients’ BMD scan results. This outcome measured is 
consistent with the currently used HEDIS (Healthcare 
Effectiveness Data and Information Set) measures for quality 
of osteoporosis care adopted by the National Committee on 
Quality Assurance (National Committee for Quality Assurance 
(NCQA), 2004, National Committee for Quality Assurance, 
2014).  
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4.1.3.9 Secondary outcomes measured 
4.1.3.9.1 Scientific assessment 
Four secondary outcomes were measured: the number of 
patients started on osteoporosis medications, the number of 
patients conducting lifestyle modifications namely: taking 
calcium supplements, increasing calcium in the diet and/or 
exercise, patients’ osteoporosis knowledge and patients’ 
satisfaction towards the pharmacist-led osteoporosis screening 
programme. 
 
4.1.3.9.1.1 The number of patients that were started 
on osteoporosis medications 
Similarly, this outcome measured is also consistent with the 
currently used HEDIS measures for quality of osteoporosis 
care adopted by the National Committee on Quality Assurance 
(National Committee for Quality Assurance (NCQA), 2004, 
National Committee for Quality Assurance, 2014). We 
measured this via patients’ self report. Subsequently we 
confirmed the data by checking the patient’s medical records.  
 
4.1.3.9.1.2 The number of patients that made lifestyle 
modifications 
We also measured the number of patients conducting lifestyle 
modifications namely: taking calcium supplements, increasing 
calcium in the diet and/or exercise. These were measured 
based on patient self report. 
 
4.1.3.9.1.3 Patients’ osteoporosis knowledge  
Based on the UK MRC framework (Medical Research Council, 
2008), it is imperative to assess the effectiveness of an 
intervention conducted. We measured the outcome of patient’s 
pre and post osteoporosis knowledge scores as part of the 
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evaluation of the intervention. We used the OPAAT to measure 
this  outcome. The development and validation of the OPAAT 
have been explained in section 4.2, Phase two. 
 
4.1.3.9.1.4 Patients’ satisfaction towards the 
pharmacist-led osteoporosis screening 
programme 
The patients’ satisfaction towards the osteoporosis screening 
programme was also measured as part of the evaluation of 
the intervention. This was measured using the SQOP which 
was previously described in section 4.3 of Phase two. 
 
4.1.3.9.2 Process assessment 
In this feasibility study we assessed the intervention’s 
processes, including response rates, follow-up rates, suitability 
of the eligibility and exclusion criteria, data collection 
methods, patients’ time and capacity to complete data 
collection procedures. This was assessed from the researcher’s 
experience and documentation from the pilot. 
 
4.1.3.9.3 Resources assessment 
We also assessed the resources in terms of whether the 
researchers had the capacity to communicate and coordinate 
the patients and primary care physicians, physical condition, 
time to conduct each stage, sufficient equipment and 
documentation. This was assessed from the researcher’s 
experience and documentation from the pilot. 
 
4.1.3.9.4 Management assessment 
This refers to accuracy when entering the data to the 
computer and adherence to ethics application. This was 
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measured by the researcher’s experience and documentation 
from the pilot. 
 
4.1.3.10 Instruments used 
4.1.3.10.1 Baseline demographics 
This instrument was used to collect baseline demographic 
information such as patients’ medical history, lifestyle and 
medication history (Appendix 1). 
 
4.1.3.10.2 Osteoporosis Screening Tools for Asians 
(OSTA)  
The OSTA was used to screen the patients’ risk for 
osteoporosis. It categorized the patients to low, moderate of 
high risk. The OSTA involves a calculation as follows: weight in 
kilograms were deducted with age in years and multiplied by -
0.2. (Please refer to section 4.3 for further details). 
 
4.1.3.10.3 WHO Fracture Risk Assessment tool (FRAX) 
The FRAX was used to provide additional information of the 
patient’s fracture risk to further aid the physician’s in deciding 
if a BMD scan was needed. It was developed to evaluate the 
fracture risk of patients (Appendix 33). It was developed by 
WHO, based on individual patient models that integrate the 
risk associated with clinical risk factors as well as BMD at the 
femoral neck. The model calculates the risk of fractures of 
men or women by using age, height, weight, prior fragility 
fracture, parental history of hip fracture, current tobacco 
smoking, ever long-term use of oral glucocorticoids, 
rheumatoid arthritis, other causes of secondary osteoporosis 
and daily alcohol consumption of three of more units daily. 
Femoral neck BMD can additionally be entered for more 
accurate estimates. The FRAX algorithms output is a 10-year 
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probability of hip fracture and the 10-year probability of a 
major osteoporosis fracture (clinical spine, forearm, hip or 
shoulder fracture). As a FRAX model based on the Malaysian 
cohort has not been developed, we used the model based on 
the Singaporean population (Kanis, 2014, McCloskey, 2009).  
 
4.1.3.10.4 Osteoporosis Prevention and Awareness 
Tool (OPAAT) 
The validated OPAAT was used to assess the knowledge of 
patients as described in section 4.2 previously. 
 
4.1.3.10.5 Satisfaction Questionnaire for Osteoporosis 
Prevention (SQOP) 
The validated SQOP was used to assess the knowledge of 
patients as described in section 4.1 previously (Toh et al., 
2014).  
 
4.1.3.11 Intervention provided 
Patients received an osteoporosis booklet (appendix 24), 30 
minutes of verbal counselling, a fracture risk assessment using 
FRAX and an osteoporosis risk assessment using OSTA. Topics 
covered during the counselling session were the definition of 
osteoporosis, consequences of untreated osteoporosis, risk 
factors for osteoporosis, the role of the BMD scan (its function, 
what the results mean, accessibility and the frequency a 
patient has to go for a BMD scan), other tests used in 
osteoporosis screening (quantitative ultrasound scanning, x-
ray, blood test and the OSTA), lifestyle changes (calcium 
intake, vitamin D intake, weight bearing exercise and fall 
prevention), and treatment of osteoporosis. A 
recommendation for a BMD scan (appendix 34) was made to 
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the doctors for patients who had a moderate or high risk for 
osteoporosis.  
 
4.1.3.12 Procedure 
Figure 5.1 demonstrates the workflow of the finalized 
pharmacists-led osteoporosis screening programme based on 
the behaviour change wheel. Eligible patients were first 
screened by nurses at the waiting area. Suitable patients were 
then recruited by the pharmacist. The study was explained to 
patients using the patient information sheet (Appendix 35). 
Informed consent and the patients’ baseline demographic data 
were obtained (Appendix 36). Subsequently, the pharmacist 
assessed the patients’ 10-year fracture risk using FRAX, 
conducted a counselling session and administered the OPAAT. 
Patients answered the questionnaire themselves. However, for 
those who experienced some difficulty in reading the questions 
themselves, the researcher read the questions out for them 
and assisted them in filling the questionnaire. The researcher 
ensured that all questions had been answered. Most patients 
required about 10-15 minutes to complete the questionnaire.  
 
All questionnaires and interventions were administered by the 
researcher. The researcher was trained by one of the 
supervisors who was well versed in osteoporosis to deliver the 
counselling session. An osteoporosis risk assessment was then 
conducted. If the OSTA score indicated that the patient was at 
risk for osteoporosis (high risk, intermediate risk, low risk plus 
one risk factor), a recommendation was made to the doctor to 
order a BMD scan and a BMD scan appointment was 
prearranged pending the doctor’s evaluation.  
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The patients were then evaluated by the doctor for the need 
for a BMD scan. An appointment for one month later was set. 
During this time, the patients would undergo a BMD scan if 
required. Two weeks after baseline, a telephone call was 
conducted to administer the SQOP and OPAAT. An 
independent postgraduate student was employed to use the 
SQOP to assess the patients’ satisfaction and the OPAAT to 
assess the patients’ knowledge during this follow up. The 
pharmacist reminded the patients of their next doctor’s 
appointment and informed the patients of their BMD results 
and answered any queries that they may have.  
 
The patient then attended their scheduled doctor’s 
appointment. A second follow up (immediately after the 
doctor’s appointment) was conducted to assess if the patient 
attended the osteoporosis clinic or was started on osteoporosis 
treatment/preventive measures. Figure 4.1 demonstrates the 
workflow of the finalized pharmacists-led osteoporosis 
screening programme based on the behaviour change wheel. 
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Pharmacist will conduct the first counselling session which includes: 
obtaining baseline information, administering OPAAT and screening patients 
using OSTA and FRAX (N=50) 
 
Low risk Medium risk High 
risk 
Pharmacist will recommend to the doctor to order a 
BMD scan using a form (Appendix 6.1) 
Low risk & 1 
risk factor 
Patients go for their BMD scan* 
Pharmacist to prearrange BMD scan appointment 
  
Follow up via phone will be conducted to administer SQOP and OPAAT. Pharmacist reminded the 
patients of their next doctor’s appointment and informed the patients of their BMD results via 
telephone. Questions regarding the BMD results and osteoporosis prevention were answered. 
 
Follow up via phone will be conducted to assess if patients attended the 
osteoporosis clinic or started on osteoporosis treatment/preventive measures. 
Patients go for subsequent 
doctor’s appointment where their 
BMD results will be reviewed 
Patients go for scheduled doctor’s appointment 
Nurses/pharmacist will measure the participant’s height and weight 
BMD scan not necessary BMD scan necessary 
Doctors to schedule the next 
appointment one month later and 
to pass the BMD form to patients 
*The patients will receive the hard copy of the results and 
the researcher will receive the softcopy 
 
Abbreviations: 
- BMD: Bone Mineral Density 
- OSTA: Osteoporosis Screening Tool for Asians 
- OPAAT: Osteoporosis Prevention and Awareness 
Assessment Tool 
- SQOP: Satisfaction Questionnaire for Osteoporosis 
Patients 
- FRAX- WHO Fracture Risk Assessment tool 
Figure 4.1: Flow chart on the pharmacist-led osteoporosis 
screening program 
Nurses will refer potential candidates to the pharmacist 
Baseline  
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4.1.3.13 Source of data 
The source of data varied from medical registers, medical 
records, observations to observe if patients were too unwell to 
participate in the study, interviews, questionnaire and informal 
discussions to find out informally if patients have osteoporosis 
during recruitment. Some of the data such as patients’ clinical 
information were obtained from medical records prior to the 
provision of service, whilst other data were obtained during 
the counselling session with the pharmacist. 
 
4.1.3.14 Ethics approval 
Ethical approval from the University Malaya Medical Centre 
Ethics Committee was obtained prior to the study (ref no. 
920.26, Appendix 37).  
 
4.1.3.15 Data analysis 
All data was entered into the IBM® SPSS® version 20 (IBM 
Corporation, Armonk, NY, US). Descriptive statistics were used 
to present patient demographics, response rate, follow up 
rates, proportions of patients who went for BMD scans, 
outcomes of patients that went for BMD scan. Mc Nemar’s test 
was used to examine the pre and post scores of the individual 
items in the OPAAT. Continuous data of the individual items 
and total domain scores of the OPAAT were analyzed using the 
Wilcoxon signed-rank. Non-parametric tests were used since 
data obtained were not normally distributed.  A p-value <0.05 
was considered as statistically significant. 
 
To ascertain the feasibility of providing this service, the data 
gathered to assessed the process, resources and management 
in this study were described. 
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4.1.4 Results  
4.1.4.1 Patients characteristics 
A total of 55 patients were approached, 5 declined 
participation. Finally 50 patients were recruited, [response 
rate= 90.9%]. Patients’ demographic data are shown in Table 
4.1.  
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Table 4.1: Baseline demographic characteristics of patients 
Characteristics Patients (n=50) 
Mean age ± S. D. (years) [range] 
(Median) 
64.7±8.2 [51-83] 
(64.5) 
Age range (years) [n (%)] 
<65 
≥ 65 
 
25 (50.0) 
25 (50.0) 
Ethnicity [n (%)] 
Malay  
Chinese 
Indian 
 
6 (12.0) 
30 (60.0) 
14 (28.0) 
 
Mean BMI ± S.D. (kg/m2)[range] 
(Median) 
23.3±3.6 [15.4-
35.6](23.5) 
BMI (kg/m2) [n (%)] 
<18.5 (underweight) 
18.5-24.9 (normal) 
25.0-29.9 (overweight) 
≥30.0 (obese) 
 
3 (6.0) 
33 (66.0) 
12 (24.0) 
2 (4.0) 
Level of education [n (%)] 
Primary (6 years of education) 
Secondary (11-13 years of education) 
Diploma/Technical school training (12-14 
years of education) 
Tertiary/Postgraduate (15-21 years of 
education) 
 
3 (6.0) 
30 (60.0) 
11 (22.0) 
60 (12.0) 
Income per month [n (%)] 
<RM1000 (<$ 310.7) 
RM1000-1999 ($ 310.7-621.0) 
RM2000-2999 ($ 621.3- 931.7) 
RM3000-3999 ($ 932.0- 1242.3) 
RM4000-4999 ($ 1242.6-1553) 
>RM5000 (>$1553.3) 
 
10 (20.0) 
10 (20.0) 
10 (20.0) 
7 (14.0) 
5 (10.0) 
8 (16.0) 
 S.D. = standard deviation; BMI=body mass index; $=US dollar 
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4.1.4.2 Proportion of patients who went for BMD scan 
Using the OSTA, 27/50 (54.0%) patients were categorized into 
moderate to high risk groups. For the low risk group, 9/23 
(39.1%) had more than one major clinical risk factor: 5/23 
(21.7%) had a family history of osteoporosis, 2/23 (8.7%) 
had a previous fracture and 2/23 (8.7%) had a family history 
of osteoporosis as well as a previous fracture. A BMD scan was 
recommended for these patients [Figure 4.2]. 
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Figure 4.2: Stratification of patients’ osteoporosis risk based on OSTA 
 
 
 
 
   
Osteoporosis risk assessment based on OSTA  
High risk, n=9 (18.0%) Moderate risk, n=18 (36.0%) Low risk, n=23 (46.0%) 
 No. of patients with >1 major risk factors, n= 9 (39.1%) 
Family 
history of 
osteoporosis, 
n=5 (21.7%) 
Previous 
fracture, 
n=2 
(8.7%) 
Family history of 
osteoporosis and 
previous 
fracture, n=2 
(8.7%) 
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Out of 36 recommendations made by the pharmacists, 28 
(77.8%) BMD scans were ordered. Reasons provided by the 
doctors on why BMD scans were not ordered were: 3/36 
(8.3%) patients’ x-ray results were normal; 1/36 (2.8%) 
doctor said that there were more urgent diseases to treat such 
as heart, endocrine and eye; 1/36 (2.8%) patient’s blood 
calcium levels were normal; 1/36 (2.8%) patients was 
considered too young (58 years old), 1/36 (2.8%) patient’s 
FRAX fracture risk was considered too low (11% major 
osteoporosis fracture and 2.2% for hip fracture) and 1/36 
(2.8%) would be exposed to too much radiation as she had 
another appointment for a computed tomography (CT) scan. 
In addition, 3 extra BMD scans were ordered by the doctors 
even though it was not recommended by the pharmacist, as 
BMDs scans were provided free of charge by the research 
fund. Therefore a total of 31 BMD scans were ordered. 
 
Ultimately, 26/31 (83.9%) went for a BMD scan: 3 /31 (9.7%) 
were busy, 1/31 (3.2%) was afraid of too much radiation as 
she was going for an electrocardiogram the next month and 
1/31 (3.2%) was not contactable [Figure 4.3].  
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Figure 5.3: Results of the feasibility study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients screened at the waiting area, n=55 
Patients recruited by the pharmacist, n=50 (response rate 90.9%) 
Baseline information, clinical risk factors was collected. FRAX, 
OSTA and the OPAAT were administered. 
High risk, n=9 (18.0%) 
Patients recommended for BMD scan, n=36 (72.0%) 
Declined (n=5) 
Response rate= 90.9% 
 
 
 
Moderate risk, n=18 (36.0%) Low risk, n=23 (46.0%) 
 No. of patients with >1 major 
risk factors, n= 9 (39.1%) 
BMD scans were ordered based on the recommendations and doctors’ evaluation, n=31 (86.1%) 
Patients that went for BMD scan, n=26 (83.9%) 
Patients that did not go for BMD scan 
n=5 (16.1%) 
BMD results reviewed by PCP, n=25 (96.2%) Patient did not go for PCP appointment, 
n=1 (3.8%) 
Normal, n=9 (36.0%) Osteopenia, n=16 (64.0%) 
No action by 
PCP, n= 9 
(100.0%) 
Patient 
initiated 
lifestyle 
changes, 
n=2 
(22.2%) 
No action by 
PCP, n= 10 
(62.4%) 
Private PCP started patients on osteoporosis 
medications, n=2 (100.0%) 
Patient 
started on 
calcium 
supplements, 
n= 1 
(11.1%) 
Patient 
started on 
calcium 
supplements
, n=5 
(50.0%) 
Patient 
initiated 
lifestyle 
changes, 
n=1 
(10.0%) 
Osteopenia n=1 (3.8%) 
PCP started 
calcium 
supplement, 
n= 5 (31.2%) 
PCP stopped 
calcium 
supplement, 
n= 1 (6.3%) 
Patient 
visited 
private 
PCP, n=2 
(20.0%) 
Abbreviations: 
OSTA= Osteoporosis screening 
tool for Asians 
BMD= Bone mineral density 
PCP- Primary care physicians 
Figure 4.3: Results of feasibility study 
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Outcome of patients that went for a bone mineral density scan 
Seventeen out of 26 (65.4%) patients had osteopenia. BMD 
results were seen by primary care physicians in 25/26 
(96.2%) patients. One (3.8%) patient did not come for a 
follow up visit as the waiting time was too long. Nonetheless, 
this patient visited a private practice primary care physician. 
She was found to be osteopenic. 
 
4.1.4.3 Outcomes of patients started on osteoporosis 
medication or patients conducting lifestyle 
modifications 
Out of the 16 osteopenic patients reviewed by the primary 
care clinic, five (31.3%) were started on calcium tablets and 
one (6.3%) was asked to stop their calcium supplements as 
her parathyroid blood test was out of range. No action was 
taken for the remaining ten (62.5%) patients. However out of 
these ten patients, five (50.0%) patients initiated calcium 
supplements on their own, one (10.0%) started some weight 
bearing exercises, whilst one (10.0%) patient visited a private 
practice primary care physician, who started her on 2g 
strontium ranelate daily. There was one (10.0%) patient who 
did not go for her primary care clinic appointment. However 
this patient visited a private practice primary care physician 
and was started on 2g strontium ranelate daily.  
 
In our study, nine out of 26 (34.6%) of the patients had 
normal BMD results. Although the primary care physicians 
decided that no action was necessary, two (22.2%) patients 
initiated lifestyle changes (such as weight bearing exercises 
and increase dietary calcium intake) and one (11.1%) patient 
started taking calcium supplements.   
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In total, two out of 26 (7.7%) patients from this study were 
started on osteoporosis medications. Additionally, 11/26 
(42.3%) patients started on calcium supplements and 3/26 
(11.5%) initiated osteoporosis preventive lifestyle measure. 
 
4.1.4.4 Knowledge score 
After one month, only 46/50 patients answered the OPAAT 
again (response rate=92.0%): 2 (4.0%) were busy, 1 (2.0%) 
was afraid of radiation and hence was excluded since she did 
not go for the BMD, and 1 (2.0%) was patient could not be 
contacted. After the intervention provided by the pharmacist, 
there was an increase in knowledge for 27/30 (90.0%) items. 
The domain scores as well as the total score for the OPAAT 
were also significantly higher after intervention [Table 4.2].  
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Table 4.2: Patients’ knowledge score at baseline and one month later. 
Domain Item 
number 
Baseline (n=50)  One month later  (n=46) McNemar’s 
test p-value 
 
Wilcoxon signed-rank test 
Mean±SD 
 
Median No. of 
correct 
responses 
[n (%)] 
Mean±SD 
 
Median No. of 
correct 
responses 
[n (%)] 
Mean/rank z-value P-value 
Osteoporosis in 
general 
1 0.64±0.48 1.00 18 (69.2) 0.89±0.31 1.00 23 (88.5) 0.002*    
2 0.32±0.47 0.00 9 (34.6) 0.65±0.48 1.00 19 (73.1) <0.001*    
3 0.34±0.48 0.00 7 (26.9) 0.43±0.50 0.00 11 (42.3) 0.289    
4 0.34±0.48 0.00 9 (34.6) 0.65±0.48 1.00 20 (76.9) 0.001*    
5 0.36±0.48 0.00 8 (30.8) 0.76±0.43 1.00 22 (84.6) <0.001*    
6 0.64±0.48 1.00 16 (61.5) 0.78±0.42 1.00 23 (88.5) 0.016*    
7 0.34±0.48 0.00 9 (34.6) 0.50±0.51 0.50 16 (61.5) 0.008*    
8 0.48±0.50 1.00 15 (57.7) 0.89±0.31 1.00 25 (96.2) <0.001*    
9 0.54±0.50 1.00 17 (65.4) 0.76±0.43 1.00 21 (80.8) 0.006*    
10 0.36±0.48 0.00 10 (38.5) 0.76±0.43 1.00 21 (80.8) <0.001*    
11 0.46±0.50 0.00 15 (57.7) 0.78±0.42 1.00 21 (80.8) 0.001*    
Domain 
score (%) 
44.72±28.03 45.45  73.54±26.04 81.82   14.50/19.13 -5.100 <0.001* 
Consequences 
of untreated 
12 0.66±0.48 1.00 15 (57.7) 1.00±0.00 1.00 26 (100.0) #    
13 0.76±0.43 1.00 19 (73.1) 1.00±0.00 1.00 26 (100.0) #    
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*Statistically significant p<0.05.  Wilcoxon signed-rank test was used for continuous variables. McNemar’s test was conducted for categorical variables. 
# Could not be calculated as all patients answered correctly one month later 
osteoporosis 14 0.68±0.47 1.00 18 (69.2) 0.96±0.21 1.00 25 (96.2) 0.007*    
15 0.22±0.42 0.00 9 (34.6) 0.83±0.38 1.00 22 (84.6) <0.001*    
16 0.22±0.42 0.00 7 (26.9) 0.91±0.28 1.00 25 (96.2) <0.001*    
Domain 
score (%) 
50.80±26.87 60.00  93.91±11.83 100.00   13.00/22.44 -5.476 <0.001* 
Prevention of 
osteoporosis 
17 0.40±0.49 0.00 9 (34.6) 0.93±0.25 1.00 25 (96.2) <0.001*    
18 0.32±0.47 0.00 8 (30.8) 0.89±0.34 1.00 24 (92.3) <0.001*    
19 0.26±0.44 0.00 7 (26.9) 0.52±0.51 1.00 17 (65.4) 0.019*    
20 0.54±0.50 0.00 17 (65.4) 0.98±0.15 1.00 26 (100.0) <0.001*    
21 0.16±0.37 0.00 3 (11.5) 0.67±0.47 1.00 20 (76.9) <0.001*    
22 0.64±0.48 1.00 19 (73.1) 1.00±0.00 1.00 26 (100.0) #    
23 0.50±0.51 0.50 15 (57.7) 0.96±0.21 1.00 26 (100.0) <0.001*    
24 0.42±0.50 0.00 12 (46.2) 0.61±0.49 1.00 18 (69.2) 0.022*    
25 0.28±0.45 0.00 9 (34.6) 0.80±0.40 1.00 24 (92.3) <0.001*    
26 0.50±0.51 0.50 15 (57.7) 0.74±0.44 1.00 23 (88.5) 0.013*    
27 0.64±0.49 0.00 10 (38.5) 0.41±0.50 0.00 11 (42.3) 0.375    
28 0.78±0.42 1.00 21 (80.8) 0.98±0.15 1.00 25 (96.2) 0.004*    
29 0.78±0.42 1.00 20 (76.9) 0.89±0.31 1.00 24 (92.3) 0.344    
30 0.52±0.50 1.00 15 (57.7) 0.76±0.43 1.00 21 (80.8) 0.013*    
Domain 
score (%) 
46.00±25.13 50.00  79.66±16.15 82.14   7.00/24.14 <0.001* 0.000* 
Total OPAAT score (%) 46.33±21.36 46.67  79.06±14.26 81.67   8.00/23.70 -5.668 <0.001* 
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4.1.4.5 Satisfaction level 
The patients’ satisfaction was not assessed during baseline. 
However the patients’ satisfaction score at one month later 
was 89.75±12.44.  
 
4.1.4.6 Process assessments 
Based on the response rate of 90.9% we found the inclusion 
criteria to be suitable. The inclusion criteria were clear and 
sufficient enabling us to target postmenopausal women >50 
years old who had not been diagnosed 
osteoporosis/osteopenia. The follow up rate was 26/31 
(83.9%) during the first follow up and 26/26 (100%) for the 
second follow up.  
 
However, modifications were made to the data collection 
method. Initially, the nurses were allocated to refer potential 
patients to the pharmacists. However, nurses did not perform 
this task. Hence, the pharmacist screened for potential 
patients herself. All patients had enough time and the capacity 
to complete the data collection procedure. Patients took 
approximately 15 minutes to complete the OPAAT and the 
SQOP. Therefore we have tested the timing and administrative 
aspect of the intervention and was found to be successful.  
 
4.1.4.7 Resources assessment 
The pharmacist initially found it difficult to communicate and 
coordinate with the doctors regarding the recommendations 
and procedures of the intervention. The doctors were not 
motivated and supportive to proceed with the intervention 
tasks. In order to resolve this, the pharmacist conducted 
individual sessions with the doctors before the clinic session, 
which aided in the coordination and communication of the 
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intervention. These individual sessions with the doctors 
involved a short briefing on the gap of osteoporosis, the aim 
and procedures of the research. There were no problems with 
communicating with the patients from baseline to follow up. 
 
This intervention was conducted at the waiting area of the 
clinic. Currently, no room has been allocated for this 
intervention. Although the intervention proceeded smoothly, 
some patients commented that it would be more professional 
if a consultation room was allocated for the pharmacist or at 
least a table and chair should be stationed for the 
intervention.  
 
As for time and capacity to conduct each stage, the 
pharmacist found that the risk assessment, counselling and 
administration of the two questionnaires took approximately 
30 minutes for each patient. The time allocated was sufficient 
as patients waiting time for their doctor’s appointment would 
normally be more than 30 minutes.  For the first follow up 
session, administration of the OPAAT, SQOP and information 
on the BMD results was approximately 15-30 minutes 
depending on the number of questions the patients had. The 
second follow up needed about five minutes. 
 
Documentation was successful, as the forms used by the 
pharmacists to make recommendations were documented into 
the patients’ medical record. Equipment to measure height 
and weight were available throughout the intervention. DEXA 
machines were also available as needed during the patients’ 
appointment.  
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4.1.4.8 Management assessment 
The pharmacist was able to document all data and outcomes 
needed into SPSS daily. There were also no problems with 
managing the procedures based on the ethics application. 
 
4.1.5 Discussion 
To our knowledge, this is the first feasibility study of a 
pharmacist-led osteoporosis screening in a primary care clinic. 
The feasibility study was a success and can be taken to the 
next step which is the implementation of a large scale 
randomized controlled trial, to assess the effectiveness of the 
intervention. The current workflow was functional and able to 
assess both primary (proportion of patients that went for the 
BMD scan) and secondary outcomes (the number of patients 
started on osteoporosis medications, the number of patients 
conducting lifestyle modifications, patients’ osteoporosis 
knowledge, patients’ satisfaction towards a pharmacist-led 
osteoporosis screening programme, process assessment, 
resources assessment and management assessment).  
 
We found the inclusion and exclusion criterion to be suitable 
as the osteoporosis screening programme was positively 
received by patients (response rate =90.9%). In our cohort, 
26 (83.9%) patients went for a BMD density scan, which 
resulted in 17(65.4%) being diagnosed with osteopenia. Only 
2(7.7%) patients were started on osteoporosis medications, 
11 (42.3%) were started on calcium supplements and 3 
(11.5%) initiated lifestyle modifications on their own accord. 
Additionally, the knowledge score of the patients significantly 
increased in all domains when compared to baseline. The 
overall OPAAT score increased significantly from 46.33±21.36 
to 79.06±14.26.  Patients were also satisfied with the 
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programme (satisfaction score=89.75±12.44). The current 
process, resource and management of the osteoporosis 
screening programme were also found to be suitable.  
 
In our study, the reasons given by the doctors for not ordering 
BMD scans highlighted several misconceptions in the areas 
regarding osteoporosis screening, interpretation of FRAX, risk 
factors, radiation of the BMD scan and the lack of priority 
towards osteoporosis. This further supports our Phase one 
findings on the healthcare professionals’ lack of osteoporosis 
knowledge in section 3.4.2.2.7.3.  
 
Some of the BMD scans were not ordered because patients’ x-
ray results were normal. Similarly, in New Zealand there was 
a misconception to judge bone mineral density using the x-ray 
results (Sale et al., 2014). According to the Malaysian 
osteoporosis guidelines, radiological osteopenia is apparent in 
plain x-ray only after more than 30% of bone loss has 
occurred (Ministry of Health Malaysia, 2012).  
 
Another reason the BMD scans were not ordered was because 
patients’ blood calcium results were normal. Based on the 
National Osteoporosis Foundation (NOF) clinician’s guide to 
prevention and treatment of osteoporosis 2014 blood calcium 
levels are not used to screen for osteoporosis but to rule out 
secondary causes of osteoporosis (Cosman et al., 2014) 
(Houillier et al., 2006). Therefore, tools such as the OSTA, 
FRAX and QUS are more suitable for osteoporosis screening 
(Cosman et al., 2014, Ministry of Health Malaysia, 2012) as 
both the x-ray results and blood calcium levels do not reflect 
the patients’ osteoporosis risk.  
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The second misconception was with the FRAX. In our study, 
the FRAX was a useful tool in improving patients’ perception of 
their osteoporotic risk. FRAX was also used in our study to 
provide additional information of the patients’ fracture risk. 
Although, the OSTA score of a 64 year old patient showed that 
she was at low risk (-0.8) for osteoporosis, she was 
recommended for a BMD scan.  This was because the patient 
reported that her parents had a previous hip fracture and was 
diagnosed as osteoporosis.  However, this patient’s BMD scan 
was not ordered as the risk of fracture based on FRAX was 
considered to be too low. The patient had an 11% probability 
of a major osteoporosis fracture and 2.2% probability for hip 
fracture. This suggest that there was a misinterpretation of 
the Malaysian osteoporosis guideline as they suggested that 
treatment should be started on osteopenic postmenopausal 
women above the age 50 years with > 20% probability of a 
major osteoporotic fracture or >3% probability of a hip 
fracture. However, this option was seen to be not cost 
effective(Ministry of Health Malaysia, 2012). There were no 
recommendations on when a patient should be referred for a 
BMD scan based on FRAX (Ministry of Health Malaysia, 2012). 
Based on the UK Osteoporosis Guideline Groups, a BMD scan 
is indicated for this patient so that the FRAX can be 
recalculated to aid the decision on whether medication is 
needed (McCloskey, 2009, Compston et al., 2014). Although, 
the threshold setting used in the UK guideline may differ from 
the Malaysian population but it serves as preliminary guide till 
a Malaysian model is developed.  
 
Another misconception noted in the area of patient risk factors 
was highlighted as a patient aged 58 years old was considered 
too young to go for a BMD scan. This patient’s OSTA score 
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was 0.4 which was categorized as low risk. The patient was 
recommended for a BMD scan due to a traumatic fracture at 
the wrist after the age 45. According to the National 
Osteoporosis Foundation (NOF) clinician’s guide to prevention 
and treatment of osteoporosis 2014 this patient could have 
been a candidate for a BMD scan as she had a previous 
fracture history as an adult and was already above the age of 
50 years (Cosman et al., 2014). However, there was 
insufficient detail in the current Malaysian guidelines.  
 
The misconception of the BMD scan being high in radiation 
was also noted as one of the patient’s BMD scan was not 
ordered for fear of being exposed to too much radiation as she 
also had a computer tomography (CT) scan appointment. Data 
has been published that a BMD scan radiation is very low and 
considered trivial (Cosman et al., 2014). Additionally, the 
benefits of conducting a BMD scan outweigh the risk of 
osteoporosis being undetected and subsequently suffering 
from fragility fractures. 
 
In addition, there was one patient whose BMD scan was not 
ordered as she had other diseases to address such as 
cardiovascular, endocrine and the eye. This shows that there 
is a lack of priority towards osteoporosis. Our qualitative 
results noted that this was one of the barriers towards 
osteoporosis screening (Toh et al., 2012). Similarly, other 
studies have found that treatment and prevention of other 
diseases was prioritized instead of osteoporosis (Otmar et al., 
2012, Jaglal et al., 2003).  
 
Conversely, there were three patients who were not 
recommended for a BMD scan but were ordered one by the 
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primary care physician, as the BMDs scans were provided free 
of charge by the research fund. Although the primary care 
physicians concerned were only making use of the opportunity 
that a BMD scan was freely available to patients during the 
study period, this act was considered unnecessary and a 
waste of funds. This indicates that there is a lack of knowledge 
among primary care physicians with regards to osteoporosis 
screening. An educational or training session could assist in 
rectifying these misconceptions among primary care 
physicians, as shown in a previous study where  student 
nurses showed an increase in osteoporosis knowledge after an 
education intervention (Zhang et al., 2012).  
 
One patient did not want to go for the BMD scan as she was 
afraid of too much radiation as she was going for an 
electrocardiogram the next month. This was a misconception 
towards the BMD scan as  a BMD scan’s radiation is very low 
and considered trivial (Cosman et al., 2014). Another 
misconception was that an electrocardiogram does not involve 
radiation, it uses electrical impulses (Sarker, 2014). Based on 
this we suggest that the counselling session should not only 
mentioned that the BMD is low in radiation, we should also 
enforce that it is safe to go for a BMD scan together with any 
other scans that the patient may require. Additionally, the 
counselling session should reinforcement that the benefits of 
conducting a BMD scan outweighs the risk of osteoporosis 
being undetected and subsequently suffering from fragility 
fractures. This also reinforced the findings and discussion from 
our qualitative study in Phase one. 
 
In our study, out of the 16 osteopenic patients reviewed by 
the primary care clinic, one of the patients was asked to stop 
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their calcium supplements as her parathyroid blood test was 
out of range. This action is appropriate as calcium 
supplements can affect parathyroid hormone levels (Riggs et 
al., 1998, Bilezikian et al., 2011). This reinforces the point 
made by the Phase one qualitative results; stakeholders 
enforced the importance of continuity of care. The importance 
of continuity of care is to ensure that the patient’s condition is 
considered as a whole which includes other co-morbidities and 
social background. Therefore, an inter-professional 
collaboration was important to ensure the patient received the 
optimal care according to each healthcare professional’s 
specialty (D'Amour et al., 2008).  
 
We would like to highlight that two osteopenic patients visited 
a private practice primary care physician and was initiated on 
2g strontium ranelate daily. One of the patients reported that 
her siblings had osteoporosis; the other patients surgically 
removed her uterus and ovaries at age 45. Therefore, based 
on the Malaysian guideline these patients were suitable 
candidate for osteoporosis treatment (Ministry of Health 
Malaysia, 2012). Similarly, this reinforces our qualitative 
findings in phase one where there was a lack of awareness of 
the Malaysian osteoporosis guidelines.  
 
Our study showed that 83.9% of the patients went for a BMD 
scan, 7.7% patients were started on osteoporosis medications, 
42.3% started on calcium supplements and 11.5% patients 
initiated lifestyle modifications This preliminary effect of our 
osteoporosis screening programme shows that our study has 
potential to improve the management of osteoporosis. Our 
results concurred with other osteoporosis screening 
programmes conducted by pharmacists which demonstrated 
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an increase in BMD scans ordered, initiation of calcium 
supplements and/or treatment (Yuksel et al., 2010, Crockett 
et al., 2008, McDonough et al., 2005, McConaha et al., 2014). 
 
The knowledge of the patients was assessed using the OPAAT.  
There were three items that did not show a significant 
difference. Item 3 (Osteoporosis occurs because bone is 
removed faster than it is formed) and item 27 (Certain 
medicines (such as sleeping tablets or high blood pressure 
medicines) may reduce the risk of falling).  These questions 
may have been too technical for the patients and was only 
briefly mentioned during the counselling session. However, 
there was still an increase in the percentage of patients 
answering these questions correctly in this study was 26.9% 
to 42.3 % (item 3) and 38.5% to 42.3% (item 27) although 
not significant. Similarly, for item 29 (Poor vision may lead to 
falls) this was briefly mentioned in the counselling. However, 
most patients already knew the answer at baseline (76.9% 
patients answering correctly at baseline), and even more 
patients answered this item correctly post intervention 
(92.3%). Nonetheless, there was a significant increase in 
knowledge for the overall scores and all domains. These 
preliminary results demonstrated that the counselling 
programme is effective.  
 
Additionally, the satisfaction score of the patients were 
89.75±12.44. This score was similar to the score achieved by 
the intervention group of the SQOP validation study. Based on 
this previous study the cut-off score was defined as 61.00 as 
the control group in this study achieved a satisfaction score of 
61.87±8.76 (Toh et al., 2014). Based on this we considered 
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patients in this study to be satisfied with the osteoporosis 
screening programme.   
 
Based on the process assessments of the osteoporosis 
screening programme, modifications were made to the data 
collection method. Initially, the nurses were asked to refer 
potential patients to the pharmacists. This method was found 
to be inefficient as the nurses had difficulty in screening for 
the patients. Therefore, the pharmacist was then used to 
screen for potential patients. This may be because nurses in 
Malaysia are not trained and have a low level of osteoporosis 
knowledge. Therefore, it was difficult for them to screen for 
potential patients. Similar results were found in a US study 
where they compared a decentralized clinical-pharmacy-based 
osteoporosis management service intervening on 
postmenopausal women following fractures, while the 
comparison group utilized a centralized registered nurses to 
manage this population. This study found that the integrated 
pharmacist-run osteoporosis management service 
demonstrated a substantial increase in the rate of 
osteoporosis drug initiation among these postmenopausal 
women who experiences a fracture compared with a centrally 
located nurse run service. However, screening rates did not 
significantly differ between groups (Heilmann et al., 2012). 
This shows that in order to include the nurses as part of the 
osteoporosis screening, a training session pertaining to 
osteoporosis screening would need to be conducted targeted 
at the nurses. 
 
4.1.6 Strengths 
The strength of this study is that the osteoporosis screening 
programme was designed specifically for this setting following 
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a qualitative study. It was then supported by the use of the 
behavioural change wheel to ensure that the underlying 
psychological reason to conducting an osteoporosis screening 
programme was addressed. Additionally the tools used such as 
the OPAAT and SQOP was specifically developed and validated 
for this intervention. The OSTA was also validated for use in 
this population.  
 
4.1.7 Limitations 
As this was a feasibility study, the sample size used was small 
and results were not generalisable. Our study was also not 
able to detect any patient diagnosed with osteoporosis. 
However, the aim of this study was not to assess the 
effectiveness of the intervention. Therefore, we achieved the 
aim of our study which was to assess the feasibility of the 
developed osteoporosis screening programme.  
 
The lack of a control group was another limitation, as changes 
in patient behaviour could have been affected by factors other 
than the intervention. In addition some results were based on 
patient self-reports and were not verified with the providers. 
Nonetheless this reflects realistic results of the daily clinical 
practice. 
 
Another potential limitation was that this study contacted 
patients via telephone to determine their satisfaction with the 
osteoporosis screening programme. Results from the 
telephone interviews may have been skewed to appear more 
favourable as the survey was not blinded. However, this 
potential bias was decreased since an independent 
postgraduate student used the SQOP to assess the patients’ 
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satisfaction; the pharmacist who performed the screening and 
education did not conduct the telephone follow-up. 
 
Additionally, although Phase two, section 4.3 found that the 
best OSTA cut-off point for this population to be ≤0, the 
feasibility study used a cut-off point of ≤-1. This is because 
there was a preference from the primary care doctors to use 
the published cut-off points of ≤-1 to screen for the patients 
as our current data is unpublished and has not been peer 
reviewed. Currently, there are plans to publish the data from 
Phase two, section 4.3. 
 
A further limitation of this study was the exclusion of men. It 
is possible that different psychological factors are related to 
the screening of osteoporosis in men, which need to be 
explore by further research. This may involve the validation of 
OSTA for men or the development of other risk assessment 
tool to screen for osteoporosis in men. 
 
4.1.8 Conclusion 
In conclusion, a pharmacist-led osteoporosis screening 
programme was demonstrated to be feasible in the Malaysian 
primary care setting. The study emphasizes that there is a 
need to conduct osteoporosis screening education sessions for 
healthcare professionals before commencing the programme. 
The results will inform the design of a larger trial that could 
provide more precise estimates of the effect of the 
osteoporosis screening programme. Further large scale studies 
need to be conducted to assess the generalisability of these 
finding towards reducing the gap in osteoporosis 
management. 
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5     CHAPTER 5: CONCLUSION 
5.1   Summary of key findings 
This study was divided into three phases applying the first two 
phases of the UK MRC framework for complex intervention as 
a theoretical guide to develop a pharmacist-led osteoporosis 
screening programme for postmenopausal women in a primary 
care clinic in Malaysia. The use of qualitative approaches in 
phase one helped to identify barriers for conducting an 
osteoporosis screening programme. Despite the need to 
address the barriers encountered for conducting the screening 
programme, the pharmacist was identified as the most 
suitable healthcare professional to conduct this programme. 
Pharmacists were seen to be knowledgeable specialist who are 
currently under utilised in the primary health care team. This 
study demonstrated that via inter-professional collaboration 
the pharmacists could expand their role to osteoporosis 
screening. Additionally, the intervention for the screening 
programme was developed based on the behavioural change 
wheel and data from the qualitative approach. 
 
In phase two, several tools were developed and validated to 
be used in Phase three to evaluate the intervention. The 
OPAAT was found to be valid and reliable to assess patients’ 
knowledge of osteoporosis; whilst the SQOP was found to be a 
valid and reliable tool to assess patients’ satisfaction towards 
the pharmacist screening programme. Additionally, six 
osteoporosis risk assessment tools were also validated among 
postmenopausal women in Malaysia. Among these tools, the 
OSTA also had the best overall specificity (36.8% and 41.0%) 
and sensitivity (83.3% and 81.3%). Additionally, the OSTA 
was found to be the most suitable tool as it was cheap, and 
 371 
 
easy to use. This tool was subsequently used in Phase three. 
The workflow for the pharmacist-led screening programme 
was developed finalized. 
 
Phase three was a feasibility study. The feasibility study 
indicated that it is feasible to deliver a pharmacist-led 
osteoporosis screening programme in the Malaysian primary 
care setting.  
 
5.2   Overall discussion 
There is a need for quality research designs and clear 
description of the process of pharmaceutical care interventions 
to evaluate the impact of the interventions (Roughead et al., 
2005). Pharmaceutical care interventions are complex 
intervention and research in this area should reveal the 
complexity of pharmacaceutical care (Tulip and Campbell, 
2001). This present study has shown that pharmaceutical care 
interventions are indeed complex as not only did it involve 
preventing and screening of osteoporosis, it involved the need 
to establish relationships with patients and interprofessional 
collaboration with pharmacists, doctors, nurses and policy 
makers. The identification of these components was made 
possible with the application of the UK MRC framework for 
complex interventions. The UK MRC frameworks emphasised 
the imporatance of conducting qualitative and feasibility 
studies to identify components of a particular intervention 
prior to developing a definitive trial (Medical Research Council, 
2008).  
 
  
Some of the findings in this study such as barriers to 
conducting an osteoporosis screening program, SQOP, OPAAT, 
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validation of risk assessment tools might be transferable to 
other healthcare settings in Malaysia. However, the 
intervention itself is tailored specifically to the current 
location. Therefore, the degree of generalisability or 
transferability to other settings could only be determined by 
the reader as it is context specific. The reader needs to decide 
on the components that are relevant to their setting based on 
the description of the setting and methodologies provided. 
Nonetheless, this study could be taken as an example for 
investigating the role of pharmacist in screening. It might be 
useful as an example for conducting different kinds of 
screening as general problems pertinent to screening may be 
similar.  
  
This study fills the gap of the lack of a satisfaction tool to 
assess patients’ satisfaction towards an osteoporosis screening 
program (the SQOP), the lack of a tool to assess patients’ 
knowledge towards osteoporosis prevention (the OPAAT) and 
the lack of a validated osteoporosis risk assessment tool by 
validating six type of tools. As these tools are validated in the 
Malaysian population they can now be used by future 
researchers or clinicians interested in this field. 
 
5.3   Strengths 
This study was developed rigorously using the UK MRC 
framework specifically targeted at the location. It identifies 
and addressed specific barriers to the setting ensuring the 
acceptability, practicalities and sustainability of the 
intervention. Additional, a feasibility study was conducted and 
has shown the program to be feasible. 
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5.4   Limitations 
Overall, the participants that we recruited in this study did not 
represent the ethnic distribution of Malaysia. The participants 
of this study were mainly Chinese ranging from 41.0-72.0% of 
the participants. However, it represented the patients who 
sought treatment in our study site.  
 
Additionally, this study did not directly involve patients during 
the development and implementation of the intervention. The 
concept of involving patients refers to, rather than using 
patients as the ‘subjects’ of research it is doing research ‘with’ 
or ‘by’ the patients. This can be done in various was such as 
having patient representative in the research group or via the 
internet. It has been found that interventions involving only 
healthcare professionals may miss perspectives of the 
patients. Patient input is needed in order to monitor the 
quality of decision making. It is important to understand what 
is important to the patients. Hence, recent intervention 
developments and implementation have involved patients 
(NHS Foundation Trust, 2006). Nonetheless, in this study the 
patients suggestions and input on the barriers were 
considered as we conducted in depth interviews with 20 
patients during phase 1.  
 
5.5   Recomendations 
It is recommended that pharmacists should play a more 
proactive role in osteoporosis management and screening. In 
summary, although the pharmacist-led osteoporosis screening 
programme has contributed towards closing the gap in 
osteoporosis screening in postmenopausal women, there 
remains room for improvement. It is recommend that a 
randomized controlled trial is required to strengthen the 
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evidence for pharmacist osteoporosis screening and to 
measure  its effectiveness in terms of clinical outcomes 
(number of fractures, number of patients who started on 
osteoporosis medications, number of patients undergoing a 
BMD scan and number of patients conducting lifestyle 
modifications) and cost effectiveness. 
 
However, based on this study there were several factors that 
may affect the sustainability of the pharmacist-led 
osteoporosis screening program. These include lack of staff, 
high workload, lack of space and lack of interprofessional 
relationship between pharmacists, nurses and doctors. In 
order to enhance and sustain the screening program, these 
issues need to be resolved.  
 
Therefore, based on the experience of conducting the 
pharmacist-led osteoporosis screening program, some of the 
recommendations include conducting the screening program 
weekly instead of daily to reduce the workload on current 
staff. This frequency of conducting the program provides the 
opportunity for patients to utilize the new service but does not 
strain the staff as it is only conducted once a week. The staffs 
are able to handle the core work and conduct the screening 
program on less hectic days. Additionally, the weekly 
osteoporosis screening program would not increase the 
number of BMD scans dramatically which may be an issue if 
the program is conducted daily as there is a lack of DEXA 
machines. Currently, pharmacist-led diabetes and asthma 
clinics are being conducted on a weekly basis. These programs 
have now been conducted for several years showing the 
sustainability of this method.  
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The second recommendation that can be made is to provide 
patient education and counselling in a dedicated  consulation 
area. As there are lack of rooms a partition can be used where 
the screening program can be conducted. It is important to 
listen, empathise, develop rapport and communicate with the 
patients. In order to do this, a certain amount of privacy is 
needed to ensure the patients feel comfortable to voice out 
their concerns. 
 
It is also suggested to enhance collaboration between 
pharmacists, physicians and nurses. For example, in the 
beginning of the feasibility study, it was difficult to get the 
doctors to cooperate as they did not understand the program 
or the role of the pharmacist. Therefore, it is important to 
conduct workshops and meetings interprofessionally to 
provide opportunites for different kind of healthcare 
professionals to understand each others’ role.  
 
 It is important to educate patients but it is also important to 
educate healthcare professionals. This study has found that 
not only there was a lack of osteoporosis knowledge in 
patients but also in healthcare professionals such as the 
doctors, pharmacists and nurses. Therefore, lectures and 
workshop targeting the areas of osteoporosis should be 
conducted more frequently.  
 
5.6   Policy implications 
As this study concluded at the feasibility of the pharmacist-led 
osteoporosis screening program, a full randomized controlled 
trial needs to be conducted to assess its effectiveness. Once 
the effectiveness of the intervention is assessed future plans 
to expand the project to other areas of Malaysia can be 
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considered with the support of policy makers. It is imperative 
to have the support of the policy makers in order for an 
intervention to make an impact on practice. Nonetheless, this 
study has established evidence that pharmacists have a role 
to play in osteoporosis screening through risk assessments, 
education and recommendations to the primary care 
physician.  
 
5.7   Healthcare professional implications 
The implication for pharmacists would be an expansion of their 
job scope and job satisfaction as they will be able to make 
recommendations to primary care physicians and be more 
involved in patients’s care. 
 
Other implications are a better interprofessional collaboration 
between healthcare professionals such as nurses, doctors and 
pharmacist. This intervention provides various opportunites for 
the healthcare professional to better understand each others’ 
respective roles and to share the responsibilities of managing 
patients’ care.  
 
5.8   Implications for patients 
Patients will benefit from this service as it provides an 
opportunity for patients to discuss their concerns about 
osteoporosis screening and prevention methods. This is also 
an opportunity for them to receive education, osteoporosis 
risk assessment and counselling. The osteoporosis risk 
assessment is beneficial for the patients as this may lead them 
to undergo a BMD scan and may prevent fragility fractures. 
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5.9   Research implications and future work 
Phase one of this study has extensively studied the barriers to 
conducting an osteoporosis screening in a primary clinic. 
However this study was conducted in urban women and did 
not consider the perspective of women leaving in more rural 
areas. Future studies, should explore the perspective of rural 
women towards conducting an osteoporosis screening 
program. 
 
In phase two, tools such as the SQOP and OPAAT were 
developed and validated in English. The English versions of 
these tools were sufficient for this study as most women who 
are postmenopausal were educated in English. However, the 
education system in Malaysia changed from English to Malay. 
Therefore a validated Malay, Mandarin and Tamil version of 
these tools would be required for future studies.  
 
Phase three, was a feasibility study of the pharmacist-led 
osteoporosis screening program. Therefore, before the RCT is 
conducted a pilot of this program should be conducted. This is 
to further assess other areas of the RCT such as the 
randomization process. 
 
As this study focuses on outpatients, future studies can be 
expanded to target inpatients such as patients who have 
already been warded for a fragility fracture and are at high 
risk of osteoporosis. Additionally, this study targeted women. 
Screening of osteoporosis should be expanded to men.  
 
5.10   Conclusion 
This study has successfully applied the UK MRC framework for 
complex intervention to develop a pharmacist-led osteoporosis 
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screening program in a primary clinic in a terriary hospital in 
Malaysia. It has laid the foundation for future work to be 
carried out in improving osteoporosis management via the 
expansion of the pharmacist role into osteoporosis screening.  
It has provided a thorough analysis of the challenges faced in 
the developmental phase prior to evaluating its effectiveness 
in a RCT.   
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APPENDICES 
5.11   Appendix 1- Baseline demographic form for 
patients 
 
  
Please circle or fill up the related sections. 
 
Appendix 1: Baseline Demographic Sheet  (Phase 1, 2, 3) Serial no    
 
Paste HIS label here: 
 
 
 
 
 
 
 
Patient Name: ___________________________________  
 
IC/RN: _____________________ 
 
Address: _________________________________________________________ 
 
_______________________________________________________________________ 
 
Tel no: (H) __________________ (HP) ___________________ (O) __________________ 
 
 
Next of kin  
 
Name:__________________________ 
 
Relationship: _____________________ 
 
Tel no: (H) __________________ (HP) ________________ (O) ___________________ 
 
 
 
 
Date of 1
st
 visit: (recruitment) _______________ 
 
Date of 1
st
 follow up: _______________ Time: _________   No of days since last visit: 
______ 
 
Date of 2
nd
 follow up: _____________ Time: _________  No of days since last visit: 
______ 
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 Baseline demographics (Phase 1, 2, 3) Serial no    
 
Section A: Patient demographics  
 
1) What language do you prefer me to 
use? 
 1Bahasa Malaysia 
 2English 
 3Chinese Specify _________________ 
 
2) Year of birth _________ 
 
 ___________ years 
3) Race 
 
 
 1Malay 
 2Chinese 
 3Indian 
 4Others ________________________ 
 
4) Marital status  1Single  
 2Married 
 3Divorced 
 4Widow/widower 
 
5) Weight  __________ kg 
 
6) Height  __________ cm 
 
7) Hip circumference______ cm/inch 
 
 
8) Are you still working? 
 1-<90cm 
 2->90cm 
 
 1-Yes, specify __________________ 
 2-No 
 
9) If no, have you worked before? 
 
 1-Yes, specify __________________ 
 2-No 
 
10) Household income per month 
 
 1<RM1000 
 2RM1000-1999 
 3RM2000-2999 
 4RM3000-3999 
 5RM4000-4999 
 6 >RM5000 
 
11) What is the highest level of 
education you have obtained? 
 1Primary 
 2Secondary 
 3Diploma / technical school training 
 4Tertiary (basic degree) 
 5Post graduate degree 
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Section B: Medical history and lifestyle  
From medical records/patient 
 
12) At what age did you start 
menstruating? 
 __________ years of age 
 
13) At what age did you reach 
menopause?  
 
 
 __________ years of age 
 
 __________ years menopausal 
 
14) How did you reach menopause?  1-Naturally 
 2-Surgical removal of the uterus & ovaries 
 3-chemotherapy / radiation 
 4-others ______________________ 
 
15) Do you think you are at risk for 
osteoporosis? 
 1-Yes  
 2-No 
 3-Maybe 
 
16) Do you have any current medical 
condition? 
 1-Yes  
 2-No 
 
17) If yes, specify: 
_________________ 
 1-Gastrointestinal disease  
 2-Heart Disease (hypertension, stroke, IHD) 
 3-Respiratory disease (asthma) 
 4-CNS (depression/migraine) 
 5-Infections (pneumonia) 
 6-Endocrine (Diabetes, Cushings) 
 7-Obstetrics & Gyn/UTI  
 8-Cancer  
 9-Nutrition & blood (anaemia) 
 10-Musculoskeletal and joint disease 
 11-Eye 
 12-ENT 
 13-Skin 
 
18) Are there any of your family 
members who have or had 
osteoporosis?  
 
 1-Yes specify_________________ 
 2-No 
 3-Don’t know 
 
19) Have you had a fracture before?  1-Yes, please specify and circle below: 
 
No of times  1 2 3 >3 
Which part  Hip/ 
Ribs/ 
Wrist/ 
Others 
Hip/ 
Ribs/ 
Wrist/ 
Others 
Hip/ 
Ribs/ 
Wrist/ 
Others 
Hip/ 
Ribs/ 
Wrist/ 
Others 
Age 45 Before 
/after 
Before
/after 
Before 
/after 
Before/
after 
 2-No  
 3-Don’t know 
 
20) Do you have rheumatoid arthritis?  
 
 1-Yes 
 2-No 
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 3-Don’t know 
 
21) Do you currently have any back 
pain or bone pain?  
 
 1-Yes 
 2-No 
 3-Don’t know 
 
22) How often do you have a drink 
containing alcohol (a glass of beer, 
wine, a mixed drink, or any kind of 
alcoholic beverage) in the last 30 
days? 
 
 1Everyday 
 2Nearly everyday  
 3Two to three times a week  
 4Occasionally  
 5Never  
 
23) How often do you have coffee or 
tea in the last 30 days? 
 1Everyday 
 2Nearly everyday  
 3Two to three times a week  
 4Occasionally  

 5Never 
 
24) Are you a _______?  1current smoker 
 2ex smoker  
 3never smoked 
 
25) How much cheese, milk or yoghurt 
do you take in a week? 
 a-cheese _________ slices 
 b-milk __________ glasses. What type of milk 
do you take?  
i) normal or skim milk  
ii) high calcium milk 
iii) both 
 c-yoghurt _______ servings 
 
26)  Are taking any thing else in your 
diet that is high in calcium 
 1-Yes specify 
 
____________________________________ 
____________________________________ 
____________________________________ 
____________________________________ 
 2-No 
 
27) Are you currently taking any 
calcium supplements? 
 1-Yes specify 
 
_________mg ____________times a day 
Type/Brand__________________________ 
____________________________________ 
____________________________________ 
 2-No 
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28) Are you currently taking any 
Vitamin D supplements? 
 1-Yes specify 
 
_________units ____________times a day 
Type/Brand__________________________ 
____________________________________ 
____________________________________ 
 2-No 
 
29) How often do you exercise in a 
week? Exercises include mopping, 
sweeping, brisk walking, jogging, 
dancing or taichi for at least 30 
minutes.  
 1-Everyday  
 2-Every other day  
 3-Twice a week  
 4-Once a week  
 5-Less than once a week  
 6-Never  
30) Are you doing any other kind of 
exercise aside from those mentioned 
above? 
 1-Yes specify 
 
____________________________________ 
____________________________________ 
____________________________________ 
____________________________________ 
 2-No 
 
31) Are you taking hormonal 
replacement therapy? 
 1Currently taking for _____ months 
 2Previously taken.  _____ months ago 
 3never tried 
 
32) Are you taking any other 
medications? This includes any 
medications obtained from outside this 
hospital, health supplements and 
traditional medicines  
 1-Yes specify 
 
____________________________________ 
____________________________________ 
____________________________________ 
____________________________________ 
 2-No 
 
33) Total no. of medications taken  
      _____________________________________ 
34) Do you do anything to prevent falls 
at home? For example, putting anti 
slip mats in the toilet and lighting up 
the stair case well? 
 
 1-Yes specify 
 
____________________________________ 
____________________________________ 
____________________________________ 
____________________________________ 
 2-No 
 
Thank you for your time 
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5.12   Appendix 2- Baseline demographic form for 
healthcare professionals (nurses, pharmacists, 
doctors) and policy makers 
Please circle or fill up the related sections. 
 
 Baseline Demographic Sheet  (Phase 1, 2) Serial no    
 
Name: ___________________________________  
 
Position: _____________________  
Department____________________________ 
 
Address: _________________________________________________________ 
 
 
Tel no: (H) __________________ (HP) ___________________ (O) __________ 
 
Date of recruitment _______________ 
 
Date of 2nd visit: _______________ Time: _________   No of days since last visit:  
Section A: Background information  
1) Year of birth _________ 
 
 ___________ years 
2) Race 
 
 
 1Malay 
 2Chinese 
 3Indian 
 4Others ________________________ 
3) Marital status  1Single  
 2Married 
 3Divorced 
 4Widow/widower 
4) What is the highest level of 
education you have obtained? 
 1- Diploma 
Name of College_________ 
 2-Tertiary (basic degree) 
Name of University__________ 
 3-Post graduate degree 
   Name of University__________ 
5) How many years have you worked?  1-< 1 year  
 2- 1- 4 years 
 3- 5-10 years 
 4- >10 years 
6) Have you worked overseas? 
 
 1-Yes, specify -hospital/community / 
clinic/ industrial sector 
 2-No 
7) Have you worked in the private 
sector?  
 1-Yes, specify -hospital/community / 
clinic/ industrial  
 2-No 
8) Have you worked in a government 
health clinic? 
 1-Yes  
 2-No 
9) Have you locum before?  1-Yes  
 2-No 
10)  Have you worked with out 
patient osteoporosis patients?  
 1-Yes  
 2-No 
11) Have you worked with in patient 
osteoporosis patients? 
 1-Yes  
 2-No 
12) Do you know any friends/family 
that has osteoporosis?  
 1-Yes  
 2-No 
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5.13   Appendix 3- Topic guide for patients 
Topic Guide- Patients 
1. Understanding of osteoporosis 
2. Feelings and attitudes towards osteoporosis 
3. Knowledge about preventive measure 
4. Feelings and attitudes towards preventive measure 
5. Knowledge of bone scans 
6. Feelings and attitudes towards bone scans 
7. Knowledge of roles of health care professionals 
8. Feelings and attitudes towards the roles of health care 
professionals in osteoporosis 
 
Topic Guide sample questions 
1. Understanding of osteoporosis 
a. Definition 
i. What are some of the health problems that 
you think post menopausal women may 
experience? 
ii. Have you heard of osteoporosis/brittle 
bones? 
iii. What do you think osteoporosis is? 
Probes: 
 Easily broken bone 
  Thinning bones 
 Weak bones 
b. Causes 
i. Why do you think osteoporosis happens? 
OR Why do you think the bones become 
weak? 
Probes: Some people think it’s: 
 calcium 
 old age 
c. Risk factors 
i. Who do you think is more susceptible to 
osteoporosis?  
ii. What makes you think so? 
iii. What other reasons/risk factors do you think 
that causes someone to get osteoporosis? 
Probes: 
  Old age 
  Calcium 
  Exercise  
 Smoking 
 419 
 
d. Symptoms/Effects 
i. How do you think someone knows they have 
osteoporosis? 
Probes 
 Pain 
 Height 
 Doctor’s diagnosis 
 
2. Feelings and attitudes towards osteoporosis 
a. Feelings about osteoporosis 
ii. Do you think that you may have 
osteoporosis? 
iii. How do you think it will affect your life if you 
had osteoporosis? 
b. Family/Friends history of osteoporosis 
i. Does anyone in your family/friends have 
osteoporosis? 
ii. What did you think of their osteoporosis? 
c. Perceptions of osteoporosis treatment 
i. Do you know what kind of treatment is 
available for osteoporosis? For example?  
ii. What do you think of the current treatment 
available? 
iii. Would you like more information on it? 
d. Sources of knowledge about osteoporosis 
i. How did you find out about osteoporosis? 
ii. How do you find this information? Did it 
help? 
iii. Would you like more information on 
osteoporosis? What? 
iv. Where would you go to find more 
information about this? 
v. Where do you think should provide this kind 
of information? 
 Probes: Pharmacist, hospitals. 
 
3. Knowledge about preventive measure 
a. Types of preventive measure 
i. What are the possible ways to prevent 
osteoporosis? 
Probes: 
  Lifestyle changes  
 Calcium Intake/ Diet/ 
Supplements 
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- From where do you think 
you get your calcium? 
- How much 
supplements/calcium rich 
food do you take? 
- When did you begin 
changing your diet/taking 
supplements? 
- Was there a particular 
reason? How did you 
begin? 
- So this is included in your 
daily routine?  
- Do you find it 
inconvenient or is it no 
trouble at all? 
 Exercise, Types 
- What type of exercise do 
you do? 
- How often? Once a week? 
For how many minutes? 
- Do you find it 
inconvenient or is it no 
trouble at all? 
 Quit Smoking and Alcohol 
- How often? 
- When did you start?  
- When did you stop? What 
made you stop? 
 Medication 
 Did you know that there are also 
medications for osteoporosis 
prevention? 
 What do you think of taking 
medication to prevent 
osteoporosis? 
  Fall prevention/ Well lit stairs/ No 
clutter/ Anti slipping mats 
 How did you fall prove your 
house? 
 Do you think it has an effect? 
b. Sources of osteoporosis preventive knowledge 
i. How did you find out about osteoporosis 
prevention? 
ii. How did you find the information? Did it 
help? 
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iii. Would you like more information on 
osteoporosis prevention? What? 
iv. Where would you go to find more 
information about this? 
v. Where do you think should provide this kind 
of information? 
 Probes: Pharmacist, hospitals. 
 
4. Feelings and attitudes towards preventive 
measure 
a. Experiences and Capability of taking preventive 
measure 
i. Do you take any preventive measures? What 
kind? 
ii. What influence you to take these measures? 
iii. How do you think these preventive 
measures have affected your life so far? 
(barriers/benefits) Has it caused any change 
in your life? 
iv. What are the reasons for taking/not taking 
these measures? 
v. What do you think you can do to prevent 
osteoporosis at this point? (What else do you 
think you can try?) 
Probe:  
 Calcium 
 Exercise 
 Weight  
 Get a check up (screening) 
vi. Do you know anyone else who have taken 
these measures? What did he/she do?  
vii. Would you ask your friends/family to take 
osteoporosis preventive measures? Which 
type and why? 
 
5. Knowledge of bone scans 
a. Do you know how osteoporosis is diagnosed? 
b. Bone scan Procedure 
i. What do you think having a bone scan 
involves? 
ii. What do you think about the radiation 
involved in the bone scan? 
c. Usefulness of Bone Scan 
i. How do you think it identifies someone as 
being osteoporosis?  
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6. Feelings and attitudes towards bone scans 
a. Feeling about undergoing a bone scan 
i. What is the first thing that comes to your 
mind if I told you that you had to go for a 
bone scan tomorrow? 
ii. How do you feel about knowing your risk 
status (including comparison with other 
illnesses) 
iii. Why would you want to know/ not know? 
iv. How do you think it will affect you after 
knowing your osteoporosis risk status? 
(feelings/actions) 
Probes: 
 See a doctor 
 Take preventive methods 
 Scared 
 
7. Knowledge of roles of health care professionals 
a. Programmes available 
i. Has your doctor/ pharmacist ever mentioned 
anything about osteoporosis? What was 
discussed? 
ii. Have you heard about any kind of 
osteoporosis seminar, risk assessment 
(screening) programme about osteoporosis? 
 Yes- Did you attend? Were they 
helpful? How? 
 No- Would you like them to be 
available? What sort? 
iii. Would you attend an osteoporosis screening 
programme if there was one? What makes 
you say that? 
iv. What do you think the screening programme 
should be like? 
v. Where do you think this programme should 
be available? 
 
8. Feelings and attitudes towards the roles of health 
care professionals in osteoporosis 
a. Expectations 
i. What do you think you need from the 
healthcare providers (pharmacist, nurses, 
doctor) for prevention of osteoporosis? 
Probe: 
 More consultation time 
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 Counseling sessions 
 Empathy 
ii.  Who would you go to for more information? 
Why? 
iii. What do you think of the current services 
available with regards to osteoporosis 
prevention?  
 Attitude/Caring 
 Enough information 
iv. Is there anything you would like to 
change/improve with regards to the current 
osteoporosis prevention healthcare services? 
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5.14   Appendix 4- Topic guide for healthcare 
professionals (nurses, pharmacists, doctors) 
Topic Guide- Pharmacist, Doctor, Nurses. 
1. Understanding of osteoporosis 
2. Feelings and attitudes towards osteoporosis 
3. Knowledge and experience towards preventive measure 
4. Knowledge of bone scans 
5. Feelings and attitudes towards bone scans 
6. Knowledge of roles of health care professionals 
7. Feelings and attitudes towards the roles of health care 
professionals in osteoporosis 
 
Topic Guide sample questions 
1. Understanding of osteoporosis 
a. Definition 
i. What are some of the health problems that 
you think post menopausal women may 
experience? 
ii. What do you think of osteoporosis impact to 
society?? 
 Serious or small impact 
iii. What do you think osteoporosis is? 
Probes: 
 Easily broken bone 
  Thinning bones 
 Weak bones 
 
2. Feelings and attitudes towards osteoporosis 
a. Feelings about osteoporosis 
i. Do you think that you may have patients 
who have undetected osteoporosis? 
iv. Do you think this should be addressed? 
 Priority 
v.  How do you think this should be tackled? 
What do you think you can do to detect 
osteoporosis?  
vi. What do you think is the role of the 
doctors/nurses/pharmacists in osteoporosis 
prevention? 
b. Experience with osteoporosis 
i. Have you had any experience with 
osteoporosis patients here? What did you 
have to do? 
Probes 
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 Osteoporosis treatment 
 Osteoporosis prevention 
 Counseling  
ii. How do you find your involvement in their 
treatment/prevention?  
Probes 
 Helpful 
 Sufficient 
 Could have done more? 
iii. What do you think patients think of 
osteoporosis? 
c. Perceptions of osteoporosis treatment? 
i. Do you know what kind of treatment is 
available for osteoporosis? For example?  
ii. What do you think of the current treatment 
available? 
iii. Would you like more types of medication to 
be available? 
iv. What do the patients think about the 
medications available? 
 
3. Knowledge and Experience towards preventive 
measure 
a. Types of preventive measure 
i. What are the possible ways to prevent 
osteoporosis? 
Probes  What do you think of…… and 
osteoporosis? 
 Lifestyle changes  
 Calcium Intake/ Diet/ 
Supplements 
- From where do you think 
patients can get their 
calcium intake? 
- Have you met any patients 
taking calcium 
supplements? (Was it for 
osteoporosis?) 
- How much/type do they 
normally take? 
- What do you think 
normally causes them to 
change their diet/taking 
supplements? 
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- Is this included in their 
daily routine? 
- How do you think it is like 
for them to include them 
in their daily routine?  
- Is it inconvenient for the 
patients or is it no trouble 
at all? 
- How do you find the effect 
of the calcium 
supplements? 
- How do you think the 
patients feel about taking 
calcium supplements?  
 Convenient? 
Effective? 
 Exercise, Types 
- What type of exercise do 
you think can help? 
- How often? Once a week? 
For how many minutes? 
- Have you known any 
patients who did any of 
these exercises? How did 
they find it? 
- How do you find the effect 
of the exercises? 
 Quit Smoking and Alcohol 
- Do you think smoking and 
alcohol has a role in 
osteoporosis? What makes 
you say so? 
- Is this a common scenario 
here?  
- Do you think that most 
people are aware that 
these may increase their 
risk of osteoporosis? What 
makes you think that? 
 Medication 
- Did you know that there 
are also medications for 
osteoporosis prevention? 
- What do you think of 
taking medication to 
prevent osteoporosis? 
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- How do you think patient’s 
perceived taking 
medications for 
osteoporosis 
 Fall prevention/ Well lit stairs/ 
No clutter/ Anti slipping mats 
- Have you heard of fall 
prevention to prevent 
fractures due to 
osteoporosis? What do you 
think of it? 
- How would you advice 
someone to fall proof their 
house? 
- Do you think it has an 
effect? 
ii. Do you think patients are aware of these 
available measures? 
b. Sources of osteoporosis preventive knowledge 
i. How did you find out about osteoporosis 
prevention? 
ii. How did you find the information? Did it 
help? 
iii. Would you like more information on 
osteoporosis prevention? What? 
iv. How much information do you think patients 
should receive? What kind? What form? 
v. Where would you go to find more 
information about this? 
vi. Where do you think should provide this kind 
of information? 
 Probes: Pharmacist, hospitals. 
 
4. Knowledge of bone scans 
a. How do you think osteoporosis is diagnosed? 
b. Bone scan Procedure 
i. What does a bone scan involve? 
ii. What do you think about the radiation 
involved in the bone scan? 
iii. What do you think of the current referral 
system?  
Probes 
 Smooth, target population 
 Criteria for referral 
 Clear guideline 
c. Usefulness of Bone Scan 
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i. What do you think of the current bone scan 
facility and its availability? 
Probes 
 Waiting time 
 Cost 
 Number of machines (Availability) 
ii. Do you think there should be a prior risk 
assessment for osteoporosis using a simpler 
and cheaper tool before actually conducting 
the bone scan? What makes you say that?  
iii. Do you think the patient’s are willing to pay 
and wait for a bone scan? 
Probes 
 Long waiting time 
 Accessibility and affordability 
 Acceptability  
 
5. Feelings and attitudes towards bone scans 
a. Feeling about bone scan referral 
i. Have you ever referred patients for a bone 
scan? What would make you do so? 
ii. Do you think pharmacist/nurses should be 
able to make a BMD referral or prescribe 
osteoporosis medications? 
b. Osteoporosis Risk status (including comparison 
with other illnesses) 
i. What are your thoughts on knowing the 
patient’s osteoporosis risk factors as 
compared to other diseases like diabetes? 
What makes you say that? (HCP and 
patients) 
ii. What do you think are the opinions of 
patients to knowing their risk status 
 
6. Knowledge of roles of health care professionals 
a. Programmes available 
i. Have you heard of any kind of osteoporosis 
screening/risk assessment programme?  
Probes 
 How was it like? What did you think of 
it? 
  Who organized it (By doctors? 
Pharmacist? Nurses?) 
 Where: Location: pharmacy? 
Hospitals? 
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ii. Have you heard about any kind of 
osteoporosis seminar? 
Probes 
 Yes- Did you attend? Were they 
helpful? How? 
 No- Would you like them to be 
available? What sort? 
iii. Would you assist in an osteoporosis 
screening programme if there was one? 
What makes you say that? 
iv. How do you think the screening programme 
should be like? 
Probes 
 By whom 
 How much (Cost) 
 How should it be done? 
 What should be done? 
 Where 
v. What benefits do you see from a screening 
programme? 
vi. What barriers do you see from a screening 
programme? 
vii. How do you think patients will response to 
this programme? 
viii. How do you think healthcare professionals 
will response to this programme 
 
7. Feelings and attitudes towards the roles of health 
care professionals in osteoporosis 
a. Expectations 
i. What do you think healthcare providers 
(pharmacist, nurses, doctor) can do for 
osteoporosis prevention care (treatment)? 
Probes: 
 More consultation time 
 Counseling sessions, Empathy 
ii. What do you think of the current services 
available with regards to osteoporosis 
prevention? How about treatment? 
Probes 
 Attitude, Information 
iii. Is there anything you would like to 
change/improve with regards to the current 
osteoporosis prevention healthcare services? 
(or treatment)  
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5.15   Appendix 5- Topic guide for policy makers 
Topic Guide- Policy makers 
1. Osteoporosis in general 
2. Feelings and attitudes towards osteoporosis 
3. Perception of Bone Scans and Medication usage 
system. 
4. Perception of Osteoporosis prevention and screening 
programmes 
5. Pharmacist role in osteoporosis prevention and 
screening 
 
Topic Guide sample questions 
 1.Osteoporosis in general 
What is the impact of osteoporosis on society? 
Probes: 
- QOL 
- Cost 
 
 2.Feelings and attitudes towards osteoporosis 
 Feelings about osteoporosis 
 What is the first thing that comes to your 
mind when I mention osteoporosis? 
 
 3. Perception of Bone Scans and Medication usage    
     system. 
a. Usefulness of Bone Scan 
i. What is the role of the BMD in 
osteoporosis? 
Probes: 
- Diagnosis, gold standard 
ii. What do you think of having a prior risk 
assessment tool? What makes you say 
that? 
b. Bone scan and Medication procedure 
 What do you think of the current process for 
the patient to get a referral for the BMD? 
Probes: 
- Smooth 
- Target a wide enough population 
- Criteria for referral 
- Clear guideline 
 What do you think of the accessibility of the 
current bone scan facility? 
Probes: 
- Any idea, how often does the machine 
break down? 
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- What are the alternatives for patients 
when the machine is down?  
- Waiting time 
 What do you think of the affordability of the 
current bone scan? 
Probes: 
- Cost 
- Number of machines 
 How do you think patients perceive the bone   
 scan facility?  
Probes: 
- Long waiting time 
- Accessibility and affordability 
- Acceptability 
 Medication 
 - What do you think about the usage of 
osteoporosis medication in this hospital? 
 Probes: Under or over used? 
 -What do you think of the Prescribing 
restriction enforced on the osteoporosis 
medication? 
Probes: Previous interviews with doctors, 
some suggested to make the prescribing 
restrictions more flexible to may be lighten 
workload or for patients convenience. What 
do you think of this? 
 -Why was it enforced to begin with? 
 
 4.Perception of Osteoporosis prevention and  
 screening programmes   
a. Future of an osteoporosis prevention programme 
 What do you think of the current services 
available with regards to osteoporosis 
prevention and screening? 
 What do you think about the detection of 
osteoporosis in this hospital? 
Probes: 
- Priority? 
 What do you think are the reasons for this 
to occur? 
 Do you think this need to be changed?  
 How do you think this should be tackled? 
- What would be the solutions?  
 -Are you aware of the National 
Osteoporosis Foundation (NOF) 
guideline/recommendation for the 
screening of osteoporosis? 
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Probes: 
- >60 age women all need screening 
 What do you think the hospital can do to 
increase osteoporosis prevention and 
screening awareness? 
Probes: 
- Provide Lifestyle education 
- Screening programmes 
 -Would you support conducting an 
osteoporosis screening and prevention 
programme if there was one? What makes 
you say that? Why? 
- Is it a necessity? 
 How do you think the programme should be  
 like? 
- By whom 
- How much 
- What should be done 
- Where 
 -How do you think patients will response to  
 this programme? 
 -How do you think healthcare professionals 
will response to this programme? 
 -What benefits do you see from a screening 
programme? 
Probes: 
- More undetected patients identifies 
- Better patient outcome 
- Less fractures 
 
b. Resources  
 Do you think it is sustainable? 
 What barriers do you see in conducting this 
programme? 
Probes: 
- Enthusiasm will fade 
- Lack of space and time 
 How do you think the budget will affect this 
programme? 
Probes: 
- Management of fund 
- Staff commitment 
 Normally what is the priority when 
allocating money from the budget? 
 Do you see the possibility of allocating 
more money for osteoporosis 
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screening/prevention/ medication purchase/ 
BMD subsidy? 
 -Are there enough staff to implement a new 
screening programme? Reasons 
 -Is the Ministry of Higher Education 
(MOHE) supportive of such programmes? 
What makes you say that? 
 -What else do you think is needed to be 
able to conduct an osteoporosis screening 
programme? 
 
c. Programmes available 
 Have you heard of any kind of osteoporosis 
screening and prevention programme 
conducted outside of this hospital? How 
was it like? What did you think of it? 
Probes: 
- By doctors? Pharmacist? Nurses? 
- Location: pharmacy? Hospitals? 
 Where do you think should the disease focus  
 of the health care be? 
 Diseases 
 Prevention/ Treatment  
 
 5.Pharmacist role in osteoporosis prevention 
and screening 
 How do you perceive the pharmacist role in 
the osteoporosis care? 
Probe: 
- Is there a role for the pharmacist in 
screening and prevention of 
osteoporosis? 
 Is there anything else you would like to 
change/improve with regards to the 
current osteoporosis healthcare services? 
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5.16   Appendix 6- Topic guide for patients, Malay 
version 
Panduan topik - Pesakit 
1. Pemahaman tentang osteoporosis  
2. Perasaan dan sikap terhadap osteoporosis 
3. Pengetahuan mengenai langkah pencegahan 
4. Perasaan dan sikap terhadap langkah pencegahan 
5. Pengetahuan tentang imbasan tulang 
6. Perasaan dan sikap terhadap imbasan tulang 
7. Pengetahuan mengenai peranan pegawai kesihatan 
8. Perasaan dan sikap terhadap peranan pegawai kesihatan 
tentang osteoporosis  
 
Contoh-contoh soalan untuk panduan topik  
1. Pemahaman tentang osteoporosis 
a. Definisi 
i. Pada pendapat anda, apakah masalah 
kesihatan yang mungkin dialami wanita 
selepas menopaus? 
ii. Pernahkah anda dengar tentang osteoporosis 
/ tulang rapuh? 
iii. Pada pendapat anda, apakah itu osteoporosis? 
Probe: 
 Tulang rapuh 
 Penipisan tulang 
 Tulang lemah 
b. Punca-punca 
i.  Pada pendapat anda mengapakah 
osteoporosis berlaku? 
ATAU Mengapa tulang menjadi lemah? 
Probe: Sesetengah orang berpendapat 
bahawa ia disebabkan oleh: 
 Kalsium 
 Usia tua 
c. Faktor-faktor risiko 
i. Siapakah yang lebih terdedah kepada 
osteoporosis? 
ii. Apakah sebab anda berpendapat sedemikian? 
iii. Pada pendapat anda, apakah sebab lain/ 
faktor risiko yang boleh menyebabkan 
seseorang itu mendapat osteoporosis? 
probe: 
 Usia tua 
 Kalsium 
 Senaman 
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 Merokok 
d. Gejala / Kesan 
i. Pada pendapat anda, bagaimanakah 
seseorang akan tahu bahawa mereka 
mengalami osteoporosis? 
Probe: 
 Sakit 
 Ketinggian  
 Diagnosis Doktor 
 
2. Perasaan dan sikap terhadap osteoporosis 
a. Perasaan mengenai osteoporosis 
i.  Pernahkan anda berfikir bahawa anda 
mungkin mengalami osteoporosis? 
ii. Pada pendapat anda, bagaimanakah kesan 
terhadap gaya hidup anda jika anda 
menghidap osteoporosis?   
b. Keluarga / Kawan sejarah osteoporosis 
i. Adakah ada di antara ahli keluarga / rakan-
rakan anda yang menghidap osteoporosis? 
ii. Apakah pendapat anda tentang osteoporosis 
mereka? 
c.  Persepsi rawatan osteoporosis 
i. Adakah anda tahu jenis rawatan yang 
disediakan untuk osteoporosis? Contohnya? 
ii. Apakah pendapat anda  tentang rawatan yang 
sedia ada? 
iii. Adakah anda ingin maklumat lanjut 
mengenainya? 
d. Sumber pengetahuan mengenai osteoporosis 
i. Bagaimanakah anda mendapat tahu tentang 
osteoporosis? 
ii. Apakah pendapat anda tentang maklumat ini? 
Adakah ia membantu? 
iii. Adakah anda inginkan maklumat lanjut 
tentang osteoporosis? Maklumat apa yang 
diperlukan? 
iv. Dimanakah anda akan pergi untuk 
mendapatkan maklumat lebih lanjut mengenai 
perkara ini? 
v. Dimanakah tempat yang sepatutnya 
menyediakan maklumat tentang penyakit ini? 
 probe: Pegawai Farmasi, hospital. 
 
 
 
3. Pengetahuan mengenai langkah pencegahan 
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a. Jenis-jenis langkah pencegahan 
i. Pada pendapat anda, apakah cara-cara untuk 
mencegah osteoporosis? 
Probe: 
 Perubahan Gaya Hidup 
 Pengambilan Kalsium / 
Pemakanan / Vitamin 
- Pada pendapat anda, dari 
manakah anda mendapatkan 
kalsium anda? 
- Berapa banyak 
vitamin/makanan berkalsium 
yang anda ambil? 
- Bilakah anda mula mengubah 
cara pemakanan anda / 
mengambil vitamin? 
- Adakah terdapatnya sebab 
tertentu? Bagaimana anda 
bermula? 
- Oleh itu, ini dimasukkan 
dalam rutin harian anda? 
- Adakah ia susah atau ia tidak 
langsung menimbulkan 
masalah bagi anda? 
 Senaman, Jenis 
- Apakah jenis senaman yang 
anda lakukan? 
- Berapa kerap? Sekali 
seminggu? Berapa minit? 
- Adakah is susah atau senang 
untuk dilakukan? 
 Berhenti Merokok dan Alkohol 
- Berapa kerap? 
- Bilakah anda bermula? 
- Bilakah anda berhenti? Apa 
yang menyebabkan anda 
berhenti? 
 Ubat  
- Adakah anda tahu bahawa 
terdapatnya ubat untuk  
pencegahan osteoporosis? 
- Apakah pendapat anda 
mengenai pengambilan ubat 
untuk mencegah 
osteoporosis? 
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 Mencegah jatuh / tangga yang 
terang / Tiada kekacauan / tikar 
anti gelincir 
- Bagaimana anda mencegah 
kejatuhan dalam rumah 
anda? 
- Adakah ia berkesan? 
b.  Sumber pengetahuan cara pencegahan 
osteoporosis 
i.  Bagaimana anda mendapat tahu tentang cara 
pencegahan osteoporosis? 
ii. Apakah pendapat anda terhadap maklumat 
ini? Adakah ia membantu? 
iii. Adakah anda inginkan maklumat lanjut 
mengenai pencegahan osteoporosis? Apakah 
jenis maklumat yang diperlukan? 
iv. Dimanakah anda akan pergi untuk 
mendapatkan maklumat lebih lanjut mengenai 
perkara ini? 
v. Dimanakah tempat yang sepatutnya 
menyediakan maklumat perkara ini? 
probes: pengawai farmasi, hospital 
 
4.  Perasaan dan sikap terhadap langkah pencegahan 
a. Pengalaman dan Keupayaan mengambil langkah 
pencegahan 
i. Adakah anda mengambil mana-mana 
langkah-langkah pencegahan? Jenis apa? 
ii. Apakah yang mempengaruhi anda untuk 
mengambil langkah-langkah ini? 
iii. Bagaimanakah langkah-langkah pencegahan 
ini telah memberi kesan dalam kehidupan 
anda setakat ini? (Halangan / faedah) Adakah 
ia menyebabkan apa-apa perubahan dalam 
hidup anda? 
iv. Apakah sebab-sebab untuk mengambil / tidak 
mengambil langkah-langkah ini? 
v. Pada pendapat anda, apakah yang anda boleh 
lakukan untuk mencegah osteoporosis pada 
ketika ini? (Apakah perkara lain yang anda 
rasa anda boleh cuba?) 
Probe: 
 Kalsium 
 Senaman 
 Berat badan 
 Dapatkan Pemeriksaan (Penyaringan) 
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vi. Adakah anda tahu sesiapa yang telah 
mengambil langkah-langkah pencegahan ini? 
Apakah yang beliau lakukan? 
vii. Adakah anda akan meminta rakan/keluarga 
anda untuk mengambil langkah-langkah 
pencegahan osteoporosis? Jenis apa dan 
mengapa? 
 
5.  Pengetahuan tentang imbasan tulang 
a. Adakah anda tahu bagaimanakah seseorang 
disahkan mengalami osteoporosis?  
b. Prosedur Tulang imbasan  
i. Pada pendapat anda, apa yang terlibat dalam 
imbasan tulang ? 
ii. Apakah pendapat anda tentang radiasi yang 
terlibat dalam imbasan tulang? 
c.  Kegunaan/Imbasan Tulang 
i. Pada pendapat anda, bagaimanakah imbasan 
tulang mengenal pasti seseorang sebagai 
mangalami osteoporosis? 
 
6.  Perasaan dan sikap terhadap imbasan tulang 
a. Perasaan tentang menjalani imbasan tulang 
i. Apakah perkara pertama yang berada di 
fikiran anda jika saya memberitahu bahawa 
anda perlu menjalani imbasan tulang esok? 
ii. Bagaimanakah perasaan anda untuk 
mengetahui tentang status risiko anda 
(termasuk perbandingan dengan penyakit-
penyakit lain) 
iii. Mengapa anda ingin tahu / tidak ingin 
mengetahui? 
iv. Bagaimanakah anda fikir ia memberi kesan 
kepada anda selepas mengetahui status risiko 
osteoporosis anda? (Perasaan/tindakan) 
Probe: 
 Berjumpa Doktor 
 Mengambil kaedah pencegahan 
 Takut 
 
7. Pengetahuan mengenai peranan pegawai 
kesihatan 
a. Programme yang disediakan 
i. Adakah doktor / ahli farmasi anda pernah 
menyebut tentang osteoporosis? Apa yang 
dibincangkan? 
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ii. Adakah anda pernah mendengar tentang apa-
apa jenis osteoporosis seminar, programme 
penilaian risiko (penyaringan) osteoporosis? 
 Ya-Adakah anda menyertainya? 
Adakah ia membantu? Bagaimana? 
 Tiada-Adakah anda ingin mereka 
mengadakan seminar atau programme 
penilaian tersebut? Jenis manakah? 
iii. Adakah anda akan menghadiri programme 
penyaringanosteoporosis jika terdapat satu? 
Apakah yang membuat anda mengatakan 
sedemikian? 
iv. Pada pendapat anda, bagaimanakah 
programme penyaringan itu harus dijalankan?  
v. Pada pendapat anda, dimanakah programme 
tersebut harus disediakan? 
 
8. Perasaan dan sikap terhadap peranan pegawai 
kesihatan tentang osteoporosis  
a. Jangkaan 
i. Pada pendapat anda, apakah yang anda perlu 
daripada pegawai-pegawai kesihatan 
(pengawai farmasi, jururawat dan doktor) 
untuk mencegah osteoporosis?   
Probe: 
 Masa perundingan yang lebih lama 
 Sesi Kaunseling 
 Belas Kasihan 
ii. Siapakah yang anda akan cari untuk 
mendapatkan maklumat lanjut? Mengapa? 
iii. Apakah pendapat anda tentang perkhidmatan 
pencegahan osteoporosis kini?  Dari segi 
 Sikap 
 Maklumat 
iv. Adakah terdapat perkara yang ingin anda 
ubah / perbaiki berhubung dengan 
perkhidmatan pencegahan  osteoporosis yang 
dijalankan sekarang? 
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5.17   Appendix 7- Topic guide for healthcare 
professionals (nurses, pharmacists, doctors), 
Malay version 
 Topik Panduan- Doktor, Pegawai Farmasi, Jururawat 
1. Pemahaman tentang osteoporosis  
2. Perasaan dan sikap terhadap osteoporosis 
3. Pengetahuan dan pengalaman mengenai langkah 
pencegahan 
4. Pengetahuan tentang imbasan tulang 
5. Perasaan dan sikap terhadap imbasan tulang 
6. Pengetahuan mengenai peranan pegawai kesihatan 
7. Perasaan dan sikap terhadap peranan pegawai kesihatan 
tentang osteoporosis  
 
Soalan sampel Panduan topik  
1. Pemahaman tentang osteoporosis 
a. Definisi 
i. Pada pendapat anda, apakah masalah 
kesihatan yang mungkin dialami oleh wanita 
menopaus? 
ii. Pada pendapat anda apakah kesan 
osteoporosis kepada masyarakat? 
 Impak yang serius atau kecil 
iii.  Pada pendapat anda apakah itu osteoporosis? 
Probe: 
Probes 
 Tulang rapuh 
 Penipisan tulang 
 Tulang lemah 
 
2. Perasaan dan sikap terhadap osteoporosis 
a. Perasaan mengenai osteoporosis 
i. Pernahkan anda terfikir bahawa anda 
mungkin mempunyai pesakit yang mengalami 
osteoporosis tetapi tidak dapat dikesan? 
ii. Adakah anda berfikir ini perlu ditangani? 
 Keutamaan 
iii. Bagaimanakah perkara ini boleh ditangani? 
Pada pendapat anda apakah yang anda boleh 
lakukan untuk mengesan osteoporosis? 
iv. Pada pendapat anda, apakah peranan doktor/ 
pegawai farmasi/ jururawat dalam 
pencegahan osteoporosis? 
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b. Pengalaman dengan osteoporosis 
i. Adakah anda mempunyai sebarang 
pengalaman dengan pesakit osteoporosis di 
sini? Apa yang anda perlu lakukan? 
probe 
Probes 
 Rawatan Osteoporosis 
 Pencegahan osteoporosis 
 Kaunseling 
ii. Pada pendapat anda, bagaimanakah 
penglibatan anda dalam rawatan / 
pencegahan mereka? 
Probe 
Probes 
 Membantu 
 Mencukupi 
  Boleh melakukannya dengan lebih? 
iii. Pada pendapat anda apkah pendapat pesakit 
terhadap osteoporosis?  
c.  Persepsi rawatan osteoporosis 
i. Adakah anda tahu jenis rawatan yang 
disediakan untuk osteoporosis? Contohnya? 
ii. Apakah pendapat anda  tentang rawatan yang 
sedia ada? 
iii. Adakah anda ingin menambahkan jenis ubat 
yang kini ada? 
iv. Pada pendapat anda apakah pendapat pesakit 
tentang jenis ubat yang sedia ada? 
 
3. Pengetahuan dan pengalaman mengenai langkah 
pencegahan 
a. Jenis-jenis langkah pencegahan 
i. Pada pendapat anda, apakah cara-cara untuk 
mencegah osteoporosis? 
Probes: Apakah pendapat anda tentang..... .. 
dan osteoporosis? 
 Perubahan Gaya Hidup 
 Pengambilan Kalsium / 
Pemakanan / Vitamin 
- Pada pendapat anda, dari 
manakah pesakit 
mendapatkan kalsium 
mereka? 
- Pernahkan anda berjumpa 
dengan pesakit yang 
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mengambil vitamin kalsium? 
(Adakah untuk osteoporosis?) 
- Berapa banyak/jenis kalsium 
yang mereka ambil? 
- Pada pendapat anda apakah 
yang menyebabkan mereka 
mengubah cara pemakanan / 
mengambil vitamin? 
- Adakah, ini dimasukkan 
dalam rutin harian mereka?  
- Adakah ia sukar ataupun 
normal untuk menambah ini 
di dalam rutin harian mereka? 
- Adakah mereka berasa 
kurang selesa atau ia tidak 
langsung menimbulkan 
masalah? 
- Pada pendapat anda, adakah 
pengambilan kalsium ini 
berkesan? 
- Pada pendapat anda, apakah 
perasaan pesakit tentang 
pengambilan kalsium 
- Senang? Berkesan 
ke? 
 Senaman, Jenis 
- Apakah jenis senaman yang 
boleh membantu? 
- Seberapa kerap? Sekali 
seminggu? Berapa minit? 
- Adakah anda berjumpa 
dengan pesakit yang 
bersenam seperti yang 
dinyatakan? Apakah perasaan 
mereka? 
- Pada pendapat anda, apakah 
kesan yang diperolehi dari 
bersenam? 
 Berhenti Merokok dan Alkohol 
- Pada pendapat anda adakah 
merokok dan alkohol 
memainkan peranan dalam 
osteoporosis? Mengapa anda 
berpendapat demikian? 
- Adakah merokok dan minum 
alkohol adalah perkara biasa 
di sini?  
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- Adakah pesakit tahu bahawa 
merokok dan meminum arak 
boleh meningkatkan risiko 
osteoporosis? Mengapakah 
anda berpendapat 
sedemikian? 
 Ubat  
- Adakah anda tahu bahawa 
terdapatnya ubat untuk  
pencegahan osteoporosis? 
- Apakah pendapat anda 
mengenai pengambilan ubat 
untuk mencegah 
osteoporosis? 
- Pada pendapat anda apakah 
persepsi pesakit tentang 
pengambilan ubat untuk 
pencegahan osteoporosis?  
 Mencegah jatuh / tangga yang 
terang / Tiada kekacauan / tikar 
anti gelincir 
- Penahkan anda mendengar 
tentang pencegahan jatuh 
untuk mengelakkan tulang 
patah kerana ostoporosis? 
Apakah pendapat anda 
tentang cara ini? 
- Bagaimanakah anda akan 
menasihati pesakit untuk 
mencegah kejatuhan? 
- Adakah ia berkesan? 
ii. Pada pendapat anda adakah pesakit tahu 
tentang cara- cara pencegahan osteoporosis? 
b.  Sumber pengetahuan cara pencegahan 
osteoporosis 
i.  Bagaimana anda mendapat tahu tentang cara 
pencegahan osteoporosis? 
ii. Apakah pendapat anda tentang maklumat ini? 
Adakah ia membantu? 
iii. Adakah anda inginkan maklumat lanjut 
mengenai pencegahan osteoporosis? Apakah 
jenis maklumat yang diperlukan? 
iv. Pada pendapat anda berapa banyak maklumat 
yang diperlukan oleh pesakit? Jenis apakah?  
v. Dimanakah anda mendapatkan maklumat 
lebih lanjut mengenai perkara ini? 
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vi. Dimanakah tempat yang sepatutnya 
mempunyai maklumat tentang penyakit ini? 
 Probes: Pegawai farmasi, hospital 
 
4. Pengetahuan imbasan tulang 
a. Pada pendapat anda bagaimanakah osteoporosis 
dikenal pastikan? 
b. Prosedur Tulang imbasan  
i. Pada pendapat anda, apakah yang terlibat 
dalam imbasan tulang ? 
ii. Apa pendapat anda tentang radiasi yang 
terlibat dalam imbasan tulang? 
iii. Apakah pendapat anda terhadap sistem 
rujukan untuk imbasan tulang di hospital ini? 
Probes 
 Lancar, populasi yang di tuju 
 Kriteria rujukan 
 Garis panduan yang senang difahami 
c.  Kepentingan/Kegunaan imbasan Tulang 
i. Bagaimanakah imbasan tulang mengenal 
pasti seseorang sebagai mangalami 
osteoporosis? 
ii. Bagaimanakah imbasan tulang dapat 
meramalkan risiko osteoporosis?  
iii. Apa yang anda fikir tentang kemudahan 
imbasan tulang kini dan keberadaannya? 
Probes 
 Masa menunggu 
 Kos 
 Bilangan mesin (Keberadaan) 
iv. Adakah perlunya untuk mengunakan alat 
yang lebih mudah dan murah untuk 
mengenalpasti risiko osteoporosis terlebih 
dahulu sebelum menggunakan imbasan 
tulang? Mengapa anda berpendapat 
sedemikian?  
v. Pada pendapat anda, adakah pesakit sanggup 
membayar dan menunggu untuk imbasan 
tulang? 
probe 
Probes 
 Waktu masa menunggu 
 Kebolehcapaian (kemudahan untuk 
pergi) dan kemampuan (harga) 
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 Penerimaan untuk menjalankan 
imbasan 
 
5. Perasaan dan sikap terhadap imbasan tulang 
a. Perasaan tentang menjalani imbasan tulang 
i. Adakah anda pernah merujuk pesakit untuk 
menjalankan imbasan tulang? Apakah yang 
akan menyebabkan anda berbuat demikian? 
ii. Pada pendapat anda adakah 
jururawat/pegawai farmasi harus di beri 
peluang untuk merujuk pesakit untuk 
menjalankan imbasan tulang?  
b. Status risiko osteoporosis (berbanding dengan 
penyakit lain) 
i. Apakah pendapat anda tentang mengetahui 
risiko osteoporosis pesakit berbanding dengan 
risiko lain seperti kencing manis? Mengapakah 
anda berpendapat sedemikian? (Anda dan 
pesakit)  
ii. Pada pendapat anda, apakah persepsi pesakit 
untuk mengetahui status risiko osteoporosis 
mereka?  
 
6. Pengetahuan mengenai peranan profesional 
penjagaan kesihatan 
a. Programme yang disediakan 
i. Adakah anda pernah mendengar tentang 
bentuk-bentuk programme berkenaan dengan 
penyaringan/penialain risiko osteoporosis? 
Probes 
 Bagaimanakah ia didakan? Apakah 
pendapat anda terhadapnya? 
 Dianjurkan oleh siapa? (oleh doktor, 
pegawai farmasi, jururawat) 
 Di mana? Lokasi: farmasi? Hospital? 
ii. Adakah anda pernah mendengar tentang 
seminar osteoporosis 
Probes 
 Ya- adakah anda pernah menyertai? 
Adakah ia berguna? Bagaimana? 
 Tidak- Adakah anda ingin seminar ini 
dianjurkan? Bagaimana?  
iii. Jika terdapatnya programme saringan 
osteoporosis, adakah anda akan 
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menyertai/membantu untuk menjalankannya?  
Mengapakah anda berkata demikian?  
iv. Pada pendapat anda, bagaimanakan program 
saringan itu harus dijalankan?  
Probes 
 Siapa 
 Berapa harga/Kos 
 Bagaimakah ia harus diadakan 
 Apakah yang perlu dilakukan 
 Di mana 
v. Apakah kebaikan program ini? 
vi. Apakah halangan untuk mengadakan program 
ini? 
vii. Pada pendapat anda, adakah pesakit akan 
menghadiri program ini? 
viii. Pada pendapat anda, adakah pegawai 
kesihatan akan menyertai/menolong program 
ini? 
 
7. Perasaan dan sikap terhadap peranan pegawai-
pegawai kesihatan terhadap osteoporosis 
a. Jangkaan 
i. Pada pendapat anda, apakah yang boleh 
dilakukan oleh pegawai-pegawai kesihatan 
untuk mencegah osteoporosis (rawatan)?   
          Probes 
 masa perundingan yang lebih lama 
  Sesi Kaunseling 
 Belas Kasihan 
ii. Apakah pendapat anda tentang perkhidmatan 
pencegahan osteoporosis masa kini?  Dari 
segi rawatan? 
Probes 
 Sikap 
 Maklumat 
Adakah terdapat perkara yang ingin anda ubah / perbaiki 
berhubung dengan perkhidmatan pencegahan  osteoporosis 
yang dijalankan sekarang? (ataupun rawat  
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5.18    
5.19   Appendix 8- Patients information sheet for 
Phase one 
Patient Information Sheet 
 
Study Title: Addressing the needs of osteoporosis 
prevention in community dwelling postmenopausal 
women in a tertiary hospital in Malaysia: An exploratory 
qualitative study (patients) 
 Version: V1-PT-08/03/12 
 
 
6      
 
Part 1 
We would like to invite you to take part in a research study.  
Before you decide whether to participate, you need to 
understand why the research is being done and what it would 
involve. Please take time to read the following information 
carefully; talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you 
wish to take part.  
 
1. What is the purpose of the study? 
In the University Malaya Medical Centre (UMMC), doctors 
from the Department of Primary Care Medicine treat 
many postmenopausal women for other conditions such 
as diabetes or hypertension. However, osteoporosis is 
usually a “silent disease’ which means that a woman with 
Part 1 tells you the purpose of this study and what will happen to 
you if you take part. 
Part 2 gives you more detailed information about the conduct of the 
study. 
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osteoporosis may experience no symptoms. 
Consequently, there may be a proportion of women who 
may have osteoporosis but who are not identified, 
resulting in unwanted fractures. 
 
Pharmacists together with doctors play an important role 
in patient care. Pharmacists can supplement the doctor’s 
role by screening for osteoporosis and educating patients 
on their osteoporosis risk. This would empower patients 
to take osteoporosis preventive measures. To date, no 
such service exists in the UMMC. 
 
Therefore, the purpose of this study is to identify the 
needs of postmenopausal women in osteoporosis 
screening, prevention and awareness. We would like to 
better understand some of the barriers and potential 
solutions so that we are able develop and to further 
improve the upcoming osteoporosis screening 
programme. 
 
2. Why have I been invited? 
Since you are currently seeing a doctor from the 
Department of Primary Care Medicine for your medical 
condition, we would like to explore your experience and 
perceptions of osteoporosis regarding its screening, 
prevention and awareness. This information will be used 
to guide the development of the new osteoporosis 
screening programme in UMMC. Your care will be more 
wholesome as you will be seen by both the doctor and the 
pharmacist. 
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A total of 20 patients who are attending the Primary Care 
Family Clinic will be invited to participate in the study.  
3. Do I have to take part? 
Your participation is entirely voluntary and it is up to you 
to decide. We will describe the study and go through this 
information sheet with you when you attend the 
interview. We will then ask you to sign a consent form to 
show you have agreed to take part. You are free to 
withdraw at any time, without giving a reason. This would 
not affect your treatment or the standard of care you 
receive. 
4. What type of study is this? 
This is a qualitative study using the method of a one-to-
one interview. It is a challenging task to identify the 
needs and barriers of postmenopausal women attending 
the clinic. For example, postmenopausal may not 
consider themselves at risk for osteoporosis and may not 
know the availability of preventive measures. To find 
out, we need to conduct one-to-one interviews with 
postmenopausal women who may be at risk for 
osteoporosis. By recording and analysing these 
interviews, we are able to obtain useful information from 
them and find out the problems they have experienced 
with regards to osteoporosis. 
5. What will happen to me if I take part? 
1. Your doctor will ask you if you would like to take 
part in this study. If you agree, you will be referred 
to the researcher. 
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2. Before the one-to-one interview, the researcher will 
go through the Patient Information Sheet with you. 
If you agree to participate, the researcher will ask 
you to sign a consent form, followed by answering a 
simple questionnaire about your background (10 
minutes).  
3. The researcher will ask questions related to your 
experience in osteoporosis screening, awareness 
and prevention. He/she will record the conversation 
using an audio tape recorder. The purpose of the 
recording is to allow the researcher to capture the 
information discussed during the interview, which is 
important for them to analyze later.  
4. The interview will be conducted in the Primary Care 
Clinic and will take about 60 minutes.  
6. Expenses and payment 
You will be given RM 20 as a reimbursement for your 
travel expenses.  
 
7. What will I have to do? 
You are required to answer the questions based on your 
personal experience during the interview. However, you 
can refuse to answer any questions which you feel 
uncomfortable and you can stop the interview at any 
time.  
 
 
 
 451 
 
8. What are the possible disadvantages and risks of 
taking part? 
You will have to spend more time in the hospital as you 
will be participating in the one-to-one interview after your 
consultation with the doctor.  
 
During the interview, you might be asked questions about 
certain topics which are sensitive and may upset you. You 
can refuse to answer any questions which you feel 
uncomfortable with, or you can stop the interview 
anytime. Even if you agree to be taped, you may choose 
to have the recorder turned off at any time and withdraw 
from the interview without any negative outcome or 
prejudice. 
 
9. What happens when the research study stops? 
Your doctor will continue to provide medical care for you. 
 
10.  What if there is a problem? 
Any complaint about the way you have been dealt with 
during the study or any possible harm you might suffer 
will be looked into. The detailed information on this is 
given in Part 2.  
 
11. Will my taking part in the study be kept 
confidential? 
Yes. We will follow ethical and legal practice and all 
information about you will be handled in confidence. The 
details are included in Part 2. 
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12. Is the purpose of this study educational? 
Yes. Part of the data from this research will be used for a 
PhD study. 
 
 
 
 
 
Part 2 
13. What will happen if I don’t want to carry on with 
the study? 
You can withdraw from the study without giving a 
reason and without affecting your care. 
 
14. What if there is a problem? 
If you have a concern about any aspect of this study, 
you should ask to speak to the researchers who will do 
their best to answer your questions. 
 
15. Will my taking part in this study be kept 
confidential? 
The recorded conversation will be transcribed by the 
researcher. Only the interviewer and the field supervisor 
will have access to the audiotape. All information will be 
coded and anonymised (no name mentioned). Once the 
transcript has been completed and checked by the 
interviewer for accuracy, the audiotape will be destroyed 
professionally. 
This completes Part 1.  
If the information in Part 1 has interested you and you 
are considering participation, please read the additional 
information in Part 2 before making any decision. 
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The information we have collected as paper copies will 
be stored under lock and key, while the electronic data 
can only be accessed with a secure password. Only the 
researchers will have access to the data. 
  
The data we collect will be used only for the purpose of 
this research; if data were to be used for future studies, 
further Research Ethics Committee approval will be 
sought.  
 
All information which is collected about you during the 
course of the research will be kept strictly confidential, 
and any information about you which leaves the clinic 
will have your name, telephone and address removed so 
that you cannot be recognized. 
 
16. Involvement of the General Practitioner/Family 
doctor (GP) 
Your doctor will be informed about your participation in 
this study. 
 
17. What will happen to the results of the research 
study? 
The results of this study will be published in medical 
journals.   
 
You will not be identified in any report, publications or 
presentation without seeking your full consent. Direct 
quotes from the interviews may be used in reports and 
publications; however, the quotes will be anonymised to 
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ensure that you cannot be identified. You will also be 
able to request a summary for the research. 
 
18. Who is organizing and funding the research? 
This research is organized by Ms. Toh Li Shean and Dr 
Pauline Lai from the University of Malaya, as well as Prof 
Claire Anderson, Associate Prof Mr Wong Kok Thong and 
Dr Low Bee Yean from the University of Nottingham. 
Funding of this research will be obtained from either 
University of Nottingham or the Ministry of Higher 
Education.  
 
19. Who has reviewed the study? 
All research in the UMMC is looked at by an independent 
group of people, called a Research Ethics Committee to 
protect your safety, rights, well-being and dignity.  
20. Further information and contact details. 
Specific information about this research project: 
Toh Li Shean 
Tel: 012-2846-849  
Email: rinoa8387@yahoo.com 
Advice as to whether you should participate: 
As above. 
Who you should approach if unhappy withthe study: 
As above. 
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6.1   Appendix 9- Patients information sheet for 
Phase one, Malay version 
Maklumat Lembaran pesakit 
 
Tajuk Projek: Menangani keperluan pencegahan 
osteoporosis di kalangan wanita menopaus di hospital 
pengajian tinggi di Malaysia: Satu kajian penerokaan 
kualitatif (pesakit) 
 Versi: V1-PT-BM-08/03/12 
 
 
7      
 
Bahagian 1 
Kami ingin menjemput anda untuk mengambil bahagian dalam 
kajian penyelidikan 
Sebelum anda membuat keputusan sama ada untuk 
menyertai kajian ini, anda perlu memahami mengapa 
penyelidikan ini dilakukan serta perkara-perkara yang 
berkaitan dengannya. Sila luangkan masa untuk membaca 
maklumat berikut dengan teliti, atau berbincang dengan orang 
lain mengenai kajian ini jika anda berminat.  
Hubungi kami jika terdapat sebarang keraguan atau inginkan 
maklumat lanjut. Luangkan masa untuk memutuskan sama 
ada anda ingin mengambil bahagian atau sebaliknya 
1. Apakah tujuan kajian ini? 
Di Pusat Perubatan Universiti Malaya (PPUM), doktor dari 
Jabatan Perubatan Rawatan Utama merawat banyak 
wanita menopause untuk pelbagai keadaan seperti 
Bahagian 1 menerangkan tentang tujuan kajian ini dan apa yang 
akan berlaku kepada anda jika anda mengambil bahagian.  
Bahagian 2 memberi anda maklumat yang lebih terperinci tentang 
cara kajian ini dijalankan. 
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kencing manis and tekanan darah tinggi. Pada 
kebiasaanya, osteoporosis merupakan ‘penyakit yang 
senyap’ di mana wanita yang menghidap osteoporosis 
berkemungkinan tidak akan mengalami sebarang gejala 
osteoporosis. Kesannya, terdapat sebahagian daripada 
wanita yang tidak sedar bahawa mereka menghidap 
osteoporosis yang akhirnya mengakibatkan keretakan 
pada tulang. 
 
Ahli farmasi bersama-sama dengan doktor memainkan 
peranan yang penting dalam rawatan pesakit. Ahli 
farmasi boleh menambah perkhidmatan kesihatan dengan 
menjalankan programme saringan osteoporosis dan 
mendidik pesakit tentang risiko osteoporosis. Ini dapat 
menambah ilmu pengetahuan mereka supaya langkah-
langkah pencegahan osteoporosis dapat diambil. 
Sehingga kini, perkhidmatan ini masih belum diwujudkan 
di PPUM. 
 
Oleh itu, tujuan kajian ini adalah untuk mengenal pasti 
keperluan wanita menopaus dalam saringan osteoporosis, 
pencegahan dan kesedarannya. Kami ingin untuk lebih 
memahami halangan dan penyelesaiannya supaya kita 
dapat membangun dan meningkatkan lagi program 
saringan osteoporosis yang akan datang. 
 
2. Mengapa saya dijemput? 
Oleh kerana anda sedang berjumpa doktor dari Jabatan 
Perubatan Rawatan Utama untuk keadaan kesihatan 
anda, kami ingin mengenalpasti pendapat dan pandangan 
anda tentang saringan osteoporosis, pencegahan dan 
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kesedaran. Maklumat ini akan digunakan untuk 
memperbaiki pelaksanaan program saringan osteoporosis 
yang akan datang.  
Sejumlah 20 pesakit yang menghadiri Jabatan Perubatan 
Rawatan Utama akan dijemput untuk mengambil 
bahagian dalam kajian ini. 
3. Adakah saya perlu mengambil bahagian? 
Penyertaan anda adalah secara sukarela dan bergantung 
kepada anda untuk membuat keputusan. Kami akan 
menerangkan tentang kajian dan lembaran maklumat ini 
kepada anda sebelum anda mengisi soal selidik. Kami 
akan meminta anda menandatangani borang persetujuan 
untuk menunjukkan bahawa anda telah bersetuju untuk 
mengambil bahagian. Anda bebas untuk menarik diri 
pada bila-bila masa, tanpa memberi sebab. Ini tidak akan 
menjejaskan rawatan anda atau tahap penjagaan yang 
akan anda terima. 
4. Apakah jenis kajian ini? 
Kajian ini merupakan kajian kualitatif yang menggunakan 
kaedah temubual secara individu. Ini merupakan satu 
tugas yang mencabar untuk mengenal pasti keperluan 
dan halangan wanita menopaus yang menghadiri klinik. 
Sebagai contoh, wanita menopaus mungkin tidak tahu 
adanya langkah-langkah pencegahan osteoporosis dan 
bahawa mereka mungkin berisiko untuk menghidap 
osteoporosis.  Untuk mengetahui, kami perlu untuk 
menjalankan temu bual ini dengan wanita menopaus 
yang mungkin berisiko menghidap osteoporosis. Dengan 
mengumpul dan menganalisis temubual ini, kami 
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berpeluang untuk mendapatkan maklumat yang berguna 
dan mengetahui masalah mengenai osteoporosis yang 
mungkin dialami. 
5. Apakah yang akan berlaku jika saya mengambil 
bahagian? 
Penyelidik akan bertanya jika anda berminat untuk 
mengambil bahagian dalam kajian ini. Sebelum 
menjalankan temubual ini, penyelidik akan menerangkan 
tentang Maklumat Lembaran Pesakit kepada anda. Jika 
anda bersetuju untuk menyertai, penyelidik akan 
meminta anda menandatangani borang persetujuan, 
diikuti dengan menjawab soal selidik ringkas mengenai 
latar belakang anda (10 minit).  
Penyelidik akan bertanya soalan yang berkaitan dengan 
pengalaman anda dalam saringan, kesedaran dan 
pencegahan osteoporosis. Perbualan audio anda akan 
dirakam dengan menggunakan pita rakaman audio. 
Tujuan rakaman adalah untuk membolehkan penyelidik 
untuk mendapatkan maklumat yang dibincangkan 
semasa temu duga supaya analisis dapat dikemudian. 
Temu bual itu akan dijalankan di Klinik Rawatan Utama 
dan akan mengambil masa kira-kira 60 minit. 
 
6. Perbelanjaan dan bayaran 
Sebagai bayaran balik untuk perbelanjaan perjalanan 
anda.  
 
 
7. Apa yang perlu saya lakukan? 
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Anda dikehendaki menjawab soalan-soalan temuduga 
berdasarkan pengalaman peribadi. Anda boleh menolak 
untuk menjawab apa-apa soalan yang anda rasa kurang 
selesa dan anda boleh memberhentikan temuduga pada 
bila-bila masa. 
 
8. Apakah kelemahan dan risiko yang mungkin terjadi 
jika saya mengambil bahagian? 
Anda dikehendaki meluangkan lebih banyak masa di 
hospital kerana anda perlu menghadiri temuduga ini 
sebelum berjumpa dengan doktor anda.  
Semasa temu bual tersebut, anda mungkin ditanya 
mengenai topik yang sensitif dan boleh menyebabkan 
anda kurang selesa. Anda boleh menolak untuk 
menjawab apa-apa soalan yang anda rasa kurang selesa 
atau anda boleh berhenti temuduga pada bila-bila masa. 
Walaupun anda bersetuju untuk dirakamkan secara audio, 
anda boleh memilih untuk menghentikan perakaman pada 
bila-bila masa dan menarik diri daripada temu bual itu 
tanpa apa-apa hasil negatif atau penjelasan. 
 
9. Apa yang akan berlaku jika kajian penyelidikan ini 
terhenti? 
Doktor anda akan meneruskan rawatan anda seperti 
biasa. 
 
10.  Bagaimana jika berlakunya masalah? 
Sebarang aduan mengenai cara anda dilayan semasa 
kajian atau sebarang bahaya yang mungkin anda alami 
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akan diberi perhatian. Maklumat terperinci mengenai 
perkara ini akan dijelaskan di Bahagian 2. 
 
11. Adakah pengambilan bahagian saya dalam kajian 
ini sulit?  
Ya. Kami akan mematuhi amalan etika dan undang-
undang serta semua maklumat mengenai anda akan 
dikendalikan secara sulit. Butirannya terdapat di 
Bahagian 2.   
12. Adakah tujuan kajian ini untuk pendidikan? 
Ya. Sebahagian daripada data dari kajian ini akan 
digunakan untuk kajian PhD. 
 
 
 
 
 
 
Bahagian 2 
13. Apakah yang akan berlaku jika saya tidak mahu 
meneruskan kajian?  
Anda boleh menarik diri dari kajian tanpa memberi 
sebab dan tanpa menjejaskan rawatan anda. 
 
14. Bagaimana jika terdapat masalah? 
Jika anda mempunyai sebarang keraguan mengenai 
mana-mana aspek kajian ini, anda boleh berbincang 
dengan penyelidik yang akan berusaha menjawab 
soalan anda dengan baik. 
Ini adalah akhir Bahagian 1. 
Jika anda berminat dan sedang mempertimbangkan 
penyertaan selapas membaca maklumat di Bahagian 1, sila 
teliti maklumat tambahan di Bahagian 2 sebelum membuat 
keputusan 
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15. Adakah penglibatan saya dalam kajian ini sulit? 
Perbualan yang direkodkan akan disalin oleh penyelidik. 
Hanya penemuduga dan penyelia bidang akan 
mempunyai akses kepada rakaman anda. Semua 
maklumat akan dikodkan dan nama anda tidak akan 
didedahkan. Sebaik sahaja traskrip itu telah diperiksa 
oleh penumuduga untuk ketepatak, rakaman audio itu 
akan dimusnahkan secara profesional. Hanya penyelidik 
terlibat akan mempunyai akses kepada nota perubatan 
anda dan data yang dikumpul. Semua maklumat tidak 
akan didedahkan. 
 
Maklumat yang kami kumpulkan sebagai salinan kertas 
akan disimpan secara sulit, manakala data elektronik 
hanya boleh diakses menggunakan kata laluan yang 
selamat. Hanya penyelidik akan mempunyai akses 
kepada data. 
 
Data yang dikumpul hanya akan digunakan untuk tujuan 
kajian ini. Jika data ini perlu digunakan untuk kajian 
lain, kelulusan baru dari Jawatankuasa Etika akan 
dipohon. 
 
Semua maklumat yang dikumpul semasa kajian adalah 
sulit, dan sebarang maklumat yang dibawa keluar dari 
klinik tidak akan mempunyai nama, nombor telefon 
serta alamat supaya tidak dapat dikenalpasti. 
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16. Penglibatan doktor 
Doktor anda akan dimaklumkan mengenai penyertaan 
anda dalam kajian ini. 
 
17. Apakah yang akan berlaku kepada hasil kajian ini? 
Keputusan kajian ini akan diterbitkan di dalam jurnal 
perubatan. 
 
Anda tidak akan dikenal pasti dalam sebarang laporan, 
penerbitan atau persembahan tanpa persetujuan penuh 
daripada anda. Petikan langsung daripada rakaman 
audio mungkin akan digunakan dalam laporan dan 
penerbitan tanpa mendedahkan identiti anda. Anda juga 
boleh meminta untuk mendapatkan naskah ringkasan 
penyelidikan. 
 
18. Siapa yang akan menganjurkan dan membiayai 
penyelidikan? 
Kajian ini dianjurkan oleh Cik Toh Li Shean dan Dr 
Pauline Lai dari Universiti Malaya, serta Prof Claire 
Anderson, Prof Madya Encik Wong Kok Thong dan Dr 
Low Bee Yean dari University of Nottingham. 
Pembiayaan penyelidikan ini akan diperolehi sama ada 
daripada University of Nottingham atau Kementerian 
Pengajian Tinggi.  
 
19. Siapakah yang telah mengkaji/memeriksa kajian 
ini? 
Semua penyelidikan di PPUM diperiksa oleh sekumpulan 
orang bebas, yang dipanggil Jawatankuasa Etika 
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Penyelidikan untuk melindungi keselamatan anda, hak, 
kesejahteraan dan maruah.  
20. Maklumat lanjut serta butiran lain. 
Maklumat khusus mengenai projek penyelidikan: 
Toh Li Shean 
Tel: 012-2846-849  
Emel: rinoa8387@yahoo.com 
Nasihat untuk penglibatan: 
Seperti diatas. 
Siapa yang perlu anda hubungi jika tidak berpuas hati  
dengan kajian: 
Seperti diatas. 
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7.1   Appendix 10- Patients consent form for Phase 
one 
 Participant identification number for this trial: 
CONSENT FORM 
Title of Project: Addressing the needs of osteoporosis prevention in 
community dwelling postmenopausal women in a 
tertiary hospital in Malaysia: An exploratory qualitative 
study (Patients) 
Name of Researchers: Prof Claire Anderson / Assoc Prof Mr Wong Kok 
Thong/ Dr Lai Siew Mei Pauline/ Dr Low Bee 
Yean/ Toh Li Shean 
 
_______________________ ________________  
Name of Participant Date Signature 
_________________________ ________________  
Name of Person taking consent Date Signature 
  
  Please initial box 
1. I confirm that I have read and understand the information sheet 
dated 08/03/12 (Version 1-PT) for the above study. I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason and without my legal 
rights being affected. 
 
3. I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals 
from the University Malaya Medical Center, the University of Malaya and 
the University of Nottingham, where it is relevant to my taking part in this 
research.  I give permission for these individuals to have access to my 
records.                                                                                                         
 
4. I agree to have the interview audio-taped as described in the information 
sheetet  dated 08/03/12 (Version 1-PT) 
 
5. I give my consent for anonymised direct quotes to be used in reports and 
publications. 
 
6. I agree to take part in the above study.  
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7.2   Appendix 11- Patients consent form for Phase 
one,  
7.3   Malay version 
Nombor pengenalan perserta untuk kajian ini:  
BORANG PERSETUJUAN 
Tajuk Projek:  Menangani keperluan pencegahan osteoporosis di 
kalangan wanita menopaus di hospital pengajian tinggi 
di Malaysia: Satu kajian penerokaan kaulitatif (pesakit) 
Nama Penyelidik: Prof Claire Anderson / Assoc Prof Mr Wong Kok 
Thong/ Dr Lai Siew Mei  Pauline/ Dr Low Bee Yean/ 
Toh Li Shean 
 
_______________________ ________________  
Nama Peserta Tarikh      Tandatangan 
_________________________  _______________  
  Sila tandatangan di 
kotak berkenaan 
1. Saya mengesahkan bahawa saya telah membaca dan memahami 
Iembaran maklumat yang bertarikh 08/03/12 (Version 1-PT-BM) 
untuk kajian di atas. Saya juga telah diberi peluang untuk 
mempertimbangkan maklumat, bertanya soalan dan 
mendapatkan jawapan yang memuaskan.  
 
2. Saya memahami bahawa penyertaan saya adalah secara 
sukarela dan saya bebas untuk menarik diri pada bila-bila masa, 
tanpa memberi apa-apa sebab, tanpa menjejaskan hak undang-
undang saya. 
 
3. Saya faham bahawa data yang berkaitan dan data yang 
dikumpulkan semasa kajian, boleh dilihat oleh individu yang 
bertanggungjawab dari Universiti Malaya, Pusat Perubatan 
Universiti Malaya dan University of Nottingham. Saya memberi 
kebenaran kepada individu-individu ini untuk mendapatkan 
maklumat daripada data ini.  
 
4. Saya bersetuju supaya wawancara audio akan dirakamkan 
seperti yang dinyatakan dalam lembaran maklumat yang 
bertarikh 08/03/12 (Version 1-PT-BM). 
 
5. Saya memberi kebenaran supaya petikan langsung daripada 
wawancara dapat digunakan dalam laporan dan penerbitan 
tanpa mendedahkan identiti saya. 
 
6. Saya bersetuju untuk menyertai kajian di atas.  
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Pihak Yang Mengambil Persetujuan      Tarikh Tandatangan 
7.4   Appendix 12- Nurses information sheet for 
Phase one 
 Participant Information Sheet 
Study Title: Addressing the needs of osteoporosis 
prevention in community dwelling postmenopausal 
women in a tertiary hospital in Malaysia: An exploratory 
qualitative study (nurses) 
 Version: V1-NUR-08/03/12 
 
 
 
8      
Part 1 
We would like to invite you to take part in a research 
study. Before you decide whether to participate, you 
need to understand why the research is being done and 
what it would involve. Please take time to read the 
following information carefully; talk to others about the 
study if you wish. 
 
Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide 
whether or not you wish to take part.  
 
1. What is the purpose of the study? 
In the University Malaya Medical Centre (UMMC), doctors 
from the Department of Primary Care Medicine treat many 
postmenopausal women for other conditions such as 
diabetes or hypertension. However, osteoporosis is usually 
Part 1 tells you the purpose of this study and what will happen to 
you if you take part. 
Part 2 gives you more detailed information about the conduct of the 
study. 
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a “silent disease’ which means that a woman with 
osteoporosis may experience no symptoms. Consequently, 
there may be a proportion of women who may have 
osteoporosis but who are not identified, resulting in 
unwanted fractures. 
 
Pharmacists together with doctors play an important role in 
patient care. Pharmacists can supplement the doctor’s role 
by screening for osteoporosis and educating patients on 
their osteoporosis risk and empower patients to take 
osteoporosis preventive measures. To date, no such service 
exists in the UMMC. 
 
Therefore, the purpose of this study is to identify the needs 
of postmenopausal community dwelling women in 
osteoporosis screening, prevention and awareness. We 
would like to better understand some of the barriers and 
potential solutions so that we are able develop and to 
further improve the upcoming osteoporosis screening 
program. 
 
2. Why have I been invited? 
You have been invited because of your experience and 
expertise in working in the Department of Primary Care 
medicine. Your views and opinions will help us to identify 
the problems and needs to be addressed in the screening, 
prevention and awareness of osteoporosis. This information 
is then used to guide the set up of the osteoporosis 
screening program. 
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A total of five nurses will be invited to participate in the 
study. We will also be interviewing twenty postmenopausal 
women, ten pharmacists, ten physicians and five 
policymakers. 
 
3. Do I have to take part? 
Your participation is entirely voluntary and it is up to you to 
decide. We will describe the study and go through this 
information sheet with you when you attend the interview. 
We will then ask you to sign a consent form to show you 
have agreed to take part. You are free to withdraw at any 
time, without giving a reason.  
4. What type of study is this? 
This is a qualitative study using the method of a one-to-one 
interview. It is a challenging task to identify the needs and 
barriers of the nurses in managing postmenopausal women 
who may be at risk for osteoporosis. To find out, we need 
to conduct one-to-one interviews. By recording and 
analysing these interviews, we are able to obtain useful 
information from you. 
5. What will happen to me if I take part? 
Before the one-to-one interview, the researcher will go 
through the Participant Information Sheet with you. If you 
agree to participate, the researcher will ask you to sign a 
consent form, followed by answering a simple questionnaire 
about your background (10 minutes).  
The researcher will ask questions related to your 
experience in osteoporosis screening, awareness and 
prevention. He/she will record the conversation using an 
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audio tape recorder. The purpose of the recording is to 
allow the researcher to capture the information discussed 
during the interview, which is important for them to 
analyze later.  
The interview will take about 60 minutes.  
6. Expenses and payment 
You will be given RM 50 to compensate for the time you 
have taken to participate in this research.  
 
7. What will I have to do? 
You are required to answer the questions based on your 
personal experience during the interview. However, you 
can refuse to answer any questions which you feel 
uncomfortable and you can stop the interview at any time.  
 
8. What if there is a problem? 
Any complaint about the way you have been dealt with 
during the study or any possible harm you might suffer will 
be looked into. The detailed information on this is given in 
Part 2.  
 
9. Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all 
information about you will be handled in confidence. The 
details are included in Part 2. 
10. Is the purpose of this study educational? 
Yes. Part of the data from this research will be used for a 
PhD study. 
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Part 2 
11. What will happen if I don’t want to carry on with 
the study? 
You can withdraw from the study without giving any 
reason. 
12. What if there is a problem? 
If you have a concern about any aspect of this study, 
you should ask to speak to the researchers who will do 
their best to answer your questions. 
 
13. Will my taking part in this study be kept 
confidential? 
The recorded conversation will be transcribed by the 
researcher. Only the interviewer and the field supervisor 
will have access to the audiotape. All information will be 
coded and anonymised (no name mentioned). Once the 
transcript has been completed and checked by the 
interviewer for accuracy, the audiotape will be destroyed 
professionally. 
The information we have collected as paper copies will 
be stored under lock and key, while the electronic data 
can only be accessed with a secure password. Only the 
researchers will have access to the data.  
The data we collect will be used only for the purpose of 
this research; if data were to be used for future studies, 
further Research Ethics Committee approval will be 
sought.  
 
This completes Part 1.  
If the information in Part 1 has interested you and you 
are considering participation, please read the additional 
information in Part 2 before making any decision. 
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All information which is collected about you during the 
course of the research will be kept strictly confidential, 
and any information about you which leaves the clinic 
will have your name, telephone and address removed so 
that you cannot be recognized. 
 
14. What will happen to the results of the research 
study? 
The results of this study will be published in medical 
journals.   
 
You will not be identified in any report, publications or 
presentation without seeking your full consent. Direct 
quotes from the interviews may be used in reports and 
publications; however, the quotes will be anonymised to 
ensure that you cannot be identified. You will also be 
able to request a summary for the research. 
 
15. Who is organizing and funding the research? 
This research is organized by Ms. Toh Li Shean and Dr 
Pauline Lai Siew Mei from the University of Malaya, as 
well as Prof Claire Anderson, Associate Prof Mr Wong 
Kok Thong and Dr Low Bee Yean from the University of 
Nottingham. Funding of this research will be obtained 
from either University of Nottingham or the Ministry of 
Higher Education.  
 
16. Who has reviewed the study? 
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All research in the UMMC is looked at by an independent 
group of people, called a Research Ethics Committee to 
protect your safety, rights, well-being and dignity.  
17. Further information and contact details. 
Specific information about this research project: 
Toh Li Shean 
Tel: 012-2846-849  
Email: rinoa8387@yahoo.com 
Advice as to whether you should participate: 
As above. 
Who you should approach if unhappy with the study: 
As above. 
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8.1   Appendix 13- Nurses information sheet for 
Phase one, Malay version 
 Maklumat Lembaran pesakit 
 
Tajuk Projek: Menangani keperluan pencegahan 
osteoporosis di kalangan wanita menopaus di hospital 
pengajian tinggi di Malaysia: Satu kajian penerokaan 
kualitatif (Jururawat) 
 Versi: V1-NUR-BM-08/03/12 
 
 
9      
 
Bahagian 1 
Kami ingin menjemput anda untuk mengambil bahagian dalam 
kajian penyelidikan. 
Sebelum anda membuat keputusan sama ada untuk 
menyertai kajian ini, anda perlu memahami mengapa 
penyelidikan ini dilakukan serta perkara-perkara yang 
berkaitan dengannya. Sila luangkan masa untuk membaca 
maklumat berikut dengan teliti, atau berbincang dengan orang 
lain mengenai kajian ini jika anda berminat.  
Hubungi kami jika terdapat sebarang keraguan atau sebarang 
maklumat lanjut. Luangkan masa untuk memutuskan sama 
ada anda ingin mengambil bahagian atau sebaliknya. 
 
1. Apakah tujuan kajian ini? 
Di Pusat Perubatan Universiti Malaya (PPUM), doktor dari 
Jabatan Perubatan Rawatan Utama merawat banyak 
Bahagian 1 menerangkan tentang tujuan kajian ini dan apa yang 
akan berlaku kepada anda jika anda mengambil bahagian.  
Bahagian 2 memberi anda maklumat yang lebih terperinci tentang 
cara kajian ini dijalankan. 
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wanita menopause untuk pelbagai keadaan seperti 
kencing manis and tekanan darah tinggi. Pada 
kebiasaanya, osteoporosis merupakan ‘penyakit yang 
senyap’ di mana wanita yang menghidap osteoporosis 
berkemungkinan tidak akan mengalami sebarang gejala 
osteoporosis. Kesannya, terdapat sebahagian daripada 
wanita yang tidak sedar bahawa mereka menghidap 
osteoporosis yang akhirnya mengakibatkan keretakan 
pada tulang. 
 
Ahli farmasi bersama-sama dengan doktor memainkan 
peranan yang penting dalam rawatan pesakit. Ahli 
farmasi boleh menambah perkhidmatan kesihatan dengan 
menjalankan program saringan osteoporosis dan 
mendidik pesakit tentang risiko osteoporosis. Ini dapat 
menambah ilmu pengetahuan mereka supaya langkah-
langkah pencegahan osteoporosis dapat diambil. 
Sehingga kini, perkhidmatan ini masih belum diwujudkan 
di PPUM. 
 
Oleh itu, tujuan kajian ini adalah untuk mengenal pasti 
keperluan wanita menopaus dalam saringan osteoporosis, 
pencegahan dan kesedarannya. Kami ingin untuk lebih 
memahami halangan dan penyelesaiannya supaya kami 
dapat membangun dan meningkatkan lagi program 
saringan osteoporosis yang akan datang. 
 
2. Mengapa saya dijemput? 
Oleh kerana anda mempunyai pengalaman dan kepakaran 
semasa bekerja di Jabatan Perubatan Rawatan Utama. 
Pandangan dan pendapat anda akan membantu kami 
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untuk mengenal pasti masalah dan keperluan yang perlu 
ditangani dalam pemeriksaan, pencegahan dan kesedaran 
osteoporosis. Maklumat ini akan digunakan untuk 
memperbaiki pelaksanaan program saringan osteoporosis 
yang akan datang.  
Sejumlah 5 orang jururawat akan dijemput untuk 
mengambil bahagian dalam kajian ini. 
3. Adakah saya perlu mengambil bahagian? 
Penyertaan anda adalah secara sukarela dan bergantung 
kepada anda untuk membuat keputusan. Kami akan 
menerangkan tentang kajian dan lembaran maklumat ini 
kepada anda sebelum anda mengisi soal selidik. Kami 
akan meminta anda menandatangani borang persetujuan 
untuk menunjukkan bahawa anda telah bersetuju untuk 
mengambil bahagian. Anda bebas untuk menarik diri 
pada bila-bila masa, tanpa memberi sebab. Ini tidak akan 
menjejaskan rawatan anda atau tahap penjagaan yang 
akan anda terima. 
4. Apakah jenis kajian ini? 
Kajian ini merupakan kajian kualitatif yang menggunakan 
kaedah temubual secara individu. Ini merupakan satu 
tugas yang mencabar untuk mengenal pasti keperluan 
dan halangan wanita menopaus yang menghadiri klinik. 
Sebagai contoh, wanita menopaus mungkin tidak tahu 
adanya langkah-langkah pencegahan osteoporosis dan 
bahawa mereka mungkin berisiko untuk menghidap 
osteoporosis.  Untuk mengetahui, kita perlu untuk 
menjalankan temu bual ini. Dengan mengumpul dan 
menganalisis temubual ini, kita berpeluang untuk 
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mendapatkan maklumat yang berguna dan mengetahui 
masalah mengenai osteoporosis yang mungkin dialami. 
5. Apakah yang akan berlaku jika saya mengambil 
bahagian? 
1. Sebelum menjalankan temubual ini, penyelidik akan 
menerangkan tentang Maklumat Lembaran Pesakit 
kepada anda. Jika anda bersetuju untuk menyertai, 
penyelidik akan meminta anda menandatangani 
borang persetujuan, diikuti dengan menjawab soal 
selidik ringkas mengenai latar belakang anda (10 
minit).  
2. Penyelidik akan bertanya soalan yang berkaitan 
dengan pengalaman anda dalam saringan, 
kesedaran dan pencegahan osteoporosis. Perbualan 
audio anda akan dirakam dengan menggunakan 
pita rakaman audio. Tujuan rakaman adalah untuk 
membolehkan penyelidik menangkap maklumat 
yang dibincangkan semasa temu duga supaya 
analisis dapat dilakukan. 
3. Temu bual itu akan dijalankan di Klinik Rawatan 
Utama dan akan mengambil masa kira-kira 60 
minit. 
6. Perbelanjaan dan bayaran 
Anda akan diberi RM 50 sebagai pampasan bagi masa 
yang anda telah ambil untuk mengambil bahagian dalam 
kajian ini.  
 
 
 
 477 
 
7. Apa yang saya perlu lakukan? 
Anda dikehendaki menjawab soalan-soalan temuduga 
berdasarkan pengalaman peribadi. Anda boleh menolak 
untuk menjawab mana-mana soalan yang anda rasa 
kurang selesa dan anda boleh memberhentikan temuduga 
pada bila-bila masa. 
 
8.  Bagaimana jika berlakunya masalah? 
Sebarang aduan mengenai cara anda dilayan semasa 
kajian atau sebarang bahaya yang mungkin anda alami 
akan diberi perhatian. Maklumat terperinci mengenai 
perkara ini akan dijelaskan di Bahagian 2. 
 
9. Adakah pengambilan bahagian saya dalam kajian 
ini sulit?  
Ya. Kami akan mematuhi amalan etika dan undang-
undang serta semua maklumat mengenai anda akan 
dikendalikan secara sulit. Butirannya terdapat di 
Bahagian 2.   
10. Adakah tujuan kajian ini untuk pendidikan? 
Ya. Sebahagian daripada data dari kajian ini akan 
digunakan untuk kajian PhD. 
 
 
 
 
 
 
 
Ini adalah akhir Bahagian 1. 
Jika anda berminat dan sedang mempertimbangkan 
penyertaan selapas membaca maklumat di Bahagian 1, sila 
teliti maklumat tambahan di Bahagian 2 sebelum membuat 
keputusan 
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Bahagian 2 
11. Apakah yang akan berlaku jika saya tidak mahu 
meneruskan kajian?  
Anda boleh menarik diri dari kajian tanpa memberi 
sebab dan tanpa menjejaskan rawatan anda. 
 
12. Bagaimana jika terdapat masalah? 
Jika anda mempunyai sebarang keraguan mengenai 
mana-mana aspek kajian ini, anda boleh berbincang 
dengan penyelidik yang akan berusaha menjawab 
soalan anda dengan baik. 
 
13. Adakah penglibatan saya dalam kajian ini sulit? 
Perbualan yang direkodkan akan disalin oleh penyelidik. 
Hanya penemuduga dan penyelia bidang akan 
mempunyai akses kepada rakaman anda. Semua 
maklumat akan dikodkan dan nama anda tidak akan 
didedahkan. Sebaik sahaja traskrip itu telah diperiksa 
oleh penumuduga untuk ketepatak, rakaman audio itu 
akan dimusnahkan secara profesional. Hanya penyelidik 
terlibat akan mempunyai akses kepada nota perubatan 
anda dan data yang dikumpul. Semua maklumat tidak 
akan didedahkan. 
 
Maklumat yang kami kumpulkan sebagai salinan kertas 
akan disimpan secara sulit, manakala data elektronik 
hanya boleh diakses menggunakan kata laluan yang 
selamat. Hanya penyelidik akan mempunyai akses 
kepada data. 
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Data yang dikumpul hanya akan digunakan untuk tujuan 
kajian ini. Jika data ini perlu digunakan untuk kajian 
lain, kelulusan baru dari Jawatankuasa Etika akan 
dipohon. 
 
Semua maklumat yang dikumpul semasa kajian adalah 
sulit, dan sebarang maklumat yang dibawa keluar dari 
klinik tidak akan mempunyai nama, nombor telefon 
serta alamat supaya tidak dapat dikenalpasti. 
 
14. Apakah yang akan berlaku kepada hasil kajian ini? 
Keputusan kajian ini akan diterbitkan di dalam jurnal 
perubatan. 
 
Anda tidak akan dikenal pasti dalam sebarang laporan, 
penerbitan atau persembahan tanpa persetujuan penuh 
daripada anda. Petikan langsung daripada rakaman 
audio mungkin akan digunakan dalam laporan dan 
penerbitan tanpa mendedahkan identiti anda. Anda juga 
boleh meminta untuk mendapatkan naskah ringkasan 
penyelidikan. 
 
15. Siapa yang akan menganjurkan dan membiayai 
penyelidikan? 
Kajian ini dianjurkan oleh Cik Toh Li Shean dan Dr 
Pauline Lai dari Universiti Malaya, serta Prof Claire 
Anderson, Prof Madya Encik Wong Kok Thong dan Dr 
Low Bee Yean dari University of Nottingham. 
Pembiayaan penyelidikan ini akan diperolehi sama ada 
daripada University of Nottingham atau Kementerian 
Pengajian Tinggi.  
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16. Siapakah yang telah mengkaji/memeriksa kajian 
ini? 
Semua penyelidikan di PPUM diperiksa oleh sekumpulan 
orang bebas, yang dipanggil Jawatankuasa Etika 
Penyelidikan untuk melindungi keselamatan anda, hak, 
kesejahteraan dan maruah.  
17. Maklumat lanjut serta butiran lain. 
Maklumat khusus mengenai projek penyelidikan: 
Toh Li Shean 
Tel: 012-2846-849  
Emel: rinoa8387@yahoo.com 
Nasihat untuk penglibatan: 
Seperti diatas 
Siapa yang perlu anda hubungi jika tidak berpuas hati  
dengan kajian: 
Seperti diatas 
  
 481 
 
9.1   Appendix 14- Pharmacists information sheet 
for Phase one 
Participant Information Sheet 
Study Title: Addressing the needs of osteoporosis 
prevention in community dwelling postmenopausal 
women in a tertiary hospital in Malaysia: An exploratory 
qualitative study (pharmacist) 
 Version: V1-PHARM-08/03/12 
 
10      
 
11      
Part 1 
We would like to invite you to take part in a research study.  
Before you decide whether to participate, you need to 
understand why the research is being done and what it would 
involve. Please take time to read the following information 
carefully; talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you 
wish to take part.  
 
1. What is the purpose of the study? 
In the University Malaya Medical Centre (UMMC), doctors 
from the Department of Primary Care Medicine treat many 
postmenopausal women for other conditions such as 
diabetes or hypertension. However, osteoporosis is usually 
a “silent disease’ which means that a woman with 
osteoporosis may experience no symptoms. Consequently, 
Part 1 tells you the purpose of this study and what will happen to 
you if you take part. 
Part 2 gives you more detailed information about the conduct of the 
study. 
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there may be a proportion of women who may have 
osteoporosis but who are not identified, resulting in 
unwanted fractures. 
 
Pharmacists together with doctors play an important role in 
patient care. Pharmacists can supplement the doctor’s role 
by screening for osteoporosis and educating patients on 
their osteoporosis risk and empower patients to take 
osteoporosis preventive measures. To date, no such service 
exists in the UMMC. 
 
Therefore, the purpose of this study is to identify the needs 
of postmenopausal community dwelling women in 
osteoporosis screening, prevention and awareness. We 
would like to better understand some of the barriers and 
potential solutions so that we are able develop and to 
further improve the upcoming osteoporosis screening 
program. 
 
2. Why have I been invited? 
You have been invited because of your experience as an 
outpatient pharmacist in managing postmenopausal 
women. Your views and opinions will help us to identify the 
problems and needs to be addressed in the screening, 
prevention and awareness of osteoporosis. This information 
is then used to guide the set up of the osteoporosis 
screening program. 
 
A total of ten pharmacists will be invited to participate in 
the study. We will also be interviewing twenty 
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postmenopausal women, ten physicians, five nurses and 
five policymakers. 
 
3. Do I have to take part? 
Your participation is entirely voluntary and it is up to you to 
decide. We will describe the study and go through this 
information sheet with you when you attend the interview. 
We will then ask you to sign a consent form to show you 
have agreed to take part. You are free to withdraw at any 
time, without giving a reason.  
4. What type of study is this? 
This is a qualitative study using the method of a one-to-one 
interview. It is a challenging task to identify the needs and 
barriers of the outpatient pharmacist in managing 
postmenopausal women who may be at risk for 
osteoporosis. To find out, we need to conduct one-to-one 
interviews. By recording and analysing these interviews, we 
are able to obtain useful information from you. 
5. What will happen to me if I take part? 
1. Before the one-to-one interview, the researcher will 
go through the Participant Information Sheet with 
you. If you agree to participate, the researcher will 
ask you to sign a consent form, followed by 
answering a simple questionnaire about your 
background (10 minutes).  
2. The researcher will ask questions related to your 
experience in osteoporosis screening, awareness and 
prevention. He/she will record the conversation using 
an audio tape recorder. The purpose of the recording 
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is to allow the researcher to capture the information 
discussed during the interview, which is important for 
them to analyze later.  
3. The interview will take about 60 minutes.  
6. Expenses and payment 
You will be given RM 50 to compensate for the time you 
have taken to participate in this research.  
 
7. What will I have to do? 
You are required to answer the questions based on your 
personal experience during the interview. However, you 
can refuse to answer any questions which you feel 
uncomfortable and you can stop the interview at any time.  
 
8. What if there is a problem? 
Any complaint about the way you have been dealt with 
during the study or any possible harm you might suffer will 
be looked into. The detailed information on this is given in 
Part 2.  
 
9. Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all 
information about you will be handled in confidence. The 
details are included in Part 2. 
10. Is the purpose of this study educational? 
Yes. Part of the data from this research will be used for a 
PhD study. 
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Part 2 
11. What will happen if I don’t want to carry on with 
the study? 
You can withdraw from the study without giving any 
reason. 
 
12. What if there is a problem? 
If you have a concern about any aspect of this study, 
you should ask to speak to the researchers who will do 
their best to answer your questions. 
 
13. Will my taking part in this study be kept 
confidential? 
The recorded conversation will be transcribed by the 
researcher. Only the interviewer and the field supervisor 
will have access to the audiotape. All information will be 
coded and anonymised (no name mentioned). Once the 
transcript has been completed and checked by the 
interviewer for accuracy, the audiotape will be destroyed 
professionally. 
 
The information we have collected as paper copies will 
be stored under lock and key, while the electronic data 
can only be accessed with a secure password. Only the 
researchers will have access to the data.  
This completes Part 1.  
If the information in Part 1 has interested you and you 
are considering participation, please read the additional 
information in Part 2 before making any decision. 
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The data we collect will be used only for the purpose of 
this research; if data were to be used for future studies, 
further Research Ethics Committee approval will be 
sought.  
 
All information which is collected about you during the 
course of the research will be kept strictly confidential, 
and any information about you which leaves the clinic 
will have your name, telephone and address removed so 
that you cannot be recognized. 
 
14. What will happen to the results of the research 
study? 
The results of this study will be published in medical 
journals.   
You will not be identified in any report, publications or 
presentation without seeking your full consent. Direct 
quotes from the interviews may be used in reports and 
publications; however, the quotes will be anonymised to 
ensure that you cannot be identified. You will also be 
able to request a summary for the research. 
 
15. Who is organizing and funding the research? 
This research is organized by Ms. Toh Li Shean and Dr 
Pauline Lai from the University of Malaya, as well as Prof 
Claire Anderson, Associate Prof Mr Wong Kok Thong and 
Dr Low Bee Yean from the University of Nottingham. 
Funding of this research will be obtained from either 
University of Nottingham or the Ministry of Higher 
Education.  
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16. Who has reviewed the study? 
All research in the UMMC is looked at by an independent 
group of people, called a Research Ethics Committee to 
protect your safety, rights, well-being and dignity.  
17. Further information and contact details. 
Specific information about this research project: 
Toh Li Shean 
Tel: 012-2846-849  
Email: rinoa8387@yahoo.com 
Advice as to whether you should participate: 
As above. 
Who you should approach if unhappy with the study: 
As above. 
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11.1   Appendix 15- Doctors information sheet for 
Phase one 
Participant Information Sheet 
Study Title: Addressing the needs of osteoporosis 
prevention in community dwelling postmenopausal 
women in a tertiary hospital in Malaysia: An exploratory 
qualitative study (physicians) 
 Version: V1-DR-08/03/12 
 
 
12      
 
Part 1 
We would like to invite you to take part in a research study.  
Before you decide whether to participate, you need to 
understand why the research is being done and what it would 
involve. Please take time to read the following information 
carefully; talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you 
wish to take part.  
 
1. What is the purpose of the study? 
In the University Malaya Medical Centre (UMMC), doctors 
from the Department of Primary Care Medicine treat many 
postmenopausal women for other conditions such as 
diabetes or hypertension. However, osteoporosis is usually 
a “silent disease’ which means that a woman with 
osteoporosis may experience no symptoms. Consequently, 
there may be a proportion of women who may have 
Part 1 tells you the purpose of this study and what will happen to 
you if you take part. 
Part 2 gives you more detailed information about the conduct of the 
study. 
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osteoporosis but who are not identified, resulting in 
unwanted fractures. 
 
Pharmacists together with doctors play an important role in 
patient care. Pharmacists can supplement the doctor’s role 
by screening for osteoporosis and educating patients on 
their osteoporosis risk and empower patients to take 
osteoporosis preventive measures. To date, no such service 
exists in the UMMC. 
 
Therefore, the purpose of this study is to identify the needs 
of postmenopausal community dwelling women in 
osteoporosis screening, prevention and awareness. We 
would like to better understand some of the barriers and 
potential solutions so that we are able develop and to 
further improve the upcoming osteoporosis screening 
program. 
 
2. Why have I been invited? 
You have been invited because of your experience and 
expertise in managing postmenopausal women in the 
Department of Primary Care Medicine. Your views and 
opinions will help us to identify the problems and needs to 
be addressed in the screening, prevention and awareness of 
osteoporosis. This information is then used to guide the set 
up of the osteoporosis screening programme. 
 
A total of ten physicians will be invited to participate in the 
study. We will also be interviewing twenty postmenopausal 
women, ten pharmacists, five nurses and five 
policymakers. 
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3. Do I have to take part? 
Your participation is entirely voluntary and it is up to you to 
decide. We will describe the study and go through this 
information sheet with you when you attend the interview. 
We will then ask you to sign a consent form to show you 
have agreed to take part. You are free to withdraw at any 
time, without giving a reason.  
 
4. What type of study is this? 
This is a qualitative study using the method of a one-to-one 
interview. It is a challenging task to identify the needs and 
barriers of the physicians in managing postmenopausal 
women who may be at risk for osteoporosis. To find out, 
we need to conduct one-to-one interviews. By recording 
and analysing these interviews, we are able to obtain useful 
information from you. 
5. What will happen to me if I take part? 
1. Before the one-to-one interview, the researcher will 
go through the Participant Information Sheet with 
you. If you agree to participate, the researcher will 
ask you to sign a consent form, followed by 
answering a simple questionnaire about your 
background (10 minutes).  
2. The researcher will ask questions related to your 
experience in osteoporosis screening, awareness and 
prevention. He/she will record the conversation using 
an audio tape recorder. The purpose of the recording 
is to allow the researcher to capture the information 
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discussed during the interview, which is important for 
them to analyze later.  
3. The interview will take about 60 minutes.  
6. Expenses and payment 
You will be given RM 50 to compensate for the time you 
have taken to participate in this research.  
 
7. What will I have to do? 
You are required to answer the questions based on your 
personal experience during the interview. However, you 
can refuse to answer any questions which you feel 
uncomfortable and you can stop the interview at any time.  
8. What if there is a problem? 
Any complaint about the way you have been dealt with 
during the study or any possible harm you might suffer will 
be looked into. The detailed information on this is given in 
Part 2.  
 
9. Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all 
information about you will be handled in confidence. The 
details are included in Part 2. 
10. Is the purpose of this study educational? 
Yes. Part of the data from this research will be used for a 
PhD study. 
 
 
 
This completes Part 1.  
If the information in Part 1 has interested you and you 
are considering participation, please read the additional 
information in Part 2 before making any decision. 
 492 
 
 
Part 2 
11. What will happen if I don’t want to carry on with 
the study? 
You can withdraw from the study without giving any 
reason. 
12. What if there is a problem? 
If you have a concern about any aspect of this study, 
you should ask to speak to the researchers who will do 
their best to answer your questions  
 
13. Will my taking part in this study be kept 
confidential? 
The recorded conversation will be transcribed by the 
researcher. Only the interviewer and the field supervisor 
will have access to the audiotape. All information will be 
coded and anonymised (no name mentioned). Once the 
transcript has been completed and checked by the 
interviewer for accuracy, the audiotape will be destroyed 
professionally. 
 
The information we have collected as paper copies will 
be stored under lock and key, while the electronic data 
can only be accessed with a secure password. Only the 
researchers will have access to the data.  
 
The data we collect will be used only for the purpose of 
this research; if data were to be used for future studies, 
further Research Ethics Committee approval will be 
sought.  
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All information which is collected about you during the 
course of the research will be kept strictly confidential, 
and any information about you which leaves the clinic 
will have your name, telephone and address removed so 
that you cannot be recognized. 
 
14. What will happen to the results of the research 
study? 
The results of this study will be published in medical 
journals.   
You will not be identified in any report, publications or 
presentation without seeking your full consent. Direct 
quotes from the interviews may be used in reports and 
publications; however, the quotes will be anonymised to 
ensure that you cannot be identified. You will also be 
able to request a summary for the research. 
 
15. Who is organizing and funding the research? 
This research is organized by Ms. Toh Li Shean and Dr 
Pauline Lai Siew Mei from the University of Malaya, as 
well as Prof Claire Anderson, Associate Prof Mr Wong 
Kok Thong and Dr Low Bee Yean from the University of 
Nottingham. Funding of this research will be obtained 
from either University of Nottingham or the Ministry of 
Higher Education.  
 
 
 
16. Who has reviewed the study? 
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All research in the UMMC is looked at by an independent 
group of people, called a Research Ethics Committee to 
protect your safety, rights, well-being and dignity.  
17. Further information and contact details. 
Specific information about this research project 
Toh Li Shean 
Tel: 012-2846-849  
Email: rinoa8387@yahoo.com 
Advice as to whether you should participate 
As above 
Who you should approach if unhappy with the study 
As above 
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12.1   Appendix 16- Policy makers information sheet 
for Phase one 
Participant Information Sheet 
Study Title: Addressing the needs of osteoporosis 
prevention in community dwelling postmenopausal 
women in a tertiary hospital in Malaysia: An exploratory 
qualitative study (policy makers) 
 Version: V1-POL-08/03/12 
 
 
13      
 
Part 1 
We would like to invite you to take part in a research study.  
Before you decide whether to participate, you need to 
understand why the research is being done and what it would 
involve. Please take time to read the following information 
carefully; talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you 
wish to take part.  
 
1. What is the purpose of the study? 
In the University Malaya Medical Centre (UMMC), doctors 
from the Department of Primary Care Medicine treat many 
postmenopausal women for other conditions such as 
diabetes or hypertension. However, osteoporosis is usually 
a “silent disease’ which means that a woman with 
osteoporosis may experience no symptoms. Consequently, 
there may be a proportion of women who may have 
Part 1 tells you the purpose of this study and what will happen to 
you if you take part. 
Part 2 gives you more detailed information about the conduct of the 
study. 
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osteoporosis but who are not identified, resulting in 
unwanted fractures. 
 
Pharmacists together with doctors play an important role in 
patient care. Pharmacists can supplement the doctor’s role 
by screening for osteoporosis and educating patients on 
their osteoporosis risk and empower patients to take 
osteoporosis preventive measures. To date, no such service 
exists in the UMMC. 
 
Therefore, the purpose of this study is to identify the needs 
of postmenopausal community dwelling women in 
osteoporosis screening, prevention and awareness. We 
would like to better understand some of the barriers and 
potential solutions so that we are able develop and to 
further improve the upcoming osteoporosis screening 
programme. 
 
2. Why have I been invited? 
You have been invited because of your position as a policy 
maker in UMMC. Your views and opinions will help us to 
identify the problems and needs to be addressed in the 
screening, prevention and awareness of osteoporosis. This 
information is then used to guide the set up of the 
osteoporosis screening programme. 
 
A total of five policy makers will be invited to participate in 
the study. We will also be interviewing twenty 
postmenopausal women, ten pharmacists, ten physicians 
and five nurses. 
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3. Do I have to take part? 
Your participation is entirely voluntary and it is up to you to 
decide. We will describe the study and go through this 
information sheet with you when you attend the interview. 
We will then ask you to sign a consent form to show you 
have agreed to take part. You are free to withdraw at any 
time, without giving a reason.  
4. What type of study is this? 
This is a qualitative study using the method of a one-to-one 
interview. It is a challenging task to identify the needs and 
barriers of policy makers in running a tertiary, referral 
centre. To find out, we need to conduct one-to-one 
interviews. By recording and analysing these interviews, we 
are able to obtain useful information from you. 
5. What will happen to me if I take part? 
1. Before the one-to-one interview, the researcher will 
go through the Participant Information Sheet with 
you. If you agree to participate, the researcher will 
ask you to sign a consent form, followed by 
answering a simple questionnaire about your 
background (10 minutes).  
2. The researcher will record the conversation using an 
audio tape recorder. The purpose of the recording is 
to allow the researcher to capture the information 
discussed during the interview, which is important for 
them to analyse later.  
3. The interview will take about 60 minutes.  
6. Expenses and payment 
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You will be given RM 50 to compensate for the time you 
have taken to participate in this research.  
 
7. What will I have to do? 
You are required to answer the questions based on your 
personal experience during the interview. However, you 
can refuse to answer any questions which you feel 
uncomfortable and you can stop the interview at any time.  
 
8. What if there is a problem? 
Any complaint about the way you have been dealt with 
during the study or any possible harm you might suffer will 
be looked into. The detailed information on this is given in 
Part 2.  
 
9. Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all 
information about you will be handled in confidence. The 
details are included in Part 2. 
10. Is the purpose of this study educational? 
Yes. Part of the data from this research will be used for a 
PhD study. 
 
 
 
 
 
 
  
This completes Part 1.  
If the information in Part 1 has interested you and you 
are considering participation, please read the additional 
information in Part 2 before making any decision. 
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Part 2 
11. What will happen if I don’t want to carry on with 
the study? 
You can withdraw from the study without giving any 
reason. 
 
12. What if there is a problem? 
If you have a concern about any aspect of this study, 
you should ask to speak to the researchers who will do 
their best to answer your questions. 
 
13. Will my taking part in this study be kept 
confidential? 
The recorded conversation will be transcribed by the 
researcher. Only the interviewer and the field supervisor 
will have access to the audiotape. All information will be 
coded and anonymised (no name mentioned). Once the 
transcript has been completed and checked by the 
interviewer for accuracy, the audiotape will be destroyed 
professionally. 
 
The information we have collected as paper copies will 
be stored under lock and key, while the electronic data 
can only be accessed with a secure password. Only the 
researchers will have access to the data.  
 
The data we collect will be used only for the purpose of 
this research; if data were to be used for future studies, 
further Research Ethics Committee approval will be 
sought.  
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All information which is collected about you during the 
course of the research will be kept strictly confidential, 
and any information about you which leaves the clinic 
will have your name, telephone and address removed so 
that you cannot be recognized. 
 
14. What will happen to the results of the research 
study? 
The results of this study will be published in medical 
journals.   
 
You will not be identified in any report, publications or 
presentation without seeking your full consent. Direct 
quotes from the interviews may be used in reports and 
publications; however, the quotes will be anonymised to 
ensure that you cannot be identified. You will also be 
able to request a summary for the research. 
 
15. Who is organizing and funding the research? 
This research is organized by Ms. Toh Li Shean and Dr 
Pauline Lai from the University of Malaya, as well as Prof 
Claire Anderson, Associate Prof Mr. Wong Kok Thong 
and Dr Low Bee Yean from the University of Nottingham. 
Funding of this research will be obtained from either 
University of Nottingham or the Ministry of Higher 
Education. 
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16. Who has reviewed the study? 
All research in the UMMC is looked at by an independent 
group of people, called a Research Ethics Committee to 
protect your safety, rights, well-being and dignity.  
 
17. Further information and contact details. 
Specific information about this research project: 
Toh Li Shean 
Tel: 012-2846-849  
Email: rinoa8387@yahoo.com 
Advice as to whether you should participate: 
As above. 
Who you should approach if unhappy with the study: 
As above. 
 
  
 502 
 
13.1   Appendix 17- Nurses consent form for Phase 
one 
Participant identification number for this trial: 
CONSENT FORM 
Title of Project: Addressing the needs of osteoporosis prevention in 
community dwelling postmenopausal women in a 
tertiary hospital in Malaysia: An exploratory qualitative 
study (Nurses) 
Name of Researchers: Prof Claire Anderson / Assoc Prof Mr Wong Kok 
Thong/ Dr Lai Siew Mei Pauline/ Dr Low Bee 
Yean/ Toh Li Shean 
 
 
_______________________ ________________  
Name of Participant Date          Signature 
 
 
_________________________ ________________  
Name of Person taking consent Date Signature 
  
  Please initial 
box 
1. I confirm that I have read and understand the 
information sheet dated 08/03/12 (Version 1-NUR) for 
the above study. I have had the opportunity to consider 
the information, ask questions and have had these 
answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time, without giving any 
reason and without my legal rights being affected. 
 
3. I agree to have the interview audio-taped as described in 
the information sheet d dated 08/03/12 (Version 1-NUR). 
 
4. I give my consent for anonymised direct quotes to be 
used in reports and publications. 
 
5. I agree to take part in the above study.  
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13.2   Appendix 18- Nurses consent form for Phase 
one, Malay version 
Nombor pengenalan perserta untuk kajian ini:  
BORANG PERSETUJUAN 
Tajuk Projek:  Menangani keperluan pencegahan osteoporosis di 
kalangan wanita menopaus di hospital pengajian tinggi 
di Malaysia: Satu kajian penerokaan kualitatif (pesakit) 
Nama Penyelidik: Prof Claire Anderson / Assoc Prof Mr Wong Kok 
Thong/ Dr Lai Siew Mei  Pauline/ Dr Low Bee Yean/ 
Toh Li Shean 
 
 
_______________________ ________________  
Nama Peserta Tarikh   Tandatangan 
 
 
_________________________  ________________  
Pihak Yang Mengambil Persetujuan      Tarikh    Tandatangan 
 
  Sila tandatangan di 
kotak berkenaan 
1. Saya mengesahkan bahawa saya telah membaca 
dan memahami Iembaran maklumat yang bertarikh 
08/03/12 (Version 1-NUR-BM) untuk kajian di atas. 
Saya juga telah diberi peluang untuk 
mempertimbangkan maklumat, bertanya soalan dan 
mendapatkan jawapan yang memuaskan.  
 
2. Saya memahami bahawa penyertaan saya adalah 
secara sukarela dan saya bebas untuk menarik diri 
pada bila-bila masa, tanpa memberi apa-apa sebab, 
tanpa menjejaskan hak undang-undang saya. 
 
4. Saya bersetuju supaya wawancara audio akan 
dirakamkan seperti yang dinyatakan dalam lembaran 
maklumat yang bertarikh 08/03/12 (Version 1- NUR-
BM). 
 
5. Saya memberi kebenaran supaya petikan langsung 
daripada wawancara dapat digunakan dalam laporan 
dan penerbitan tanpa mendedahkan identiti saya. 
 
6. Saya bersetuju untuk menyertai kajian di atas.  
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13.3   Appendix 19- Pharmacists consent form for 
Phase one 
Participant identification number for this trial: 
CONSENT FORM 
Title of Project: Addressing the needs of osteoporosis prevention in 
community dwelling postmenopausal women in a 
tertiary hospital in Malaysia: An exploratory qualitative 
study (Pharmacist) 
Name of Researchers: Prof Claire Anderson / Assoc Prof Mr Wong Kok 
Thong/ Dr Lai Siew Mei Pauline/ Dr Low Bee 
Yean/ Toh Li Shean 
 
 
_______________________ ________________  
Name of Participant Date     Signature 
 
 
_________________________ ________________  
Name of Person taking consent Date    Signature 
 
  
  Please initial box 
1. I confirm that I have read and understand the 
information sheet dated 08/03/12 (Version 1-
PHARM) for the above study. I have had the 
opportunity to consider the information, ask 
questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary 
and that I am free to withdraw at any time, 
without giving any reason and without my legal 
rights being affected. 
 
3. I agree to have the interview audio-taped as 
described in the information sheet d 
dated 08/03/12 (Version 1-PHARM). 
 
4. I give my consent for anonymised direct quotes 
to be used in reports and publications. 
 
5. I agree to take part in the above study.  
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13.4   Appendix 20- Doctors consent form for Phase 
one 
 Participant identification number for this trial: 
CONSENT FORM 
Title of Project: Addressing the needs of osteoporosis prevention in 
community dwelling postmenopausal women in a 
tertiary hospital in Malaysia: An exploratory qualitative 
study (Doctor) 
Name of Researchers: Prof Claire Anderson / Assoc Prof Mr Wong Kok 
Thong/ Dr Lai Siew Mei Pauline/ Dr Low Bee 
Yean/ Toh Li Shean 
 
 
_______________________ ________________  
Name of Participant Date    Signature 
 
 
_________________________ ________________  
Name of Person taking consent Date     Signature 
  
  Please initial box 
1. I confirm that I have read and understand the 
information sheet dated 08/03/12 (Version 1-
DR) for the above study. I have had the 
opportunity to consider the information, ask 
questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is 
voluntary and that I am free to withdraw at 
any time, without giving any reason and 
without my legal rights being affected. 
 
3. I agree to have the interview audio-taped as 
described in the information sheet d 
dated 08/03/12 (Version 1-DR). 
 
4. I give my consent for anonymised direct 
quotes to be used in reports and publications. 
 
5. I agree to take part in the above study.  
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13.5   Appendix 21- Policy makers consent form for 
Phase one 
13.6   Participant identification number for this trial: 
CONSENT FORM 
Title of Project: Addressing the needs of osteoporosis prevention in 
community dwelling postmenopausal women in a 
tertiary hospital in Malaysia: An exploratory qualitative 
study (Policy maker) 
Name of Researchers: Prof Claire Anderson / Assoc Prof Mr Wong Kok 
Thong/ Dr Lai Siew Mei Pauline/ Dr Low Bee 
Yean/ Toh Li Shean 
 
 
_______________________ ________________  
Name of Participant Date       Signature 
 
 
_________________________ ________________  
Name of Person taking consent Date      Signature 
 
  
  Please initial box 
1. I confirm that I have read and understand the 
information sheet dated 08/03/12 (Version 1-POL) for 
the above study. I have had the opportunity to consider 
the information, ask questions and have had these 
answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time, without giving any 
reason and without my legal rights being affected. 
 
3. I agree to have the interview audio-taped as described in 
the information sheet d dated 08/03/12 (Version 1-POL). 
 
4. I give my consent for anonymised direct quotes to be 
used in reports and publications. 
 
5. I agree to take part in the above study.  
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13.7   Appendix 22- Ethical approval for Phase one 
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13.8   Appendix 23- Finalized version of the 
Satisfaction questionnaire for osteoporosis 
Prevention (SQOP) 
Satisfaction Questionnaire for Osteoporosis Prevention (SQOP)    
self/assisted 
This questionnaire is to assess your satisfaction about a pharmacist conducted 
osteoporosis prevention programme. Filling out this questionnaire will provide 
information for us to further improve our services.  
Please tick the answer that best suits your opinion.  
 
A. Clinical Services 
 
   
 509 
 
1 The service was conducted at 
 a time that   _______ (fill in the 
blank) for you.  
 5 Was definitely suitable 
 4 Was probably suitable 
 3 Made  no difference 
 2 Was probably unsuitable 
 1 Was definitely unsuitable  
 
2 During the session, what did you 
think about the time given to 
discuss your problems with the 
pharmacist? 
 5 Definitely enough time 
 4 Probably enough time 
 3  No difference 
 2  Probably insufficient time 
 1  Definitely insufficient time 
 
3. How would you rate the location 
of this service? 
 5 Very convenient 
 4 Somewhat convenient 
 3  No difference 
 2   Somewhat inconvenient 
 1  Very inconvenient  
 
4 How would you rate the comfort 
of the location? 
 5 Very comfortable 
 4 Somewhat comfortable 
 3  No difference 
 2   Somewhat uncomfortable 
 1  Very uncomfortable 
 
5 If you have questions about 
osteoporosis, would you ask the 
pharmacist?   
 5 Yes, I would definitely trust the 
answer given by the pharmacist. 
 4 Yes, I would probably trust the 
answer given by the pharmacist. 
 3 No comment. 
 2 No, I probably would not trust the 
answer given by the pharmacist. 
 1 No, I definitely would not trust the 
answer given by the pharmacist. 
 
 
6 Was the pharmacist easy to talk 
to? 
 5  Definitely  approachable 
 4  Probably approachable 
 3  No difference 
 2   Probably unapproachable  
 1  Definitely  unapproachable 
 
7 How would you rate the service 
provided by the pharmacist? 
 5 Definitely useful 
 4 Useful 
 3  No difference 
 2  Not useful 
 1  Definitely not useful 
 
8 How would you rate the advice 
given by the pharmacist? 
 
 
 5 Definitely  helpful 
 4  Probably helpful 
 3  No difference 
 2   Probably not helpful 
 1   Definitely not helpful at all 
 
9 How would you rate the overall 
quality of service that was given 
by the pharmacist to you? 
 5Excellent 
 4Good 
 3Satisfactory 
 2Fair 
 1Poor 
 
10 This pharmacist service should 
_______ (fill in the blank) 
 5 Definitely be continued 
 4 Probably be continued 
 3  No comment 
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 2  Probably be discontinued 
 1  Definitely be discontinued 
 
11 What do you think about having 
the same pharmacist to see you 
for subsequent osteoporosis 
care? 
 5 Yes, I would definitely like that 
 4 Yes, I  would probably like that 
 3  No difference 
 2  No, I probably would not like that 
 1  No, I definitely would not like that 
 
12 Pharmacist in other hospitals  
should ______ (fill in the blank) 
this service 
 5 Definitely  provide 
 4 Probably provide 
 3  No comment 
 2  Probably not provide 
 1  Definitely  not provide 
 
13 How would you rate the amount 
of information provided to 
prevent falls? 
 5 Definitely enough 
 4 Probably enough 
 3  No difference 
 2  Probably not enough 
 1  Definitely not enough 
 
 
14 
 
How would you rate the amount 
of information provided to 
change your diet to prevent bone 
loss? 
 
 5 Definitely enough 
 4 Probably enough 
 3  No difference 
 2  Probably not enough 
 1  Definitely not enough 
 
 
15 How would you rate the amount 
of information provided on the 
exercises to help strengthen 
bones? 
 
 5 Definitely enough 
 4 Probably enough 
 3  No difference 
 2  Probably not enough 
 1  Definitely not enough 
 
 
16 Would you pay for a pharmacist 
counselling service? 
 5 Yes, definitely 
 4 Yes, probably 
 3  No difference 
 2  No, probably not 
 1  No, definitely not 
 
17 If yes, how much are you willing 
to pay for each visit to the 
pharmacist?  
 
If you are not willing to pay 
anything for the service, please 
proceed to question 18. 
 5RM1-5 
 4RM6-10 
 3RM11-15 
 2RM16-20 
 1More than RM20 
 
18 How would you rate your 
understanding of osteoporosis 
now? 
 5Much better than before 
 4Slightly better than before 
 3Same as before 
 2Slightly worse than before 
 1Much worse than before 
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B. Types of counselling 
 
Please indicate how you found the following information which the pharmacist may 
have provided. If you were not provided with any counselling, please omit this 
section. 
 
  
   
   
   
19 Explanation of osteoporosis  0Not Applicable 
 1Definitely not useful 
 2Not useful 
 3No difference 
 4Useful 
 5Extremely useful 
 
20 Explanation of consequences 
of untreated osteoporosis 
 0Not Applicable 
 1Definitely not useful 
 2Not useful 
 3No difference 
 4Useful 
 5Extremely useful 
 
21 Explanation on how 
osteoporosis  can be 
prevented via lifestyle 
change(s) 
 0Not Applicable 
 1Definitely not useful 
 2Not useful 
 3No difference 
 4Useful 
 5Extremely useful 
 
22 Explanation on the available 
methods to screen for 
osteoporosis 
 0Not Applicable 
 1Definitely not useful 
 2Not useful 
 3No difference 
 4Useful 
 5Extremely useful 
 
23 Osteoporosis booklet provided  0Not Applicable 
 1Definitely not useful 
 2Not useful 
 3No difference 
 4Useful 
 5Extremely useful 
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13.9   Appendix 24- Osteoporosis booklet 
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13.16   Appendix 25- Patients information sheet for 
Phase two- Satisfaction questionnaire for 
osteoporosis Prevention (SQOP) 
Patient Information Sheet 
 
Study Title: The development and validation of tools for 
the screening and prevention of osteoporosis in 
community dwelling postmenopausal women in a 
tertiary hospital in Malaysia. (Patients): The validation 
of the satisfaction tool. 
 Version: V1-SATISFT-VLD-PT-17/03/12 
 
 
14      
 
Part 1 
We would like to invite you to take part in a research study.  
Before you decide whether to participate, you need to 
understand why the research is being done and what it would 
involve. Please take time to read the following information 
carefully; talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you 
wish to take part.  
 
1. What is the purpose of the study? 
In the University Malaya Medical Centre (UMMC), doctors 
from the Department of Primary Care Medicine treat 
many postmenopausal women for other conditions such 
as diabetes or hypertension. However, osteoporosis is 
Part 1 tells you the purpose of this study and what will happen to 
you if you take part. 
Part 2 gives you more detailed information about the conduct of the 
study. 
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usually a “silent disease’ where women with osteoporosis 
may experience no symptoms. Consequently, there may 
be a proportion of women who may have osteoporosis but 
who are not aware, resulting in unwanted fractures. 
 
Pharmacists together with doctors play an important role 
in patient care. Pharmacists can supplement the doctor’s 
role by screening for osteoporosis and educating patients 
on their osteoporosis risk. This would empower patients 
to take osteoporosis preventive measures. To date, no 
such service exists in the UMMC. 
 
Therefore, the purpose of this study is to develop and 
validate a tool on evaluating patient’s satisfaction towards 
an osteoporosis screening programme. This tool will be 
used as a quality indicator for the upcoming osteoporosis 
screening programme. 
 
2. Why have I been invited? 
Since you are currently seeing a doctor from the 
Department of Primary Care Medicine for your medical 
condition, we would like to explore your satisfaction with 
the current osteoporosis healthcare practices and your 
preferences for future improvements using this tool. This 
information will be used to guide the development and 
validation of a patient satisfaction evaluation tool for the 
new osteoporosis screening programme in UMMC. Your 
care will be more wholesome as you will be seen by both 
the doctor and the pharmacist. 
A total of 96 patients who are attending the Primary Care 
Family Clinic will be invited to participate in this study.  
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3. Do I have to take part? 
Your participation is entirely voluntary and it is up to you 
to decide. We will describe the study and go through this 
information sheet with you before you fill up the 
questionnaire. We will then ask you to sign a consent 
form to show you have agreed to take part. You are free 
to withdraw at any time, without giving a reason. This 
would not affect your treatment or the standard of care 
you receive. 
4. What type of study is this? 
This is a quantitative study using questionnaires. It is a 
challenging task to determine whether patients are 
satisfied with the current osteoporosis health treatment 
and services received. To find out, we need to develop 
and validate a tool on evaluating patients’ satisfaction 
towards an osteoporosis screening programme. By 
collecting and analysing these data, we are able to 
obtain useful information from them and find out the 
effectiveness of this tool in evaluating patient satisfaction 
with regards to an osteoporosis screening programme. 
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5. What will happen to me if I take part? 
The researcher will ask you if you would like to take 
part in this study. Before filling up the questionnaire, 
the researcher will go through the Patient Information 
Sheet with you. If you agree to participate, the 
researcher will ask you to sign a consent form, 
followed by answering a simple questionnaire about 
your background (10 minutes).  
You will then need to fill up the patient satisfaction 
questionnaire for the first time. This will take about 15 
minutes.  
After filling up the questionnaire, you will be randomly 
allocated to the control or intervention group. 
Participants in the intervention group will receive a 30 
minute counseling session and a follow up phone 
counseling session two weeks later; whilst the control 
group will receive the standard care with no counseling 
intervention.  
All participants will be scheduled a second 
appointment for a month later. 
During your second appointment (a month later) you 
will need to fill up the patients’ satisfaction 
questionnaire for the second time. 
However, the control group will not be at a 
disadvantage as they will receive the counseling 
session at the end of the study and a follow up phone 
counseling 6 weeks later. 
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6. Expenses and payment 
You will be given RM 20 per visit as a reimbursement for 
your travel expenses.  
 
7. What will I have to do? 
You are required to attend one counseling session and 
answer all the questions in the questionnaire during two 
separate occasions based on your experience.  
 
8. What are the possible disadvantages and risks of 
taking part? 
You will have to spend more time in the hospital as you 
will need to come back for your second appointment one 
month later. 
 
9. What happens when the research study stops? 
Your doctor will continue to provide medical care for you. 
 
10. What if there is a problem? 
Any complaint about the way you have been dealt with 
during the study or any possible harm you might suffer 
will be looked into. The detailed information on this is 
given in Part 2.  
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11. Will my taking part in the study be kept 
confidential? 
Yes. We will follow ethical and legal practice and all 
information about you will be handled in confidence. The 
details are included in Part 2. 
12. Is the purpose of this study educational? 
Yes. Part of the data from this research will be used for a 
PhD study. 
 
 
 
 
 
 
Part 2 
13. What will happen if I don’t want to carry on with 
the study? 
You can withdraw from the study without giving a 
reason and without affecting your care. 
 
14. What if there is a problem? 
If you have a concern about any aspect of this study, 
you should ask to speak to the researchers who will do 
their best to answer your questions. 
 
 
 
 
This completes Part 1.  
If the information in Part 1 has interested you and you 
are considering participation, please read the additional 
information in Part 2 before making any decision. 
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15. Will my taking part in this study be kept 
confidential? 
Only the researchers involved will have access to your 
medical notes and data collected. All information will be 
anonymised (no name mentioned).  
 
The information we have collected as paper copies will 
be stored under lock and key, while the electronic data 
can only be accessed with a secure password. Only the 
researchers will have access to the data.  
 
The data we collect will be used only for the purpose of 
this research; if data were to be used for future studies, 
further Research Ethics Committee approval will be 
sought.  
 
All information which is collected about you during the 
course of the research will be kept strictly confidential, 
and any information about you which leaves the clinic 
will have your name, telephone and address removed so 
that you cannot be recognized. 
 
16. Involvement of the General Practitioner/Family 
doctor (GP) 
Your doctor will be informed about your participation in 
this study. 
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17. What will happen to the results of the research 
study? 
The results of this study will be published in medical 
journals.   
 
You will not be identified in any report, publications or 
presentation without seeking your full consent. You will 
also be able to request a summary for the research. 
 
18. Who is organizing and funding the research? 
This research is organized by Ms. Toh Li Shean and Dr 
Pauline Lai Siew Mei from the University of Malaya, as 
well as Prof Claire Anderson, Associate Prof Mr Wong 
Kok Thong and Dr Low Bee Yean from the University of 
Nottingham. Funding of this research will be obtained 
from either University of Nottingham or the Ministry of 
Higher Education.  
 
19. Who has reviewed the study? 
All research in the UMMC is looked at by an independent 
group of people, called a Research Ethics Committee to 
protect your safety, rights, well-being and dignity.  
 
20. Further information and contact details. 
Specific information about this research project: 
Toh Li Shean 
Tel: 012-2846-849  
Email: rinoa8387@yahoo.com. 
Advice as to whether you should participate: 
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As above. 
Who you should approach if unhappy with the study: 
As above. 
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14.1   Appendix 26- Patients consent form for Phase 
two- Satisfaction questionnaire for 
osteoporosis Prevention (SQOP) 
Participant identification number for this trial: 
CONSENT FORM 
Title of Project: The development and validation of tools for the screening 
and prevention of osteoporosis in community dwelling 
postmenopausal women in a tertiary hospital in Malaysia. 
(Patients) The validation of the satisfaction tool. 
Name of Researchers: Prof Claire Anderson / Assoc Prof Mr Wong Kok 
Thong/ Dr Lai Siew Mei Pauline/ Dr Low Bee 
Yean/ Toh Li Shean 
 
_______________________ ________________  
Name of Participant Date     Signature 
 
 
_________________________ ________________  
Name of Person taking consent Date      Signature 
  Please initial box 
1. I confirm that I have read and understand the 
information sheet dated 17/03/12 (Version 1-
SATISFT-VLD-PT) for the above study. I have had 
the opportunity to consider the information, ask 
questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and 
that I am free to withdraw at any time, without 
giving any reason and without my legal rights 
being affected. 
 
3. I understand that relevant sections of any of my 
medical notes and data collected during the study 
may be looked at by responsible individuals from 
the University Malaya Medical Center, the 
University of Malaya and the University of 
Nottingham, where it is relevant to my taking part 
in this research.  I give permission for these 
individuals to have access to my records.                                                                                                         
 
4. I agree to take part in the above study.  
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14.2   Appendix 27- Ethical approval for Phase two 
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14.3   Appendix 28- The finalized Osteoporosis 
Prevention and Awareness  Tool (OPAAT) 
21. Osteoporosis Prevention And Awareness Tool 
(OPAAT) 
Serial no    
 Total score___________ 
Please tick at the appropriate box: 
1. A.  What can you tell me about 
osteoporosis? 
 True1 False2 Don’t 
know3 
1. Makes bones weaker, more brittle 
and more likely to break (fracture)  
 
      
2. Everybody will get osteoporosis as it 
is part of aging  
 
      
3. Osteoporosis occurs because bone is 
removed faster than it is formed 
 
      
4. Osteoporosis and osteoarthritis are 
different names we can use to 
describe the same disease  
 
      
5. Osteoporosis usually has no 
symptoms  
 
      
6. Postmenopausal women are not at 
risk for osteoporosis  
 
      
7. Osteoporosis is an untreatable 
disease. 
 
      
8. A bone mineral density test is used to 
diagnose osteoporosis  
 
      
9. I do not need a bone mineral density 
test unless I fracture my bones.  
 
      
10. A bone mineral density test is high in 
radiation  
 
      
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11. A bone mineral density test should be 
performed monthly to monitor bone 
loss  
      
 
B. What will happen if your osteoporosis is left untreated? 
 True1 False2 Don’t 
know3 
12. Results in back pain  
 
      
13. Loss of height or hunchback  
 
      
14. Loss of mobility (unable to move 
around myself) 
  
      
15. Results in tooth loss  
 
      
16. Results in joint pain or swelling of 
fingers 
      
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C. What can you tell me about osteoporosis prevention? 
 
 True1 False2 Don’t 
know3 
17. The recommended daily intake for 
calcium in women above 50 years 
of age is 1000mg  
 
      
18. It is too late to increase calcium 
intake after the age 50 
  
      
19. Glucosamine can help prevent 
osteoporosis 
 
      
20. Calcium supplements can help 
prevent osteoporosis  
 
      
21. The regular dose of calcium 
supplements can cause kidney 
stones. 
 
      
22. Foods such as milk, tofu, 
anchovies (ikan bilis), yellow dhal 
and spinach are rich in calcium  
 
      
23. You can obtain your recommended 
daily intake of vitamin D via 
exposing your skin to sunlight for 
about 15 minutes a day   
 
      
24. Increasing coffee and tea intake 
can help in osteoporosis 
prevention 
 
      
25. Weight bearing exercise (such as 
brisk walking and line dancing) can 
decrease bone loss. 
  
      
26. Exercise will wear out bones  
 
      
27. Certain medications (such as 
sleeping tablets or high blood 
pressure medications) may reduce 
the risk of falling  
 
      
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28. To prevent falls, comfortable shoes 
with a good grip should be used.  
 
      
29. Poor vision may lead to falls 
 
      
30. Being under weight helps prevent 
osteoporosis  
      
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14.4   Appendix 29- Patients information sheet for 
Phase two- Osteoporosis Prevention and 
Awareness  Tool (OPAAT) and risk assessment 
too 
Patient Information Sheet  
 
Study Title: The validation of tools for the screening and 
prevention of osteoporosis in community dwelling 
postmenopausal women in a tertiary hospital in 
Malaysia. (patients): The validation of the knowledge 
tool and the validation of the osteoporosis risk 
assessment tools. 
 Version: V1-KNOWL/SCREEN-VLD-PT-17/03/12 
 
 
22.  
 
Part 1 
We would like to invite you to take part in a research study.  
Before you decide whether to participate, you need to 
understand why the research is being done and what it would 
involve. Please take time to read the following information 
carefully; talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you 
wish to take part.  
 
1. What is the purpose of the study? 
In the University Malaya Medical Centre (UMMC), doctors 
from the Department of Primary Care Medicine treat 
Part 1 tells you the purpose of this study and what will happen to 
you if you take part. 
Part 2 gives you more detailed information about the conduct of the 
study. 
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many postmenopausal women for other conditions such 
as diabetes or hypertension. However, osteoporosis is 
usually a “silent disease’ where women with osteoporosis 
may experience no symptoms. Consequently, there would 
a proportion of women who have osteoporosis but who 
are not aware, resulting in unwanted fractures. 
 
Pharmacists together with doctors play an important role 
in patient care. Pharmacists can supplement the doctor’s 
role by screening for osteoporosis and educating patients 
on their osteoporosis risk. This would empower patients 
to take osteoporosis preventive measures. To date, no 
such service exists in the UMMC. 
 
Therefore, the purpose of this study is to develop and 
validate two tools. The first is a tool to assess the 
knowledge of osteoporosis screening, prevention and 
awareness among patients in Malaysia. The second is to 
validate several osteoporosis risk assessment tools for 
use in Malaysia. These tools will be used to assist the 
upcoming osteoporosis screening programme. 
 
2. Why have I been invited? 
Since you are currently seeing a doctor from the 
Department of Primary Care Medicine for your medical 
condition, we would like to explore your knowledge and 
understanding of osteoporosis regarding its screening, 
prevention and awareness using OPAAT knowledge tool. 
This information will be used to validate the knowledge 
tool for the new osteoporosis screening programme in 
UMMC.  
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Secondly, we would like to ask you some questions about 
your past medical history and diet to calculate your risk of 
getting osteoporosis using some osteoporosis risk 
assessment tools.  We will also require you to go for a 
bone mineral density (BMD) to confirm the results 
obtained from these risk assessment tools. This process is 
to validate the use of the osteoporosis risk assessment 
tools among Malaysian patients. Your care will be more 
wholesome as you will be seen by both the doctor and the 
pharmacist. 
A total of 150 patients who are attending the Primary 
Care Family Clinic will be invited to participate in the 
study.  
3. Do I have to take part? 
Your participation is entirely voluntary and it is up to you 
to decide. We will describe the study and go through this 
information sheet with you before you fill up the 
questionnaire. We will then ask you to sign a consent 
form to show you have agreed to take part. You are free 
to withdraw at any time, without giving a reason. This 
would not affect your treatment or the standard of care 
you receive. 
4. What type of study is this? 
This is a quantitative study using questionnaires. It is a 
challenging task to determine whether patients are 
getting sufficient information about osteoporosis and 
whether patients at risk for osteoporosis are being 
identified adequately. For example, postmenopausal 
women may not know the availability of osteoporosis 
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preventive measures and that they may be at risk for 
osteoporosis. To find out, we need to develop and 
validate a knowledge assessment questionnaire.  
Aside from that, based on the results of your BMD scans 
we will compare the results obtained from the 
osteoporosis risk assessment tool. By collecting and 
analysing these data, we are able to obtain useful 
information from them and find out the effectiveness of 
these tools in identifying the knowledge gaps of the 
current practices and its effectiveness in assessing the 
risk of osteoporosis. 
5. What will happen to me if I take part? 
The researcher will ask you if you would like to take 
part in this study. Before filling up the questionnaire, 
the researcher will go through the Patient Information 
Sheet with you. If you agree to participate, the 
researcher will ask you to sign a consent form, 
followed by answering a simple questionnaire about 
your background (10 minutes).  
You will then need to fill up the knowledge assessment 
questionnaire for the first time. This will take about 10 
minutes. 
Subsequently, there will be a short interview of about 
5 minutes to assess your osteoporosis risk factors.  
The researcher will schedule a date for your BMD scan 
appointment. A BMD request form will be given to you 
which you MUST BRING to the ANOC Neuroscience 
and Orthopedic centre.You will then need to call 
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up ANOC to confirm the time and date that you 
are available for the BMD scan. 
Lastly, a phone follow up will be scheduled two weeks 
later where the pharmacist will review your BMD 
results. You will be asked questions from  the 
knowledge assessment questionnaire for the second 
time. 
The copy of your BMD scan results will be sent to you 
via registered mail. 
6. What is a Bone Mineral Density (BMD) Scan? 
A BMD scan uses a Dual Energy X-ray Absortiometry 
(DEXA) machine to measure how strong, or dense your 
bones are. The results show how much risk there is of the 
bones fracturing.  The scan will take about 10 to 20 
minutes and is not unpleasant or painful in any way. You 
will be asked to lie on a firm couch, fully clothed, whilst 
the machine takes the pictures. You will NOT go into a 
tunnel or have an injection. In addition, the scan is very 
safe and the dose of radiation is tiny. The dose of 
radiation is similar to spending a day out in the sun.  
 
7. Expenses and payment 
You will be given RM 20 per visit as a reimbursement for 
your travel expenses and another RM20 will be given for 
your time during the phone follow up. This research 
project will cover the RM180 fee of your BMD scan at 
ANOC. 
  
 557 
 
8. What will I have to do? 
You are required to answer all the questions in the 
questionnaire during two separate occasions based on 
your current knowledge. You will also need to stop taking 
any calcium supplements 3 days before your BMD scan. 
 
9. What are the possible disadvantages and risks of 
taking part? 
You will have to spend more time in the hospital. 
 
10. What happens when the research study stops? 
Your doctor will continue to provide medical care for you. 
 
11. What if there is a problem? 
Any complaint about the way you have been dealt with 
during the study or any possible harm you might suffer 
will be looked into. The detailed information on this is 
given in Part 2.  
 
12. Will my taking part in the study be kept 
confidential? 
Yes. We will follow ethical and legal practice and all 
information about you will be handled in confidence. The 
details are included in Part 2. 
 
13. Is the purpose of this study educational? 
Yes. Part of the data from this research will be used for a 
PhD study. 
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Part 2 
14. What will happen if I don’t want to carry on with 
the study? 
You can withdraw from the study without giving a 
reason and without affecting your care. 
 
15. What if there is a problem? 
If you have a concern about any aspect of this study, 
you should ask to speak to the researchers who will do 
their best to answer your questions.  
 
16. Will my taking part in this study be kept 
confidential? 
Only the researchers involved will have access to your 
medical notes and data collected. All information will be 
anonymised (no name mentioned).  
The information we have collected as paper copies will 
be stored under lock and key, while the electronic data 
can only be accessed with a secure password. Only the 
researchers will have access to the data.  
The data we collect will be used only for the purpose of 
this research; if data were to be used for future studies, 
further Research Ethics Committee approval will be 
sought.  
All information which is collected about you during the 
course of the research will be kept strictly confidential, 
and any information about you which leaves the clinic 
This completes Part 1.  
If the information in Part 1 has interested you and you 
are considering participation, please read the additional 
information in Part 2 before making any decision. 
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will have your name, telephone and address removed so 
that you cannot be recognized. 
 
17. Involvement of the General Practitioner/Family 
doctor (GP) 
Your doctor will be informed about your participation in 
this study. 
 
18. What will happen to the results of the research 
study? 
The results of this study will be published in medical 
journals.   
 
You will not be identified in any report, publications or 
presentation without seeking your full consent. You will 
also be able to request a summary for the research. 
 
19. Who is organizing and funding the research? 
This research is organized by Ms. Toh Li Shean and Dr 
Pauline Lai Siew Mei from the University of Malaya, as 
well as Prof Claire Anderson, Associate Prof Mr Wong 
Kok Thong and Dr Low Bee Yean from the University of 
Nottingham. Funding of this research is from the  
Ministry of Higher Education.  
 
20. Who has reviewed the study? 
All research in the UMMC is looked at by an independent 
group of people, called a Research Ethics Committee to 
protect your safety, rights, well-being and dignity.  
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21. Further information and contact details. 
Specific information about this research project: 
Toh Li Shean 
Tel: 012-2846-849  
Email: rinoa8387@yahoo.com 
Advice as to whether you should participate: 
As above. 
Who you should approach if unhappy with the study: 
As above. 
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14.5   Appendix 30- Patients consent form for Phase 
two- Osteoporosis Prevention and Awareness  
Tool (OPAAT) and risk assessment tools 
Participant identification number for this trial: 
CONSENT FORM 
Title of Project: The validation of tools for the screening and prevention of 
osteoporosis in community dwelling postmenopausal 
women in a tertiary hospital in Malaysia. (Patients): The 
validation of the knowledge tool and the validation of the 
osteoporosis risk assessment tools.  
Name of Researchers: Prof Claire Anderson / Assoc Prof Mr Wong Kok 
Thong/ Dr Lai Siew Mei Pauline/ Dr Low Bee 
Yean/ Toh Li Shean 
 
_______________________ ________________  
Name of Participant Date   Signature 
 
_________________________ ________________  
Name of Person taking consent Date   Signature 
  Please initial box 
1. I confirm that I have read and understand the 
information sheet dated 17/03/12 (Version 1- 
KNOWL/SCREEN-VLD-PT) for the above study. I 
have had the opportunity to consider the 
information, ask questions and have had these 
answered satisfactorily. 
 
2. I understand that my participation is voluntary and 
that I am free to withdraw at any time, without 
giving any reason and without my legal rights 
being affected. 
 
3. I understand that relevant sections of any of my 
medical notes and data collected during the study 
may be looked at by responsible individuals from 
the University Malaya Medical Center, the 
University of Malaya and the University of 
Nottingham, where it is relevant to my taking part 
in this research.  I give permission for these 
individuals to have access to my records.                                                                                                         
 
4. I agree to take part in the above study.  
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14.6   Appendix 31- Pharmacists information sheet 
for Phase two - Osteoporosis Prevention and 
Awareness  Tool (OPAAT)  
Participant Information Sheet 
Study Title: The development and validation of tools for 
the screening and prevention of osteoporosis in 
community dwelling postmenopausal women in a 
tertiary hospital in Malaysia. (Healthcare professionals-
doctors and pharmacists): The validation of the 
knowledge tool. 
 Version: V1-KNOWL-VLD-HCP-18/03/12 
 
23.  
 
 
Part 1 
We would like to invite you to take part in a research study.  
Before you decide whether to participate, you need to 
understand why the research is being done and what it would 
involve. Please take time to read the following information 
carefully; talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you 
wish to take part.  
 
1. What is the purpose of the study? 
In the University Malaya Medical Centre (UMMC), doctors 
from the Department of Primary Care Medicine treat many 
postmenopausal women for other conditions such as 
Part 1 tells you the purpose of this study and what will happen to 
you if you take part. 
Part 2 gives you more detailed information about the conduct of the 
study. 
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diabetes or hypertension. However, osteoporosis is usually 
a “silent disease’ which means that a woman with 
osteoporosis may experience no symptoms. Consequently, 
there may be a proportion of women who may have 
osteoporosis but who are not identified, resulting in 
unwanted fractures. 
 
Pharmacists together with doctors play an important role in 
patient care. Pharmacists can supplement the doctor’s role 
by screening for osteoporosis and educating patients on 
their osteoporosis risk and empower patients to take 
osteoporosis preventive measures. To date, no such service 
exists in the UMMC. 
 
Therefore, the purpose of this study is to develop and 
validate an instrument to assess the knowledge of 
osteoporosis screening, prevention and awareness. This 
tool will be used to assist the upcoming osteoporosis 
screening programme. 
 
2. Why have I been invited? 
You have been invited because of your experience as an 
outpatient healthcare professional in managing 
postmenopausal women. Your views and knowledge 
assessment will help us to develop and validate a tool to 
identify the knowledge gaps in the screening, prevention 
and awareness of osteoporosis. This information is then 
used to guide the development and validation of a 
knowledge assessment tool for the new osteoporosis 
screening programme in UMMC. 
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A total of 30 healthcare professionals will be invited to 
participate in the study.  
 
3. Do I have to take part? 
Your participation is entirely voluntary and it is up to you to 
decide. We will describe the study and go through this 
information sheet with you before you fill up the 
questionnaire. We will then ask you to sign a consent form 
to show you have agreed to take part. You are free to 
withdraw at any time, without giving a reason.  
4. What type of study is this? 
This is a quantitative study using questionnaires. It is a 
challenging task to determine whether there is sufficient 
information and awareness about osteoporosis in the 
current practices. For example, postmenopausal women 
may not know the availability of osteoporosis preventive 
measures and that they may be at risk for osteoporosis. To 
find out, we need to develop and validate a knowledge 
assessment questionnaire. By collecting and analysing 
these data, we are able to obtain useful information from 
them and find out the effectiveness of this tool in identify 
the knowledge gaps in osteoporosis. 
5. What will happen to me if I take part? 
1. An appointment will be made at a time convenient to 
you. The researcher will go through the Participant 
Information Sheet with you. If you agree to 
participate, the researcher will ask you to sign a 
consent form, followed by answering a simple 
questionnaire about your background (10 minutes).  
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2. You will then need to fill up the knowledge 
assessment questionnaire for the first time. This will 
take about 15 minutes. A second appointment will be 
made for a month later. 
3. During the second appointment (one month later), 
you would need to fill up the knowledge questionnaire 
for the second time.  
6. What will I have to do? 
You are required to answer all the questions in the 
questionnaire during two separate occasions based on your 
current knowledge.  
 
7. What if there is a problem? 
Any complaint about the way you have been dealt with 
during the study or any possible harm you might suffer will 
be looked into. The detailed information on this is given in 
Part 2.  
 
8. Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all 
information about you will be handled in confidence. The 
details are included in Part 2. 
9. Is the purpose of this study educational? 
Yes. Part of the data from this research will be used for a 
PhD study. 
 
 
 
This completes Part 1.  
If the information in Part 1 has interested you and you 
are considering participation, please read the additional 
information in Part 2 before making any decision. 
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Part 2 
10. What will happen if I don’t want to carry on with 
the study? 
You can withdraw from the study without giving any 
reason. 
 
11. What if there is a problem? 
If you have a concern about any aspect of this study, 
you should ask to speak to the researchers who will do 
their best to answer your questions. 
 
12. Will my taking part in this study be kept 
confidential? 
Only the researchers involved will have access to the 
data collected. All information will be anonymised (no 
name mentioned).  
 
The information we have collected as paper copies will 
be stored under lock and key, while the electronic data 
can only be accessed with a secure password. Only the 
researchers will have access to the data.  
 
The data we collect will be used only for the purpose of 
this research; if data were to be used for future studies, 
further Research Ethics Committee approval will be 
sought.  
 
All information which is collected about you during the 
course of the research will be kept strictly confidential, 
and any information about you which leaves the clinic 
 567 
 
will have your name, telephone and address removed so 
that you cannot be recognized. 
 
13. What will happen to the results of the research 
study? 
The results of this study will be published in medical 
journals.   
 
You will not be identified in any report, publications or 
presentation without seeking your full consent. You will 
also be able to request a summary for the research. 
 
14. Who is organizing and funding the research? 
This research is organized by Ms. Toh Li Shean and Dr 
Pauline Lai Siew Mei from the University of Malaya, as 
well as Prof Claire Anderson, Associate Prof Mr Wong 
Kok Thong and Dr Low Bee Yean from the University of 
Nottingham. Funding of this research will be obtained 
from either University of Nottingham or the Ministry of 
Higher Education.  
 
15. Who has reviewed the study? 
All research in the UMMC is looked at by an independent 
group of people, called a Research Ethics Committee to 
protect your safety, rights, well-being and dignity.  
16. Further information and contact details. 
Specific information about this research project: 
Toh Li Shean Tel: 012-2846-849  
Email: rinoa8387@yahoo.com 
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Advice as to whether you should participate: 
As above. 
Who you should approach if unhappy with the study: 
As above.  
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14.7   Appendix 32- Pharmacists consent form for 
Phase two- - Osteoporosis Prevention and 
Awareness  Tool (OPAAT) 
Participant identification number for this trial: 
CONSENT FORM 
Title of Project: The development and validation of tools for the screening 
and prevention of osteoporosis in community dwelling 
postmenopausal women in a tertiary hospital in Malaysia. 
(Healthcare professionals- pharmacist and doctors): The 
validation of the knowledge tool. 
Name of Researchers: Prof Claire Anderson / Assoc Prof Mr Wong Kok 
Thong/ Dr Lai Siew Mei Pauline/ Dr Low Bee 
Yean/ Toh Li Shean 
 
 
 
 
_______________________ ________________  
Name of Participant Date      Signature 
 
 
 
_________________________ ________________  
Name of Person taking consent Date Signature 
  
  Please initial box 
1. I confirm that I have read and understand the 
information sheet dated 18/03/12 (Version 1-
KNOWL-VLD-HCP) for the above study. I have 
had the opportunity to consider the information, 
ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary 
and that I am free to withdraw at any time, 
without giving any reason and without my legal 
rights being affected. 
 
4. I agree to take part in the above study.  
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14.8   Appendix 33- WHO Fracture Risk Assessment tool
  
14.9   Appendix 34- Pharmacist recommendation 
form 
  
  
14.10   Appendix 35- Patients information sheet for 
Phase three 
 
Patient Information Sheet 
 
Study Title: Addressing the needs of osteoporosis 
prevention in community dwelling postmenopausal 
women in a tertiary hospital in Malaysia: A feasibility 
study of an osteoporosis screening programme 
(patients) 
 Version: V1-OP-SCREEN-PT-24/03/12 
 
 
24.  
 
Part 1 
We would like to invite you to take part in a research study.  
Before you decide whether to participate, you need to 
understand why the research is being done and what it would 
involve. Please take time to read the following information 
carefully; talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you 
wish to take part.  
 
1. What is the purpose of the study? 
In the University Malaya Medical Centre (UMMC), doctors 
from the Department of Primary Care Medicine treat 
many postmenopausal women for other conditions such 
as diabetes or hypertension. However, osteoporosis is 
Part 1 tells you the purpose of this study and what will happen to 
you if you take part. 
Part 2 gives you more detailed information about the conduct of the 
study. 
  
usually a “silent disease’ where women with osteoporosis 
may experience no symptoms. Consequently, there would 
be a proportion of women who have osteoporosis but who 
are not aware, resulting in unwanted fractures. 
 
Pharmacists together with doctors play an important role 
in patient care. Pharmacists can supplement the doctor’s 
role by screening for osteoporosis and educating patients 
about their risk of osteoporosis. This would empower 
patients to take osteoporosis preventive measures. To 
date, no such service exists in the UMMC. 
 
Therefore, the purpose of this study is to evaluate the 
effectiveness of a pharmacist screening programme of 
community dwelling postmenopausal women in a tertiary 
hospital in Malaysia using the Osteoporosis Screening Tool 
for Asians (OSTA). 
 
2. Why have I been invited? 
Since you are currently seeing a doctor from the 
Department of Primary Care Medicine for your medical 
condition, we would like you to participate in this 
osteoporosis screening programme. The information 
obtained from your participation will be used to improve 
future wide scale implementations of an osteoporosis 
screening programme. Your care will be more holistic as 
you will be seen by both the doctor and the pharmacist. 
A total of 50 patients who are attending the Primary Care 
Family Clinic will be invited to participate in the study.  
 
  
  
  
3. Do I have to take part? 
Your participation is entirely voluntary and it is up to you 
to decide. We will describe the study and go through this 
information sheet with you before your participation. We 
will then ask you to sign a consent form to show you have 
agreed to take part. You are free to withdraw at any time, 
without giving a reason. This would not affect your 
treatment or the standard of care you receive. 
4. What type of study is this? 
This is a prospective. It is a challenging task to identify 
patients who are at risk of osteoporosis using the gold 
standard Bone Mineral Density (BMD) scan due to its 
cost. At this point there are many postmenopausal 
women who are unaware of their osteoporosis risk and 
that they are able to take steps to prevent osteoporosis. 
Therefore, this study would like to establish a cost 
effective osteoporosis screening programme whereby we 
would include a section on patient education and an 
osteoporosis risk assessment using a simple and cheap 
tool called OSTA. To find out if this programme is 
effective, we need to conduct a feasibility study to be 
able to identify barriers of conducting an osteoporosis 
screening programme. This will also help us to establish 
an effective workflow for future implementation. 
5. What will happen to me if I take part? 
1. The nurse will recommend the pharmacist if you are 
potential participant. The researcher/pharmacist 
will then ask you if you would like to take part in 
this study. Before beginning the study, the 
  
pharmacist will go through the Patient Information 
Sheet with you. If you agree to participate, the 
pharmacist will ask you to sign a consent form, 
followed by answering a simple questionnaire about 
your background (10 minutes).  
2. You will then need to fill up 1 questionnaire which 
will assess your knowledge on osteoporosis. You 
will then be measured for your weight and height 
and interviewed for other risk factors for 
osteoporosis. 
3. You will be provided an “intervention package” 
which consists of: 
i. A counseling session at baseline (1st visit).  
1. In addition, depending on your 
osteoporosis risk assessment the 
pharmacist may recommend to the GP 
to schedule a Bone Mineral Density 
(BMD) scan.  
ii. An appointment for the BMD scan. 
1. If both you and your GP agrees for a 
BMD scan, your BMD scan will be 
scheduled on the same day or three 
days later depending on whether you 
have been taking calcium supplements. 
(You will have to go for a BMD scan 
within two weeks) 
2. Subsequently, an appointment for 1 
month later with the GP will be made to 
review your BMD.  
  
3. The pharmacist will also call you the 
next day. You will need to fill up two 
questionnaires which will assess your 
satisfaction of the services received and 
your knowledge of osteoporosis before 
the counseling session. There will also 
be a short interview to ask if there were 
any changes in your lifestyle. The 
interview will take about 5 minutes. 
4. For participants that do not require a 
BMD scan or decline to go for a BMD 
scan or where the GP does not order a 
BMD scan, an appointment will be given 
to the patient 1 month later to fill up 
the two questionnaires. 
5. A phone call will be placed to all 
participants the day before, to remind 
them about their appointment with the 
pharmacist. 
4. Finally, after two months all participants will receive 
a phone interview to find out if you attended the 
osteoporosis clinic or have started on any 
osteoporosis medications.  
6. What is a Bone Mineral Density (BMD) Scan? 
A BMD scan uses a Dual Energy X-ray Absortiometry 
(DEXA) machine to measure how strong, or dense your 
bones are. The results show how much risk there is of the 
bones fracturing.  The scan will take about 10 to 20 
minutes and is not unpleasant or painful in any way. You 
will be asked to lie on a firm couch, fully clothed, whilst 
  
the machine takes the pictures. You will NOT go into a 
tunnel or have an injection. In addition, the scan is very 
safe and the dose of radiation is tiny. The dose of 
radiation is similar to spending a day out in the sun.  
 
7. Expenses and payment 
You will be given RM 20 per visit as a reimbursement for 
your travel expenses.  
 
8. What will I have to do? 
You are required to attend two GP appointments and 
answer all the questions in each questionnaire during 
three separate occasions based on your current 
knowledge and experiences. You may need to stop taking 
any calcium supplements for 3 days if you are involved 
with the BMD scan. Lastly, you will need to participate in 
a phone interview.  
 
9. What are the possible disadvantages and risks of 
taking part? 
You will have to spend more time in the hospital as you 
may need to undergo a BMD scan. Also, you need to 
come back for one extra appointment after one month. 
 
10. What happens when the research study stops? 
Your doctor will continue to provide medical care for you. 
 
 
 
 
  
11. What if there is a problem? 
Any complaint about the way you have been dealt with 
during the study or any possible harm you might suffer 
will be looked into. The detailed information on this is 
given in Part 2.  
 
12. Will my taking part in the study be kept 
confidential? 
Yes. We will follow ethical and legal practice and all 
information about you will be handled in confidence. The 
details are included in Part 2. 
13. Is the purpose of this study educational? 
Yes. Part of the data from this research will be used for a 
PhD study. 
 
 
 
 
Part 2 
1. What will happen if I don’t want to carry on with 
the study? 
You can withdraw from the study without giving a 
reason and without affecting your care. 
 
2. What if there is a problem? 
If you have a concern about any aspect of this study, 
you should ask to speak to the researchers who will do 
their best to answer your questions . 
This completes Part 1.  
If the information in Part 1 has interested you and you are 
considering participation, please read the additional 
information in Part 2 before making any decision. 
 
  
3. Will my taking part in this study be kept 
confidential? 
Only the researchers involved will have access to your 
medical notes and data collected. All information will be 
anonymised (no name mentioned).  
The information we have collected as paper copies will 
be stored under lock and key, while the electronic data 
can only be accessed with a secure password. Only the 
researchers will have access to the data.  
 
The data we collect will be used only for the purpose of 
this research; if data were to be used for future studies, 
further Research Ethics Committee approval will be 
sought.  
 
All information which is collected about you during the 
course of the research will be kept strictly confidential, 
and any information about you which leaves the clinic 
will have your name, telephone and address removed so 
that you cannot be recognized. 
 
4. Involvement of the General Practitioner/Family 
doctor (GP) 
Your doctor will be informed about your participation in 
this study. 
5. What will happen to the results of the research 
study? 
The results of this study will be published in medical 
journals.   
  
You will not be identified in any report, publications or 
presentation without seeking your full consent. You will 
also be able to request a summary for the research. 
 
6. Who is organizing and funding the research? 
This research is organized by Ms. Toh Li Shean and Dr 
Pauline Lai Siew Mei from the University of Malaya, as 
well as Prof Claire Anderson, Associate Prof Mr Wong 
Kok Thong and Dr Low Bee Yean from the University of 
Nottingham. Funding of this research will be obtained 
from either University of Nottingham or the Ministry of 
Higher Education.  
 
7. Who has reviewed the study? 
All research in the UMMC is looked at by an independent 
group of people, called a Research Ethics Committee to 
protect your safety, rights, well-being and dignity.  
8. Further information and contact details. 
Specific information about this research project: 
Toh Li Shean 
Tel: 012-2846-849  
Email: rinoa8387@yahoo.com 
Advice as to whether you should participate: 
As above. 
Who you should approach if unhappy with the study: 
As above. 
  
  
14.11   Appendix 36- Patients consent form for Phase 
three 
Participant identification number for this trial: 
CONSENT FORM 
Title of Project: Addressing the needs of osteoporosis prevention in 
community dwelling postmenopausal women in a 
tertiary hospital in Malaysia: A feasibility study of an 
osteoporosis screening programme (Patients) 
Name of Researchers: Prof Claire Anderson / Assoc Prof Mr Wong Kok 
Thong/ Dr Lai Siew Mei Pauline/ Dr Low Bee 
Yean/ Toh Li Shean 
 
 
_______________________ ________________  
Name of Participant Date Signature 
 
 
_________________________ ________________  
Name of Person taking consent Date   Signature 
  
  Please initial box 
1. I confirm that I have read and understand the information 
sheet dated 24/03/12 (Version 1-OP-SCREEN-PT) for the 
above study. I have had the opportunity to consider the 
information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time, without giving any reason 
and without my legal rights being affected. 
 
3. I understand that relevant sections of any of my medical 
notes and data collected during the study may be looked at 
by responsible individuals from the University Malaya 
Medical Center, the University of Malaya and the University 
of Nottingham, where it is relevant to my taking part in this 
research.  I give permission for these individuals to have 
access to my records.                                                                                                         
 
4. I agree to take part in the above study.  
  
14.12   Appendix 37- Ethical approval for Phase three 
  
  
14.13   Appendix 38- Journal publication for the 
Osteoporosis Prevention and Awareness Tool 
(OPAAT) 
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Abstract  
Objectives: To develop and validate Osteoporosis Prevention 
and Awareness Toole (OPAAT) in Malaysia. 
Methods: The OPAAT was modified from the Malaysian 
Osteoporosis Knowledge Tool and developed from an 
exploratory study on patients. Face and content validity was 
established by an expert panel. The OPAAT consists of 30 
items, categorized into three domains. A higher score 
indicates higher knowledge level. English speaking non-
osteoporotic postmenopausal women ≥50 years of age and 
pharmacists were included in the study.  
Results: A total of 203 patients and 31 pharmacists were 
recruited. Factor analysis extracted three domains. Flesch 
reading ease was 59.2. The mean±SD accuracy rate was 
0.60±0.22 (range:0.26-0.94). The Cronbach’s α for each 
domain ranged from 0.286-0.748.  All items were highly 
correlated (Spearman’s rho:0.761-0.990, p<0.05), with no 
significant change in the overall test-retest scores, indicating 
that OPAAT has achieved stable reliability. Pharmacists had 
higher knowledge score than patients (80.9±8.7vs63.6±17.4, 
p<0.001), indicating that the OPAAT was able to discriminate 
between the knowledge levels of pharmacists and patients.  
Conclusion: The OPAAT was found to be a valid and reliable 
instrument for assessing patient’s knowledge about 
osteoporosis and its prevention in Malaysia. The OPAAT can be 
used to identify individuals in need of osteoporosis educational 
intervention. 
 
Keywords: osteoporosis; knowledge; validation; prevention; 
education; postmenopausal 
 
  
Introduction  
The validation of an instrument is necessary to ensure that the 
cultural differences and language used are suitable for a 
population, and that the instrument measures what it was 
designed to measure (Smith, 2002, Lai, 2013). Seven 
knowledge tools for osteoporosis have been developed and 
validated: the Facts on Osteoporosis (Ailinger et al., 2003, 
Ailinger et al., 1998, Ailinger and Emerson, 1998), the 
Osteoporosis Knowledge Assessment Tool (OKAT) 
(Winzenberg et al., 2003), the Osteoporosis Questionnaire 
(OPQ) (Pande et al., 2000), the Osteoporosis Knowledge Test 
(OKT) (Kim et al., 1991), the Osteoporosis and You (Cadarette 
et al., 2007), the Osteoporosis Knowledge Questionnaire 
(OKQ) (Curry and Hogstel, 2001), and the Malaysian 
Osteoporosis Knowledge Tool (MOKT) (Lai et al., 2008). All 
these tools were developed and validated in English (Ailinger 
et al., 2003, Ailinger et al., 1998, Ailinger and Emerson, 1998, 
Winzenberg et al., 2003, Pande et al., 2000, Kim et al., 1991, 
Cadarette et al., 2007, Lai et al., 2008). These studies were 
mainly conducted in Australia (Winzenberg et al., 2003), 
United Kingdom (Pande et al., 2000), United States of America 
(Ailinger et al., 2003, Ailinger et al., 1998, Ailinger and 
Emerson, 1998, Kim et al., 1991, Curry and Hogstel, 2001) 
and Canada (Cadarette et al., 2007). None of these tools were 
validated in an Asian population except for the MOKT, which 
was developed and validated in Malaysia (Lai et al., 2008). 
These tools focused mainly on assessing knowledge of 
osteoporosis and its treatment (Lai et al., 2008, Kim et al., 
1991, Ailinger et al., 2003, Ailinger et al., 1998, Ailinger and 
Emerson, 1998, Winzenberg et al., 2003, Pande et al., 2000, 
Cadarette et al., 2007, Curry and Hogstel, 2001).  
 
  
In Malaysia, the English version of the OKT was translated to 
Malay and validated in men and women aged 38-90 years with 
diabetes mellitus (Abdulameer et al., 2013, Kim et al., 1991). 
However, the Malay version of the OKT was unsuitable for our 
study, as the OKT assessed prevention knowledge by rating 
the likelihood of getting osteoporosis based on the type of 
preventive measure taken.  The items in the OKT were also 
based on the American population and lifestyle, making it 
unsuitable for the current study (Kim et al., 1991). 
 
Knowledge of osteoporosis plays an important role in 
developing attitudes towards the disease which in turn 
impacts health care behaviors (Andersen, 1995). Patients’ 
health beliefs are defined by attitudes, values and knowledge 
about health and health services. Although knowledge is not 
the only component to cause behavioural changes in patients, 
it is one of the essential components. Therefore patients 
should be equipped with the knowledge of the various 
prevention measures available to increase the likelihood of 
osteoporosis prevention and its fractures.This includes 
knowledge on physical activity, adequate calcium intake, 
adequate vitamin D intake, fall prevention and screening of 
osteoporosis (Ministry of Health Malaysia, 2012).  
 
Primary prevention of osteoporosis is directed at identifying 
high risk non-osteoporotic individuals, while secondary 
prevention of osteoporosis refers to the early detection of the 
disease and prevention of subsequent fragility fracture. Both 
primary and secondary prevention involve osteoporosis 
preventing behaviours  (Lundy and Janes, 2009). Therefore, it 
is important to educate patients on the importance of 
screening and prevention, as studies have found that early 
  
detection of osteoporosis  are the most cost-effective ways to 
reduce the number of hospital admittance due to osteoporotic 
fractures (Hajcsar et al., 2000, Cranney et al., 2008, Davis et 
al., 2007, Richy et al., 2004a). 
 
Although there are many methods to increase osteoporosis 
preventive behaviour such as physician reminders (Cranney et 
al., 2008) and screening programs (Yuksel et al., 2010), 
patient education has been found to be an effective 
component in increasing knowledge and frequency of 
osteoporosis preventive behavior (Nielsen et al., 2008, Gaines 
and Marx, 2011)Studies have found a positive relationship 
between osteoporosis knowledge and preventive behaviour 
(Burke-Doe et al., 2008, Terrio and Auld, 2002). Additionally, 
a systematic review found that educational programs may 
have a positive impact on the patients’ ability to engage in 
preventing and managing osteoporosis (Jensen et al., 
2013)However, some studies suggest otherwise (Etemadifar, 
2013, Kasper et al., 1994).  The differences in their 
methodologies makes it difficult to generalize results,  as 
some studies used qualitative methods (Terrio and Auld, 
2002) whilst others used quantitative methods (Etemadifar, 
2013, Burke-Doe et al., 2008, Kasper et al., 1994). 
Additionally, these variation in results may also suggest that 
knowledge is not the only component that affects behavioural 
change, Beliefs, attitudes and values are other components 
that may be a barrier to implementing osteoporosis preventive 
efforts (Andersen, 1995). Nonetheless, knowledge is one of 
the components in behavioral change and should be addressed 
when implementing osteoporosis prevention efforts. 
Previous studies have found that the knowledge of 
osteoporosis in adult women aged 21-90 years in Europe 
  
(Alexandraki et al., 2008, Gemalmaz and Oge, 2007, Ungan 
and Tumer, 2001), Canada (Cadarette et al., 2007), United 
States (Ailinger and Emerson, 1998, Burke-Doe et al., 2008), 
Middle East (Baheiraei et al., 2005b), and Australia 
(Winzenberg et al., 2003) was low. In Asia, the knowledge of 
osteoporosis  ranged fromlow to moderate for women aged 
19-90 in Brunei (Liza et al., 2009), Singapore (Saw et al., 
2003) and Malaysia (Abdulameer et al., 2013, Yeap et al., 
2010, Khan et al., 2014). However, another study in Malaysia 
found that the knowledge of osteoporosis was moderate in 
women aged 49-84 (Lai et al., 2008). Additionally, we would 
like to highlight the lack of knowledge on osteoporosis occurs 
in women who have not experienced a fracture, as well as 
those who had a previous fracture (Beaton et al., 2012). 
Conversely, women and men aged 16-79 years in Norway 
were knowledgeable about osteoporosis (Magnus et al., 1996). 
The different tools used to assess knowledge and the different 
cohorts in which the tool was administered to (Lai et al., 2008, 
Abdulameer et al., 2013, Khan et al., 2014, Yeap et al., 2010) 
made comparison between studies difficult. In addition, most 
studies did not report the use of validated tools to assess 
knowledge levels (Alexandraki et al., 2008, Gemalmaz and 
Oge, 2007, Ungan and Tumer, 2001, Burke-Doe et al., 2008, 
Liza et al., 2009, Yeap et al., 2010, Khan et al., 2014, Kasper 
et al., 1994, Etemadifar, 2013, Magnus et al., 1996).  
In Malaysia, there is currently no available tool to assess the 
knowledge of osteoporosis and its prevention in Asia. Hence, 
we aimed to develop and validate the English version of the 
Osteoporosis Prevention and Awareness Tool (OPAAT) in 
Malaysia. 
 
  
Method: 
Design: 
This study was divided into 2 phases:  development and 
validation of the OPAAT. The development of the OPAAT 
involved modifications of the MOKT and qualitative findings. 
The validation of the OPAAT was a prospective study 
conducted at a primary care clinic of a tertiary hospital, from 
October 2013 to January 2014.  
14.14    
14.15   The development of the Osteoporosis 
Prevention 
14.16   and Awareness Tool (OPAAT) 
Despite Malay being the national language of Malaysia, 
postmenopausal women aged 50 years and above are more 
fluent in English as schooling was only conducted in the 
English language then. Hence, the OPAAT was developed in 
English, based on modifications from the MOKT (Lai et al., 
2008) and findings from a qualitative study which examined 
the barriers and needs towards an osteoporosis screening and 
prevention service in Malaysia (Toh et al., 2012).  
 
We took 10 out of the 50 items from the MOKT, as the other 
items were related to assessing knowledge on risk factors of 
osteoporosis, osteoporosis medication or misconceptions 
about osteoporosis. Six items were rephrased. For item 1, we 
added the word “fracture” in parenthesis to emphasize that 
the word “broken bones” means fracture (Refer to 
supplementary document 1). For item 5,  “early on” was 
removed as patients were unaware that osteoporosis was 
asymptomatic and the phrase “early on” may confuse them 
(Toh et al., 2012). As for item 13 and 16, we combined the 
original four questions to develop two questions; as “a loss of 
  
height” and “hunchback” were essentially assessing the same 
thing, and “joint pain” and “swelling of the fingers” were both 
referring to symptoms of osteoarthritis.   Four items from the 
MOKT were used in its original format. 
 
Results from the qualitative study found that patients, nurses, 
general practitioners, pharmacists and policy makers lacked 
knowledge in the following areas: screening and prevention of 
osteoporosis, and misconceptions of osteoporosis (Toh et al., 
2012).  Therefore 22 new items were added. The final OPAAT 
consist of 30 items, and was divided into three domains: 
osteoporosis in general (Domain A), consequences of 
untreated osteoporosis (Domain B) and osteoporosis 
prevention (Domain C).  
 
Face and content validity of the OPAAT was established via 
consultation with an expert panel consisting of four 
pharmacists with many years of research and clinical 
experience. Comprehension of the questionnaire was tested on 
10 postmenopausal women who understood English. This 
involved asking the patients for their opinions about the 
phrasing, format and content of the tool. The patients 
encountered no difficulty in answering the questionnaire. 
Hence, no further changes were made.  
14.17    
14.18   Participants 
Patient group 
English speaking postmenopausal women aged 50 years and 
above, who had not been diagnosed with 
osteoporosis/osteopenia was included.  The patients’ clinical 
information on the diagnosis of osteoporosis/osteopenia were 
obtained from medical records prior to the provision of 
  
service.  Participants who were feeling too unwell to 
participate in the study were excluded. The OPAAT was 
administered to the patient group at baseline and 2 weeks 
later to assess reliability. 
 
Professional group 
To assess discriminant validity, pharmacists were recruited 
from the same tertiary hospital as the healthcare 
professionals. Pharmacists were expected to have higher 
knowledge of osteoporosis than patients. The OPAAT was 
administered to the pharmacists only once, as we wanted to 
assess the instrument’s ability to discriminate between the 
knowledge scores of patients and healthcare professionals at 
baseline.  
 
Sample size 
Patient group 
Sample size was calculated based on a 5:1 participant ratio for 
factor analysis (Gorsuch, 1983). Since the OPAAT had 30 
items, the total number of participants needed was 150. 
Allowing for a 20% loss to follow up, the final number of 
participants required was 180. 
 
  
  
Professional group 
The sample size of the professional group was 31 as that was 
the total number of pharmacists in the setting. Nonetheless, 
we recruited the pharmacist to  assess the discriminant 
validity using the Mann-Whitney U test and chi-square test. 
Both these test were able to assess the discriminant validity 
using unequal sample sizes (Mann and Whitney, 1947, 
McHugh, 2013). The pharmacists were excluded from factor 
analysis. 
 
14.19   Validation of the Osteoporosis Prevention and 
Awareness Tool (OPAAT)  
14.20   Instruments used 
Baseline demographics 
Baseline demographic information such as patients’ medical 
history, lifestyle and medication history was collected. 
Pharmacists’ baseline information, work experience and 
education level were also collected.  
 
Osteoporosis Prevention and Assessment tool (OPAAT) 
The OPAAT consist of 30 items with three domains: 
osteoporosis in general, consequence of untreated 
osteoporosis and osteoporosis preventive measure.  
 
Procedure 
Patients were recruited at two waiting rooms as the waiting 
time for the general practitioner’s appointment is normally one 
to two hours. This makes it an ideal time to recruit the 
patients without increasing the frequency of the patients’ visit 
to the hospital. Additionally, we recruited patients at the 
waiting room as not all patients who attended the primary 
care clinic had a scheduled appointment. Primary care patients 
  
include both walk-in and appointment patients. We wanted to 
include both these groups of patients in our study to reflect 
the actual clinic scenario. Additionally, not all patients’ contact 
number was updated as the primary care clinic uses both 
paper and electronic records. Therefore it was not possible to 
randomly contact the participants. 
 
A 1:2 systematic random sampling method was used by the 
researcher to recruit participants as it was not possible for one 
researcher to recruit all the potentially eligible participants at 
the clinic.  The medical folders of eligible participants were 
labelled from 1-40, and a number was randomly drawn from a 
bag to determine the starting number at the start of each day 
that the researcher recruited participants. This was performed 
to ensure that sampling was random. Subsequently every 2nd 
medical folder was selected for recruitment.   
 
Additionally, some participants (11 participants) were also 
recruited using the “snowballing” method as the validation of 
the OPAAT was conducted concurrently with the validation of 
several osteoporosis risk assessment tools. As the awareness 
of the project spread the participants began to refer their 
friends and family. Although this is a non-randomized method 
or recruiting the patients, it only comprise of 7.3% of the 
participants in our study and should not affect the outcome as 
20% of the sample size was allocate for drop-outs.. 
 
The patient’s baseline demographic information was collected. 
Patients answered the questionnaire themselves. For those 
who experienced some difficulty in reading the questions, the 
researcher assisted them. The researcher then checked the 
questionnaire to ensure that questions were answered. Most 
  
patients took approximately 10 minutes to complete the 
questionnaire. The OPAAT was administered again to the same 
group of patients after two weeks to assess reliability. A 
duration of two weeks was used as this time interval is 
generally accepted to be long enough that the participants do 
not remember their original responses but not long enough for 
their knowledge of the material to have change (DeVon et al., 
2007). atients were questioned about significant changes or 
events occurring within two weeks and all changes were 
documented.  Pharmacist baseline information was collected. 
The OPAAT was administered to the pharmacists only once at 
baseline.  
 
14.21   Ethics approval 
Written consent was obtained from all participants. This study 
was approved by the Medical Ethics Committee of the hospital 
(University Malaya Medical Centre) under study (ref no 
920.27).  
 
14.22   Data analysis 
All data was entered into the IBM® SPSS® version 20 (IBM 
Corporation, Armonk, NY, USA). For the OPAAT, a score of one 
was given for a correct response and zero for an incorrect or 
do not know response. The total score was converted into 
percentage ranging from 0-100. Each domain score was also 
analyzed. Flesch reading ease was calculated using Microsoft 
Office® Word® 2007 (Microsoft Corporation, Redmond, WA, 
USA). Non-parametric tests were used since data obtained 
were not normally distributed.  A p-value <0.05 was 
considered as statistically significant. 
 
  
Factor analysis 
The construct validity of OPAAT was examined by using 
exploratory factor analysis (EFA). Traditionally, factor analysis 
such as EFA and confirmatory factor analysis (CFA) can only 
be performed when data are of continuous scale (Harrington, 
2009, Kim and Mueller, 1978). However, Bruin (2006) 
developed a new algorithm of EFA to account for categorical 
data. In this study, EFA was performed on three separate 
domains to explore the appropriateness of factor structure of 
the current questionnaire (Bruin, 2006). Factors with 
eigenvalues greater than one were considered as having 
significant contribution in explaining the overall model 
variation and were retained (Kaiser, 1960, Harman, 1976).  
 
Flesch reading ease 
Flesch reading index is a tool used for estimating the reading 
comprehension level necessary to understand a written 
document based on the average number of syllables per word 
and the average number of words per sentence. The Flesch 
reading ease was calculated using the formula below: 
 
Flesch reading ease= 206.835- (1.015x average sentence 
length) - (84.6 x average number of syllables per word) 
 
The Flesch reading score (which range from 0 to 100) 
indicates the level of difficulty in understanding the document. 
The lower the score, the greater the difficulty. An average 
document should have a score of 60-70 (Flesch, 1948). 
 
Accuracy rate 
The accuracy rate is used to measure the difficulty of a 
question. It is calculated by the number of correct responses 
  
divided by the total number of responses. The higher the 
accuracy rate, the easier the question is. The optimal level 
should be 0.5 as a value of higher than 0.75 is deemed to be 
poor as the question may be too easy. Items with difficulty 
values between 0.3 and 0.7 are most effective. (University 
Testing Services). 
 
Cronbach’s α 
Cronbach’s α coefficient is a tool used to assess internal 
consistency. Cronbach’s α value: >0.9- Excellent, >0.8- Good, 
>0.70- Acceptable, >0.6- Questionable, >0.5 – Poor and 
<0.5- Unacceptable (George and Mallery, 2003). If omitting 
an item increases Cronbach’s α significantly, then excluding 
the item will increase the homogeneity of the scale (Cronbach, 
1951). 
 
Corrected inter-item correlations are the correlations between 
each item and the total score from the questionnaire. All items 
should correlate with the total to be considered a reliable 
scale. A value of less than 0.3 shows a poor correlation and 
these items should be considered to be excluded. (Field, 
2005).  
 
Test-retest for reliability 
For test- retest, categorical data were analysed using the 
kappa measure of agreement and the Mc Nemar’s test. In 
order to define inter-rater reliability, a kappa measure of 
agreement was calculated for each item. A kappa value of 0.5 
represents moderate agreement, above 0.7 represents good 
agreement and above 0.8 represents very good agreement 
(Peat, 2001). Mc Nemar’s test was used to examine the test-
retest reliability on the individual items. Continuous data of 
  
the individual items and total domain scores were analyzed 
using the Wilcoxon signed-rank test and Spearman’s rho 
correlation coefficient. According to Cohen 1988, a value of 
0.10-0.29 showed a low correlation, 0.30-0.49 moderate 
correlation and 0.50-1.00 high correlation (Cohen, 1988).  
 
Discriminative validity 
To assess discriminative validity, the chi square test was used 
on categorical data of the individual items to detect the 
difference between the patient group and professional group. 
The Mann-Whitney U test was used for continuous data of the 
individual items and total domains score to compare if there 
was any significant difference between the patient and 
professional group. 
 
Factors associated with knowledge score  
Linear multiple regression was used to identify factors 
associated with knowledge. It used to estimate the linear 
relationship between a dependent variable (knowledge score) 
and one or more independent variables (demographic 
variables).   
 
Results 
A total of 253 patients were approached, 19 declined. 234 
participants were recruited (patients=203, hospital 
pharmacists=31), [patient response rate=91.4%, pharmacists 
response rate= 100.0%]. Patients’ demographic data are 
shown in Table 1.  Pharmacists recruited worked in different 
areas of the pharmacy, with working experience ranging from 
1-10 years.   
 
  
14.23   Factor analysis  
As shown in Table 2(a), for domain A, EFA yielded one factor 
with eigenvalue of 4.04 which contributed to 81.0% of total 
variation. Ten items within this domain have factor loadings 
greater than 0.3 in Table 3(a), suggesting substantial 
contribution in explaining overall variation. In Table 2(b),for 
domain B, EFA also produced only one factor with eigenvalue 
greater than one, i.e. 1.9 which explained 87.3% of total 
variation. All five questions within this domain had factor 
loadings greater than 0.3 as shown in Table 3(b). In Table 
2(c), for domain C, EFA generated the only one factor with 
eigenvalue greater than one (4.4). This factor contributed to 
69.4% of total variation. Table 3(c) showed that factor 
loadings of all 12 items within this domain were above 0.3. 
Overall, the data from the three EFAs suggested the adequacy 
of one factor for each of the domain [Table 2 and 3]. 
 
14.24   Psychometric properties of the Osteoporosis 
Prevention And Awareness Tool (OPAAT) 
Flesh reading ease was 59.2. The mean ± SD accuracy rate 
was 0.60±0.22 (range:0.26-0.94). Four out of 30(13.3%) 
items had values <0.3 and 11/30(36.7%) items had values of 
>0.75. The remaining 15/30(50.0%) items had values 
between 0.3-0.75.  
 
Cronbach’s α was analyzed for the three domains. All domains 
had a Cronbach’s α of ≥0.6 except for the domain B (0.286).. 
All 30 items met the requirement of >0.3 for the corrected 
item –total correlations except for items 13/30(43.3%) [Table 
4]. However all items were retained 
 
  
14.25   Test-retest reliability 
At retest, 9(4.4%) patients could not be contacted. Hence, 
194 questionnaires from patients (response rate = 95.6%) 
were included in test-retest [See table 5]. The Kappa 
measurement of agreement showed that 29/30 items (96.7%) 
were in very good agreement, and 1/30 items (3.3%) was in 
good agreement. The McNemar’s test showed no significant 
differences for all test-retest items. The Wilcoxon signed-rank 
test showed no significant difference for all domain scores 
except for the domain score on ‘consequences of untreated 
osteoporosis.’ Nonetheless, the total score showed no 
significant difference. All domains and items were significantly 
correlated using the Spearman’s rho correlation coefficient 
(0.760-0.990, p<0.05) [Table 5].  
 
The overall total knowledge score for the pharmacist group 
was significantly higher than the patient group (80.9±8.7 vs 
63.6±17.4, p<0.001) [Table 6]. The chi square test showed 
no significant difference for 16/30(53.3%) items between the 
patient and pharmacist group. There were significant 
differences in all domains based on the Mann-Whitney U-test. 
   
14.26   Factors associated with knowledge 
Knowledge was higher in patients who completed their high 
school education, and patients who conducted fall prevention 
activities (R2=0.208, F=3.949, df=18, p<0.001).  These two 
factors explained 27.9% of the variances. 
 
  
14.27   Comparison of the Osteoporosis Prevention 
And Awareness Tool (OPAAT) with other 
validated instruments 
The OPAAT had a similar Flesch reading ease as the MOKT 
59.2 and 57 respectively. The Cronbach’s α if the OPAAT 
ranged from 0.27-0.75 which was similar to the MOKT, 
Osteoporosis and you, OKAT and FOOQ which ranged from 
0.60-0.82. This shows that the psychometric properties of the 
OPAAT were similar to that of other validated instruments for 
measuring patients’ knowledge [Table 7]. 
 
 
14.28   Discussion  
The OPAAT performed satisfactorily in its psychometric 
properties and was able to discriminate between knowledge 
level of patients and pharmacists. This indicates that the 
English version of OPAAT is suitable to assess knowledge of 
postmenopausal women about osteoporosis prevention in 
Malaysia. 
 
EFA confirmed that there were three domains (osteoporosis in 
general, consequences of untreated osteoporosis and 
osteoporosis prevention) in the OPAAT to assess patient’s 
knowledge on osteoporosis and its prevention. This provides 
support for the construct validity of our tool. To the best of 
our knowledge no other osteoporosis knowledge assessment 
tool has validated the construct of their tool via this method.  
 
Flesch reading ease was at 59.2. This indicates the OPAAT can 
be understood by patients who have completed primary 
education. Since all of our participants have completed 
primary education, they were able to complete the OPAAT 
  
without any problems.  The OPAAT had a satisfactory accuracy 
rate of 0.60±0.22 (range: 0.26-0.94). Out of the 30 items, 
four items were considered difficult (accuracy rates <0.3) and 
five considered easy (accuracy rates >0.7). The optimum 
difficulty level would be 0.5. This indicates that the OPAAT was 
moderately easy for the participants to answer.  
 
The construct of the tool was considered to be multi-
dimensional and an overall Cronbach’s α was unsuitable. We 
then analyzed the Cronbach’s α by domain. All domains 
demonstrated good and acceptable internal reliability except 
the domain on the ‘consequences of untreated osteoporosis’ 
with a Cronbach α value of 0.286.  This could be because 
there were only 5 items in this domain, and knowing the 
correct answer for one item may not necessarily mean that 
they knew the correct answer for the next item. However, 
increasing the number of items within the domain would have 
made the questionnaire too lengthy reducing the likelihood of 
completion. Corrected item-total correlations showed that all 
items measured the same main component which is 
satisfaction except items 13/30(43.3%). However all items 
were retained as removing any of the items did not improve 
the overall Cronbach’s α significantly.  
 
All 30 items performed satisfactorily at test-retest except for 
the domain on “consequences of untreated osteoporosis.”  
Patients may have forgotten the answer they selected at test 
(as they were just guessing) as opposed to knowing the right 
answer. This led to a significant difference in this domain score 
as it had a small number of items. Although this limits how 
well this domain can measure the knowledge on the 
consequences of untreated osteoporosis, the guessing of 
  
answer reflects actual practice.  Nonetheless, there was no 
significant difference in the overall scores.This indicates the 
OPAAT has achieved stable reliability. The domains and items 
had a high Spearman’s rho correlation coefficient ranging from 
0.760-0.990. They were all significantly correlated at p<0.05. 
Therefore, all items were retained. 
 
Although pharmacists were expected to have a higher score 
than patients for all items, there were three items (items no. 
13, 17 and 23) where no significant difference was found.  
This may be because more than 80.0% of both patients and 
pharmacists correctly answered items no. 13 and 23, 
indicating that their knowledge level for these items were 
high. As for item no. 17 which was pertaining to calcium 
intake, less than 60.6% of patients and pharmacists answered 
this item correctly. This concurs with our previous qualitative 
findings that found that both patients and pharmacists lacked 
knowledge in this area. (Toh et al., 2012). Nonetheless, the 
overall score and all domain scores of the OPAAT showed a 
significant difference between the patient and pharmacist 
group. This indicates that the OPAAT has achieved 
discriminative validity. 
Patients’ overall knowledge score was 63.6±17.4, which 
indicate that their knowledge level was moderate. Our results 
were similar to a previous study conducted in Malaysia which 
assessed knowledge on osteoporosis and its prevention (Lai et 
al., 2008). This may be because both studies were conducted 
in the same setting. In addition, participants in both studies 
were mainly health seeking urban patients.  
 
However, we would like to highlight that the cohort of patients 
used in the Lai et al study was on patients who had 
  
osteoporosis. Our study evaluated non-osteoporotic patients, 
this shows that there was no difference in knowledge in 
osteoporotic patients and undiagnosed patients.  Another tool, 
the Osteoporosis Knowledge Questionnaire (OKQ) assessed on 
osteoporosis risk factors, diagnosis, prevention and treatment 
in female population aged 60 and above scored 57.4% (Curry 
and Hogstel, 2001). OKQ score was similar to OPAAT as they 
assessed non-osteoporotic postmenopausal population of a 
similar age group. 
 
Other studies using the Osteoporosis Knowledge Assessment 
Tool (OKAT) assessed osteoporosis knowledge and risk factors 
in females aged 25-44 years scored only 44% (Winzenberg et 
al., 2003). Osteoporosis and You assessed knowledge of 
osteoporosis, risk factors, consequences of untreated 
osteoporosis and prevention in females aged 65-90 years 
scored even lower at 37.7% (Cadarette et al., 2007). Both the 
OPAAT and OKAT had a similar number of items with low 
difficulty level of 17.9% and 15% respectively. Hence, the 
difference of OPAAT and OKAT’s score may be because OKAT 
examined the younger generation who may not have reached 
menopause leading to a lack of awareness of osteoporosis. 
Similarly, Osteoporosis and You examined more elderly 
population and they may not have been as educated as the 
younger generation. People have become more aware of 
osteoporosis in the recent years but this may not have 
reached older people. Osteoporosis and you had 60% of its 
items in the low difficulty level which was more than the 
OPAAT.  
 
Patients’ knowledge was lowest on the domain on the 
‘consequences of untreated osteoporosis.’ This concurs with 
  
findings from our qualitative research which indicates that 
there is a need to educate patients in this area (Toh et al., 
2012). Correspondingly, Osteoporosis and You noted a deficit 
in knowledge in the area of consequences of untreated 
osteoporosis (Cadarette et al., 2007). These tools were 
developed mainly to assess the knowledge of domains of 
osteoporosis in general and treatment, the OPAAT was 
developed specifically to evaluate osteoporosis prevention.  
 
In our study, factors with a positive correlation to the 
knowledge score includes patients with a secondary or higher 
education level, and patients who conducted fall prevention 
activities. Similarly, a Greek and Turkish study noted an 
association with knowledge and level of education 
(Alexandraki et al., 2008, Gemalmaz and Oge, 2007, Khan et 
al., 2014). Additionally, Khan et al’s findings concurred with 
our study as they noted a significant association between 
knowledge and ethnicity (Khan et al., 2014). Conversely, 
Ailinger et al stated neither education level, age nor the 
menopause status increase osteoporosis knowledge (Ailinger 
and Emerson, 1998). Patients who conduct fall preventive 
measure had more knowledge of osteoporosis. This further 
justifies the importance of a higher knowledge level about 
osteoporosis prevention to ensure its implementation.  
 
One of the limitations was that convergent validity could not 
be performed as a gold standard tool to measure knowledge of 
osteoporosis prevention and screening was unavailable during 
the period of study. Additionally, the patients in our study 
were mainly Chinese (62.1%), Malay (14.8%) and Indians 
(21.7%). This does not represent the ethnic distribution of 
Malaysia, but it represents the patients who sought treatment 
  
in our study site. Future validation studies of our tool to Malay 
and Mandarin, and enrolment of patients from multi-sites 
would be more representative of the Malaysian population. 
Nonetheless, a large proportion of our patients had a monthly 
household income above $1553 (81/203) which was 
representative of the married Malaysian household population 
income. Seventy six percent (155/203) of our participants 
were married. The average individual monthly income in 
Malaysia ranges from RM1445-3137 ($451.6-980.3) 
depending on the location (rural or urban) (Department of 
statistics Malaysia, 2013) 
 
Another limitation is that our research used mixed methods 
when administering the OPAAT. At baseline we used self-
administration and interviewed participants who had difficulty 
answering the OPAAT (2.5% patients required assistance).  
Subsequently, the OPAAT was administered using telephones 
interviews during the two week follow up. We used this 
approach to optimize response rate and cost. However, mixing 
the administration method increases the probability that the 
participants will give different answers due to the difference in 
administrations mode rather than in opinion (Check and 
Schutt, 2012). Nonetheless, we have carefully designed the 
survey to ensure that the survey was equivalent across modes 
(De Leeuw, 2005). The researcher was also trained to reduce 
interviewer bias (Check and Schutt, 2012).  
14.29   Conclusion:  
The English version of the OPAAT was found to be a reliable 
and valid instrument for assessing patient knowledge on 
osteoporosis and its prevention in Malaysia. Future studies, 
using Bahasa Malaysia and Mandarin versions of the 
questionnaire are required to assess patient knowledge for 
  
Malaysians that are not fluent in English. The OPAAT can 
assists in identifying patients who need more information on 
osteoporosis and its prevention. These patients can then be 
enrolled in an osteoporosis prevention and screening program 
with an education intervention component. OPAAT can 
subsequently be used to evaluate the effectiveness of the 
education efforts provided. 
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Tables 
Table 1: Baseline demographic characteristics of patients 
Characteristics Patients (n=203) 
Mean age ± S. D. (years) [range] (Median) 62.1±7.2 [50-79] (61.0) 
Age range (years) [n (%)] 
<65 
≥ 65 
 
120 (59.1) 
83 (40.9) 
Ethnicity [n (%)] 
Malay  
Chinese 
Indian 
Eurasian 
 
30 (14.8) 
126 (62.1) 
44 (21.7) 
3 (1.5) 
Mean BMI (kg/m2) ± S.D. (Median) 24.2±4.6 (23.3) 
BM I (kg/m2) [n (%)] 
<18.5 (underweight) 
18.5-24.9 (normal) 
25.0-29.9 (overweight) 
≥30.0 (obese) 
 
10 (4.9) 
118 (58.1) 
55 (27.1) 
20 (9.9) 
Level of education [n (%)] 
                      Primary (6 years of education) 
Secondary (11-13 years of education) 
Diploma/Technical school training (12-14 years of education) 
Tertiary/Postgraduate (15-21 years of education) 
 
10 (4.9) 
78 (38.4) 
39 (19.2) 
 
76 (37.4) 
Income per month [n (%)] 
<RM1000 (<$ 310.7) 
RM1000-1999 ($ 310.7-621.0) 
RM2000-2999 ($ 621.3- 931.7) 
RM3000-3999 ($ 932.0- 1242.3) 
RM4000-4999 ($ 1242.6-1553) 
>RM5000 (>$1553.3) 
 
36 (17.7) 
25 (12.3) 
23 (11.3) 
21 (10.3) 
17 (8.4) 
81 (39.9) 
  S.D. = standard deviation; BMI=body mass index; $= US dollar 
 
 
  
  
Table 2: Eigenvalues of the domains in the Osteoporosis Prevention and Awareness Tool (OPAAT) using 
exploratory factor analysis (EFA) 
(d) Eigenvalues of domain A 
 
Domain A Eigenvalue 
Factor1 4.04065 
Factor2 0.80586 
Factor3 0.50583 
Factor4 0.22203 
Factor5 0.11458 
Factor6 0.01873 
Factor7 -0.02871 
Factor8 -0.10657 
Factor9 -0.16125 
Factor10 -0.19727 
Factor11 -0.22522 
 
(a) Eigenvalues of domain B 
Domain B Eigenvalue 
Factor1 1.8924 
Factor2 0.74467 
Factor3 -0.04495 
Factor4 -0.19105 
Factor5 -0.23417 
 
(a) Eigenvalues of domain C 
Domain C Eigenvalue 
Factor1 4.36008 
Factor2 0.84406 
Factor3 0.56791 
Factor4 0.44087 
Factor5 0.31589 
Factor6 0.26055 
Factor7 0.17115 
Factor8 0.01055 
Factor9 -0.04459 
Factor10 -0.15964 
Factor11 -0.21151 
Factor12 -0.27104 
 
 
 
 
  
  
Table 3: Factor loadings of the Osteoporosis Prevention and Awareness Tool (OPAAT) using exploratory 
factor analysis (EFA) 
(d) Factor loadings of domain A 
 
Only the factor loadings (represented as eigenvalue) greater than 1 were selected (Harman, 1976) 
 
(e) Factor loadings of domain B 
Only the factor loadings (represented as eigenvalue) greater than 1 were selected (Harman, 1976 
 
 
(f) Factor loadings of domain C 
 
Only the factor loadings (represented as eigenvalue) greater than 1 were selected (Harman, 1976) 
Variable Factor1 Factor2 Factor3 Factor4 Factor5 Factor6 Factor7 Factor8 
ITEM1 0.3207 0.2394 -0.1778 0.1858 0.2448 0.2203 -0.0682 0.0334 
ITEM2 0.3641 -0.2981 0.389 0.1759 0.1214 -0.05 -0.177 -0.0281 
ITEM3 0.6867 0.4137 -0.0234 -0.2121 -0.1167 0.0259 -0.1924 0.0187 
ITEM4 0.5165 -0.277 0.1993 0.0702 -0.2318 0.104 -0.0083 0.0588 
ITEM5 0.7448 0.2325 0.057 0.3106 -0.1576 -0.1444 -0.0722 -0.0153 
ITEM6 0.4156 0.4079 0.0697 0.27 0.0308 -0.0044 0.2128 -0.012 
ITEM7 0.6944 -0.1801 0.1375 -0.04 0.1071 0.2178 0.0844 -0.0266 
ITEM8 0.3345 0.1019 0.359 -0.1986 0.0684 0.0893 0.1261 0.019 
ITEM9 0.6472 0.0113 -0.1588 -0.1892 -0.1781 0.172 -0.0105 -0.0556 
ITEM10 0.6949 -0.3275 -0.3495 0.0851 0.1654 0.0115 -0.04 0.0059 
ITEM11 0.7208 0.0986 0.0598 -0.2682 0.2446 -0.256 0.0009 0.0059 
ITEM12 0.8021 -0.264 -0.1945 -0.0087 -0.1141 -0.1628 0.1512 0.0155 
Variable Factor1 Factor2 Factor3 Factor4 Factor5 Factor6 Factor7 Factor8 
ITEM12 0.3207 0.2394 -0.1778 0.1858 0.2448 0.2203 -0.0682 0.0334 
ITEM13 0.3641 -0.2981 0.389 0.1759 0.1214 -0.05 -0.177 -0.0281 
ITEM14 0.6867 0.4137 -0.0234 -0.2121 -0.1167 0.0259 -0.1924 0.0187 
ITEM15 0.5165 -0.277 0.1993 0.0702 -0.2318 0.104 -0.0083 0.0588 
ITEM16 0.7448 0.2325 0.057 0.3106 -0.1576 -0.1444 -0.0722 -0.0153 
Variable Factor1 Factor2 Factor3 Factor4 Factor5 Factor6 Factor7 Factor8 
ITEM17 0.3207 0.2394 -0.1778 0.1858 0.2448 0.2203 -0.0682 0.0334 
ITEM19 0.3641 -0.2981 0.389 0.1759 0.1214 -0.05 -0.177 -0.0281 
ITEM20 0.6867 0.4137 -0.0234 -0.2121 -0.1167 0.0259 -0.1924 0.0187 
ITEM21 0.5165 -0.277 0.1993 0.0702 -0.2318 0.104 -0.0083 0.0588 
ITEM22 0.7448 0.2325 0.057 0.3106 -0.1576 -0.1444 -0.0722 -0.0153 
ITEM23 0.4156 0.4079 0.0697 0.27 0.0308 -0.0044 0.2128 -0.012 
ITEM24 0.6944 -0.1801 0.1375 -0.04 0.1071 0.2178 0.0844 -0.0266 
ITEM25 0.3345 0.1019 0.359 -0.1986 0.0684 0.0893 0.1261 0.019 
ITEM26 0.6472 0.0113 -0.1588 -0.1892 -0.1781 0.172 -0.0105 -0.0556 
ITEM27 0.6949 -0.3275 -0.3495 0.0851 0.1654 0.0115 -0.04 0.0059 
ITEM29 0.7208 0.0986 0.0598 -0.2682 0.2446 -0.256 0.0009 0.0059 
ITEM30 0.8021 -0.264 -0.1945 -0.0087 -0.1141 -0.1628 0.1512 0.0155 
  
Table 4: Psychometric properties of the Osteoporosis Prevention And Awareness Tool (OPAAT) 
Domains Item 
Number 
 Accuracy rate Cronbach’s α Corrected Item 
correlation 
Cronbach’s α if item 
deleted 
 
 
 
Osteoporosis in 
general (A) 
1 Makes bones weaker, more brittle and more likely to break 
(fracture)  
0.91  
 
 
 
0.668 
0.421 0.639 
2 Everybody will get osteoporosis as it is part of aging  0.32 0.173 0.672 
3 Osteoporosis occurs because bone is removed faster than it is 
formed 
0.52 0.176 0.673 
4 Osteoporosis and osteoarthritis are different names we can use to 
describe the same disease  
0.58 0.455 0.619 
5 Osteoporosis usually has no symptoms  0.48 0.065 0.693 
6 Postmenopausal women are not at risk for osteoporosis  0.72 0.416 0.629 
7 Osteoporosis is an untreatable disease. 0.56 0.232 0.663 
8 A bone mineral density test is used to diagnose osteoporosis  0.76 0.428 0.628 
9 I do not need a bone mineral density test unless I fracture my 
bones.  
0.79 0.555 0.608 
10 A bone mineral density test is high in radiation  0.45 0.321 0.646 
11 A bone mineral density test should be performed monthly to 
monitor bone loss  
0.60 0.407 0.629 
 
Consequences of 
untreated 
osteoporosis (B) 
12 Results in back pain  0.72  
 
0.286 
0.272 0.095 
13 Loss of height or hunchback  0.88 0.235 0.173 
14 Loss of mobility (unable to move around myself) 0.78 0.164 0.215 
15 Results in tooth loss  0.26 0.006 0.373 
16 Results in joint pain or swelling of fingers 0.27 0.056 0.319 
 
 
 
 
 
 
17 The recommended daily intake for calcium in women above 50 
years of age is 1000mg  
0.61  
 
 
 
 
 
0.274 0.744 
18 It is too late to increase calcium intake after the age 50 0.55 0.417 0.727 
19 Glucosamine can help prevent osteoporosis 0.29 0.181 0.753 
20 Calcium supplements can help prevent osteoporosis  0.85 0.397 0.731 
21 The regular dose of calcium supplements can cause kidney stones. 0.26 0.264 0.744 
  
 
 
 
 
 
 
  
Osteoporosis 
prevention (C) 
22 Foods such as milk, tofu, anchovies (ikan bilis), yellow dhal and 
spinach are rich in calcium  
0.90  
0.748 
0.398 0.73 
23 You can obtain your recommended daily intake of vitamin D via 
exposing your skin to sunlight for about 15 minutes a day 
0.87 0.300 0.739 
24 Increasing coffee and tea intake can help in osteoporosis 
prevention 
0.67 0.479 0.719 
25 Weight bearing exercise (such as brisk walking and line dancing) 
can decrease bone loss. 
0.68 0.248 0.747 
26 Exercise will wear out bones  0.78 0.459 0.723 
27 Certain medications (such as sleeping tablets or high blood 
pressure medications) may reduce the risk of falling  
0.57 0.421 0.726 
28 To prevent falls, comfortable shoes with a good grip should be 
used.  
0.94 0.524 0.728 
29 Poor vision may lead to falls 0.92 0.380 0.734 
30 Being under weight helps prevent osteoporosis  0.60 0.490 0.718 
Total  Cronbach’s α   0.820   
  
Table 5: Test and retest reliability of the individual items for the Osteoporosis Prevention And Awareness Tool (OPAAT) 
Domain Item number Test (n=203)  Retest (n=194) McNemar’s 
test p-
value  
 
Kappa 
measuremen
t of 
agreement* 
P-value 
Spearman’s 
rho 
correlation 
coefficient* 
Wilcoxon signed-rank test 
Mean±SD 
 
Media
n 
No. of 
correct 
responses 
[n (%)] 
Mean±SD 
 
Median No. of correct 
responses 
[n (%)] 
Mean/rank z-value P-value 
Osteoporosi
s in general 
(A) 
1 0.91±0.28 1.00 185 (91.1) 0.89±0.32 1.00 172 (88.7) 0.219 0.833 0.838    
2 0.32±0.47 0.00 64 (31.5) 0.30±0.46 0.00 58 (29.9) 0.250 0.964 0.964    
3 0.52±0.50 1.00 105(51.7) 0.52±0.50 1.00 101 (52.1) 1.000 0.979 0.979    
4 0.58±0.50 1.00 117 (57.6) 0.57±0.50 1.00 110 (56.7) 1.000 0.958 0.958    
5 0.48±0.50 0.00 97 (47.8) 0.48±0.50 0.00 94 (48.5) 1.000 0.990 0.990    
6 0.72±0.45 1.00 147 (72.4) 0.71±0.46 1.00 137 70.6) 0.508 0.886 0.887    
7 0.56±0.50 1.00 113 (55.7) 0.54±0.50 1.00 105 (54.1) 0.453 0.927 0.928    
8 0.76±0.43 1.00 155 (76.4) 0.74±0.44 1.00 144 (74.2) 0.219 0.917 0.918    
9 0.79±0.41 1.00 160 (78.8) 0.78±0.42 1.00 152 (78.4) 1.000 0.970 0.970    
10 0.45±0.50 0.00 92 (45.3) 0.46±0.50 0.00 90 (46.4) 0.219 0.938 0.938    
11 0.60±0.49 1.00 121 (59.6) 0.60±0.49 1.00 118 (60.8) 0.754 0.892 0.893    
Domain score 
(%) 
60.7±22.2 63.64  60.0±23.8 63.63    0.953 14.54/11.33 -0.724 0.469 
Consequenc
es of 
untreated 
osteoporosis 
(B) 
12 0.72±0.45 1.00 147 (72.4) 0.72±0.45 1.00 140 (72.2) 1.000 0.923 0.923    
13 0.88±0.33 1.00 178 (87.7) 0.89±0.31 1.00 173 (89.2) 0.250 0.925 0.927    
14 0.78±0.42 1.00 158 (77.8) 0.78±0.41 1.00 152 (78.4) 0.500 0.970 0.971    
15 0.26±0.44 0.00 52 (25.6) 0.27±0.45 0.00 53 (27.3) 0.453 0.908 0.908    
16 0.27±0.44 0.00 54 (26.6) 0.29±0.45 0.00 56 (28.9) 0.219 0.923 0.924    
Domain score 
(%) 
58.0±21.3 60.00  59.2±21.7 60.00    0.909 7.50/10.27 -2.216 0.027* 
Prevention 
of 
osteoporosis 
17 0.61±0.49 1.00 123 (60.6) 0.60±0.49 1.00 116 (59.8) 0.687 0.935 0.936    
18 0.55±0.50 1.00 112 (55.2) 0.55±0.50 1.00 106 (54.6) 1.000 0.948 0.948    
19 0.29±0.46 0.00 59 (29.1) 0.28±0.45 0.00 55 (28.4) 1.000 0.962 0.962    
  
*Statistically significant at p<0.05.  Wilcoxon signed-rank test and Spearman’s rho correlation coefficient was used for continuous variables. McNemar’s test and Kappa measurement of agreement 
was conducted for categorical variables 
 
  
(C) 20 0.85±0.36 1.00 173 (85.2) 0.83±0.38 1.00 161 (83.0) 0.250 0.943 0.945    
21 0.26±0.44 0.00 52 (25.6) 0.26±0.44 0.00 51 (26.3) 0.375 0.932 0.933    
22 0.90±0.30 1.00 183 (90.1) 0.88±0.32 1.00 171 (88.1) 0.375 0.869 0.872    
23 0.87±0.34 1.00 176 (86.7) 0.85±0.36 1.00 165 (85.1) 0.453 0.852 0.854    
24 0.67±0.47 1.00 137 (67.5) 0.68±0.47 1.00 131 (67.5) 0.727 0.905 0.905    
25 0.68±0.47 1.00 138 (68.0) 0.65±0.48 1.00 126 (64.9) 0.070 0.908 0.910    
26 0.78±0.41 1.00 159 (78.3) 0.76±0.43 1.00 148 (76.3) 0.289 0.882 0.884    
27 0.57±0.50 1.00 116 (57.1) 0.55±0.50 1.00 106 (54.6) 0.405 0.760 0.761    
28 0.94±0.24 1.00 191 (94.1) 0.92±0.28 1.00 178 (91.8) 0.125 0.846 0.856    
29 0.92±0.28 1.00 186 (91.6) 0.90±0.30 1.00 174 (89.7) 0.250 0.910 0.914    
30 0.60±0.49 1.00 122 (60.1) 0.59±0.49 1.00 115 (59.3) 1.000 0.947 0.947    
Domain score 
(%) 
67.8±20.2 71.42  66.4±22.6 71.43    0.937 21.17/19.50 -1.339 0.171 
Total OPAAT score (%) 63.6±17.4 66.67  62.9±19.1 66.67    0.950 28.98/27.05 -0.107 0.914 
  
Table 6: Knowledge scores of the patient and pharmacist group at test and retest 
Domains Item Number Patients(n=203) Pharmacist(n=31) Mann-Whitney U-test p-value a 
 Mean±SD Median Participants 
that 
answered 
correctly 
[n (%)] 
Mean±SD Median Participants 
that 
answered 
correctly 
[n (%)] 
Mean/rank Z-value p-value 
Osteoporosis in 
general (A) 
1 0.91±0.28 1.00 185 (91.1) 0.97±1.8
0 
1.00 30 (96.8)    0.482 b 
2 0.32±0.47 0.00 64 (31.5) 0.58±0.5
0 
1.00 18 (58.1)    0.007* 
3 0.52±0.50 1.00 105(51.7) 0.90±0.3
0 
1.00 28 (90.3)    0.000* 
4 0.58±0.50 1.00 117 (57.6) 0.94±0.2
5 
1.00 29 (93.5)    0.000* 
5 0.48±0.50 0.00 97 (47.8) 0.55±0.5
1 
1.00 17 (54.8)    0.590 
6 0.72±0.45 1.00 147 (72.4) 1.00±0.0
0 
1.00 31 (100.0)    0.002* 
7 0.56±0.50 1.00 113 (55.7) 0.68±0.4
8 
1.00 21 (67.7)    0.284 
8 0.76±0.43 1.00 155 (76.4) 0.94±0.2
5 
1.00 29 (93.5)    0.052 
9 0.79±0.41 1.00 160 (78.8) 0.97±0.1
8 
1.00 30 (96.8)    0.033* 
10 0.45±0.50 0.00 92 (45.3) 0.48±0.5
1 
0.00 15 (48.4)    0.900 
11 0.60±0.49 1.00 121 (59.6) 0.77±0.4
3 
1.00 24 (77.4)    0.088 
  
Domain score (%) 60.7±22.2 63.64  79.8±12.
6 
81.82  109.23/171.68 -4.834 0.000*  
Consequences of 
untreated 
osteoporosis (B) 
12 0.72±0.45 1.00 147 (72.4) 0.77±0.4
3 
1.00 24 (77.4)    0.713 
13 0.88±0.33 1.00 178 (87.7) 0.84±0.3
7 
1.00 26 (83.9)    0.565 b 
14 0.78±0.42 1.00 158 (77.8) 0.81±0.4
0 
1.00 25 (80.6)    0.905 
15 0.26±0.44 0.00 52 (25.6) 0.51±0.5
1 
1.00 16 (51.6)    0.006* 
16 0.27±0.44 0.00 54 (26.6) 0.74±0.4
4 
1.00 23 (74.2)    0.000* 
Domain score (%) 58.0±21.3 60.00  73.6±17.
4 
80.00  110.98/160.21 -4.086 0.000*  
Prevention of 
osteoporosis (C) 
17 0.61±0.49 1.00 123 (60.6) 0.58±0.5
0 
1.00 18 (58.1)    0.944 
18 0.55±0.50 1.00 112 (55.2) 0.84±0.3
7 
1.00 26 (83.9)    0.005* 
19 0.29±0.46 0.00 59 (29.1) 0.78±0.4
3 
1.00 24 (77.4)    0.000* 
20 0.85±0.36 1.00 173 (85.2) 0.94±0.2
5 
1.00 29 (93.5)    0.271 b 
21 0.26±0.44 0.00 52 (25.6) 0.61±0.5
0 
1.00 19 (61.3)    0.000* 
22 0.90±0.30 1.00 183 (90.1) 1.00±0.0
0 
1.00 31 (100.0)    0.084 b  
23 0.87±0.34 1.00 176 (86.7) 0.81±0.4
0 
1.00 25 (80.6)    0.405 b 
24 0.67±0.47 1.00 137 (67.5) 0.94±0.2
5 
1.00 29 (93.5)    0.006* 
25 0.68±0.47 1.00 138 (68.0) 0.71±0.4 1.00 22 (71.0)    0.900 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Statistically significant at p<0.05, The Mann-Whitney U-test was conducted for continuous variables and the chi square was conducted for categorical variables.  
a Chi-square test  
b Fisher’s exact test was used as the number of cells with expected count less that 5 is more than 20% of the total number of cells 
 
  
6 
26 0.78±0.41 1.00 159 (78.3) 0.84±0.3
7 
1.00 26 (83.9)    0.638 
27 0.57±0.50 1.00 116 (57.1) 0.94±0.2
5 
1.00 29 (93.5)    0.000* 
28 0.94±0.24 1.00 191 (94.1) 0.97±0.1
8 
1.00 30 (96.8)    1.000 b 
29 0.92±0.28 1.00 186 (91.6) 1.00±0.0
0 
1.00 31 (100.0)    0.138 b 
30 0.60±0.49 1.00 122 (60.1) 0.87±0.3
4 
1.00 27 (87.1)    0.007* 
Domain score (%) 67.8±20.2 71.42  84.3±10.
5 
85.71  109.14/172.26 -4.876 0.000*  
 Total (%) 63.6±17.4 66.67  80.9±8.7 83.33  107.67/181.84 -5.694 0.000*  
  
Table 7: Comparison of psychometric properties of the Osteoporosis Prevention And Awareness Tool (OPAAT) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OPAAT: Osteoporosis Prevention And Awareness Tool;  MOKT: Malaysian Osteoporosis Knowledge Test (Lai et al., 2008), Osteoporosis and You (Cadarette et al., 2007); OKAT: Osteoporosis 
Knowledge Assessment Tool (Winzenberg et al., 2003); FOOQ: facts on Osteoporosis Quiz (Ailinger et al., 1998, Ailinger et al., 2003); OKQ: Osteoporosis Knowledge Questionnaire (Curry and 
Hogstel, 2001); OPQ: Osteoporosis Questionnaire (Pande et al., 2000) 
  
 OPAAT MOKT Osteoporosis and 
You 
OKAT FOOQ OKQ OPQ 
Age (years) 
 
50-79 49-84 65-90 25-44 - ≥ 60 ≥ 50 
Number of subjects 
 
203 88 871 467 256 188 50 
Number of items with 
low difficulty level (%) 
 
4(13.3) 19 (47.5) 6 (60) 3(15) - - (44) 
Flesch reading ease 59.2 57 - 45 81-90 - 74.3 
Cronbach’s α or Kuder 
Richardson (KR) 
 
0.27-0.75 0.82 0.60 0.70 0.76 0.80 (KR) 0.84 (KR) 
Mean score (%) 63.6 69.0 37.7 44.0 - 57.4 - 
  
14.30   Appendix 39- Journal publication for the Satisfaction 
Questionnaire for Osteoporosis Prevention (SQOP) 
 
